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ABSTRACT 
The EFSA ANS Panel provides a scientific opinion on the safety of aspartame (E  951). Aspartame is a 
sweetener authorised as a food additive in the EU. In previous evaluations by JECFA and the SCF, an ADI of 40 
mg/kg bw/day was established based on chronic toxicity in animals. Original reports, previous evaluations, 
additional literature and data made available following a public call were evaluated. Aspartame is rapidly and 
completely hydrolysed in the gastrointestinal tract to phenylalanine, aspartic acid and methanol. Chronic and 
developmental toxicities were relevant endpoints in the animal database. From chronic toxicity studies in 
animals, a NOAEL of 4000 mg/kg bw/day was identified. The possibility of developmental toxicity occurring at 
lower doses than 4000 mg/kg in animals could not be excluded. Based on MoA and weight-of-evidence 
analysis, the Panel concluded that developmental toxicity in animals was attributable to phenylalanine. 
Phenylalanine at high plasma levels is known to cause developmental toxicity in humans. The Panel concluded 
that human data on developmental toxicity were more appropriate for the risk assessment. Concentration-
response modelling was used to determine the effects of aspartame administration on plasma phenylalanine 
using human data after phenylalanine administration to normal, PKU heterozygote or PKU homozygote 
individuals. In normal and PKU heterozygotes, aspartame intakes up to the ADI of 40 mg/kg bw/day, in 
addition to dietary phenylalanine, would not lead to peak plasma phenylalanine concentrations above the current 
clinical guideline for the prevention of adverse effects in fetuses. The Panel concluded that aspartame was not of 
safety concern at the current aspartame exposure estimates or at the ADI of 40 mg/kg bw/day. Therefore, there 
was no reason to revise the ADI of aspartame. Current exposures to aspartame - and its degradation product 
DKP - were below their respective ADIs. The ADI is not applicable to PKU patients. 
© European Food Safety Authority, 2013 
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SUMMARY 
Following a request from the European Commission, the Panel on Food Additives and Nutrient 
Sources added to Food (ANS) of the European Food Safety Authority (EFSA) was asked to deliver a 
scientific opinion on the re-evaluation of aspartame (E 951) as a food additive.  
Aspartame (E  951) is a sweetener authorised as a food additive in the EU that was previously 
evaluated by the Joint FAO/WHO Expert Committee on Food Additives (JECFA), the EU Scientific 
Committee for Food (SCF) and the European Food Safety Authority (EFSA). Both JECFA and SCF 
established an Acceptable Daily Intake (ADI) of 40 mg/kg body weight (bw)/day.  
The Panel based its evaluation on original study reports and information submitted following public 
calls for data, previous evaluations, and additional literature that has become available until the end of 
the public consultation on the draft Scientific Opinion on the re-evaluation of aspartame (E 951) as a 
food additive (15
th February 2013). The Panel also evaluated literature published after the end of the 
public consultation, until 15
th November 2013 (EFSA ANS Panel, 2013). The Panel noted that 
although many of the studies were old and were not performed according to current standards (e.g. 
Good Laboratory Practice (GLP) and Organisation for Economic Co-operation and Development 
(OECD) guidelines), they should be considered in the re-evaluation of the sweetener as long as the 
design of such studies and the reporting of the data were considered appropriate. In its re-evaluation 
of aspartame, the Panel also considered the safety of its gut hydrolysis metabolites methanol, 
phenylalanine and aspartic acid and of its degradation products 5-benzyl-3,6-dioxo-2-piperazine 
acetic acid (DKP) and β-aspartame, which may be present in the sweetener as impurities.  
Aspartame (E 951) is a dipeptide of L-phenylalanine methyl ester and L-aspartic acid bearing an 
amino group at the α-position from the carbon of the peptide bond (α-aspartame). The major 
hydrolysis and degradation products of aspartame are L-phenylalanine, aspartic acid, methanol and 
DKP. DKP is formed through the intramolecular reaction of the primary amine with the methyl ester 
group of aspartame. β-Aspartame is a non-sweet isomer of α-aspartame.  
Specifications have been defined in the European Commission Regulation (EU) No 231/2012 and by 
JECFA.  
Studies in experimental animals and humans have shown that after oral ingestion, aspartame is fully 
hydrolysed within the gastro-intestinal tract. The products resulting from these reactions are methanol 
and the amino acids aspartic acid and phenylalanine. Hydrolysis of aspartame releases a 
corresponding 10  % by weight of methanol. Due to the very efficient hydrolysis in the gastro-
intestinal tract the amount of intact aspartame that enters the bloodstream has been reported as 
undetectable in several studies conducted in various species, including rats, dogs, monkeys and 
humans. Further studies conducted in monkeys and pigs have also shown that the potential 
intermediate metabolite, phenylalanine methyl ester, is rapidly broken down to phenylalanine and 
methanol in the gastro-intestinal tract. Therefore, the Panel considered that phenylalanine, aspartic 
acid and methanol are absorbed and enter normal endogenous metabolic pathways.  
The acute toxicity of aspartame was tested in mice, rats, rabbits and dogs and was found to be very 
low. Similarly, sub-acute and sub-chronic studies did not indicate any significant toxic effects in rats, 
mice or dogs.  
Aspartame has been tested for genotoxicity in a number of in vitro and in vivo studies. The Panel 
concluded that in mammalian systems, apart from a valid UDS study, which was negative, no 
conclusion could be drawn at the gene and chromosomal level, as no studies dealing with these 
endpoints were available. However, the Panel considered that the weight-of-evidence was sufficient to 
conclude that aspartame was not mutagenic in bacterial systems. In vivo, the majority of investigations 
on genotoxicity reported negative findings. Equivocal findings were only described in one NTP (US 
National Toxicology Program) study, positive in female but not in male p53 haploinsufficient mice. In Opinion on the re-evaluation of aspartame (E951) as a food additive 
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two other transgenic mouse strains the genotoxicity results were negative. The available in vitro data 
did not indicate a direct genotoxic activity of aspartame that might predispose to a site of first contact 
effect in vivo. Overall, the Panel concluded that the available data do not indicate a genotoxic concern 
for aspartame.  
The results from three chronic toxicity and carcinogenicity studies in rats and one in mice revealed no 
aspartame-related increase in any type of neoplasms at all doses tested. The incidences of intracranial 
neoplasms observed in some studies were within the range of spontaneous brain tumours observed in 
the strain of rats used. In the rat studies, the highest doses tested (4000 or 8000 mg aspartame/kg 
bw/day) produced minor renal changes, considered by the Panel to be of minimal toxicological 
significance. A dose-dependent depression of body weight gain at 2000 and 4000  mg/kg bw/day 
correlating with decreased feed consumption was reported in one study. Overall, the Panel derived a 
no observable adverse effect level (NOAEL) of 4000 mg/kg bw/day from the four studies.  
Furthermore, the NTP carried out several 9-month carcinogenicity studies with aspartame in 
genetically modified Tg.AC hemizygous, p53 haploinsufficient and Cdkn2a deficient mice. The Panel 
agreed that there was no evidence of treatment-related neoplastic or non-neoplastic lesions in any of 
these studies.  
Since the last evaluation of aspartame by the SCF in 2002, two new long term carcinogenicity studies 
on aspartame in rats and one in mice were published by the European Ramazzini Foundation. The two 
rat studies have already been evaluated by the former Scientific Panel on Food Additives, 
Flavourings, Processing Aids and Materials in Contact with Food (AFC) and the ANS Panel and were 
considered to have methodological flaws. In addition to a high background incidence of chronic 
inflammatory changes in the lungs and other vital organs and tissues there is uncertainty about the 
diagnoses of some tumour types, which rendered the validity of the findings questionable. Moreover, 
EPA has recently concluded that many of the malignant neoplasms and the lymphoid dysplasias 
diagnosed in the studies from the European Ramazzini Foundation were hyperplasias related to 
unknown chronic infection in the animals and not related to aspartame intake. Furthermore, in the 
mouse study, the ANS Panel noted that the hepatic and pulmonary tumour incidences reported fell 
within the institute’s own historical control ranges for spontaneous tumours.  
The available reproductive and developmental toxicity studies on aspartame comprised nine studies: 
an embryotoxicity and teratogenicity study performed in the mouse, a two-generation reproduction 
toxicity study in the rat, five peri- and postnatal developmental studies in the rat, a reproductive 
performance and developmental study in the rat and an embryotoxicity and teratogenicity study in the 
rat. In addition, eight embryotoxicity and teratogenicity studies were performed in the rabbit, four 
with administration of aspartame by diet and four by gavage.  
From the rodent studies, the Panel identified a NOAEL of 5700 mg/kg bw/day, the highest dose level 
tested, in a developmental toxicity study in the mouse. The results of the reproductive and 
developmental toxicity studies in rats indicated NOAELs that ranged from 2000  to 4000  mg 
aspartame/kg bw/day. The Panel noted that developmental changes in pup body weight were observed 
at birth in studies at the dose of 4000  mg aspartame/kg bw/day and considered, these could be 
attributed to a combination of malnutrition and nutritional imbalance due to excessive exposure to 
phenylalanine derived from aspartame. In support of this hypothesis, the Panel noted that 
administration of a dose of L-phenylalanine equimolar to aspartame led to a similar decrease in 
maternal and pup body weight, as observed in a concurrent aspartame group.  
Several reproductive and developmental toxicity studies performed in rabbits, where aspartame was 
administered via the diet or by gavage, were available to the Panel. Overall, the Panel considered that 
the data from these studies were confounded both by the decrease in feed intake (when aspartame was 
administered via the diet or by gavage), or the poor health of the animals, and, in many cases, by the 
number of deaths of pregnant rabbits in the treated groups possibly related to misdosing during 
gavage treatment. In one particular study with aspartame, pregnant rabbits were also dosed by gavage Opinion on the re-evaluation of aspartame (E951) as a food additive 
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with L-phenylalanine and L-aspartic acid at dose levels equimolar to the top dose of 2000  mg 
aspartame/kg bw tested. A decrease in feed consumption was observed in the high aspartame dose and 
the L-phenylalanine-treated animals in this study and a significant body weight loss in the high 
aspartame dose was reported. Maternal toxicity and growth reduction were observed in the high dose 
aspartame group and to a lesser extent in the L-phenylalanine group compared to the controls. Mean 
fetal body weight and length were significantly reduced in both the high aspartame group and the L-
phenylalanine group animals and a significantly higher rate of total (major and minor) malformations 
in the 2000 mg aspartame/kg bw/day group animals as compared to the concurrent control group was 
reported. The Panel considered the possibility that, in addition to a reduced feed intake by the mothers 
and gastrointestinal disturbances, exposure to high levels of aspartame-derived phenylalanine may be 
in part responsible for these effects in the high dose aspartame group because similar effects, though 
less severe, were seen in the phenylalanine group. Based on the above considerations the Panel 
identified a NOAEL of 1000 mg aspartame/kg bw/day for maternal (weight loss) and developmental 
toxicity (weight loss and malformations).  
The Panel noted there was no epidemiological evidence for possible associations of aspartame with 
various cancers in the human population.  
A large prospective cohort study in Denmark found no consistent association between the 
consumption of artificially sweetened beverages (but not with aspartame specifically) during 
pregnancy and the diagnosis of asthma or allergic rhinitis in children.  
Another analysis of the same cohort showed a small but significantly elevated risk of medically 
induced pre-term delivery in women with higher reported consumption of artificially sweetened 
drinks. However, another prospective study in Norway found that the association of pre-term delivery 
with artificially sweetened soft drinks was much weaker and barely discernible, and applied more to 
spontaneous than medically induced deliveries and was exceeded by an association with consumption 
of sugar-sweetened soft drinks. 
Methanol is a metabolite of aspartame and is subject to significant first pass metabolism. The main 
route of metabolism of methanol proceeds by stepwise oxidation via formaldehyde to formate and 
then to carbon dioxide. Formate can also enter the one-carbon metabolic pool. Since some authors 
have suggested that methanol is responsible for the potential carcinogenicity and toxicity of 
aspartame, the Panel evaluated the available toxicological information on methanol.  
The Panel considered the database on the genotoxicity of methanol and concluded that the data set 
was limited but that the available reliable in vitro and  in vivo data did not indicate a genotoxic 
potential for methanol.  
The oral studies on chronic toxicity and carcinogenicity of methanol are limited to a mouse study and 
a rat study. Overall, the Panel concluded that the mouse study was inadequate for the assessment of 
the carcinogenic potential of methanol and that the rat study was not suitable for the cancer risk 
assessment of methanol.  
The reproductive and developmental toxicity database of methanol is limited. As oral studies available 
on methanol performed at high dose levels (4000 or 5000 mg/kg bw/day) did not allow the Panel to 
identify a NOAEL for reproductive and developmental toxicity for methanol by oral exposure, the 
Panel calculated the oral NOAEL using available data from animals exposed to methanol via 
inhalation. The Panel identified NOAECs of 1300 mg methanol/m
3 in mice and 6500 mg methanol/m
3 
in rats that were exposed to methanol via the inhalation route. Based on these NOAECs, the Panel 
calculated oral NOAELs for mice and rats of approximately 560 and 2070  mg/kg bw/day, 
respectively.  
The Panel considered the NOAEL of 560 mg/kg bw/day as the most conservative taking into account 
that the developmental effects observed in the mouse study tend to disappear as the pups grow. The Opinion on the re-evaluation of aspartame (E951) as a food additive 
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Panel noted that the calculated NOAELs for methanol by oral exposure are 140 and 515-fold higher 
than the maximum amount of methanol that could be released when aspartame is consumed at the 
ADI.  
The Panel concluded that the data on reproductive and developmental toxicity did not suggest that 
there was a risk from methanol derived from aspartame at the current exposure estimates or at the 
ADI of 40 mg/kg bw/day.  
In addition, the Panel concluded that, based on recent measurements of basal levels of formaldehyde 
in blood and on the modelling of its biological turnover and steady state concentration in cells, 
formaldehyde formed from aspartame-derived methanol was not of safety concern at the current 
exposure estimates or at the ADI of 40 mg/kg bw/day. 
Another aspartame metabolite, aspartic acid is itself a neurotransmitter and can be converted to the 
more potent excitatory neurotransmitter glutamate. The Panel noted that there was no evidence in vivo 
for neurotoxicity associated with aspartame exposure. The Panel concluded, however, that aspartic 
acid generated from aspartame was not of safety concern at the current exposure estimates or at the 
ADI of 40 mg/kg bw/day.  
Concerning the third aspartame metabolite, phenylalanine, the Panel concluded that it is the main 
metabolite of concern in terms of potential developmental effects in humans. The Panel considered 
that it was plausible that phenylalanine could be responsible for some or all of the adverse effects 
reported for aspartame in rat and rabbit developmental toxicity studies.  
Humans heterozygous for phenylalanine hydroxylase mutations, show a slightly reduced capacity to 
metabolise phenylalanine compared to normal individuals. Individuals homozygous for phenylalanine 
hydroxylase mutations (phenylketonuria (PKU) patients) have a markedly reduced capacity for 
phenylalanine metabolism. After birth, homozygous PKU babies show severe impairment in 
development and cognition if the phenylalanine intake via the diet is not strictly controlled.  
PKU mothers with poorly controlled phenylalanine intake in their diet during pregnancy may give 
birth to babies with congenital heart diseases, microcephalus and impaired neurological function.  
The Panel considered that adverse effects reported for aspartame in animal studies could be attributed 
to the metabolite phenylalanine, which was particularly the case for the rat and rabbit developmental 
toxicity studies. The Panel noted that adverse developmental effects were seen in children born to 
PKU patients and that these effects appeared to be related to maternal phenylalanine levels. The Panel 
was aware that the knowledge on effects of phenylalanine in PKU mothers and their children both 
before and after birth had developed considerably since the initial evaluation of aspartame.  
The Panel undertook a formal Mode of Action (MoA) analysis of the putative role of phenylalanine in 
the developmental toxicity seen in animal studies. This MoA analysis is described in Section 11.  
The Panel considered that the proposed MoA is plausible and relevant based on the weight-of-
evidence of the available data, summarised in the opinion. There are uncertainties from the limited 
kinetic data in animals and in the human aspartame dose-phenylalanine concentration response data. 
The Panel decided to base the risk characterisation on comparison of plasma phenylalanine levels 
following aspartame administration with plasma phenylalanine levels associated with developmental 
effects in children born from mothers with PKU. The Panel decided these human data were more 
appropriate than the results of animal studies of reproductive and developmental toxicity for the risk 
characterization of aspartame.  
Having established that the MoA was plausible and relevant, the Panel reviewed the information on 
plasma levels of phenylalanine associated with adverse effects on the fetuses of mothers with PKU. 
The Panel noted that current clinical guidelines recommend that plasma levels of phenylalanine Opinion on the re-evaluation of aspartame (E951) as a food additive 
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should be maintained below 360 μM. In calculating a safe level of aspartame exposure (based on 
plasma phenylalanine concentrations), the Panel assumed the worst-case scenario that intake of 
aspartame occurs in combination with a meal which leads to circulating plasma phenylalanine 
concentrations of 120 µM (the maximum plasma concentration based on conservative assumptions of 
dietary exposure to phenylalanine). The concentration of plasma phenylalanine derived from 
aspartame was therefore set to 240 µM (i.e. 360 µM minus 120 µM) by the Panel. Based on the 
modelling, a plasma phenylalanine concentration of 240 µM would result from the administration of a 
bolus dose of 103 mg aspartame/kg bw (lower bound distributions: 88 mg aspartame/kg bw; 95
th 
percentile, CI 59-125) to a normal subject. For a PKU heterozygous individual the concentration of 
240 µM would be reached by the administration of a bolus dose of 59 mg aspartame/kg bw (lower 
bound distributions: 50 mg aspartame/kg bw; 95
th percentile, CI 28-69). The Panel considered that 
given the conservative assumptions and the confidence intervals provided by the modelling, for 
realistic (i.e. non-bolus) dietary intake of aspartame, the peak plasma phenylalanine levels would not 
exceed 240 µM.  
The Panel noted that in the normal population the 95
th percentile confidence interval of the lower 
bound estimate of the dose resulting in a peak plasma level of 240  µM following a bolus 
administration of aspartame was greater than 40 mg/kg bw (which is equivalent to the current ADI). 
In the PKU heterozygous population the 95
th percentile confidence interval for the lower bound of the 
dose resulting in a peak plasma level of 240 µM following a bolus administration of aspartame was 
greater than 40 mg/kg bw (which is equivalent to the current ADI) in 82 % of the simulations. The 
Panel considered that following bolus administration of aspartame of 40  mg/kg bw (which is 
equivalent to the current ADI) the PKU heterozygous population would not exceed the current clinical 
guideline of 360 µM.  
The Panel also noted that in order to exceed the phenylalanine plasma concentration of 240  μM 
following repeated administration of aspartame in normal individuals, a bolus administration at 
40 mg/kg bw (which is equivalent to the current ADI) would need to be given every hour.  
The Panel considered the following: 
•  the conservative assumptions used in the modelling, which all overestimate peak plasma 
concentrations 
•  the available information on adverse effects on development in humans with PKU 
•  the allocation of 2/3 of the current clinical guideline level of 360 µM phenylalanine in plasma 
to phenylalanine from ingested aspartame, in order to account for simultaneous ingestion of 
phenylalanine from other components of the diet results of the modelling 
•  kinetic data from repeated oral administration of aspartame in humans 
•  bolus intakes based on consumption of one litre of soft drink containing aspartame at the 
maximum permitted level (MPL) of 600 mg/L by a child of 20-30 kg will not exceed 30 mg 
aspartame/kg bw.  
Based on these considerations and evaluations, the Panel concluded that under realistic conditions of 
aspartame intake, phenylalanine plasma levels would not exceed 240  µM in normal or PKU 
heterozygous individuals. The Panel noted that this was well below the concentrations at which 
adverse effects in the fetus are reported and is also below the current clinical guideline (360 µM) for 
prevention of effects in the fetuses of pregnant PKU patients. The Panel noted that in young children 
who did not suffer from PKU, plasma levels of phenylalanine resulting from aspartame ingestion at or 
below the ADI (as either a bolus or other aspartame consumption patterns) were likely to remain 
below 240  μM. For pregnant women, the Panel noted that there was no risk to the fetus from Opinion on the re-evaluation of aspartame (E951) as a food additive 
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phenylalanine derived from aspartame at the current ADI (40  mg/kg bw/day) in normal or PKU 
heterozygous individuals.  
The Panel noted that it was currently not possible to include chronic endpoints in the postulated MoA. 
The Panel noted that the ADI previously derived by JECFA and SCF of 40  mg/kg bw/day was 
established based on the long-term animal studies using the default uncertainty factor of 100. The 
Panel considered that this remained appropriate for the evaluation of long-term effects of aspartame.  
The current evaluation was based on analysis of human reproductive and developmental effects of 
phenylalanine in PKU patients, who are more susceptible than the general and PKU heterozygous 
population. Therefore, no additional allowance for toxicodynamic variability was required. The 
modelling of the aspartame dose-phenylalanine concentration response was based on data from PKU 
heterozygous individuals who at any dose would have a higher plasma phenylalanine concentration 
than the normal population; therefore, no additional allowance for toxicokinetic variability was 
required for the general population. The Panel concluded that exposures at or below the current ADI 
were not of safety concern for reproductive and developmental toxicity in humans excluding PKU 
homozygous individuals.  
The Panel also conducted an uncertainty analysis of the assumptions used in the postulated MoA. 
While the Panel was not able to place a specific numerical value on the uncertainties related to these 
assumptions, the Panel considered that these assumptions would be more likely to overestimate than 
underestimate any potential developmental risk. Therefore, the Panel considered that the results of the 
uncertainty analysis further support its conclusion, that there is no safety concern for aspartame at the 
current ADI in normal and heterozygous subjects.  
Overall, the Panel concluded from the present assessment of aspartame that there were no safety 
concerns at the current ADI of 40 mg/kg bw/day. Therefore, there was no reason to revise the ADI for 
aspartame.  
The Panel emphasised that its evaluation of phenylalanine plasma levels from a dose of aspartame at 
the ensuing ADI is not applicable to PKU patients. These individuals require total control of dietary 
phenylalanine intake to manage the risk from elevated phenylalanine plasma levels. The Panel noted it 
is a requirement of EU legislation that products containing aspartame indicate through labelling that 
they contain a source of phenylalanine.  
Conservative estimates of exposure to aspartame made by the Panel for the general population were 
up to 36 mg/kg bw/day at the 95
th percentile. These were below the ADI. The current ADI for DKP is 
7.5 mg/kg bw/day. Estimates of DKP exposure at the ADI for aspartame are below this ADI based on 
the current specification for DKP in aspartame (1.5 %) and up to the highest value (24 % for soft 
drinks) used from the whole database; this latter percentage was taken into account for all food 
categories where no degradation percentage of DKP was available. The Panel noted that high-level 
exposure estimates for the general population are up to 5.5 mg/kg bw/day at the 95
th percentile, which 
is below the ADI. Finally, conservative estimates of exposure to methanol showed that aspartame-
derived methanol contributed to less than 10 % of the total mean anticipated exposure to methanol 
from all sources.    Opinion on the re-evaluation of aspartame (E951) as a food additive 
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BACKGROUND AS PROVIDED BY THE EUROPEAN COMMISSION 
Regulation (EC) No  1333/2008 of the European Parliament and of the Council on food additives 
requires that food additives are subject to a safety evaluation by the European Food Safety Authority 
(EFSA) before they are permitted for use in the European Union. In addition, it is foreseen that food 
additives must be kept under continuous observation and must be re-evaluated by EFSA.  
For this purpose, a programme for the re-evaluation of food additives that were already permitted in the 
European Union before 20 January 2009 has been set up under the Regulation (EU) No 257/2010
4. This 
Regulation also foresees that food additives are re-evaluated whenever necessary in light of changing 
conditions of use and new scientific information. For efficiency and practical purposes, the re-
evaluation should, as far as possible, be conducted by group of food additives according to the main 
functional class to which they belong.  
The order of priorities for the re-evaluation of the currently approved food additives should be set on the 
basis of the following criteria: the time since the last evaluation of a food additive by the Scientific 
Committee on Food (SCF) or by EFSA, the availability of new scientific evidence, the extent of use of a 
food additive in food and the human exposure to the food additive taking also into account the outcome 
of the Report from the Commission on Dietary Food Additive Intake in the EU
5 of 2001. The report 
‘Food additives in Europe 2000
6‘ submitted by the Nordic Council of Ministers to the Commission, 
provides additional information for the prioritisation of additives for re-evaluation. As colours were 
among the first additives to be evaluated, these food additives should be re-evaluated with a highest 
priority.  
In 2003, the Commission already requested EFSA to start a systematic re-evaluation of authorised food 
additives. However, as a result of adoption of Regulation (EU) 257/2010 the 2003 Terms of References 
are replaced by those below.  
TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION 
The Commission asks the European Food Safety Authority to re-evaluate the safety of food additives 
already permitted in the Union before 2009 and to issue scientific opinions on these additives, taking 
especially into account the priorities, procedures and deadlines that are enshrined in the Regulation (EU) 
No 257/2010 of 25 March 2010 setting up a programme for the re-evaluation of approved food additives 
in accordance with the Regulation (EC) No 1333/2008 of the European Parliament and of the Council 
on food additives. 
                                                      
4  Commission Regulation (EU) No 257/2010 of 25 March 2010 setting up a program for the re-evaluation of approved food 
additives in accordance with Regulation (EC) No 1333/2008 of the European Parliament and of the Council on food 
additives. OJ L 80, 26.3.2010, p. 19-27. 
5   Report from the Commission on dietary food additive intake in the European Union. Commission of the European 
Communities, COM (2001) 542 final. 
6  Food Additives in Europe 2000. Status of safety assessments of food additives presently permitted in the EU. Nordic Council 
of Ministers, TemaNord 2002:560. Opinion on the re-evaluation of aspartame (E951) as a food additive 
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ASSESSMENT 
1.  Introduction 
The present opinion deals with the re-evaluation of the safety of aspartame (E 951) when used as a 
sweetener added to foods, and including its use as a tabletop sweetener.  
Aspartame is a sweetener authorised as a food additive in the EU that was previously evaluated by the 
Joint FAO/WHO Expert Committee on Food Additives (JECFA), the latest in 1981 (JECFA, 1975, 
1980, 1981), the EU Scientific Committee for Food (SCF), the latest in 2002 (SCF 1985, 1989, 1997, 
2002), the European Food Safety Authority (EFSA), the latest in 2011 (EFSA, 2006, 2009a 2009b, 
2011a; EFSA ANS Panel, 2011).  
The Panel based its evaluation on original study reports and information submitted following public 
calls for data
7, previous evaluations, and additional literature that has become available until the end of 
the public consultation on the draft Scientific Opinion on the re-evaluation of aspartame (E 951) as a 
food additive (15
th February 2013). The Panel also evaluated literature published after the end of the 
public consultation, until 15
th November 2013 (EFSA ANS Panel, 2013). 
The selection criteria for scientific data consideration for the re-evaluation of aspartame described in 
this opinion applied to both the existing published and unpublished scientific literature. These criteria 
were agreed at the 28
th Scientific Panel on Food Additives and Nutrient Sources added to Food (ANS) 
Plenary meeting on 25-27 October 2011 and were published with the minutes of that meeting. These 
criteria are reproduced in Appendix A.  
In its re-evaluation of aspartame, the ANS also considered the safety of its gut derived metabolites, 
methanol, phenylalanine and aspartic acid and its degradation products 5-benzyl-3,6-dioxo-2-piperazine 
acetic acid (DKP) and β-aspartame, which also may be present in the sweetener as an impurity.  
The Panel noted that in the early studies, the stereochemical forms of the amino acids and other 
metabolites formed from aspartame were not specified.  
2.  Technical data 
2.1.  Identity of the substances 
Aspartame is a dipeptide of L-phenylalanine methyl ester and L-aspartic acid bearing an amino group at 
the α-position from the carbon of the peptide bond (Figure 1).  
Aspartame has a molecular formula of C14H18N2O5. It has a molecular weight of 294.31 g/mol, the CAS 
Registry Number is 22839-47-0 and the EINECS number 245-261-3. The chemical name for aspartame 
is (S)-3-amino-N-[(S)-1-methoxycarbonyl-2-phenylethyl] succinamic acid. The structural formula of 
aspartame is presented in Figure 1.  
Aspartame is a white odourless, crystalline powder having a sweet taste.  
At pH 7 and room temperature, aspartame has a solubility in water of approximately 10 g/L (Homler et 
al., 1991). According to data from a producer, aspartame has a solubility in ethanol of 0.37 % and is 
insoluble in oil.
8 The theoretical log Po/w value calculated with Advanced Chemistry Development Labs 
software (ACD Labs) is 0.542 ± 0.626 (at 25 °C). Aspartame has two melting points, melting initially at 
                                                      
7  ‘Call for scientific data on Aspartame (E951)’ (published: 1 June 2011). Available online:  
 http://www.efsa.europa.eu/en/dataclosed/call/110601.htm  
‘Call for scientific data on aspartame (E 951) related to 5-benzyl-3,6-dioxo-2-piperazine acetic acid (DKP) and other 
primary or secondary degradation products from aspartame’ (published: 26 July 2012 ). Available online: 
http://www.efsa.europa.eu/en/dataclosed/call/120726.htm 
8  http://www.nutrasweet.com/articles/sendfile.asp?Id=130&filename=AG%2DTB%2D03%2D001%2Epdf Opinion on the re-evaluation of aspartame (E951) as a food additive 
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190 °C, solidifying and re-melting at 246-247 °C. A possible explanation for this behaviour is that the 
intramolecular reaction of the primary amine with the methyl ester takes place at the initial melting 
point to generate 5-benzyl-3,6-dioxo-2-piperazine acetic acid (DKP) and methanol (Prankerd, 2002).  
 
Figure 1:   Structural formula of aspartame E951 (α-aspartame). 
Some of the synonyms of aspartame include α-aspartame, α-APM, N-L-alpha-aspartyl-L-phenylalanine-
1-methyl ester, aspartyl phenylalanine methyl ester, L-aspartyl-L-phenylalanyl methyl ester, L-aspartyl-
L-3-phenylalanine methyl ester, L-alpha-aspartyl-L-phenylalanine methyl ester, alpha-L-aspartyl-L-
phenylalanine methyl ester, methyl aspartylphenylalanate, L-aspartame, alpha-aspartame.  
Identity of degradation products of aspartame 
The major degradation products of aspartame are listed in Table 1. 
Table 1:   Major degradation products of aspartame 
Name  CAS Registry Number  Structural formula 
5-benzyl-3,6-dioxo-2-
piperazine acetic acid 
(DKP) 
55102-13-1 (stereochemistry 
not specified) 
5262-10-2 (configuration 
2S,5S-)   
Methanol 67-56-1  CH3OH 
L-Aspartyl-L-
phenylalanine (α-AP) 
 
13433-09-5 
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Name  CAS Registry Number  Structural formula 
L-Phenylalanine 
methyl ester  
2577-90-4 
 
L-Phenylalanine (Phe)  63-91-2 
 
L-Aspartic acid (Asp)  56-84-8 
 
L-Phenylalanine-L-
aspartic acid 
 
 
 
β-Aspartame  
(β-APM) 
2577-90-4 
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Name  CAS Registry Number  Structural formula 
N-L-β-Aspartyl-L-
phenylalanine (β-AP) 
 
 
5-benzyl-3,6-dioxo-2-piperazine acetic acid (DKP) 
Via the intramolecular reaction of the primary amine in α-aspartame with its methyl ester group, DKP 
and methanol are formed. The molecular formula of DKP is C13H14N2O4. Its molecular weight is 
262.26 g/mol.  
The log Po/w value is -0.269 ± 0.515 at 25 °C, the pKa1 is 4.02 ± 0.10 and pKa2 is -1.55 ± 0.60 both at 
25 °C, values calculated with Advanced Chemistry Development (ACD/Labs).  
The synonyms for DKP include 3-benzyl-6-(carboxymethyl)-2,5-diketopiperazine, 3-benzyl-6- 
carboxymethyl-2,5-dioxopiperazine, 3-carboxymethyl-6-benzyl-2,5-diketopiperazine, cyclo(aspartyl-
phenylalanyl) and 5-benzyl-3,6-dioxo-2-piperazineacetic acid (5BZ).  
Hydrolysis of one of the amides in the diketopiperazine may occur leading to the formation of 
phenylalanine aspartic acid or α-aspartylphenylalanine (see Table 1). The stereochemistry of the 
compounds is not given due to possible racemisation of aspartic acid and phenylalanine moieties in 
DKP (Boehm and Bada, 1984). Both intermediates hydrolyse to yield two amino acids: aspartic acid 
and phenylalanine
9 (Prodolliet and Bruelhart, 1993; Langguth et al., 1991).  
β-Aspartame  
β-Aspartame has as chemical name N-L-β-aspartyl-L-phenylalanine 1-methyl ester. Unlike α-
aspartame, β-Aspartame has no sweet taste. 
2.2.  Specifications 
Specifications for aspartame according to Commission Regulation (EU) No 231/2012
10 and to JECFA 
(2006) are listed in Table 2. 
Table 2:   Specifications for aspartame according to Commission Regulation (EU) No 231/2012 and 
JECFA (2006) 
                                                      
9  The term phenylalanine and phenyalanine methyl ester are used when the stereochemistry of the compounds is not specified 
in the original reference. 
10   Commission Regulation (EU) No 231/2012 of 9 March 2012 laying down specifications for food additives listed in Annexes 
II and III to Regulation (EC) No 1333/2008 of the European Parliament and of the Council OJ L 83, 22.3.2012 p 1-295. 
 
  Commission Regulation (EU) 
231/2012  JECFA (2006) 
Assay 
Not less than 98 % and not more 
than 102% of C14H18N2O5 on the 
anhydrous basis 
Not less than 98 % and not more 
than 102 % on the dried basis Opinion on the re-evaluation of aspartame (E951) as a food additive 
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In the JECFA specifications, aspartame is identified by an amine test and an ester test, whilst the EC 
specifications do not include these tests. JECFA specifications analyse aspartame for the presence of 
other optical isomers whilst the EC specifications do not include this test.  
The Panel noted that the EC specifications for aspartame do not include a maximum limit for β-
aspartame, which may be formed as a by-product of the chemical synthesis of aspartame or from 
aspartame degradation.  
Description 
White odourless, crystalline 
powder having a sweet taste. 
Approximately 200 times as sweet 
as sucrose 
White, odourless, crystalline 
powder, having a strong sweet 
taste 
Identification    
Solubility  Slightly soluble in water and in 
ethanol 
Slightly soluble in water and in 
ethanol 
Test for amine group  - 
Dissolve 2 g of ninhydrin in 75 ml 
of dimethyl sulphoxide, add 62 mg 
of hydrindantin, dilute to 100 ml 
with 4 M lithium acetate buffer 
solution (pH 9) and filter. Transfer 
about 10 mg of the sample to a test 
tube, add 2 ml of the reagent 
solution, and heat. A dark purple 
colour is formed. 
Test for ester  - 
Dissolve about 20 mg in 1 ml of 
methanol, add 0.5 ml of methanol 
saturated with hydroxylamine 
hydrochloride, mix, and then add 
0.3 ml of 5 N potassium hydroxide 
in methanol. Heat the mixture to 
boiling, then cool, adjust the pH to 
between 1 and 1.5 with 
hydrochloric acid TS, and add 
0.1 ml of ferric chloride TS. A 
burgundy colour is produced. 
pH (1 in 125 solution)  4.5 and 6.0   4.5-6.0  
Specific rotation (Determine in a 
4:100, 15 N formic acid solution 
within 30 minutes after preparation 
of the sample solution) 
[α]D
20 : + 14.5 to + 16.5 ° 
 
[α]D
20 : + 14.5 to + 16.5 ° 
 
Purity    
Loss on drying (105 °C, 4 hours)  Not more than 4.5 %   Not more than 4.5 %  
Sulphated ash  Not more than 0.2 %  
(expressed on a dry weight basis) 
Not more than 0.2 % 
Test 1 g of the sample (Method I) 
Transmittance/ Spectrophotometry 
The transmittance of a 1 % 
solution in 2 N hydrochloric acid, 
determined in a 1-cm cell at 430 
nm with a suitable 
spectrophotometer, using 2 N 
hydrochloric acid as reference, is 
not less than 0.95, equivalent to an 
absorbance of not more than 
approximately 0.022 
The transmittance of a 1 in 100, 
2 N hydrochloric acid solution, 
determined in a 1 cm cell at 
430 nm with a suitable 
spectrophotometer, using 2 N 
hydrochloric acid as a reference, is 
not less than 0.95, equivalent to an 
absorbance of not more than 
approximately 0.022 
Arsenic   Not more than 3 mg/kg    
Lead   Not more than 1 mg/kg   Not more than 1 mg/kg 
 
5-Benzyl-3,6-dioxo-2-
piperazineacetic acid (DKP)   Not more than 1.5 %   Not more than 1.5 % 
Other optical isomers  -  Passes test Opinion on the re-evaluation of aspartame (E951) as a food additive 
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The Panel noted that the EC specifications for aspartame may need to be amended to include a 
restriction for protein content due to the potential use of enzymes in the production of aspartame.  
The Panel noted that both EC and JECFA specifications for aspartame are dated in terms of the tests 
proposed for identification. These specifications should be updated to include characterisation of 
aspartame by chromatographic and mass spectrometric methodologies.  
2.3.  Manufacturing process 
There are several methods to produce aspartame on a commercial scale, either through chemical or 
enzymatic synthesis (Prankerd, 2002; Yagasaki and Hashimoto, 2008).  
According to the information provided by a producer, the chemical synthesis of aspartame involves the 
reaction of L-aspartic acid and L-phenylalanine methyl ester (Burdock Group, 2006). L-phenylalanine 
methyl ester reacts with N-protected L-aspartic anhydride to form N-protected aspartame. After re-
crystallisation, the protecting group is removed to yield aspartame. Both α-aspartame (the sweet isomer) 
and  β-aspartame (the non-sweet isomer) are produced, requiring separation step to obtain only α-
aspartame. A similar description of the manufacturing process was provided by another manufacturer 
that uses L-phenylalanine and N-protected L-aspartic anhydride (Nutrasweet, 2012). Two major 
producers have indicated that the chemical synthesis is the process used for their aspartame production 
(Ajinomoto, 2012a; Nutrasweet 2012).  
One of the difficulties encountered in the chemical synthesis of aspartame is avoiding the formation of 
the non-sweet isomer (β-aspartame) as one of the by-products.  
Enzymatic methods allow the use of racemic starting materials, and the process has the advantage of 
producing only α-aspartame. The enzyme typically used is thermolysin, derived from Bacillus 
thermoproteolyticus.  Enzymatic synthesis using protected and unprotected aspartic acid and 
phenylalanine methyl ester are described in the literature (Yagasaki and Hashimoto, 2008). The Panel 
noted that Bacillus thermoproteolyticus is not included in the list of qualified presumption of safety 
(QPS) biological agents intentionally added to food and feed (EFSA BIOHAZ Panel, 2012).  
2.4.  Methods of analysis in food 
There is a number of published methods for the determination of aspartame alone or in combination 
with other sweeteners (Zygler et al., 2009). Most methods are based on extraction, with or without 
subsequent clean-up and high performance liquid chromatographic (HPLC) analysis using various 
detectors (Lino et al., 2008; Ma et al., 2012; Cheng and Wu, 2011; Kobayashi et al., 1999; Ji et al., 
2009; Kang et al., 2012; Serdar and Knezevic, 2011; Sik 2012) or ion chromatography (Chen and Wang, 
2001). There are three EU standardised inter-laboratory validated methods for determination of 
aspartame in foods. Methods EN 12856:1999
11 and CEN/TS 15606:2009
12 employ HPLC with UV 
detection and EN 15911:2010
13 uses HPLC with evaporative light scattering detector (ELSD). A 
validated HPLC-ELSD method has been reported for aspartame in carbonated and non-carbonated 
beverages, canned and bottled fruits and yoghurt (Wasik  et al., 2007). For samples fortified with 
aspartame, at the maximum permitted limits for aspartame according to the EU regulation, the method 
gave recoveries ranging from 90 to 100 % and RSDR values < 7 %. HorRat values of < 1.7 indicated 
satisfactory performance of the method for determination of aspartame in all matrices tested 
(Buchgraber and Wasik, 2007). Others have employed various forms of combined liquid 
chromatography-mass spectrometry (LC-MS) for determining aspartame in Chinese liquors (Xia et al., 
2011), in beverages, dairy and fish products (Zygler  et al., 2011), juices and syrups (Ferrer and 
Thurman, 2010), wine (Cheng and Wu, 2011) and other foods (Yang et al., 2008, Koyama et al., 2005, 
Liu et al., 2010). LC-MS methods are rapid, do not require extensive clean-up and offer low limits of 
                                                      
11     http://webstore.ansi.org/RecordDetail.aspx?sku=BS+EN+12856%3A1999 
12   https://www.astandis.at/shopV5/preview.action;jsessionid=B20DC77D150ABD17C37DD9EEF850B4EB?preview=&dokk
ey=354291&selectedlocale=en  
13     http://webstore.ansi.org/RecordDetail.aspx?sku=BS+EN+15911:2010 Opinion on the re-evaluation of aspartame (E951) as a food additive 
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detection with high specificity, but have, up to now, not been validated by any inter-laboratory studies. 
Other successful approaches for direct analysis of aspartame in commercial sweeteners have employed 
Fourier transform infrared spectroscopy (FT-IR) (Mazurek and Szostak, 2011), in soft drinks and 
tabletop sweeteners capillary electrophoresis with capacitively coupled contactless conductivity 
detection (CE-C
4D) (Bergamo et al., 2011) and in carbonated beverages proton nuclear magnetic 
resonance (
1H-NMR) (Maes et al., 2012).  
2.5.  Stability, reaction and fate in food 
The stability of aspartame is affected by moisture, pH, temperature and storage time.  
Figure 2 shows the degradation pathways (Bell and Labuza, 1991; Prodolliet and Bruelhart, 1993). At 
neutral and alkaline pH, aspartame releases methanol and forms α-aspartylphenylalanine or undergoes 
cyclisation to form DKP. DKP and α-aspartylphenylalanine can interconvert, but do not revert to 
aspartame to any significant rate. Conversion of aspartame into DKP or α-aspartylphenylalanine results 
in the loss of the sweet taste. At acidic pH below 4.5, in addition to the two main reaction pathways 
occurring at neutral and alkaline pH, aspartame can undergo structural rearrangement to produce β-
aspartame. Also the peptide bond of aspartame can be cleaved, producing L-phenylalanine methyl ester 
and L-aspartic acid. β-aspartylphenylalanine can be produced via structural rearrangement of α-
aspartylphenylalanine. Phenylalanine is produced by hydrolysis of phenylalanine methyl ester. Finally, 
α-aspartylphenylalanine can hydrolyse to the individual amino acids. Opinion on the re-evaluation of aspartame (E951) as a food additive 
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Stability of aspartame in solid state 
According to industry at moisture contents of less than 8 %, aspartame in its pure form is stable with a 
minimum shelf life of 5  years (storage temperature not indicated) (Ajinomoto, 2012). Solid-state 
stability studies showed that at temperatures higher than 80 
oC, aspartame cyclises with the release of 
methanol to form DKP (Leung and Grant 1997; Lin and Cheng 2000; Conceicao et al., 2005). Homler 
reported that under dry conditions, conversion of aspartame into DKP is slow (5 % per 100 hours at 
105 °C). At higher temperatures, the rate of conversion to DKP increases (around 50 % per 80 hours at 
120 °C and 100 % per 30 hours at 150 °C) (Homler, 1984). Graves and Luo (1987) reported that when 
heated in an acidified and dried state at 110 °C for 24 hours in vacuo, in addition to the degradation 
products, aspartame could dehydrate to form an anhydro derivative. In addition, oligopeptides may be 
generated containing ratios of L-aspartic acid to L-phenylalanine that are higher than the starting 
material.  
Decomposition of aspartame in lyophilised instant coffee with a residual moisture content of 3-4 % 
was less than 10 % after 260 days of storage (Jost et al., 1982).  
The degradation kinetics of aspartame as a function of the water activity (relative vapour pressure, aw) 
in low and intermediate moisture food systems showed that an increase in aw for each 0.1 units in the 
0.3-0.7 range, resulted in about 30-80 % increase in the degradation rate (Bell and Labuza, 1991). 
Stability of aspartame in solution 
Aspartame has limited stability in solutions and undergoes pH, temperature and time-dependent 
degradation (Pariza et al., 1998). Extensive studies on the kinetics of aspartame degradation in 
solution have been performed and the degradation has been reported to follow first order kinetics 
(Langguth et al., 1991).  
Aspartame is most stable between pH  4-5 (Homler, 1984; Neirynck and Nollet, 1988; Bell and 
Labuza, 1991; Bell and Labuza, 1994; Sabah and Scriba, 1998; Rowe et al., 2003). Rowe et al. (2003) 
showed that within this range of pH, aspartame dissolved in aqueous buffers at 25 °C has a half-life 
> 250 days. When the pH was decreased to 3, the half-life was shortened to 100-125 days and further 
decreased to below 25 days at pH 1. When the pH was increased from 5 to 6, the half-life was reduced 
to 50-100  days and further decreased to below 25 days at pH  7. Pattanaargson et al. (2001) 
investigated the degradation products of aspartame at different pH ranges. The major degradation 
product found at pH  2-6 was L-phenylalanine methyl ester, in the range of pH  7-10 the major 
degradation product was DKP and at pH 12, it was L-aspartyl-phenylalanine.  
In addition to the pathways discussed above, due to its free amino group, aspartame can react with 
reducing sugars in the presence of water via the Maillard reaction. This was determined through 
measurement of brown colour formation that resulted from mixing aspartame and glucose in solution 
at 70, 80, 90 and 100  °C at aw of 0.8. Browning of aspartame followed zero order kinetics; the 
respective time to reach a browning absorbance of 0.1 absorbance units at 420 nm was 11.4, 5.3, 2.15 
and 1.0 hour at the given temperatures (Stamp and Labuza 1983; Huang et al., 1987). The formation of 
a Schiff base, a step in the Maillard degradation pathway, was also noted between aspartame and 
vanillin in methanol/water solutions (Cha and Ho, 1988).  
Aspartame, at room temperature, is stable with respect to racemisation at mildly acidic pH values, but 
at 100 °C, racemisation of the DKP generated from aspartame takes place (Boehm and Bada 1984; 
Gaines and Bada 1988; Gund and Veber, 1979). The authors’ explanation was that DKP formation is 
accelerated by electrostatic repulsion between the two carboxy groups which force the dipeptide into 
the cis conformation. At neutral pH the relative racemisation rates of aspartame dipeptides are much 
slower than of DKP, and amino acids at the N-terminal position racemise more rapidly than C-terminal 
amino acids (Gaines and Bada, 1988).  Opinion on the re-evaluation of aspartame (E951) as a food additive
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The analytical results of the electro-thermal and microwave induced hydrolysis of aspartame in cola 
samples imply that the hydrolysis of aspartame increases with an increase in temperature, microwave 
power and hydrolysis time. D-aspartic acid and D-phenylalanine can be observed with the electro-
thermal racemisation at the hydrolysis temperature of 120 °C for 1 day and only D-aspartic acid can be 
observed at the hydrolysis temperature of 90 °C for 2 and 3 days. For microwave-induced hydrolysis, 
only L-aspartic acid was detected at a power of 56 W for 1 minute and 320 W for 3 minutes (Cheng 
and Wu, 2011).  
The study by Lawrence and Yuan (1996) showed that aspartame, in aqueous acidic solutions in the 
presence of ascorbic acid and a transition metal catalyst, such as copper (II) or iron (III), under aerobic 
conditions can produce benzaldehyde via a free radical attack on aspartame. Benzaldehyde production 
was dependent on ascorbic acid concentration, but the yield of benzaldehyde decreased as the 
concentration of ascorbic acid exceeded that of aspartame.  
In lime-lemon carbonated beverages with pH 3.14-3.21 stored for 60 days at temperatures of 4 °C and 
37 °C, the loss of aspartame was 4.5 % and 29.5 % respectively (Malik et al., 2002). In lime-lemon 
and diet cola drinks stored at 22 °C, after 6 months, 28 and 37 % of the label claim of aspartame was 
detected, respectively, and after 36 months, the detected level was reduced to 6 and 4 % (Tsang et al., 
1985).  
According to Jost et al. (1982), the half-life of aspartame in cola is approximately 150 days at 23 °C 
and pasteurization of orange juice results in immediate loss of approximately half of the initial 
aspartame content.  
Stability tests in sterilised flavoured dairy beverages with pH 6.7 showed that aspartame had a half-life 
of 1-4 days at 30 °C and 24-58 days at 4 °C. Decreasing the pH from 6.7 to 6.4 doubles the half-life of 
aspartame (Bell and Labuza, 1994).  
Noda et al. (1991) demonstrated the instability of aspartame in fresh juice solutions of particular kinds 
of fruit such as kiwi, pineapple, papaya and melon, probably by the action of proteolytic enzymes. 
Yogurt cultures (strains of Lactobacillus bulgaricus and Streptococcus thermophilus) degrade 
aspartame during fermentation; however, losses of aspartame appeared related to the rate of the 
metabolism of the cultured microorganisms. Aspartame degradation was highest during culture growth 
and became negligible once the pH of yogurt dropped below 5.0 and when the culture reached a 
stationary phase (Keller et al., 1991; Prodolliet and Bruelhart 1993).  
Review of DKP concentration in food from aspartame degradation 
The content of aspartame and its degradation products, DKP, aspartyl-phenylalanine and 
phenylalanine, were analysed in 24 different commercial foods by Prodolliet and Bruelhart (1993). 
The decomposition of aspartame was particularly high in fruit cream (40 %), milk chocolate (26 %), 
malted beverage (22 %) and fruit yogurt (15 %). It has been determined that up to 21 % and 12 % of 
the aspartame in cola drink and fruit cream, respectively, is in the form of DKP.  
The degradation of aspartame to DKP in soft drinks depends on the storage temperature. DKP 
concentration in soft drinks after two months storage was about four times higher at a temperature 
range of 25-27 °C compared to 4-5 °C (Saito et al., 1989).  
Grosse et al. (1991) determined the level of degradation of aspartame and the extent of the formation 
of DKP in heat-treated dessert products. In acidified (pH 3) gelatin-based desserts, no formation of 
DKP was observed, whereas in dessert products containing milk or cacao having a pH of 6, the 
degradation of aspartame rose to 20-35 %. According to the authors in heat-treated cacao containing 
desserts with starch and milk as basic ingredients, at pH  6 a degradation of about 34  % of the 
aspartame to DKP can occur, whereas in heat-treated vanilla containing desserts at pH 6, about 21-
25 % is degraded to DKP.  Opinion on the re-evaluation of aspartame (E951) as a food additive
 
 
EFSA Journal 2013;11(12):3496  23
Cyprus submitted analytical data on levels of DKP in soft drinks sold in the Cyprus market. Levels 
found range between 3.4 and 19.4  mg/L. No information on the packaging or storage conditions 
(duration, temperature) was given (Cyprus, 2012). 
The Panel was provided with data on the determination of aspartame and its main degradation 
products in carbonated beverages (UN11, 1986), in baked goods (UN12, 1990), in beer (UN13), instant 
and quick cooked oatmeal (UN14, 1987), in soft candy (UN15, 1987). Table 3 shows the concentration 
of DKP in food from aspartame degradation observed in the above-mentioned studies as well as in the 
available literature. 
Table 3:   Concentration of 5-benzyl-3,6-dioxo-2-piperazine acetic acid  (DKP) in food from 
aspartame (APM) degradation 
Food Conditions  APM degraded 
(%) 
Degradation of 
APM to DKP (%)  Reference 
Carbonated 
Beverages 
APM initial: 0.5 g/L 
pH 2.5 
Time: 52 weeks 
T 20 °C 
75 24 
UN11, 1986 
pH 2.5 
Time: 39 weeks 
T 30 °C 
95 31 
pH 4.4 
Time: 38 weeks 
T 20 °C 
21 8.3 
pH 4.4 
Time: 52 weeks 
T 30 °C 
62 26.6 
Cheese cake 
(APM encapsulated) 
APM: 1.5 g/kg 
Time: 50 min 
T 121 °C  16  6.4 
UN12, 1990 
Chocolate cake 
(APM encapsulated) 
APM: 4.5 g/kg 
Time: 35 min 
T 177 °C  24  15 
Beer 
APM: 20 mg/kg 
pH 4.3 
Time: 90 days 
T 22 °C 
Ethanol 2.7 % 
8-10 5 UN13 
Instant cereals 
APM: 
1400-2000 mg/kg 
Boiling water added, 
time in cooling 
water: 17 min 
6 3 
UN14, 1987  Instant cereals 
APM: 
1400-2000 mg/kg 
Cooked in 
microwave, time in 
cooling water: 
16 min 
2.5 2.3 
Gelled candy 
APM: 0.84 g/kg 
21.1 °C 
Time 22 weeks  21 17 
UN15, 1987 
26.6 °C 
Time 17 weeks  41 25 
Lime-lemon  Time 6 months 
T : 22 °C  43-63 17-22 
Tsang et al., 1985 
Time 36 months 
T : 22 °C  86-94 32-34 
Diet Cola  Time 6 months 
T : 22 °C  62-72 24-28 
Time 36 months 
T : 22 °C 
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Food Conditions  APM degraded 
(%) 
Degradation of 
APM to DKP (%)  Reference 
Diet cola 
APM: 20-100 μg/mL 
All samples 
analysed were all 
commercial 
products. The 
samples were 
dissolved to yield an 
aspartame 
concentration of 
20-100 μg/mL, 
taking into account 
the declared values. 
40 21 
Prodolliet and 
Bruelhart, 1993 
Malted beverage 
APM: 20-100 μg/mL 
22 3 
Fruit (prune) 
yogurt 
APM: 20-100 μg/mL 
15 3 
Vanilla cream 
APM: 20-100 μg/mL 
8 7 
Fruit cream  
APM: 20-100 μg/mL 
40 12 
Milk chocolate 
APM: 20-100 μg/mL 
26 7 
The Panel noted that in the carbonated beverage study (UN11, 1986) it was observed that aspartame 
was also degraded to β−aspartame (β-APM) and β−aspartyl-L-phenylalanine (β-AP). At the beginning 
(4-12 weeks), aspartame was degraded into β−APM and with time (>  12  weeks), β−APM was 
hydrolysed to β-AP. Table 4 shows the concentration of β− APM and β-AP in food from aspartame 
degradation.  
Table 4:   Concentration of β−aspartame (β-APM) and β−aspartyl-L-phenylalanine (β-AP) in food 
from aspartame degradation 
Food Conditions 
APM 
degraded 
(%) 
Degradation of 
APM to β-AP 
(%) 
Degradation of 
APM to β-APM 
(%) 
Reference 
Carbonated 
Beverages 
APM initial: 
0.5 g/L 
pH 2.5 
Time: 52 weeks 
T 20 °C 
75 9  3.4 
UN11, 1986 
pH 2.5 
Time: 39 weeks 
T 30 °C 
95 18.3  1.8 
pH 4.4 
Time: 38 weeks 
T 20 °C 
21 1  1.4 
pH 4.4 
Time: 52 weeks 
T 30 °C 
62 10.5  3.8 
2.6.  Case of need and proposed uses 
Aspartame (E 951) is authorised in the EU as a sweetener. The maximum permitted levels (MPLs) 
range from 25 to 6000  mg/kg in foods, except for tabletop sweeteners for which it is authorised 
quantum satis.  
Table 5 summarises foods that are permitted to contain aspartame (E 951) and the corresponding 
MPLs as set by Commission Regulation (EU) No 1129/2011
14 on food additives for use in foodstuffs.  
                                                      
14     Commission regulation (EU) No 1129/2011 of 11 November 2011 amending Annex II to Regulation (EC) N°1333/2008  
    of the European Parliament and of the Council establishing a Union list of food additives. The Panel noted that the  
    Commission Regulation (EC) No. 1129/2011 of 11 November 2011 will enter into force on June, 1
st 2013 but confirm the  
    approved uses of aspartame as a food additives as described in previous directive: Council Directive No. 94/35/EC of 30  
    June 1994 on sweeteners for use in foodstuffs. Opinion on the re-evaluation of aspartame (E951) as a food additive
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Table 5:   MPLs of aspartame (E 951) in foods according to the Commission Regulation (EU) No 
1129/2011 
Category 
number  Foods restrictions/exception 
Maximum level  
(mg/L or mg/kg 
as appropriate) 
1.4  Flavoured fermented milk products including heat-
treated products 
only energy-reduced products or with no 
added sugar  1000 
3 Edible  ices  only energy-reduced or with no added sugar  800 
4.2.2  Fruit and vegetables in vinegar, oil, or brine  
only sweet-sour preserves of fruit and 
vegetables  300 
4.2.3  Canned or bottled fruit and vegetables 
only fruit energy-reduced or with no added 
sugar  1000 
4.2.4.1  Fruit and vegetable preparations excluding compote  only energy-reduced  1000 
4.2.5.1  Extra jam and extra jelly as defined by Directive 
2001/113/EEC 
only energy-reduced jams jellies and 
marmalades  1000 
4.2.5.2  Jam, jellies and marmalades and sweetened chestnut 
puree as defined by Directive 2001/113/EEC 
only energy-reduced jams, jellies and 
marmalades   1000 
4.2.5.3 Other  similar  fruit or vegetable spreads  only dried-fruit-based sandwich spreads, 
energy-reduced or with no added sugar  1000 
5.1  Cocoa and Chocolate products as covered by Directive 
2000/36/EC 
only energy-reduced or with no added 
sugars  2000 
5.2  Other confectionery including breath refreshing 
microsweets 
only cocoa or dried fruit based, energy 
reduced or with no added sugar  2000 
5.2  Other confectionery including breath refreshing 
microsweets 
only cocoa, milk, dried fruit or fat based 
sandwich spreads, energy-reduced or with 
no added sugar 
1000 
5.2  Other confectionery including breath refreshing 
microsweets 
only starch based confectionary energy 
reduced or with no added sugar  2000 
5.2  Other confectionery including breath refreshing 
microsweets 
only confectionary with no added sugar  1000 
5.2  Other confectionery including breath refreshing 
microsweets 
only breath-freshening micro-sweets, with 
no added sugar  6000 
5.2  Other confectionery including breath refreshing 
microsweets 
only strongly flavoured freshening throat 
pastilles with no added sugar  2000 
5.3 Chewing  gum  only with added sugars or polyols, as 
flavour enhancer  2500 
5.3 Chewing  gum  only with no added sugar  5500 
5.4  Decorations, coatings and fillings, except fruit based 
fillings covered by category 4.2.4  
only starch based confectionary energy 
reduced or with no added sugar  2000 
5.4  Decorations, coatings and fillings, except fruit based 
fillings covered by category 4.2.4  
only confectionary with no added sugar  1000 
5.4  Decorations, coatings and fillings, except fruit based 
fillings covered by category 4.2.4  
only cocoa or dried fruit based, energy 
reduced or with no added sugar  2000 
5.4  Decorations, coatings and fillings, except fruit based 
fillings covered by category 4.2.4  
only sauces  350 
6.3 Breakfast  cereals 
only breakfast cereals with a fibre content of 
more than 15 %, and containing at least 20 
% bran, energy reduced or with no added 
sugar 
1000 
7.2  Fine bakery wares  only essoblaten - wafer paper  1000 
7.2  Fine bakery wares  only fine bakery products for special 
nutritional uses  1700 
9.2.  Processed fish and fishery products including 
molluscs and crustaceans 
only sweet-sour semi-preserves of fish and 
marinades of fish, crustaceans and molluscs  300 
11.4.1  Table-top Sweeteners in liquid form     quantum satis 
11.4.2  Table-top Sweeteners in powder form     quantum satis 
11.4.3  Table-top Sweeteners in tablets     quantum satis 
12.4 Mustard     350 
12.5  Soups and broths  only energy-reduced soups  110 
12.6 Sauces     350 
12.7  Salads and savoury based sandwich spreads  only Feinkostsalat  350 Opinion on the re-evaluation of aspartame (E951) as a food additive
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Category 
number  Foods restrictions/exception 
Maximum level  
(mg/L or mg/kg 
as appropriate) 
13.2 
Dietary foods for special medical purposes defined in 
Directive 1999/21/EC (excluding products from food 
category 13.1.5) 
Products in this category can also use 
additives that are allowed in the 
corresponding food counterparts categories  
1000 
13.3 
Dietary foods for weight control diets intended to 
replace total daily food intake or an individual meal 
(the whole or part of the total daily diet) 
   800 
14.1.3 
Fruit nectars as defined by Council Directive 
2001/112/EC and vegetable nectars and similar 
products 
only energy-reduced or with no added sugar  600 
14.1.4 Flavoured  drinks  only energy reduced or with no added sugar  600 
14.2.1  Beer and malt beverages 
only alcohol-free beer or with an alcohol 
content not exceeding 1.2 % vol; ‘Bière de 
table/Tafelbier/Table beer’ (original wort 
content less than 6 %) except for 
‘Obergäriges Einfachbier'; Beers with a 
minimum acidity of 30 milli-equivalents 
expressed as NaOH; Brown beers of the 
‘oud bruin’ type 
600 
14.2.1  Beer and malt beverages  only energy-reduced beer  25 
14.2.3 Cider  and  perry     600 
14.2.8 
Other alcoholic drinks including mixtures of alcoholic 
drinks with non-alcoholic drinks and spirits with less 
than 15 % of alcohol 
   600 
15.1  Potato-, cereal-, flour- or starch-based snacks      500 
15.2 Processed  nuts     500 
16  Desserts excluding products covered in category 1, 3 
and 4 
only energy-reduced or with no added sugar  1000 
17.1 
Food supplements supplied in a solid form including 
capsules and tablets and similar forms excluding 
chewable forms 
   2000 
17.2  Food supplements supplied in a liquid form     600 
17.3  Food supplements supplied in a syrup-type or 
chewable form 
   5500 
 
Considering the very specific foods in which aspartame is allowed and the restrictions within each 
food group, it was not possible to disaggregate the foods in the food consumption database used for 
this estimate. Therefore, approximations have been made and are explained in detail later in this 
section.  
2.6.1.  Actual level of use of aspartame 
2.6.1.1.  Reported use levels or data on analytical levels of aspartame (E 951) 
Most food additives in the EU are authorised at a specific MPL. However, a food additive may be used 
at a lower level than the MPL. For those additives where no MPL is set and which are authorised as 
quantum satis, information on actual use levels is required. In the framework of Regulation (EC) No 
1333/2008 on food additives and of Regulation (EC) No 257/2010 regarding the re-evaluation of 
approved food additives, EFSA issued a public call for scientific data on 1 June 2011 for aspartame 
(E  951) including current use and use patterns (i.e. which food categories and subcategories, 
proportion of food within categories/subcategories in which it is used, actual use levels (typical and 
maximum use levels), especially for those uses which are only limited by quantum satis).  
Following the EFSA call, data from industry and others sources were received: 
•  from FoodDrinkEurope (FDE, 2011): usage data for several food uses were provided by its 
memberships Opinion on the re-evaluation of aspartame (E951) as a food additive
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•  from the International Sweetener’s Association (ISA) for table-top sweetener products in the 
form of tablet and powder (ISA, 2011, 2012) 
•  from the International chewing gum association (ICGA, 2011): data on the uses of aspartame 
as a sugar substitute in chewing gum and as flavour enhancer in chewing gum with added 
sugars 
•  from the Spanish association on sweets (ProDulce, 2012): data on the uses of aspartame in 
sweets and flavoured drinks (only cocoa-based) 
•  from national authorities: 
o  the Austrian Agency for Health and Food Safety (AGES)  
o  the Dutch Food and Consumer Product Safety Authority (NVWA)  
o  The Slovakian State Veterinary and Food Institute of Bratislava 
•  data from an Italian publication (Arcella et al., 2004) were also made available to EFSA.  
2.6.1.2.  Summarised data on reported use levels in foods from industries and other sources 
Table 6 provides data on the use levels of aspartame in foods as reported by industry and as analysed 
by national agencies. This table also shows the levels used for the refined exposure assessment 
identified by the Panel based on data for several food categories in finished products reported by 
industry or analytical data from other sources (Member States, scientific literature).  
In the EU regulation, tabletop sweeteners are allowed to contain aspartame at quantum satis level. 
Industrial data provided for this food group come from the International Sweetener’s Association only, 
which did not consider them as being representative for the European market because these data were 
received from only two tabletop sweeteners companies. However, in order to take into account this 
food group in the refined exposure assessment, the Panel decided to use available information from the 
other sources (analytical and published data). Therefore, in place of quantum satis (QS) data, a 
maximum estimated usage level of 500 000 mg/kg was used by the Panel in its refined exposure 
assessment for tabletop sweeteners. This estimated usage level appears to be consistent with the upper 
end of the range reported by industry (ISA) for the tablet form.  
The Panel noted that FoodDrinkEurope’s membership and ISA do not cover all manufacturers in a 
particular sector or country and that the values reported for each individual food category are a general 
output, i.e. a compilation of the individual contributions provided by their members. Due to the limited 
representativeness of some of the data received for the European market, the Panel decided not to take 
these data into account for use in the refined exposure assessment with the exception of data received 
from the International chewing gum association (ICGA, 2011) on the uses of aspartame as a sugar 
substitute in chewing gum and as flavour enhancer in chewing gum with added sugars. Opinion on the re-evaluation of aspartame (E951) as a food additive
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Table 6:   Summary of levels used in the refined exposure assessment 
Matching Foodex 
Food codes  Food items 
MPL 
(mg/kg 
or 
mg/L) 
Use levels reported by industry (mg/kg or mg/L) 
Analytical data reported by food 
agencies/literature range min-max in mg/kg 
or mg/L (number of samples) 
Levels used 
for 
calculation 
(mg/kg or 
mg/L)  FDE ISA  ICGA  ProDulce  Comments 
from industry 
Austria  The 
Netherlands  Slovakia Italy 
      typical max typical-
max 
typical-
max 
typical 
(range)           
1.4 - Flavoured 
fermented milk 
products including 
heat-treated products 
Water-based 
flavoured drinks, 
energy-reduced or 
with no added sugar 
1000  50-350  50-
1000          
Partly 
representative of 
the European 
market 
   54-132 
(n=12) 
93.5 
(n=1)     1000 
3 - Edible ices 
Edible ices energy 
reduced or with no 
added sugar 
800  40 50          
Limited 
representation of 
the European 
market 
            800 
4.2 - Processed fruit 
and vegetables 
Energy-reduced 
jams, jellies and 
marmalades/energy-
reduced fruit and 
vegetable 
preparation 
1000  350-
800  1000          
Partly 
representative of 
the European 
market 
107-695 
(n=137)     74.5 
(n=1)     1000 
5.1 - Cocoa and 
Chocolate products as 
covered by Directive 
2000/36/EC 
   2000              500-1000 
No information on 
the 
representativeness, 
most probably 
only representative 
of Spanish 
products 
            2000 
5.2.2 - Other 
confectionery without 
added sugar 
   1000  500-
800 
500-
1000        100-1000 
Partly 
representative of 
the European 
market 
68.3 
(n=7)  12 (n=4) 
151.1-
911.7 
(n=6) 
   1000 
5.3.1 - Chewing gum 
with added sugar 
   2500           600-
1450    
Maximum levels 
up to 7 % of 
chewing-gums and 
50 % of chewing-
gum contains 
aspartame as 
flavour enhancer 
at a typical level. 
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Matching Foodex 
Food codes  Food items 
MPL 
(mg/kg 
or 
mg/L) 
Use levels reported by industry (mg/kg or mg/L) 
Analytical data reported by food 
agencies/literature range min-max in mg/kg 
or mg/L (number of samples) 
Levels used 
for 
calculation 
(mg/kg or 
mg/L)  FDE ISA  ICGA  ProDulce  Comments 
from industry 
Austria  The 
Netherlands  Slovakia Italy 
      typical max typical-
max 
typical-
max 
typical 
(range)           
5.3.2 - Chewing gum 
without added sugar 
   5500           3650-
5420    
Maximum levels 
for 4 % of the 
products and up to 
70 % of sugar-free 
chewing gum 
contain aspartame 
at a typical level. 
40-1747 
(n=5)     560.8 
(n=1)     5420 
6.3 - Breakfast cereals     1000                                1000 
9.2 - Processed fish and 
fishery products 
including molluscs and 
crustaceans 
   300                                300 
11.4 - Table-top 
Sweeteners 
   QS       
8700-
36,000 
(Powder 
form) 
     
Limited 
representation of 
the European 
market. Response 
from 2 table-top 
sweeteners  
< 0.25-
238,600
* (n=19) 
230 647 
(n=1, tablet 
form) 
  
0-
500,000 
(n=10) 
tablet 
form) 
500,000  100,000
-
360,000 
(tablet 
form) 
12.4 - Mustard     350                                350 
12.5 - Soups and broths     110                                110 
12.6 - Sauces     350  200  200          
Limited 
representation of 
the European 
market. Levels 
refer to ketchup 
< 4 
(n=2)           350 
12.7 - Salads and 
savoury based 
sandwich spreads 
only Feinkostsalat  350                    < 20 
(n=6)           350 
13.2 - Dietary foods for 
special medical 
purposes defined in 
Directive 1999/21/EC 
   1000  180  180          
Limited 
representation of 
the European 
market 
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Matching Foodex 
Food codes  Food items 
MPL 
(mg/kg 
or 
mg/L) 
Use levels reported by industry (mg/kg or mg/L) 
Analytical data reported by food 
agencies/literature range min-max in mg/kg 
or mg/L (number of samples) 
Levels used 
for 
calculation 
(mg/kg or 
mg/L)  FDE ISA  ICGA  ProDulce  Comments 
from industry 
Austria  The 
Netherlands  Slovakia Italy 
      typical max typical-
max 
typical-
max 
typical 
(range)           
(excluding 13.1.5) 
13.3 - Dietary foods for 
weight control diets 
intended to replace 
total daily food intake 
or an individual meal 
   800                                800 
14.1.3 - Fruit nectars as 
defined by Council 
Directive 2001/112/EC 
and vegetable nectars 
and similar products 
   600                    < 20 -71 
(n=19)           75
1 
14.1.4.2 - Flavoured 
drinks with sweeteners 
   600  100-
350  600        110  
FDE: 
Representative for 
the European 
market. 600 mg/L 
only apply in 1 
product, rest of the 
applications 
reported usage 
levels below 
430 mg/L 
ProDulce: refer to 
powder, only for 
cocoa-based soft 
drinks 
< 1-496 
(n=272) 
< 3-470 
(n=40) 
3.5-
2559.1*
*(n=60) 
   600 
14.2 - Alcoholic 
beverages, including 
alcohol-free and low-
alcohol counterparts 
Drinks consisting of 
a mixture of a non-
alcoholic drink and 
beer, cider, perry, 
spirits or wine. 
Spirits drinks 
containing less than 
15% alcohol by 
volume 
600  100-
350  600          
Partly 
representative of 
the European 
market 
< 1-104 
(n=47)     7.4-25.6 
(n=4)     600 Opinion on the re-evaluation of aspartame (E951) as a food additive
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Matching Foodex 
Food codes  Food items 
MPL 
(mg/kg 
or 
mg/L) 
Use levels reported by industry (mg/kg or mg/L) 
Analytical data reported by food 
agencies/literature range min-max in mg/kg 
or mg/L (number of samples) 
Levels used 
for 
calculation 
(mg/kg or 
mg/L)  FDE ISA  ICGA  ProDulce  Comments 
from industry 
Austria  The 
Netherlands  Slovakia Italy 
      typical max typical-
max 
typical-
max 
typical 
(range)           
15.1 - Potato-, cereal-, 
flour- or starch-based 
snacks 
   500                                500 
15.2 - Processed nuts     500                                500 
16 - Desserts excluding 
products covered in 
category 1, 3 and 4 
   1000                                1000 
17 - Food supplements 
as defined in Directive 
2002/46/EC[5] 
excluding food 
supplements for infants 
and young children 
   5500                   
< 20-
1845.4 
(n=3) 
< 20-2245 
(n=17)        2245 
1  rounded figure  
*no clear information on the form of the tabletop sweeteners but the Panel assumes that values refer to tablet forms. 
** 2 values out of the 60 exceed the MPL of 600 mg/kg (one on ‘herbal tea with honey, cinnamon and orange’; another on ‘milk chocolate with added sweeteners’)  Opinion on the re-evaluation of aspartame (E951) as a food additive
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Following rules defined by the Panel (Appendix B.I), maximum values between use levels and 
analytical data were used for the refined exposure. Data from industry could be considered as non-
representative due to the comments provided. Analytical data were considered as representative when 
the number of data reported was above or equal to 10 samples. When no data were suitable, MPLs 
were used to estimate the exposure. 
2.7.  Information on existing authorisations and evaluations of aspartame, methanol and 
DKP 
2.7.1.  Existing authorisations and evaluations of aspartame 
Aspartame has been authorized in the EU for use in foods and as a tabletop sweetener by several 
Member States since the 1980s.  
The SCF evaluated aspartame in 1984 (SCF, 1985) and in 1988 (SCF, 1989). The SCF established an 
acceptable daily intake (ADI) of 40  mg/kg body weight (bw)/day. Further reviews of data on 
aspartame were carried out by the SCF in 2002 (SCF, 2002). In the 2002 evaluation, the SCF 
concluded that there was no evidence to suggest a need to revise the ADI previously established for 
aspartame.  
The European legislation harmonized its use in foodstuffs in 1994 through the European Parliament
15 
and Council Directive 94/35/EC, following safety evaluations by the SCF (SCF, 1985; SCF 1989). 
Aspartame was evaluated by the Joint FAO/WHO Expert Committee on Food Additives on several 
occasions (JECFA, 1975, 1976, 1980, 1981). JECFA established an ADI of 40 mg/kg bw/day (1980, 
1981).  
In 1974, US FDA (US Food and Drug Administration) approved aspartame for restricted use in dry 
foods in the United States. This was followed by its full approval for use as an artificial sweetener in 
1981. The FDA has set the ADI for aspartame at 50 mg/kg bw.  
In 1996, a report suggesting a connection between aspartame and an increase in the incidence of brain 
tumours in the USA was published (Olney et al., 1996). The conclusions of this epidemiological study 
have been criticised by a number of scientists who questioned the methodology used and the 
interpretation of the data (Levy and Heideker, 1996; Ross, 1998; Smith et al., 1998; Seife, 1999). The 
SCF considered this report at its 107
th meeting in June 1997 and concluded that the data did not 
support the proposed biphasic increase in the incidence of brain tumours (SCF, 1997). The issue has 
also been considered by the FDA and by the UK Committee on Carcinogenicity of Chemicals in Food, 
Consumer Products and the Environment (COC, 1996). The FDA stated that analysis of the National 
Cancer Institute database on cancer incidence in the USA did not support an association between the 
use of aspartame and increased incidence of brain tumours (FDA, 1996). The COC agreed that the 
findings provided no evidence for the proposed biphasic increase in the incidence of either all brain 
tumours or selected tumour types in the USA during the 1980’s and concluded that the data published 
by Olney et al. (1996) did not raise any concerns about the use of aspartame in the UK (COC, 1996).  
In 2002, a review of aspartame safety was published by AFSSA (Agence française de sécurité 
sanitaire des aliments). AFSSA (2002) concluded that aspartame was not genotoxic and that the 
previously conducted carcinogenicity tests in rodents did not indicate a relationship between treatment 
with aspartame and the appearance of brain tumours: 
‘Taking into account all the studies that have been conducted, the frequency of spontaneous tumours 
in laboratory rats, the types of tumours observed and the absence of a dose-response relationship, it 
                                                      
15   Directive 94/35/EC of the European Parliament and of the Council of 30 June 1994 on sweeteners for use in foodstuffs. 
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was concluded that aspartame had no carcinogenic potential on the brain in experimental animals 
(FDA FR, 1981-1984; Koestner, 1984; Cornell et al., 1984; Flamm, 1997)’. 
AFSSA concluded that the epidemiological study by Olney et al. (1996) did not provide any scientific 
evidence of a relationship between exposure to aspartame and the appearance of brain tumours. 
AFSSA (2002) also reported on the study by Gurney et al. (1997) who published the results of a case-
control study on the relationship between the consumption of aspartame and the frequency of brain 
tumours. AFSSA agreed with the authors’ conclusion that no relationship could be established 
between the consumption of aspartame and the frequency of brain tumours.  
Furthermore AFSSA noted that the epidemiological data from the cancer registers in France did not 
permit a possible aspartame-brain tumour relationship to be clearly determined, but they did show that, 
at the time, the sale of this food additive in France was not accompanied by an increase in the 
frequency of brain tumours or increased mortality from this disease in the general population.  
The SCF in its opinion of 2002 agreed with the AFSSA evaluation of data on a relationship between 
exposure to aspartame and brain tumours in humans. The SCF conclusions in the opinion from 2002 
were supported by the UK Food Standards Agency (FSA, 2002).  
In 2006, at the request from the European Commission, the Scientific Panel on Food Additives, 
Flavourings, Processing Aids and Materials in Contact with Food (AFC) assessed a long-term 
carcinogenicity study in rats exposed to aspartame performed by European Ramazzini Foundation 
(ERF) (Soffritti et al., 2006). On the basis of all the evidence available from the Soffritti et al. (2006) 
study, other recent studies and previous evaluations, the AFC Panel concluded that there was no 
reason to revise the previously established ADI for aspartame of 40 mg/kg bw/day, as established by 
the SCF in 1984 (SCF, 2002; EFSA, 2006). The UK Committee on Carcinogenicity of Chemicals in 
Food Consumer Products and the Environment (COC) also evaluated the Soffritti et al. (2006) study 
on aspartame following the evaluation by EFSA (COC, 2006). In light of the limitations in the design 
of this study and the use of animals with a high infection rate, the COC considered that no valid 
conclusions could be drawn from this study. Therefore, the COC agreed that the Soffritti et al. (2006) 
study did not indicate a need for a review of the ADI for aspartame (COC, 2006).  
In 2009, following a request from the European Commission, the ANS Panel delivered a scientific 
opinion on the results of a second long-term carcinogenicity study in rats starting with prenatal 
exposure to aspartame, performed by the ERF (Soffritti et al., 2007). The ANS Panel concluded that 
there was no indication of any genotoxic or carcinogenic potential of aspartame and no reason to 
revise the previously established ADI for aspartame of 40 mg/kg bw/day (EFSA 2009a, b).  
In 2009 a series of meetings of National Experts nominated by the EU Member States was organized, 
with the support of the EFSA Advisory Forum, to review the scientific literature on aspartame, 
including non-peer-reviewed and anecdotal evidence that had become available since 2002. The report 
of these meetings was published in 2010, and included a re-evaluation of the data on the potential 
carcinogenicity (including cancer epidemiology), genotoxicity and neurotoxicity of aspartame (EFSA, 
2010). The conclusion by the National Expert meeting of the EFSA Advisory Forum was that there 
was no new evidence that required a recommendation to EFSA that the previous opinions on 
aspartame adopted by the AFC and ANS Panels and the SCF should be reconsidered.  
In 2011 the ANS Panel and EFSA evaluated a new long-term carcinogenicity study in mice exposed to 
aspartame from the 12
th day of fetal life until death (Soffritti et al., 2010) and a prospective cohort 
study on the association between intakes of artificially sweetened soft drinks and pre-term delivery 
(Halldorsson et al., 2010). The authors of the first study concluded that aspartame induced cancer in 
the livers and lungs of male Swiss mice. EFSA and the ANS Panel observed that the hepatic and 
pulmonary tumour incidences reported by Soffritti et al. (2010) all fell within their own historical 
control ranges for spontaneous tumours and noted that Swiss mice are known to have a high 
background incidence of spontaneous hepatic and pulmonary tumours. The overall conclusion by the Opinion on the re-evaluation of aspartame (E951) as a food additive
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ANS Panel and EFSA was that the information available from the Soffritti et al. (2010) publication did 
not give reason to reconsider the previous evaluations of aspartame (EFSA 2011a; EFSA ANS Panel, 
2011). The authors of the Halldorsson et al. (2010) study concluded that there was an association 
between intake of artificially sweetened soft drinks and pre-term delivery in the cohort; however, 
additional studies were required to reject or confirm the association. The ANS Panel advised EFSA on 
the need for epidemiological expertise to provide additional insights on the methodology and 
statistical aspects of this study, taking into account confounding factors (EFSA ANS Panel, 2011). 
EFSA concluded that there was no evidence available to support a causal relationship between the 
consumption of artificially sweetened soft drinks and preterm delivery and that additional studies were 
required to reject or confirm the association (EFSA, 2011a). In 2011, the French Agency for Food, 
Environmental, and Occupational Health and Safety (ANSES) also concluded that no causal 
relationship was established between the consumption of artificially sweetened beverages and the risk 
of pre-term delivery, and, as the authors of the Halldorsson study mentioned, there was a need to 
perform further studies to negate or confirm the results (ANSES, 2011).  
2.7.2.  Existing authorisations and evaluations of methanol 
In 1997, WHO (World Health Organization) stated that both methanol and its metabolite formate 
occur naturally in humans and that normal background levels should not pose any risk to health and 
consequently that levels of human exposure that do not result in levels of blood formate above 
background levels could be considered to pose insignificant risk. Based on information from limited 
studies in humans, WHO concluded that occupational exposure to current exposure limits (around 
260 mg/m
3) or single oral exposure to approximately 20 mg/kg bw would fall into this category.  
In 2003, the Center for the Evaluation of Risks to Human Reproduction (CERHR) evaluated the 
potential effects of methanol on human reproduction and development and concluded that there was 
minimal concern for adverse developmental effects when humans are exposed to methanol levels that 
result in low blood methanol concentrations, i.e., < 10 mg/L blood (NTP-CERHR, 2003). The CERHR 
Panel also concluded that there was negligible concern for adverse male reproductive effects when 
exposed to methanol levels that result in a low blood methanol level (< 10 mg/L blood) but there was 
insufficient evidence to assess the effects of methanol on female reproduction.  
The Subcommittee on the Classification of Carcinogenic Substances of the Dutch Expert Committee 
on Occupational Exposure Safety (DECOS), a committee of the Health Council, concluded that 
methanol cannot be classified with respect to its carcinogenicity (comparable with EU class ‘not 
classifiable’) (Health Council of the Netherlands, 2010). The subcommittee was further of the opinion 
that results from genotoxicity tests indicate that methanol is not likely to have a genotoxic potential.  
In March 2011, the UK COT (UK Committee on Toxicity of Chemicals in Food, Consumer Products 
and the Environment) issued a statement on effects of chronic dietary exposure to methanol. The COT 
was asked to consider the effects of chronic oral methanol exposure in the light of consumer concerns 
that methanol arising from the breakdown of the sweetener aspartame could be harmful (COT, 2011). 
In its statement, the COT concluded that exposure to methanol at the levels found in the diet (dietary 
methanol has been estimated to be up to 1  g/day), both naturally occurring and from currently 
permitted levels of aspartame, would not be expected to result in adverse effects.  
The US Environmental Protection Agency (EPA) recently conducted a toxicological review of 
methanol for all non-cancer endpoints. The report is expected to be published by the end of 2013.  
2.7.3.  Existing authorisations and evaluations of DKP 
JECFA and SCF established an ADI for DKP of 7.5  mg/kg bw/day (JECFA, 1980; SCF, 1989). 
According to Commission Regulation (EU) No 231/2012, aspartame can contain DKP up to 1.5 % 
(expressed on a dry weight basis). In 1983, the US FDA established an ADI for DKP of 30 mg/kg 
bw/day (FDA, 1983).  Opinion on the re-evaluation of aspartame (E951) as a food additive
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2.8.  Exposure assessment 
Anticipated exposures to aspartame from its use as a food additive and its related by-product 
compounds, methanol, DKP, phenylalanine and aspartic acid, have been estimated in this section of 
the opinion. β-aspartame exposure was not considered due to its low presence, as aspartame is not 
degraded to this product.  
The estimated exposures are based on the degradation process of aspartame as presented in Figure 2. 
Exposure calculations are based on the complete metabolism of aspartame to phenylalanine, aspartic 
acid and methanol. The calculation of exposure to DKP is based on the occurrence data received by 
EFSA and summarised in Table 3.  
2.8.1.  Food consumption data used for exposure assessment 
In 2010, the EFSA Comprehensive European Food Consumption Database (Comprehensive Database) 
was built from existing national information on food consumption at a detailed level. Competent 
authorities in European countries provided EFSA with data on the level of food consumption by the 
individual consumer from the most recent national dietary survey in their country (cf. Guidance of 
EFSA ‘Use of the EFSA Comprehensive European Food Consumption Database in Exposure 
Assessment’ (EFSA, 2011b)).  
The food consumption data gathered at EFSA were collected by different methodologies and thus 
direct country-to-country comparison should be made with caution.  
Anticipated exposures to aspartame from its use as a food additive and its related by-product 
compounds (methanol, DKP, phenylalanine and aspartic acid) have been calculated (mean and 95th 
percentile of consumers only) using the food consumption data at the individual level (e.g. raw data on 
food consumption by the individual consumer).  
High-level consumption was only calculated for those foods and population groups where the sample 
size was sufficiently large to allow calculation of the 95
th percentile (EFSA, 2011b). The Panel 
estimated chronic exposure for the following population groups: toddlers, children, adolescents, adults 
and the elderly. Calculations were performed using individual body weights.  
Thus, for the present assessment, food consumption data were available from 26 different dietary 
surveys carried out in 17 different European countries, as mentioned in Table 7.  
  Opinion on the re-evaluation of aspartame (E951) as a food additive
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Table 7:   Population groups considered for the exposure estimates of aspartame (E 951) 
Population  Age range  Countries with food consumption surveys 
covering more than one day 
Toddlers  from 12 up to and including 35 
months of age 
Belgium, Bulgaria, Finland, Germany, Italy, 
Netherlands, Spain 
Children
a  from 36 months up to and 
including 9 years of age  
Belgium, Bulgaria, Czech Republic, Denmark, 
Finland, France, Germany, Greece, Italy, Latvia, 
Netherlands, Spain, Sweden  
Adolescents  from 10 up to and including 17 
years of age  
Belgium, Cyprus, Czech Republic, Denmark, France, 
Germany, Italy, Latvia, Spain, Sweden 
Adults  from 18 up to and including 64 
years of age 
Belgium, Czech Republic, Denmark, Finland, France, 
Germany, Hungary, Ireland, Italy, Latvia, 
Netherlands, Spain, Sweden, UK  
The elderly
a   Older than 65 years  Belgium,  Denmark, Finland, France, Germany, 
Hungary, Italy 
a:  The terms ‘children’ and ‘the elderly’ correspond respectively to ‘other children’ and the merge of ‘elderly’ and ‘very  
  elderly’ in the Guidance of EFSA on the ‘Use of the EFSA Comprehensive European Food Consumption Database in  
  Exposure Assessment’ (EFSA, 2011b). 
 
Consumption records were codified according to the FoodEx classification system (EFSA, 2011b). 
Nomenclature from FoodEx classification system has been linked to the Food Classification System as 
presented in the Commission Regulation (EU) No 1129/2011, part D, to perform exposure estimates.  
In order to have an accurate selection of foods in which aspartame is authorised and thus an accurate 
exposure estimate of aspartame, in addition to the FoodEx nomenclature, the original national food 
names (i.e. original food descriptors as written in the national surveys) were used as much as possible.  
2.8.2.  Exposure to aspartame from its use as a food additive 
Exposure to aspartame (E 951) from its use as a food additive has been calculated by using (1) MPLs 
as listed in Table 5 and (2) data on reported use levels, or data reported on analytical levels as listed in 
Table 6, both combined with national consumption data for the five population groups. Detail 
summary of total estimated exposure (using MPLs and use levels) per age class and survey is 
presented in Appendix C.  
No specific food consumption data for diabetics were available, therefore this sub-group of the 
population was not considered in this exposure estimate. However, aspartame intakes by diabetics 
have been estimated in several publications based on conservative dietary exposure to aspartame 
(using individual consumption data from food dairy method and MPLs). The exposure ranges from 
1.2-5.3 mg/kg bw/day at the mean, to 1.9-15.6 mg/kg bw/day at the high level (Garnier-Sagne et al., 
2001; Magnusson et al., 2007; Huvaere et al., 2012). 
Most of the food items in which aspartame is authorised are subject to limitations (Table 5), therefore, 
specific foods within the Comprehensive Database were selected. The Panel noted that its estimates 
should be considered as being conservative as it is assumed that all processed foods contain the 
sweetener aspartame (E 951) added at the MPL or the maximum reported use levels.  
However, due to the very detailed limitations laid down in the legislation, it was not always possible to 
match food categories in the food consumption database. 
-  Fine bakery wares for special nutritional purposes are not defined by EU legislation. Some 
Member States have their own definition, such as bakery ware that is targeted at diabetics. As 
it is not the intention of the Commission to define this category under ‘foods intended for 
particular nutritional uses’ (PARNUTS), category 13, it is referred to under category 7.2, fine Opinion on the re-evaluation of aspartame (E951) as a food additive
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bakery ware in the food categorisation system
16. Indeed, these products are not targeted at the 
general population; therefore, the Panel decided not to consider this category in the dietary 
exposure estimate for aspartame in the general population.  
-  Essoblaten-wafer paper is a specific food item in the fine bakery ware category that is not 
present in the FoodEx nomenclature. Since its weight is very low and its consumption most 
probably marginal, this food was not taken into account.  
-  Breakfast cereals with a fibre content of more than 15 % and containing at least 20 % bran, 
energy-reduced or with no added sugar are a very specific kind of breakfast cereals, not 
consumed by children and not described as such in the consumption data nomenclature. 
Therefore, this food was not taken into account in the present estimate.  
-  The distinction between products with and without added sugar was only possible for the food 
groups: flavoured drinks, confectionery and chewing gums, although this was unclear for 
some surveys. This may result in an over/under-estimation depending on the reporting of these 
products in the surveys. Therefore, the whole food groups were taken into account for 
flavoured fermented milk products including heat-treated products, edible ices, soups and 
broths, fruit nectars, desserts, jams and other fruit and vegetable preparations. This may result 
in an over-estimation depending of the real consumption of these products within the food 
groups.  
-  The food group decorations, coatings, fillings are not described and available in the 
nomenclature of the consumption database; thus, this food group could not be taken into 
account. This resulted in a minor underestimation.  
-  The distinction between the form of tabletop sweeteners (tablet, powder, liquid) was not 
available in the EFSA Comprehensive Database. Therefore, these three food groups were 
considered as a whole and the highest reported use level (from tablets) was taken into account. 
This would result in an overestimation.  
-  The same applies to the food supplements: no distinction between the forms of the food 
supplements (liquid, solid, chewable forms) is possible within the FoodEx nomenclature, 
therefore these three food groups were considered as a whole and the highest levels (MPLs 
and reported use levels) were taken into account. This represents a minor overestimation.  
Table 8 summarises the estimated exposure to aspartame (E 951) from its use as a food additive in all 
five population groups. 
  
                                                      
16 Part D (food categories) of the Commission Regulation (EU) N°1129/2011 of 11 November 2011. Opinion on the re-evaluation of aspartame (E951) as a food additive
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Table 8:   Summary of anticipated exposure to aspartame (E 951) from its use as a food additive 
using MPLs and reported use levels or analytical data on use levels in five population groups (min-
max across the dietary surveys in mg/kg bw/day) 
  Toddlers Children Adolescents Adults  The elderly  
  (12-35 months) (3-9 years)  (10-17 years)  (18-64 years)  (> 65 years) 
Estimated exposure using 
MPLs 
•  Mean  
•  High level
a 
 
 
3.2-16.3 
11.8-36.9 
 
 
2.3-12.8 
7.1-32.9 
 
 
0.8-4.0 
2.3-13.3 
 
 
0.8-8.6 
2.5-27.5 
 
 
0.5-4.4 
1.5-23.5 
Estimated exposure using 
reported use levels or 
analytical data 
•  Mean  
•  High level
a 
 
 
 
1.6-16.3 
7.5-36.0 
 
 
 
1.8-12.6 
6.3-32.4 
 
 
 
0.8-4.0 
2.3-13.2 
 
 
 
0.7-8.5 
2.4-27.5 
 
 
 
0.4-4.4 
1.4-23.5 
a: 95
th percentile of consumers only 
Despite being presented as the estimated exposure based on MPLs, the reported use levels for tabletop 
sweeteners were used for this exposure estimate. Indeed, tabletop sweeteners do not have MPLs but 
their conditions of use are defined in the legislation at Quantum Satis (QS).  
The Panel noted that no major changes were seen in the anticipated exposure to aspartame using the 
reported use levels in comparison to the use of MPLs due to a very small difference observed between 
reported use levels and MPLs (Table 8). 
2.8.3.  Main food categories contributing to exposure of aspartame using MPLs 
Table 9:   Main food categories contributing to the total anticipated mean dietary exposure to 
aspartame (E 951) (> 5 % of total exposure) using MPLs and number of surveys in which each food 
category is contributing over 5 %. 
   Toddlers  Children  Adolescents  Adults  The 
elderly  
Food Categories  % contribution to total exposure (Number of surveys)* 
1.4 - Flavoured fermented milk 
products including heat-treated 
products 
15-72 (7)  13-52 (13)  8-47 (10)  6-16 (13)  6-33 (7) 
5.1 - Cocoa and chocolate 
products as covered by Directive 
2000/36/EC 
10-17 (6)  8-35 (15)  8-52 (12)  5-25 (14)  12-22 (2) 
3 - Edible ices  5-22 (4)  5-21 (14)  5-29 (11)  7-17 (6)  8 (2) 
14.1.4 - Flavoured drinks with 
sweeteners  6-25 (2)  7-15 (8)  8-44 (6)  7-35 (11)  11 (1) 
4.2 - Processed fruit and 
vegetables**  13 (2)  5-10 (9)  6-8 (9)  5-26 (11)  6-46 (7) 
14.1.3 - Fruit nectars as defined 
by Council Directive 
2001/112/EC and vegetable 
nectars and similar products 
10-56 (2)  44 (1)    20-33 (2)  13 (1) 
16 - Desserts excluding products 
covered in category 1, 3 and 4  6.5-19 (3)  5.1-17.6 
(7)  7-14 (4)  7-10 (3)  7 (1) 
11.4 - Table-top sweeteners***  -  6-14.7 (2)  9-16 (2)  5-55 (11)  36-66 (5) 
12.5 - Soups and broths  -  14 (1)  13 (1)  5 (1) 
12.7 - Salads and savoury based 
sandwich spreads  -  9-12 (2)  14 (1)  7-25 (2)   Opinion on the re-evaluation of aspartame (E951) as a food additive
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   Toddlers  Children  Adolescents  Adults  The 
elderly  
Food Categories  % contribution to total exposure (Number of surveys)* 
14.2 - Alcoholic beverages, 
including alcohol-free and low-
alcohol counterparts 
- -    6-7 (5)   
15.1 - Potato-, cereal-, flour- or 
starch- based snacks  7 (1)  5 (1)  6-11 (3)    
12.6 - Sauces  -  5.8-8.2 (2)  5-9 (6)  8 (1) 
17 - Food supplements  10 (1) 
 
*   Total number of surveys may be greater than total number of countries as listed in Table 7, as some countries submitted  
  more than one survey for a specific age range. 
**  this category fruits and vegetables encompasses all the foods under the 4.2 category (Table 5): fruit and vegetables in 
vinegar, oil, or brine, canned or bottled fruit and vegetables, fruit and vegetable preparations excluding compote, extra 
jam and extra jelly as defined by Directive 2001/113/EEC, jam, jellies and marmalades and sweetened chestnut puree as 
defined by Directive 2001/113/EEC, other similar fruit or vegetable spreads. 
*** by default, reported use levels for tabletop sweeteners were used for this estimate in order to take them into account even 
if QS. 
As expressed previously, the Panel noted that the exposure estimate calculated with reported use 
levels/analytical levels was comparable to that calculated with MPLs. For this reason, a separate table 
on the contributions of food groups to the total exposure calculated with the reported use levels and 
analytical levels is not presented.  
2.8.4.  Exposure to methanol 
The Panel noted that exposure to methanol is not only from aspartame as a food additive and from 
natural sources through the diet where it is a normal constituent, but also to a large extent from 
endogenous sources (basal endogenous pathway, endogenously metabolised pectin).  
Methanol exposure from all sources is presented in Table 12. A detailed summary of total estimated 
exposure to methanol from all sources per age class and survey is presented in Appendix D.  
2.8.4.1.  Methanol from anticipated exposure to aspartame from its use as a food additive 
Consumers may be exposed to methanol from consumption of aspartame containing products as 
methanol is released from aspartame in the gastrointestinal tract. Approximately 10 % methanol is 
released by weight of aspartame. Based on the anticipated exposure estimates for aspartame (Table 5) 
using MPLs or reported use levels or analytical data the estimated exposure to methanol from all food 
and beverage applications of the sweetener for the five population groups would range from 0.05 to 
1.6 mg/kg bw/day at the mean and from 0.2 to 3.7 mg/kg bw/day at the high level (95
th percentile 
consumers only) (Table 10). 
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Table 10:   Summary of anticipated exposure to methanol from anticipated exposure to aspartame 
(E 951) as a food additive using MPLs and reported use levels or analytical data on use levels in five 
population groups (min-max across the dietary surveys in mg/kg bw/day) 
  Toddlers  Children Adolescents Adults  The elderly  
  (12-35 months) (3-9 years)  (10-17 years)  (18-64 years)  (> 65 years) 
Estimated exposure using 
MPLs 
•  Mean  
•  High level
a 
 
 
0.3-1.6 
1.2-3.7 
 
 
0.2-1.3 
0.7-3.3 
 
 
0.1-0.4 
0.2-1.3 
 
 
0.1-0.9 
0.3-2.7 
 
 
0.05-0.4 
0.2-2.4 
Estimated exposure using 
reported use levels or 
analytical data 
•  Mean  
•  High level
a 
 
 
 
0.2-1.6 
0.8-3.6 
 
 
 
0.2-1.3 
0.6-3.2 
 
 
 
0.1-0.4 
0.2-1.3 
 
 
 
0.1-0.8 
0.2-2.7 
 
 
 
0.04-0.4 
0.1-2.4 
a: 95
th percentile of consumers only 
2.8.4.2.  Methanol from natural food occurrence 
Methanol may be present per se or can be released from foods including fruits, fruit juices, vegetables, 
roasted coffee, honey and alcoholic beverages. In fruit juices, concentrations vary widely (1-640 mg 
methanol/L) with an average of 140 mg/L (WHO, 1997). More recent measurements have confirmed 
that juices from fruits such as apples, bananas, grapes and oranges may contain methanol at levels 
ranging from 8-148 mg/L (Wu et al., 2007; Hou et al., 2008; Hammerle et al., 2011). In the case of 
tomatoes, levels of methanol up to 240 mg/L juice and 200 mg/kg diced and canned tomatoes have 
been reported (Hou et al., 2008; Anthon and Barrett, 2010). Likewise, vegetable juices (e.g. from 
alfalfa sprouts, carrots and spinach) were found to contain methanol levels ranging from 53-194 mg/L 
(Hou et al., 2008). The highly variable methanol content not only depends on the type of fruit and 
vegetable, i.e. methanol present before processing, but also on methanol released from pectin through 
the action of pectinesterase during processing and storage (Massiot et al., 1997).  
Methanol is also found in alcoholic drinks. It is a residue of the manufacturing process of alcoholic 
beverages and maximum levels of methanol have been defined for spirit drinks in the Regulation (EC) 
No 110/2008. WHO reported methanol concentrations of 6-27 mg/L in beer, 96-321 mg/L in wine and 
10-220 mg/L in distilled spirits (WHO, 1997). Depending on the cultivars, apple ciders have been 
reported to contain 300-700 mg methanol/L, whereas a methanol content of up to 1.6 g/L has been 
reported in apple spirit (Hang and Woodams, 2010).  
To estimate exposure to methanol due to its natural presence in foods, the Panel used data from VCF 
(Volatile Compounds in Food) a TNO database (2012) compiled from 340 literature references for 
methanol in foods from papers dating from 1965 to 2006. The Panel noted that occurrence of methanol 
predominantly in fruit and fruit-based beverages is consistent and in line with current knowledge 
(Appendix B-II) and that methanol levels for individual products vary considerably.  
In its review, the Panel considered that quantitative measurements of methanol in foods were generally 
reliable and that data generated using what would now be considered out-dated methodologies could 
be considered reasonably accurate (the current analytical method used for the determination of 
methanol in foods is based on headspace GC/MS).  
Exposure to methanol has been estimated by the Panel using the raw individual food consumption data 
at the most detailed level from the Comprehensive Database (EFSA, 2011b) and using the mean 
methanol concentration, calculated from the natural occurrence data range reported in Appendix B-II. 
Mean values have been calculated by the Panel for the purpose of estimating background chronic 
intake of methanol from natural food occurrences which were based on the assumption that the Opinion on the re-evaluation of aspartame (E951) as a food additive
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distribution of composition data per category (only when range is expressed) followed a uniform 
distribution.  
Considering all the dietary surveys and populations groups, the exposure estimates for methanol from 
natural food occurrence range from 0.2-1.4 mg/kg bw/day at the mean, to 0.6-3.8 mg/kg bw/day for 
high level consumers (Table 11).  
Table 11:   Summary of anticipated exposure to methanol from natural food occurrence in five 
population groups (min-max across the dietary surveys in mg/kg bw/day) 
  Toddlers  Children Adolescents Adults  The elderly  
  (12-35 months) (3-9 years)  (10-17 years)  (18-64 years)  (> 65 years) 
Estimated exposure  
•  Mean  
•  High level
a 
 
0.2-1.4 
0.9-3.8 
 
0.3-1.4 
0.9-3.3 
 
0.2-0.6 
0.6-1.4 
 
0.3-0.6 
0.7-1.6 
 
0.2-0.6 
0.6-1.4 
a:   95
th percentile of consumers only 
Mean and 95
th percentile total intakes of methanol from foods naturally containing methanol have 
been reported to be 10.7 and 33.3 mg methanol/kg bw/day for US consumers among the general 
population using Daily Intake via Natural Food Occurrence (DINFO) analysis (Magnuson et al., 
2007). However, this analysis did not include intake from processed foods or from food sources such 
as potatoes or onions, or the methanol released by pectin breakdown in fruits and vegetables during 
processing and storage, and as such will be an underestimation of the true dietary exposure to 
methanol.  
The Panel noted that exposure estimates for methanol from natural sources reported in the above 
mentioned literature though lower, were globally within the same order of magnitude as the estimates 
derived by the Panel (assuming a 70 kg body weight, the mean and high consumers would have an 
exposure range of 0.2 to 0.5 mg/kg bw/day, respectively, in comparison to 0.2-1.6 mg/kg bw/day in 
the adult population). 
2.8.4.3.  Methanol from endogenous pathways  
In addition to the direct contribution of methanol from fruits and vegetables and their juices, there is 
clear evidence for the production of methanol in the gastrointestinal tract from ingested pectins and 
endogenous production in other parts of the body, such as liver and brain (WHO, 1997).  
In two papers (Taucher et al., 1995; Lindinger et al., 1997), methanol concentration was measured in 
the breath of human volunteers using proton-transfer-reaction mass spectrometry in a selected ion flow 
drift tube. The volunteers were male, in a fasted state to minimize the contribution of dietary pectin to 
the measured methanol and had received ethanol at time zero and at 2.5 hours in order to maintain 
blood ethanol concentration in excess of 150 mg/L. The latter approach was used to competitively 
inhibit methanol metabolism by alcohol dehydrogenase and CYP2E1, thereby enabling the 
measurement of methanol production by the body. The authors showed that basal endogenous 
methanol production by the human body, measured over a period of 6-12 hours, amounted to between 
300 and 600 mg methanol/day (Lindinger et al., 1997). The same authors showed that the ingestion of 
10 to 15  g of pectin (corresponding to 1  kg apples) resulted in the additional production of 400-
1400 mg methanol/person/day.  
Dhareshwar and Stella (2008) estimated that exposure to methanol from combined endogenous and 
exogenous sources was between 0.13 and 1.03 g/day.  
In another study performed in six healthy male subjects, basal endogenous methanol production was 
assessed over a period of 5 hours. The subjects were given an infusion of ethanol to inhibit methanol 
metabolism after a period of fasting and abstinence from alcohol (Haffner et al., 1998). Methanol was Opinion on the re-evaluation of aspartame (E951) as a food additive
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measured in blood using gas chromatography. The observed rate of increase in blood methanol 
concentration was linear between 30  min and 5  hours and ranged from 0.08–0.35  mg/L/hour. The 
Panel noted that when converting the blood levels to whole body production using a volume of 
distribution (VD) for methanol of 0.77 l/kg (Graw et al., 2000), the daily endogenous production of 
methanol could be approximated to 1.5-6.5 mg/kg bw/day, or 107-453 mg/person/day.  
Basal endogenous methanol production was measured in 22 female and 13 male volunteers given 4-
methylpyrazole to inhibit ADH in a cross-over study (Sarkola and Eriksson, 2001). Compared to the 
placebo control, a linear increase in blood methanol levels was measured of up to 3.6 μM/hour, after 
4-methylpyrazole application. The Panel noted that when converting the blood levels to whole body 
production using a volume of distribution (VD) for methanol of 0.77 L/kg (Graw et al., 2000), a daily 
endogenous production of methanol could be estimated to be 2.1 mg/kg bw/day or 149 mg/person/day.  
Ernstgård et al. (2005) investigated uptake and disposition of inhaled methanol in four female and four 
male subjects who had not consumed any alcohol, drugs or fruits for at least 48 hours prior to the 
beginning of the measurements. From the absorption, half-life and area under the concentration-time 
curve (AUC) values reported by the authors for methanol, the Panel derived a value for endogenous 
production of 9.1 mg/kg bw/day or 640 mg methanol/person/day.  
The Panel concluded that basal endogenous methanol production ranges from 2 to 9 mg/kg bw/day 
(minimum to maximum) in adults. In the elderly, the endogenous methanol production may be up to 
15 % less, as the resting metabolic rate is decreasing with age (Speakman and Westerterp, 2010). In 
infants and children less than 18 years of age there is a higher metabolic rate per body mass as 
compared to the adult (Wang, 2012). Hence, use of the endogenous production rate of the adult 
(expressed in mg/kg) in lieu of experimentally measured methanol production rates in toddlers may 
underestimate the endogenous production rate in this age by a factor of two. In addition, the body 
increases methanol production following consumption of pectin-containing foods such as apples by an 
additional 6-20 mg/kg bw/day (Lindinger et al., 1997).  
To estimate exposure to methanol due to pectin degradation, the Panel used data on pectin content 
from Baker (1997), Mahattanotawee et al. (2006) and Holloway et al. (1983).  
The exposure to methanol from pectins has been estimated by the Panel using the raw individual food 
consumption data at the most detailed level from the Comprehensive Database (EFSA, 2011b) and 
using the occurrence levels of methanol derived from pectin contents reported. Values are detailed in 
Appendix B-III. The Panel noted that occurrence of pectin is predominantly in fruit and vegetables. 
The degradation factor from pectin to methanol was derived from Lindinger et al. (1997) i.e. 10 g 
pectins resulted in a mean additional production of methanol of 900 mg.  
2.8.4.4.  Combined exposure to methanol from endogenous and exogenous sources 
The Panel estimated the anticipated combined exposure to methanol from endogenous sources (basal 
endogenous pathway, endogenously metabolised pectin) and exogenous sources (aspartame as a food 
additive and natural food occurrence). A summary of the estimated exposures is given in Table 12.  
The exposure to methanol has been estimated by the Panel using the raw individual food consumption 
data at the most detailed level from the Comprehensive Database (EFSA, 2011b) and using the 
occurrence data (Table 5 and Appendixes B-II; B-III).  
The Panel estimated that the exposure to methanol from all sources (basal endogenous pathway and 
endogenously metabolised pectin, natural food occurrence through the diet and aspartame as a food 
additive) in five population groups would range from 8.4 to 18.9 mg/kg bw/day at the mean and from 
15.1 to 35.1 mg/kg bw/day for high-level consumers.  
 Opinion on the re-evaluation of aspartame (E951) as a food additive
 
 
EFSA Journal 2013;11(12):3496  43
Table 12:   Total estimated exposure of methanol from all sources (food additive, endogenous pathways and natural food occurrence) in five population 
groups (min-max across the dietary surveys in mg/kg bw/day) 
 Toddlers  Children  Adolescents  Adults  The  elderly 
  Mean  High level Mean  High level  Mean  High level  Mean  High level  Mean  High level 
  mg/kg bw/day 
Exposure range of methanol 
from basal endogenous 
pathway 
5.5
a 9  5.5
 a 9 5.5
 a 9  5.5
 a  9  5.5
 a 9 
Exposure range of methanol 
from endogenously 
metabolised pectin 
7.9-12.5 15.2-24.1  3.9-10.5 7.7-20.0 2.1-5.0 5.3-10.5  2.4-4.2 5.1-7.9  3.0-4.5  6.0-8.1 
Exposure range of methanol 
from natural food occurrence   0.2-1.4 0.9-3.8  0.3-1.4 0.9-3.3 0.2-0.6 0.6-1.4  0.3-0.6 0.7-1.6  0.2-0.6  0.6-1.4 
Exposure range of methanol 
from all endogenous 
pathways (basal, 
endogenously metabolised 
pectin) and natural food 
occurrence 
13.8-18.4 25.2-34.2 9.8-17.4 17.2-31.5 8.0-10.7 15.0-19.9  8.2-10.3 14.7-18.1  8.9-10.6  15.7-17.7 
Exposure range of methanol 
from aspartame as a food 
additive (using MPLs)  
0.3-1.6 1.2-3.7  0.2-1.3 0.7-3.3 0.1-0.4 0.2-1.3  0.1-0.9 0.3-2.7  0.05-0.4  0.2-2.4 
Total anticipated exposure 
ranges for methanol from all 
sources (endogenous 
pathways (basal, 
endogenously metabolised 
pectin) and natural food 
occurrence and aspartame as 
a food additive)
b 
14.7-18.9 26.3-35.1  10.4-17.6 18.1-31.8 8.4-11.0 15.5-20.2  8.4-10.3 15.1-18.2  9.0-10.7  15.8-17.9 
a:   average of 2-9 mg/kg bw/day (assuming uniform distribution)  
b:   the exposure ranges were calculated by the Panel using individual data from each survey (figures listed in Appendix D). Note: it is not scientifically valid to simply sum all the high 
percentile values for each methanol source to derive the total high level exposure to methanol from all sources. Individuals who are high level consumers in one category are unlikely to be high 
level consumers in the other categories (EFSA, 2011b).Opinion on the re-evaluation of aspartame (E951) as a food additive
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The contribution of aspartame-derived methanol is shown in Table 13.  
Table 13:   Total contribution of aspartame–derived methanol to the exposure from all sources 
(aspartame as a food additive, endogenous (basal and pectin-derived) and natural food occurrence) in 
five population groups (min-max in %) 
   Toddlers  Children  Adolescents  Adults  The elderly 
    Mean Mean Mean Mean Mean 
   % 
Contribution of aspartame-derived 
methanol (using MPLs) for average 
consumers of aspartame to total mean 
anticipated exposure to methanol from 
all sources 
1.7-9.2 1.6-9.7 0.8-4.8 0.7-9.4 0.5-4.7 
Contribution of methanol from 
endogenous source (basal + pectin 
derived) to total mean anticipated 
exposure to methanol from all sources  
84-95 86-94 91-96 87-96 91-97 
Contribution of methanol from natural 
food occurrence to total mean 
anticipated exposure to methanol from 
all sources  
1.2-7.6 2.1-7.8 1.9-5.5 2.7-6.2 2.4-5.3 
 
The Panel noted that for average consumers of aspartame, the contribution from aspartame to the 
overall exposure to methanol ranged from 1 % to 10 % in the general population.  
In this estimate, the Panel also noted that exposure to methanol from natural food occurrence is a 
minor contributing source (< 10 %) compared to exposure from endogenous pathways (> 80 % in all 
population groups), and also that the exposure from aspartame-derived methanol is similar to methanol 
exposure from natural food occurrence.  
In addition to aspartame, there are other food additives that release methanol as a result of their 
metabolism. Examples of methanol releasing food additives include dimethyldicarbonate (E  242, 
DMDC), which is used in beverages and breaks down to CO2 and methanol; pectins (E 440) that are 
subject to the methyl ester linkage cleavage in the upper gastrointestinal tract as described above; 
methyl p-hydroxybenzoate and sodium methyl p-hydroxybenzoate  (E 218,  E 219);  hexamethylene 
tetramine (E 239). Therefore, while not considering the methanol release from other food additives the 
present estimation is considered as being an under-estimation of the total exposure to methanol.  
An additional source of exposure to methanol is from extraction solvents. The Panel noted that in the 
EU the maximum residue limits for methanol in extracted foodstuff or food ingredients is set at 
10 mg/kg.
17  
2.8.5.  Exposure to 5-benzyl-3,6-dioxo-2-piperazine acetic acid (DKP) from anticipated 
exposure to aspartame from its source as a food additive 
5-Benzyl-3,6-dioxo-2-piperazine acetic acid (DKP) exposure intakes were estimated from anticipated 
exposure to aspartame (E  951) from its use as a food additive. DKP is a degradation product of 
aspartame. The degradation from aspartame to DKP ranges from 1.5 % (EU specifications) up to 24 % 
based on the analytical data reviewed by the Panel and reported in Table 3. The maximum of 24 % is 
for soft drinks and is estimated from an average degradation of 80 % of aspartame of which DKP 
accounts for 30 %. The concentrations of DKP in foods taken into account by the Panel in estimating 
exposure were assigned to the relevant food categories in which aspartame is authorised according to 
MPLs and use levels scenarios as described in Appendix B-IV. For foods categories where data were 
                                                      
17 Directive 2009/32/EC of the European Parliament and of the Council of 23 April 2009. Opinion on the re-evaluation of aspartame (E951) as a food additive
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available, the highest value was taken into account; for the ones where no degradation percentage of 
DKP was available, the highest value (24  %) from the whole database was used. In a few food 
categories (processed fish and fishery products, tabletop sweeteners, food supplements) depending on 
the food type (solid vs. liquid), other degradation percentages of DKP were used.  
Anticipated exposures to DKP from aspartame consumption are described in the Table 14. Detail 
summary of total estimated exposure (from the use of aspartame MPLs) per age class and survey is 
presented in Appendix E. 
Table 14:   Summary of anticipated exposure to DKP from anticipated exposure to aspartame (E 951) 
as a food additives using MPLs and reported use levels or analytical data on use levels in five 
population groups (min-max across the dietary surveys in mg/kg bw/day) 
  Toddlers Children Adolescents Adults  The elderly  
  (12-35 months) (3-9 years)  (10-17 years)  (18-64 years)  (> 65 years) 
Estimated exposure using 
MPLs 
•  Mean  
•  High level
a 
 
 
0.3-1.9 
1.2-4.1 
 
 
0.2-1.3 
0.5-3.2 
 
 
0.1-0.7 
0.3-2.5 
 
 
0.1-1.6 
0.3-5.5 
 
 
0.1-0.8 
0.2-4.8 
Estimated exposure using 
reported use levels or 
analytical data 
•  Mean  
•  High level
a 
 
 
 
0.2-1.9 
0.7-3.9 
 
 
 
0.2-1.3 
0.5-3.1 
 
 
 
0.1-0.7 
0.3-2.5 
 
 
 
0.1-1.6 
0.3-5.5 
 
 
 
0.1-0.8 
0.2-4.8 
a: 95
th percentile of consumers only 
Based on the anticipated exposure estimates for aspartame using MPLs (Table 5), the estimated 
exposure to DKP from all food and beverage use of the sweetener would approximately, 0.1 to 
1.9 mg/kg bw/day at the mean and 0.2 to 5.5 mg/kg bw/day for the 95th percentile consumer across 
the dietary surveys and populations groups.  
2.8.6.  Exposure to phenylalanine  
The Panel noted that exposure to phenylalanine is not only from aspartame as a food additive but also 
largely from natural food occurrence through the diet.  
Phenylalanine exposure from both sources is presented in Table 16. Detail summary of total estimated 
exposure (from the use of aspartame MPLs) per age class and survey is presented in Appendix E.  
2.8.6.1.  Phenylalanine from natural food occurrence  
Phenylalanine is an essential amino acid and therefore must be supplied by the diet. The recommended 
aromatic amino acid requirement (phenylalanine or tyrosine) is set at 25 mg/kg bw/day (WHO, 2007). 
In the US, the Institute of Medicine sets estimated average requirement (EAR) for amino acids; 
phenylalanine + tyrosine EAR for adults are estimated at 27 mg/kg bw/day (IOM, 2005). The mean 
daily consumption of phenylalanine is estimated in the US at 3.4 g/day (IOM, 2005). A French study 
(Rousseau et al., 2006) reported in an AFSSA report on protein intake (AFSSA, 2007) estimated the 
daily intakes of different populations,: from sedentary people to sportspersons (several levels of 
expenditure of physical energy). The mean phenylalanine intake for sedentary people was estimated to 
be 3.8 g/day.  
Additional information on phenylalanine intake from natural food occurrence through the diet and 
phenylalanine content per food category of the EFSA Comprehensive Database was provided to EFSA 
(König et al., (2012) unpublished data). Concentration data of phenylalanine in foods came from the 
German food composition database (Bundeslebensmittelschlüssel). The levels of phenylalanine Opinion on the re-evaluation of aspartame (E951) as a food additive
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content per food category (according to level 2 of the food additives nomenclature from Regulation 
No 1129/2011) range from 0.01 mg/g in wine to 31.05 mg/g in meat substitutes; some food groups do 
not contain any phenylalanine. These levels linked to the EFSA Comprehensive Database allow 
calculation of phenylalanine intake from the diet. These intakes range from 0.9 g/day (corresponding 
to 93.0 mg/kg bw/day for toddlers) up to 4.1 g/day (corresponding to 58.7 mg/kg bw/day for adults) at 
the mean within the EU population (see Table 16).  
2.8.6.2.  Phenylalanine from anticipated exposure to aspartame from its source as a food 
additive 
Phenylalanine exposure intakes were estimated from anticipated exposure to aspartame (E 951) from 
its use as a food additive. Aspartame is fully hydrolysed in the gastrointestinal tract to L-
phenylalanine, L-aspartic acid and methanol. Taking the molecular weight of phenylalanine into 
account, the factor for aspartame exposure to phenylalanine exposure is 56 %. Phenylalanine intakes 
from aspartame consumption are described in Table 15.  
Table 15:   Summary of anticipated exposure to phenylalanine from estimated exposure to aspartame 
(E 951) as a food additive using MPLs and reported use levels or analytical data on use levels in five 
population groups (min-max across the dietary surveys in mg/kg bw/day) 
  Toddlers Children Adolescents Adults  The elderly  
  (12-35 months) (3-9 years)  (10-17 years)  (18-64 years)  (> 65 years) 
Estimated exposure using 
MPLs 
•  Mean  
•  High level
a 
 
 
1.8-9.2 
6.6-20.7 
 
 
1.3-7.2 
4.0-18.4 
 
 
0.4-2.3 
1.3-7.5 
 
 
0.4-4.8 
1.4-15.4 
 
 
0.3-2.5 
0.9-13.2 
Estimated exposure using 
reported use levels or 
analytical data 
•  Mean  
•  High level
a 
 
 
 
0.9-9.2 
4.2-20.2 
 
 
 
1.0-7.1 
3.5-18.2 
 
 
 
0.4-2.3 
1.3-7.4 
 
 
 
0.4-4.8 
1.3-15.4 
 
 
 
0.2-2.5 
0.8-13.2 
a: 95
th percentile of consumers only 
2.8.6.3.  Combined exposure to phenylalanine from the use of aspartame as a food additive and 
from natural food occurrence through the diet 
In this estimate, the Panel noted that exposure to phenylalanine from aspartame-derived phenylalanine 
for all population groups ranged from 1  % to 8  % at the mean (compared to the total intake of 
phenylalanine from aspartame and natural food occurrence).  
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Table 16:   Summary of anticipated combined exposure to phenylalanine from exposure to aspartame 
(E 951) as a food additive using MPLs and from natural food occurrence in five population groups 
(min-max across the dietary surveys in mg/kg bw/day) 
  Toddlers Children Adolescents Adults  The elderly  
  (12-35 months) (3-9 years)  (10-17 years)  (18-64 years)  (> 65 years) 
Estimated exposure from 
natural food occurrence 
•  Mean  
•  High level
a 
 
 
93.0-167.1 
144.2-322.2 
 
 
72.2-136.7 
126.5-214.3 
 
 
39.1-79.0 
73.1-130.3 
 
 
35.3-58.7 
60.2-88.7 
 
 
32.5-41.6 
54.6-64.4 
Estimated exposure using 
MPLs 
•  Mean  
•  High level
a 
 
 
1.8-9.2 
6.6-20.7 
 
 
1.3-7.2 
4.0-18.4 
 
 
0.4-2.3 
1.3-7.5 
 
 
0.4-4.8 
1.4-15.4 
 
 
0.3-2.5 
0.9-13.2 
Combined exposure to PHE 
•  Mean  
•  High level
a 
 
95.4-176.3 
146.5-331.1 
 
74.0-140.5 
130.9-224.1 
 
41.3-80.7 
78.4-136.9 
 
37.9-59.1 
64.8-89.1 
 
34.8-41.9 
58.9-68.2 
a: 95
th percentile of consumers only 
2.8.7.  Exposure to aspartic acid from anticipated exposure to aspartame from its source as a 
food additive 
Aspartic acid exposure intakes were estimated from anticipated exposure to aspartame (E 951) from its 
use as a food additive. Taking the molecular weight into account, the factor to derive aspartic acid 
exposure from aspartame exposure is 45 %. Aspartic acid intakes from aspartame consumption are 
described in the Table 17. Detail summary of total estimated exposure (from the use of aspartame 
MPLs) per age class and survey is presented in Appendix E. 
Table 17:   Summary of anticipated exposure to aspartic acid from estimated exposure to aspartame 
(E 951) as a food additives using MPLs and reported use levels or analytical data on use levels in five 
population groups (min-max across the dietary surveys in mg/kg bw/day) 
  Toddlers Children Adolescents Adults  The elderly  
  (12-35 months) (3-9 years)  (10-17 years)  (18-64 years)  (> 65 years) 
Estimated exposure using 
MPLs 
•  Mean  
•  High level
a 
 
 
1.5-7.4 
5.3-16.7 
 
 
1.0-5.8 
3.2-14.9 
 
 
0.4-1.8 
1.0-6.0 
 
 
0.3-3.9 
1.1-12.4 
 
 
0.2-2.0 
0.7-10.6 
Estimated exposure using 
reported use levels or 
analytical data 
•  Mean  
•  High level
a 
 
 
 
0.7-7.4 
3.4-16.3 
 
 
 
0.8-5.7 
2.8-14.7 
 
 
 
0.4-1.8 
1.0-6.0 
 
 
 
0.3-3.8 
1.1-12.4 
 
 
 
0.2-2.0 
0.6-10.6 
a: 95
th percentile of consumers only 
In the US, the Third National Health and Nutrition Examination Survey (1988-1994) estimated the 
mean intake of aspartic acid of 6.5 g/day (IOM, 2005). High levels (99
th percentile) were estimated at 
15.4 g/day for the 31-50 year old male population.  
2.9.  Uncertainty analysis 
According to the guidance provided by the EFSA opinion (EFSA, 2006), the following sources of 
uncertainties have been considered. These have been presented and discussed in detail in the sections 
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-  Input data: 
•  Food consumption data: the data used for the exposure estimates were data reported at the 
individual level in several different dietary surveys that applied different methodologies. 
Under-reporting and/or misreporting often represent a bias in dietary surveys.  
•  Food nomenclature: the food nomenclatures used in the dietary surveys considered and 
then the FoodEx nomenclature used in the Comprehensive database are different from the 
Food Classification System developed for the definition of food additives uses in the 
Commission Regulation (EU) No 1129/2011. Therefore, linking between different food 
nomenclatures leads to uncertainties.  
•  Reported use levels: the estimates calculated are considered as being conservative because 
they are based on the assumption that all products within a given food category contain 
aspartame at the maximum reported use level.  
Table 18:   Qualitative evaluation of influence of uncertainties 
Sources of uncertainties  Direction 
a 
Consumption data: different methodologies / representativeness / under reporting 
/ misreporting / no portion size standard  +/- 
Extrapolation from food consumption survey of few days to estimate chronic 
exposure  + 
Linkage between reported use levels and food items in the consumption database: 
uncertainties on which precise types of food the use levels refer.  +/- 
Occurrence data: maximum reported use levels within a food category  + 
Exposure model: uncertainty in possible national differences in use levels of food 
categories, data set not fully representative of foods on the EU market, exposure 
calculations based on the maximum reported use levels (no use of typical use 
levels when available) 
+ 
a:   +:   uncertainty with potential to cause over-estimation of exposure;  
  -:   uncertainty with potential to cause under-estimation of exposure. 
 
As a whole, the total estimated uncertainty from all sources should generally lead to an overestimation 
of the calculated exposures (for aspartame and its related by-products: DKP, methanol, aspartic acid, 
phenylalanine), thus providing conservative estimates.  
3.  Biological and toxicological data of aspartame 
A public call was launched by EFSA in 2011 following which original reports of unpublished studies 
were received (http://www.efsa.europa.eu/en/dataclosed/call/110601.htm). The Panel was aware that 
many of these reports would have been available at the time of the JECFA and SCF evaluations. The 
present evaluation by the Panel of the biological and toxicological data includes the assessment of all 
these unpublished studies, together with the published literature identified until the end of November 
2012.  
The Panel noted that the majority of these unpublished studies were performed in the period 1970-
1978 and as such had not been performed according to Good Laboratory Practice (GLP) and 
Organisation for Economic Co-operation and Development (OECD) test guidelines 
(http://www.oecd.org/chemicalsafety/testingofchemicals/oecdseriesonprinciplesofgoodlaboratorypract
iceglpandcompliancemonitoring.htm). However, according to the Panel, the fact that the studies were 
old and were not performed according to current standards should not per se disqualify them from 
being included in the risk assessment of aspartame. As long as the design of any such study and the 
reporting of the data were appropriate, the Panel agreed that the study should be considered in the re-
evaluation of the sweetener.  Opinion on the re-evaluation of aspartame (E951) as a food additive
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3.1.  Absorption, distribution, metabolism and excretion of aspartame 
Throughout the following sections, the term aspartame refers to the α-form.  
3.1.1.  Studies on absorption, distribution, metabolism and excretion received following a 
public call for data which were available at the time of the previous JECFA and SCF 
evaluations 
The Panel noted studies conducted in the 1970s using methods that were available and appropriate at 
that time. Although advances in analytical methodologies have occurred since, the Panel considered 
the results suitable for assessment despite the methodological limitations of these studies.  
In various animal species, including mouse, rat, rabbit, dog and monkey, the absorption, distribution, 
metabolism and excretion of aspartame have been investigated using different radiolabelled forms of 
14C- aspartame (E15, 1972; E17, 1972; E18, 1972; E80, 1974). Radiolabelling was located either on 
the phenylalanine or aspartic acid moiety, or on the methyl group. In some studies (in rats and dogs) 
data have been compared with corresponding animals receiving 
14C(U)-phenylalanine, 
14C(U)-aspartic 
acid or 
14C-methanol.  
In mice given 20 mg/kg bw of [
14C(U)-phe]-aspartame by gavage, the radioactivity found in plasma, 
urine, faeces and expired air clearly demonstrated that aspartame was hydrolysed in the gut of the 
mouse before absorption of its phenylalanine moiety occurred (E18, 1972). In plasma, the major 
fractions of 
14C-materials corresponded to phenylalanine or tyrosine, both of which were incorporated 
in plasma proteins.  
Several studies have been carried out in rats, primates and man receiving oral 
14C-aspartame 
(20-30 mg/kg bw) radiolabelled at the phenylalanine or aspartic acid moiety or on the methyl group 
(E15, 1972). Comparisons were made with rats given 
14C(U)-phenylalanine, 
14C(U)-aspartic acid, 
14C-
methylphenylalanine or 
14C-methanol. In all studies, results clearly indicated that aspartame was 
hydrolysed in the gut.  
When aspartame was radiolabelled at the phenylalanine moiety, ([
14C(U)-phe]-aspartame), it was 
handled in a fashion similar to that of the naturally occurring amino acid phenylalanine.  
When aspartame was radiolabelled at the aspartic acid moiety, [
14C(U)-asp]-aspartame, the compound 
was metabolised by experimental animals to free 
14C-L-aspartic acid, which was subsequently 
metabolised in the same way as aspartic acid in the diet. The major fraction (60-70 % of the dose) of 
the 
14C was excreted as 
14CO2 in the expired air, while the remainder was incorporated into body 
proteins.  
When aspartame was radiolabelled at the methyl group, like 
14C-methylphenylalanine, the compound 
was rapidly hydrolysed by esterases in the gastrointestinal tract, and the methyl group was handled by 
the body in a manner equivalent to the methyl group of methanol.  
In rabbits, unlabelled aspartame was administered daily for 4 days (20 mg/kg bw/day) and a 8.2 mg/kg 
bw dose of [
14C(U)-phe]-aspartame was given the following day (E18, 1972). As in mice and rats, 
aspartame was hydrolysed in the gut before absorption of phenylalanine. A biphasic mean plasma 
radioactivity curve was observed, the authors suggested a rapid appearance of the phenylalanine 
moiety of aspartame as a plasma peptide fraction with a short half-life. Aspartame was metabolised in 
a fashion qualitatively similar to the other species. However, the cumulative excretion of 
14CO2 by the 
rabbit (7 %) was lower than in rat or monkey (17 %).  
In a further study (E80, 1974), plasma metabolites were isolated and identified in rabbits given 
[
14C(U)-phe]-aspartame. Since the plasma metabolic profile was similar to that identified in other 
species, the authors concluded that the differences observed in plasma kinetics would be due to 
differences in the rates of digestion and absorption in rabbits.  Opinion on the re-evaluation of aspartame (E951) as a food additive
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In dogs, unlabelled aspartame (20  mg/kg bw/day) or phenylalanine (11.2  mg/kg bw/day) were 
administered for 5 days; on the following day, animals received 20 mg of [
14C(U)-phe]-aspartame or 
11.2 mg of 
14C(U)-phenylalanine by gavage (E17, 1972). The administered aspartame was hydrolysed 
in the gut (extent of hydrolysis not quantified) and the resulting radiolabelled amino acid 
(phenylalanine) was handled by the body identically to phenylalanine administered alone or ingested 
in the diet. No unchanged aspartame was detected in plasma of dogs receiving aspartame. The 
biological half-life of plasma 
14C after oral administration of [
14C(U)-phe]-aspartame was about 
12 days. The authors state that this value would be consistent with reported half-lives for various 
plasma proteins in experimental animals and in human volunteers.  
In rhesus monkeys, [
14C(U)-phe]-aspartame, [
14C(U)-CH3]-aspartame, 
14C(U)-phenylalanine or 
14C-
methanol were given as separate single oral doses of 0.068 mmol/kg (20 mg/kg for aspartame) (E15, 
1972). These data demonstrated that monkeys metabolised phenylalanine via the same metabolic route 
as rats. Little phenylalanine was excreted in the urine or as 
14CO2 in the expired air and the absorbed 
labelled material entered the normal metabolic pathways for phenylalanine. In monkeys receiving 
[
14C(U)-CH3]-aspartame or 
14C-methanol, the kinetics of the methyl group metabolism illustrated the 
similarity with which monkeys and rats metabolise this moiety of aspartame. The methyl moiety was 
hydrolysed by esterases in the intestine, absorbed, and metabolised in the carbon pool of the body. The 
only difference appeared to be a slower hydrolysis in the gut of the monkey compared to the rat.  
In a further study, monkeys were administered unlabelled aspartame (20 mg/kg bw/day) or aspartic 
acid (9 mg/kg bw) orally for 5 days; on the following day, the animals received 20 mg/kg of [
14C(U)-
asp]-aspartame or 9 mg/kg of 
14C(U)-aspartic acid by gavage (E17, 1972). Results clearly indicated 
that aspartate from aspartame was released by hydrolysis of the parent compound in the gut and that 
the free amino acid was metabolised in the same way as the dietary aspartic acid.  
The data of these early reports on pharmacokinetics of aspartame (E15, 1972; E17, 1972; E18, 1972; 
E80, 1974) showed that radioactivity associated with unchanged aspartame was not detectable in 
plasma of experimental animals. Based on the sensitivity of the detection of radioactivity following 
labelling of the phenylalanine, aspartate and methyl moieties of aspartame, it can be concluded that 
aspartame is completely hydrolysed in the gut to yield aspartate, phenylalanine and methanol. These 
metabolites are then absorbed and enter normal endogenous metabolic pathways.  
3.1.2.  Additional studies on absorption, distribution, metabolism and excretion 
In addition to these basic kinetic studies, further studies (summarised below) have been performed 
elucidating specific aspects of absorption, distribution, metabolism and excretion. 
Studies in rats, dogs and monkeys have shown that after oral ingestion, aspartame is hydrolysed, either 
within the lumen of the gastro-intestinal (GI) tract, or within the mucosal cells lining the GI-tract. 
While aspartame in acidic aqueous solutions under ex vivo conditions has a half-life of several days 
(Prankerd et al., 1992), its half-life in the GI tract is in the order of minutes. The accelerated hydrolysis 
of aspartame in the GI-tract is mediated by specialised enzymes in the intestine, including esterases 
and peptidases (especially aminopeptidase A) (Oppermann, 1984; Hooper et al., 1994). The products 
that result from these reactions are methanol and the amino acids, aspartic acid and phenylalanine. 
Hydrolysis of aspartame releases a maximum of 10 % methanol by weight (Magnuson et al., 2007). 
Hydrolysis is very efficient and the amount of aspartame that enters the bloodstream has been reported 
as undetectable in several studies (Oppermann, 1984; Burgert et al., 1991).  
Burton et al. (1984) investigated the fate of phenylalanine methyl ester in two female rhesus monkeys 
fitted with hepatic portal vein cannulae. Following intragastric and intraduodenal administration of 
20 mg doses of [
14C(U)-phe]phenylalanine methyl ester hydrochloride, small amounts of unchanged 
phenylalanine methyl ester were detected during the first 1-2 hour after administration, but none was 
detectable (< 0.001 µg/mL) at later times. When comparing the areas under the phenylalanine methyl 
ester and total radioactivity blood concentration-time curves, the authors concluded that only 0.2 % of Opinion on the re-evaluation of aspartame (E951) as a food additive
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the administered phenylalanine methyl ester reached the portal blood unchanged and ≤ 0.1 % reached 
the peripheral blood unchanged. Additional in vitro work showed that intestinal mucosa homogenates, 
blood and plasma rapidly metabolise phenylalanine methyl ester to phenylalanine and methanol 
(Burton et al., 1984).  
The intestinal metabolism of aspartame and L-phenylalanine methyl ester in the gut lumen was further 
studied in a young pig model in vitro and in vivo (Burgert et al., 1991). In the in vivo studies, 6 young 
female Chester white pigs (10-15 kg) were catheterised and had a 10-French double lumen tube with a 
proximal port opening in the proximal jejunum and the distal port 30 cm further down the intestine. At 
least three days were allowed for recovery after surgery. In bolus dosing studies, compounds (L-
phenylalanine methyl ester, aspartame or L-phenylalanine) were administered at a dose of 
2.5 mmol/kg in a Latin square design. For aspartame, this corresponded to 735 mg/kg bw. Portal vein 
and vena cava blood samples were taken over a period of 4 hours following dosing, and each animal 
received all three compounds with three days for recovery between doses. In steady state perfusion 
studies, equimolar solutions (25 mM) of each compound were administered directly into the jejunum 
at a rate of 5 ml/min and the perfusate was analysed.  
In the bolus dosing studies, no intact L-phenylalanine methyl ester, aspartame or 
aspartylphenylalanine were detected in blood samples from either the portal vein or the inferior vena 
cava after dosing with L-phenylalanine methyl ester, aspartame or L-phenylalanine. No significant 
differences were observed with regard to AUC in the concentration of phenylalanine in portal blood 
after dosing with L-phenylalanine methyl ester, aspartame or L-phenylalanine. A similar pattern was 
observed in vena caval blood although the absolute phenylalanine concentration detected and 
corresponding AUCs were lower by 15 %. Portal blood tyrosine concentration was similar after all 
three compounds but lower than phenylalanine concentration (mean peak values of 167  µM for 
tyrosine vs. 2510 µM for phenylalanine).  
Neither portal nor vena caval methanol levels changed after bolus administration of phenylalanine, but 
values in portal blood increased from a baseline of 0 mM to 3.50 ± 0.75 mM after aspartame and 
3.25 ± 0.65 mM after phenylalanine methyl ester, while vena caval levels peaked at 3.26 ± 0.65 mM 
after aspartame and 3.13 ± 0.75 mM after phenylalanine methyl ester. Thus, the vena caval values 
were slightly, but not significantly, lower than those in the portal circulation.  
In steady state perfusion studies, direct infusion of aspartame into the jejunum resulted in the 
appearance of methanol, aspartic acid, phenylalanine and aspartylphenylalanine in the perfusate, with 
the concomitant disappearance of aspartame from the perfusate (1.46  µmol/min/cm gut). L-
Phenylalanine methyl ester was also present at detectable levels. Perfusion with L-phenylalanine 
methyl ester itself resulted in the appearance of phenylalanine and methanol in the perfusate. Perfusion 
with L-phenylalanine resulted in rapid disappearance of phenylalanine but not any of the other 
compounds in the perfusate. From the steady state perfusion data the authors concluded that aspartame 
was hydrolysed to methanol and aspartylphenylalanine in the intestinal lumen (Burgert et al., 1991).  
In a study by Trocho et al. (1998), [
14C-methyl]-aspartame was administered to male Wistar rats (1-
5 animals per time point investigated) at a single oral dose level of 68 μmol/kg bw (20 mg/kg bw) and 
122 μCi/kg bw by gavage. The authors reported that in liver, kidney and plasma about 0.1-0.4 % of the 
dose of radioactivity/g tissue was detected at 1 hour and persisted between 6-24 hours. In particular, in 
blood (0.1-0.2 % of the dose of radioactivity/g tissue) approximately 98 % of the radioactivity was 
incorporated into protein and in the liver about 78 % was incorporated to protein or nucleic acids at 
6  hours. In an additional study, two rats were administered radiolabelled [
14C-methyl]-aspartame 
(37 MBq;  85.5 μmoles) orally after pre-treatment for 2  days with unlabelled aspartame. At an 
unspecified time point, plasma was collected and subjected to acid precipitation followed by 
hydrolysis (6N HCl, 48 hours), liberating amino acids from proteins. The hydrolysate was then filtered 
to remove ‘Maillard adducts’. Maillard adducts are produced through the reaction of sugar carbonyl 
groups with amino groups (in, for example, amino acids) and would have been produced during the 
hydrolysis procedure and therefore as artefacts associated with sample processing. The authors Opinion on the re-evaluation of aspartame (E951) as a food additive
 
 
EFSA Journal 2013;11(12):3496  52
reported that the filtered Maillard adducts were radioactive. The filtered amino acids, which were 
assumed not to contain any Maillard adducts, were then derivatised with dinitrofluorobenzene and 
analysed by 2D thin layer chromatography.  
The authors present data to show that a single radiolabelled species was observed in plasma after 
hydrolysis and derivatisation. The authors speculated that the bound radioactivity resulted from the 
formation of formaldehyde from aspartame-derived 
14C-methanol (Trocho et al., 1998).  
The Panel noted that the methodology used by Trocho was not able to differentiate between 
14C 
incorporated into proteins through the metabolic one carbon tetrahydrofolate pathway and direct 
covalent reaction (e.g. through Schiff base formation) of formaldehyde with proteins. The Panel noted 
that methanol liberated from aspartame in the gut is rapidly metabolised to formaldehyde, formic acid 
and CO2 and that the radioactivity that the authors have identified to be present in nucleic acids and 
proteins in liver and serum (protein only) could be attributed to other metabolic pathways (e.g. 
creatinine synthesis, DNA and protein methylation, 5’ cap mRNA methylation and 
phosphatidylcholine synthesis) that have not been fully investigated.  
The authors failed to compare the single radioactive species obtained after hydrolysis of plasma 
protein and derivatisation of amino acids, with several of the amino acids susceptible to reaction with 
formaldehyde. This did not exclude the possibility that the single radioactive species in hydrolysates 
was not a trace level of a Maillard adduct (and therefore an artefact from sample processing) as well as 
omitting other controls.  
The Panel noted that the study of Trocho et al. (1998) has also been criticised by Tephly (1999) 
arguing that the adducts were not identified with certainty and adduct formation with 
14C-methanol or 
14C-formaldehyde were not studied in vivo to allow adequate comparison.  
Overall the Panel concluded that the work of Trocho et al. (1998) does not demonstrate unequivocally 
that formaldehyde from aspartame-derived methanol reacts with tissue macromolecules.  
3.1.3.  Human Studies 
3.1.3.1.  Single Dose Administration Studies 
The pharmacokinetics and metabolism of [
14C(U)-phe]-aspartame were determined in three healthy 
male adults receiving a single dose of 500  mg aspartame/person in water (E15, 1972). Results 
demonstrated that the radiolabel from aspartame was handled in a fashion similar to that of the natural 
amino acid phenylalanine. As in mice, rats, rabbits, dogs and monkeys, aspartame was hydrolysed in 
the intestine (extent of hydrolysis not quantified), and the resulting 
14C-phenylalanine was rapidly 
absorbed from the gut and was detected in the plasma as naturally occurring polar components 
comprising a mixture of proteins, peptides and free amino acids. Both qualitatively and quantitatively 
the metabolites of [
14C(U)-phe]-aspartame found in the plasma appeared to be the same as those 
detected in the other animal species studied.  
When human volunteers were given a single oral dose of 34  mg aspartame/kg bw, no detectable 
increase in the blood methanol concentration was observed (limit of detection: 3.5-4 mg/L) (Tephly 
and McMartin, 1984). When adults were given a dose of 50 mg aspartame/kg bw, peak blood levels 
were around the limit of detection. With doses of 100, 150 or 200 mg aspartame/kg bw, peak blood 
levels of 13, 21 and 26 mg methanol/L blood were observed between 1-2 hours post dosing. Following 
a dose of 100 mg/kg bw, the blood methanol returned to undetectable levels at 8 hours post dosing. 
With the 150 and 200 mg/kg bw doses, methanol persisted longer in the blood, but at 24 hours post 
dosing, blood methanol was below the limit of detection. Both blood peak levels and blood AUCs 
were proportional to the dose. The values reported are consistent with the known kinetics of methanol 
(Horton et al., 1992).  Opinion on the re-evaluation of aspartame (E951) as a food additive
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Plasma levels of formate and the (reactive) formaldehyde intermediate metabolite have also been 
examined (Stegink, 1984). After giving aspartame to human volunteers at oral dose levels up to 
200 mg/kg bw, no clear increase in the blood concentration of formic acid could be observed because 
of the high background before dosing and the high variability of the value 3 hours and 24 hours after 
dosing. At this dose (200 mg/kg bw), the background level of blood formic acid was 18 + 5.3 mg/L, 
22 + 11 mg/L 3 hours after dosing and 11 + 8.4 mg/L 24 hours after dosing (values derived from Fig 
28, Stegink, 1984). Renal excretion of formic acid was higher by 2 to 3-fold over basal levels 
(34 + 22 μg/mg creatinine) during the 0-8 hour period following aspartame intake.  
The same author (Stegink, 1984) reported a series of experiments in humans to investigate the dose 
relationships between oral intake of aspartame and systemic plasma levels of aspartic acid, 
phenylalanine and methanol. The relationships were studied for doses ranging from 0-200  mg 
aspartame/kg bw/day, and the studies focused on blood levels that occurred following one single dose 
of 34  mg/kg bw/day, because at that time, this was the 99
th percentile of the ‘projected’ daily 
ingestion
18. Plasma phenylalanine, aspartate and methanol concentrations were measured in normal 
subjects ingesting aspartame at 34, 50, 100, 150 and 200 mg/kg bw in a randomised crossover study.  
Following administration of aspartame at a dose level of 34 mg/kg bw, plasma phenylalanine levels 
increased significantly (p ≤ 0.001) from a normal baseline level of 50-60 µM to 110 ± 25 µM. At a 
dose of 50 mg/kg bw of aspartame, plasma phenylalanine levels increased significantly (p ≤ 0.001) 
from baseline values reaching a mean (± SD) peak value of 162 ± 49 µM. Mean (± SD) peak plasma 
phenylalanine levels were 203  ± 20.5,  351 ± 113  and  487 ± 151 µM  following  administration  of 
aspartame at 100, 150 and 200 mg/kg bw, respectively, and were statistically higher than baseline 
levels. All peak values were reached between 30 min and 2 hours following dosing.  
Following administration of aspartame at a dose of 34 mg/kg bw and 50 mg/kg bw, no significant 
differences from baseline values of 2.2 + 0.8 µM were noted in plasma aspartate. The mean (± SEM) 
peak plasma aspartate levels (after 0.5  hours from aspartame administration) were 4.3  ±  2.3  µM 
(p < 0.02) (at 100 mg/kg bw dose), 10.0 ± 7.0 µM (at 150 mg/kg bw dose) (not statistically significant) 
and 7.6 ± 5.7 µM (at 200 mg/kg bw dose) (not statistically significant), showing that aspartate levels 
did not appear to be dose-dependently increased. The authors concluded that these data indicate that 
rapid metabolism of the aspartate portion of aspartame occurred at all doses studied (Stegink, 1984).  
Peak plasma levels of amino acids after aspartame intake have been compared to peak plasma levels 
after ingestion of dietary proteins. It was noted that amino acids from proteins in meals were liberated 
in the gut and absorbed more slowly than the amino acids in small peptides such as aspartame (EFSA 
2006).  
Stegink et al. (1979a) measured plasma, erythrocyte and milk levels of free amino acids in six normal 
female subjects with established lactation after oral administration of either aspartame or lactose at 
50 mg/kg body weight in a cross-over study. No significant change in plasma or erythrocyte aspartate 
levels was noted following aspartame or lactose administration. Plasma phenylalanine levels increased 
approximately four-fold over fasting values 45  minutes after aspartame loading (P  <  0.001), and 
returned to baseline by 4 hours. Milk phenylalanine, but not aspartate, levels were increased between 1 
and 12 hours after aspartame intake.  
                                                      
18   Projected levels of aspartame ingestion have been calculated by the FDA, the Market Research Corporation of America  
  (MRCA), and by Stegink research group. If aspartame totally replaces estimated mean daily sucrose intake, aspartame  
  intake would range between 3 and 11 mg/kg bw with the highest daily aspartame ingestion would vary from 22 to  
  34 mg/kg bw. The latter is equivalent to ingesting 12-19 mg/kg bw phenylalanine, 9.8-15.2 mg/kg bw aspartate and 2.4- 
  3.7 mg/kg bw methanol. According to the MRCA, an aspartame intake of 34 mg/kg bw represented the 99
th percentile of  
  projected daily ingestion (calculation carried out before approval of aspartame for use in carbonated beverages). Opinion on the re-evaluation of aspartame (E951) as a food additive
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3.1.3.2.  Studies in adults heterozygous for phenylketonuria and other sub-populations 
In addition to the aforementioned studies investigating the metabolism of aspartame in healthy adult 
volunteers, t here are a number of additional absorption, distribution, metabolism and excretion 
(ADME) studies on aspartame that were conducted in one-year-old infants, lactating women, in 
individuals who respond adversely to monosodium glutamate (MSG; so-called ‘Chinese Restaurant 
Syndrome’), in adults heterozygous for phenylketonuria (PKU) and the elderly.  
The study by Filer et al. (1983) shows that the metabolism of a single dose of aspartame (up to 
100 mg/kg bw, measured as peak plasma levels and AUC for phenylalanine and aspartate) given orally 
to one-year-old infants was not different from that measured in adults. Likewise, the metabolism of a 
single oral dose of aspartame of 50 mg/kg bw in lactating women (measured as plasma phenylalanine 
and aspartate levels) was not different from other adults (Stegink et al., 1979a; E93, 1977). There was 
also no apparent difference in aspartame metabolism in individuals who respond adversely to 
monosodium glutamate (E110, 1979).  
Several studies on the metabolism of aspartame in adults heterozygous for PKU were conducted using 
single doses ranging from 10 to 100 mg aspartame/kg bw (E108, 1978; E109, 1978; Stegink et al., 
1979b; Stegink et al., 1980; Caballero et al., 1986; Stegink et al., 1987b; Filer and Stegink, 1989, 
Curtius et al., 1994). In two studies (Stegink et al., 1979b, 1981a) fasted subjects heterozygous for 
PKU were compared with fasted normal subjects following a dose of 34  mg aspartame/kg bw 
(dissolved in orange juice). In heterozygotes, basal plasma phenylalanine levels and the phenylalanine 
levels following administration of aspartame were significantly higher and the plasma concentration-
time curve broader than those recorded in normal subjects. While maximal plasma phenylalanine 
levels in healthy normal adults (111 + 24.9 μM) were in the range observed postprandially (Stegink, 
1984), maximal plasma phenylalanine levels in subjects heterozygous for PKU were 160 + 22.5 μM, 
and therefore were slightly above the normal postprandial level. The plasma phenylalanine 
concentration-time curve was also significantly greater in heterozygous female subjects 
(21.36 ± 5.10 IU) than in normal female subjects (10.84 ± 2.32 IU). In a further study (Stegink et al., 
1980) subjects known to be heterozygous for PKU and subjects assumed to be normal were 
administered a dose of aspartame of 100 mg/kg bw (dissolved in orange juice). Plasma phenylalanine 
levels in heterozygous subjects after aspartame loading were significantly higher than values in normal 
subjects from 30 to 180 min, and the area under the plasma concentration-time curve greater. The 
maximal plasma phenylalanine level in heterozygous subjects after aspartame administration was 
417 + 23.5 μM vs. 202 + 67.7 μM in normal subjects. The authors concluded that fasted heterozygotes 
given an acute dose of aspartame metabolised the phenylalanine part of aspartame approximately half 
as fast as normal subjects. In another study (Curtius et al., 1994), the effect of a protein-rich meal 
alone or in combination with 25  mg aspartame/kg bw on plasma phenylalanine levels in normal 
subjects and subjects known to be heterozygous for PKU was investigated. In meals supplemented 
with aspartame (25  mg/kg bw), the highest mean plasma phenylalanine levels were only slightly 
higher than the postprandial range for normal subjects (values for normal subjects were not reported 
but the Panel estimated mean values from the graph in the publication to be 80 μM vs. 110 μM). In the 
case of subjects known to be heterozygous for PKU, the increase was from a postprandial level of 
126 + 21 μM to 153 + 21 μM.  
A study that compared young with elderly adult volunteers revealed that following a single dose of 
40  mg aspartame/kg bw, Cmax and AUC values for plasma phenylalanine were modestly but 
significantly higher in the elderly due to a rise in the elimination half-life of phenylalanine from 3.5 to 
3.9 hours (Puthrasingam et al., 1996).  
3.1.3.3.  Repeat Dose Administration Studies 
Several studies were conducted to address the effects of repeated ingestion of aspartame on its 
metabolism, and plasma phenylalanine and aspartate levels, and are summarised as follows. The 
ingestion by volunteers of a 600 mg aspartame dose every hour for eight hours resulted in significant 
increases in plasma phenylalanine and tyrosine levels, reaching a plateau after several doses (five Opinion on the re-evaluation of aspartame (E951) as a food additive
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doses for phenylalanine levels, three to six doses for tyrosine levels) (UN05, 1987; Stegink et al., 
1989). However, the plateau levels did not exceed the normal postprandial range in plasma and 
returned to baseline values by 24 hours. The peak ratios of phenylalanine levels to large neutral amino 
acids (LNAA) levels were increased compared to the placebo in the subjects, similar to that observed 
following a single 34 mg/kg bw dose of aspartame. Similarly, the peak tyrosine/LNAA ratio was 
increased. The Panel noted that in this study, volunteers received hourly doses of 600 mg aspartame 
for 8 hours each day, a daily dose of 4800 mg or 80 mg/kg bw/day. This total dose corresponded to the 
administration of a dose equivalent to twice the ADI each day. Since the plateau levels of 
phenylalanine did not exceed the normal postprandial range, the Panel considered that there is no 
accumulation of phenylalanine resulting from this high dose of aspartame.  
Healthy adults (108 volunteers) were given either placebo or 75 mg/kg bw/day aspartame in three 
divided doses for 6  months (Leon et al., 1989). Throughout the treatment period, there were no 
changes in phenylalanine, aspartate or methanol plasma concentrations, in phenylalanine/LNAA ratio 
and in urinary formate excretion. The Panel noted that in this study healthy adults received almost 
twice the ADI for 6  months without any consequences in terms of phenylalanine or methanol 
accumulation. In further studies, the effect of repeated ingestion of aspartame (in increasing doses 
from 600 up to 8100 mg per person per day) over periods of up to 27 weeks on plasma amino acid 
levels were also investigated in obese subjects, insulin-dependent and -independent diabetic subjects 
and in children (E23, 1972; E24, 1972; E60, 1973; E61, 1972; E64, 1972). None of the studies showed 
a significant difference in plasma phenylalanine or aspartate levels compared to controls.  
Stegink et al. (1990) showed that the hourly ingestion of 600 mg aspartame by adults heterozygous for 
PKU over a period of 8 hours significantly increased plasma phenylalanine levels, reaching a plateau 
after five doses (see also UN05, 1987). The highest mean value was 165 + 34.4 μM at 7.5 hours, 
which remains within the normal postprandial range. Phenylalanine plasma levels returned to baseline 
values by 24  hours. The peak ratio of phenylalanine levels to LNAA levels, but not the peak 
tyrosine/LNAA ratio, was increased compared to the placebo. In another study (E25, 1972), aspartame 
was administered in increasing doses from 600 up to 8100 mg person per day to adults heterozygous 
for PKU for six weeks. No statistically significant difference in plasma phenylalanine levels were 
observed between placebo controls and aspartame-exposed subjects. In a follow-up to this study, 
adults heterozygous for PKU were given 1800 mg aspartame per day (600 mg doses three times daily) 
over 21 weeks. Again, there was no difference between placebo and aspartame-exposed individuals in 
terms of plasma phenylalanine levels except for a small but statistically significant difference at week 
16 (107 vs. 126 μM for control and aspartame, respectively).  
Overall, the Panel noted that in all the repeat dose administration studies, healthy adults, children or 
patients suffering various diseases including heterozygous for PKU received daily dose of aspartame 
above the current ADI of 40 mg/kg bw/day for periods up to 6 months. Considering the absence of a 
significant increase in plasma phenylalanine concentration from the normal postprandial range, the 
Panel concluded that in line with normal uses and use levels there is no risk of phenylalanine 
accumulation in such human populations.  
3.1.4.  β-Aspartame 
β-Aspartame (β-L-aspartyl-L-phenylalanine methyl ester) is formed to a minor extent during the 
manufacturing process and in storage of aspartame-containing beverages. In a series of studies, the 
pharmacokinetics and metabolism of orally administered 
14C-β-aspartame were determined in humans 
and in various animal species. In all these studies, 
14C-β-aspartame was radiolabelled on the 
phenylalanine moiety.  
In humans, six healthy subjects received a single oral dose of 
14C-β-aspartame dissolved in water (31.9 
or 40 mg, corresponding to 0.5-0.7 mg/kg bw) and were observed for 7 days (E172, 1987; E173, 
1988). The use of HPLC enabled quantification of both the unchanged β-aspartame and its major 
metabolites in plasma, urine and faeces. The authors reported that more than 90  % of the orally Opinion on the re-evaluation of aspartame (E951) as a food additive
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administered radioactivity was absorbed based on the low recovery of radioactivity excreted in faeces 
for 7 days (9.6 % of the radioactive dose). Unchanged 
14C-β-aspartame was not detected in plasma and 
less than 0.15 % of the dose was excreted unchanged in the urine after 7 days. The demethylated 
metabolite (
14C-β-L-aspartyl-L-phenylalanine) was the major metabolite observed in plasma 
(Tmax = 1.5 hours, plasma half-life = 1.1 hours) and was an important urinary metabolite (7 % of the 
administered radioactivity). In plasma, phenyl-acetyl-glutamine was detected as another major 
circulating metabolite whereas free 
14C-phenylalanine appeared as a minor one. The major route of 
excretion of radioactivity was urine (42 % of the radioactive dose). The major urinary metabolite was 
14C-phenyl acetyl glutamine, its excretion accounted for 30.8  % of the radioactive dose. 
14C-
phenylalanine was the only metabolite recovered in faeces. There were no clinical effects related to 
14C-β-aspartame administration at these dose levels in healthy subjects.  
In rabbits (E170, 1986), dogs (E169, 1987) and monkeys (E171, 1985) similar data were obtained 
including the absence of unchanged 
14C-β-aspartame in plasma and the percentages of excretion in 
urine and faeces. In these animal species, 4 to 5 % of the radioactive dose was excreted in the breath.  
The Panel noted that these studies indicated that there is a negligible systemic bioavailability of the 
unchanged β-aspartame. The Panel also noted the low plasma level of free phenylalanine subsequent 
to the administration of β-aspartame and that the major urinary metabolites are phenyl-acetyl-
glutamine and β-L-aspartyl-L-phenylalanine, a normal constituent of human urine (Burton et al., 
1989).  
3.1.5.  Overall summary of the ADME data 
Overall, the Panel noted that no unchanged aspartame was identified in body fluids or in tissues from 
experimental animals or humans in any of the studies. Therefore, the Panel concluded that after oral 
ingestion, aspartame was hydrolysed in the gastrointestinal tract to yield aspartic acid, phenylalanine 
and methanol. These metabolites are then absorbed and enter normal endogenous metabolic pathways. 
In humans, only subjects heterozygous for PKU showed a somewhat reduced capacity to metabolise 
the phenylalanine moiety of the aspartame molecule. 
3.2.  Toxicological data of aspartame 
The content of DKP in the aspartame used in these studies, as reported by the authors of the original 
reports, varied from 0.1 % to 4.0 % per batch of aspartame; the aspartame dose was not corrected for 
this. In some of the unpublished reports, the DKP content is not reported. 
3.2.1.  Acute toxicity of aspartame  
3.2.1.1.  Acute toxicity studies received following a public call for data which were available at 
the time of the previous JECFA and SCF evaluations  
The acute toxicity of aspartame was studied in three species, mice, rats, and rabbits (E46, 1973). 
Aspartame was administred by gavage (as 15-25 % suspension in 1 % Tween 80) at doses up to 
5000 mg/kg bw (E46, 1973) or by i.p. injection (in mice and rats only). Male Schmidt Ha/ICR mice 
(n = 6) were dosed by gavage at 1000 or 5000 mg/kg bw or by i.p. injection at 200 or 450 mg/kg bw 
(n = 2) or 1000 mg/kg bw (n = 6) (E46, 1973). Male Sprague Dawley rats (n = 6) were dosed by 
gavage at 5000 mg/kg bw or by i.p. injection at 2033 mg/kg bw. Male New Zealand White Luenberg 
rabbits were dosed by gavage at 2000, 2500 or 3200 mg/kg bw (n = 1) and 4000 or 5000 mg/kg bw 
(n = 3) (E46, 1973). The animals were observed intermittently during the 7 day post-treatment period 
and no remarkable motor or behavioural activites were noted. No mortalities were observed in the 
experimental period. According to the authors, the LD50 values were in excess of the highest doses 
administered to each species.  
Male Charles River CD rats (10 weeks of age; 6 animals/group) received 100 mg/kg of aspartame by 
intravenous injection (5  ml/kg bw of 2  % aspartame in 0.9  % aqueous sodium chloride solution 
administered into the jugular vein over a period of 10 minutes); control animals received an equivalent Opinion on the re-evaluation of aspartame (E951) as a food additive
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volume of sodium chloride (E84, 1974). The animals were monitored for a 72-hour period post-
treatment, then sacrificed and representative tissues examined microscopically. Survival was 100 % in 
both control and treated animals. Physical, ophthalmoscopic and body weight changes were 
unremarkable. No compound-related changes were observed at the gross or microscopic level, organ 
weights and organ to body weight ratios were unchanged. Moderate to severe phlebitis was observed 
at the site of implantation of the cannula in all rats; the authors concluded that the inflammation 
observed in the kidneys and endocardium could be a result of an infection.  
Two groups of four male Beagle dogs received either 0 or 100 mg/kg of aspartame by intravenous 
injection (5 ml/kg injections of 0.5 % aqueous sodium chloride solutions administered over a period of 
10  minutes) (E85, 1974). The dogs were monitored for 72  hours post-injection before sacrifice. 
Physical appearance, feed consumption and body weight were recorded. All animals survived during 
the observation period and no remarkable changes were observed. Electrocardiograms were made at 0, 
0.5, 3, 6, 24, 48 and 72 hours, patterns were unremarkable pre and post-injection in both placebo and 
treated dogs. No statistically significant changes were observed in the haematology, clinical chemistry 
and urinalysis parameters evaluated. Post-mortem gross and microscopic changes were unremarkable.  
The overview of these studies is presented in Appendix F.  
3.2.2.  Short-term and sub-chronic toxicity of aspartame 
3.2.2.1.  Studies of short-term and sub-chronic toxicity received following a public call for data 
which were available at the time of the previous JECFA and SCF evaluations 
Mice of the Ha/ICR strain (8 weeks of age) were randomly assigned, five per group to study groups 
(E2, 1972). It was planned to administer aspartame for 4 weeks at dose levels of 0, 2000, 4000 and 10 
000 mg/kg bw/day, but due to an unforeseen increase in feed consumption, the actual intake of the test 
compound exceeded this by 25-30 % in all the groups. The actual intake was calculated to be 3000, 
5000 and 13 000  mg/kg bw/day in the test groups. No statistically significant difference in body 
weight was observed between treated and control animals. No adverse clinical conditions were noted 
and 100  % survival was reported. Upon sacrifice, no treatment-related pathological changes were 
reported except that the intestinal mucosa from the high dose treated mice was heavily coated with a 
clear, moderately viscous fluid. Only the control animals and those from the high dose group were 
examined.  
In a sub-acute study, aspartame was given in the diet for 4 weeks to male and female Charles River 
CD rats (E3, 1972). Seven-week-old rats (5 animals per dose group) were administered aspartame 
incorporated in the diet on a w/w basis, resulting in an exposure of 0, 2000, 4000 or 10 000 mg/kg 
bw/day. Actual consumption was estimated to be within 10 % of the proposed dose. No consistent 
statistically significant effect in body weight was observed, though a significant decrease in feed 
consumption was reported in the high dose females at weeks 2 and 3; however, this was not reflected 
in body weight gain, which increased during the treatment-period. No adverse clinical conditions were 
reported during the study period and 100 % survival was reported in both control and treated groups. 
Only five control animals (3 males and 2 females) and the animals from the high dose groups were 
examined histopathologically. No treatment-related changes were reported except that the intestinal 
mucosa from the treated rats was heavily coated with a clear, moderately viscous fluid.  
Groups of 10 male and 10 female sexually mature Charles River CD rats were dosed for 8 weeks with 
aspartame incorporated into the diet, resulting in a dose of 5 or 125 mg/kg bw/day, with further groups 
of 10  animals acting as controls (E20, 1969). Dosages were adjusted weekly based on weight of 
animals and feed consumption for each sex at the end of the preceding week. Survival was reported to 
be 100  %. No effect on body weight and feed consumption was reported. No effect on physical 
appearance or behaviour was observed at either test level. At sacrifice, biochemistry and pathological 
examination was conducted on five animals from each dose and the control group. No treatment-
related changes in haematology or urinanalysis were reported, organ weights were unaltered except in Opinion on the re-evaluation of aspartame (E951) as a food additive
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the high dose males where a significantly higher liver to body weight ratio was observed for the high 
dose group males compared to controls. There were no remarkable histopathological findings; bile 
duct hyperplasia and pericholangitis were present in the livers of animals of all three groups, with no 
apparent increase in severity in the treated animals.  
Groups of 5 male and 5 female weanling Charles River CD rats (23 days of age at commencement of 
study) were randomly assigned to groups receiving either basal diet or diet containing aspartame (9 % 
w/w, average dosage of 12.2 mg/kg day), or phenylalanine (5 % w/w, average dosage 6.5 mg/kg day) 
for 9 weeks (E4, year not reported). Phenylalanine and aspartame were consumed at progressively 
decreasing mean daily dosage levels of 13 to 4 mg/kg and 24 to 7 mg/kg. Two deaths occurred during 
the study period, one control male and one aspartame-treated male, but no physical or behavioural 
abnormalities were observed in the surviving animals. No significant treatment-related changes in 
haematology, clinical chemistry, urinalysis were recorded and no treatment-related changes in relative 
organ weight or pathology were observed. Reduced body weight gain was noted for both treatments 
and both sexes (though less marked in females); mean relative feed consumption (g/kg bw/day) was 
equivalent to control values; absolute (g/rat/day) feed consumption was reduced proportionally to the 
depressed body weight gain.  
Aspartame was administered in the form of gelatine capsules to groups of male and female Beagle 
dogs (n = 2) daily for a period of 8 weeks (E21, 1969). The dogs are described as ‘young’ and weighed 
7.2-13.2 kg at initiation. In order to administer an appropriate dose of aspartame, capsules were 
prepared specifically for the individual animals calculated upon their body weight at the end of the 
previous week. Animals received either 5 or 125 mg aspartame/kg bw/day, further groups of male and 
female dogs (n = 2) served as controls and received empty capsules. The dogs were described as being 
generally normal in appearance and behaviour throughout the study, with a variable pattern of weight 
loss/gain/maintenance reported. All dogs survived the study period; animals were then sacrificed at the 
end of the 8-week dosing regime. Upon sacrifice, no consistent effects upon organ weights were 
recorded and no consistent changes in haematological and clinical chemistry parameters, gross 
pathology and histopathology were observed.  
The overview of these studies is presented in Appendix G.  
3.2.2.2.  Additional studies on short-term and sub-chronic toxicity  
In two consecutive reports, the effects of aspartame on liver (Abhilash et al., 2011) and brain 
(Abhilash et al., 2013) antioxidant systems and tissue injury were studied in male Wistar rats. The 
animals (6/group) were dosed daily by gavage for 6  months with 3  ml of aspartame (500 or 
1000 mg/kg bw/day) dissolved in water; control rats received the same volume of water. A range of 
enzyme activities was assayed in serum, liver homogenates and brain homogenates. Histological 
examination was also performed on tissue from the liver and brain (left half). The authors reported that 
rats that had received aspartame (1000  mg/kg bw/day) showed a significant serum increases in 
activities of alanine aminotransferase, aspartate amino-transferase, alkaline phosphatase and 
gammaglutamyl transferase. The concentration of reduced glutathione (GSH) and the activities of 
glutathione peroxidase and glutathione reductase (GR) were significantly reduced in the liver of rats 
that had received aspartame (1000 mg/kg bw/day). The levels of GSH were significantly decreased in 
the two experimental groups. Histopathological examination revealed leukocyte infiltration in the 
livers of aspartame-treated rats (1000 mg/kg bw/day). As regards the brain, the authors reported that 
the concentration of GSH and GR activity were significantly reduced in rats that had received the dose 
of 1000 mg/kg bw/day of aspartame, whereas only a significant reduction in GSH concentration was 
observed in the 500 mg/kg bw/day aspartame-treated group. Histopathological examination revealed 
mild vascular congestion in the 1000  mg/kg bw/day group of aspartame-treated rats. The authors 
concluded from these observations that ‘long-term consumption of aspartame leads to hepatocellular 
injury’ and that ‘an alteration in the glutathione-dependent system in the brain by long-term intake of 
aspartame is dose dependent’ suggesting a relationship between aspartame toxicity and GSH. Opinion on the re-evaluation of aspartame (E951) as a food additive
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The Panel noted that only six rats were used per group and that the exposure was not long-term but 
only 6 months. The Panel noted that in the article by Abhilash et al., 2011, the abstract and main text 
described the method of dose administration differently (drinking water and gavage respectively). 
Only two doses were tested and the dose at which some statistically significant effects were reported 
by the authors was 25 times greater than the ADI. In addition, the changes were mild and limited both 
qualitatively (many markers of antioxidant system were unchanged) and quantitatively and cannot be 
interpreted in the absence of historical values from the institute for these rats. The Panel also noted 
that the method used by the authors for the determination of GSH is not specific for GSH (since it 
detects a variety of reduced cellular thiols). Finally, focal inflammatory infiltration of the liver is a 
variable (even within the same liver) but a common occurrence in rodents, particularly in the portal 
tract regions of the liver. This phenomenon is often observed in liver sections from control populations 
of rodents. According to the authors, a detailed investigation with a large sample size is necessary to 
substantiate the findings and to understand the exact mechanism behind the vascular congestion. The 
Panel considered that the histopathological and biochemical findings presented in the reports did not 
convincingly support the conclusion of the authors.  
3.2.3.  Genotoxicity of aspartame 
3.2.3.1.  Studies on genotoxicity received following a public call for data which were available at 
the time of the previous JECFA and SCF evaluations 
In vitro studies 
Aspartame was tested for mutagenicity in Salmonella typhimurium strains TA1535, TA1537, TA1538, 
TA98 and TA100 both in the absence and the presence of a rat liver metabolic activation system at 
dose levels from 10 up to 5000 µg/plate (E97, 1978; E101, 1978) (Appendix H). The Panel considered 
that, for both studies, the methods implemented appeared to be sufficiently robust to support the 
results reported. Aspartame was not mutagenic in this test system, either in the absence or in the 
presence of the metabolic activation system.  
In vivo studies 
Mutagenicity of aspartame was studied using a host-mediated assay in mice (E81, 1974). Mice were 
treated by gavage with 0 (control), 1000, 2000, 4000, 8000 mg aspartame/kg bw/day (as three separate 
doses given at two hour intervals for five consecutive days) (E81, 1974). Thirty minutes after the final 
dose, the animals were inoculated with Salmonella typhimurium, G-46, by intraperitoneal injection. 
Three hours later the bacteria were recovered and the peritoneal washing was evaluated for the 
presence of mutants. In mice, the host-mediated assay revealed no evidence for mutagenicity of 
aspartame. The Panel noted some discrepancies in description of doses in different sections of the 
report and that the test system employed has not received further validation and is presently 
considered obsolete and therefore, the results of the study were not included in the assessment.  
Two dominant lethal tests in rats (15 males/group) were reported (E40, 1973; E41, 1973). Aspartame 
was dosed by gavage to 21-week-old male albino rats of the Charles River CD strain at a dose level of 
2000  mg/kg bw given in two equally divided doses administered on the same day. Immediately 
following treatment, each male was mated with two sexually mature virgin females weekly for eight 
consecutive weeks. On gestation day (GD) 14, the mated females were sacrificed for ovarian and 
uterine examinations. The Panel considered that the methods implemented were thought to be 
sufficiently robust to support the results reported. The following parameters were analysed: paternal 
growth, maternal pregnancy rate, uterine and ovary examination data and incidence of fetal deaths. 
None of these parameters was affected by aspartame treatment.  
Aspartame was administered by gavage to five groups of 10 male albino rats for five consecutive days, 
at dose levels of 0 (control), 500, 1000, 2000 and 4000 mg/kg bw/day (E43, 1972). Twenty-four hours 
after the last dose, each animal was administered colcemid to arrest mitosis, and sacrificed. Bone 
marrow cells were prepared and evaluated for chromosome aberrations. Aspartame did not increase Opinion on the re-evaluation of aspartame (E951) as a food additive
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the normal aberration frequencies compared to the control rats. The authors concluded that aspartame 
was not mutagenic. The Panel considered that the methods implemented were sufficiently robust to 
support the results reported, but considered the study limited since mitotic indices were not reported 
(Appendix H).  
Aspartame was reported not to induce chromosome aberrations in bone marrow or spermatogonial 
cells after administration by gavage to rats for five days (E12, 1970). However, the dose levels applied 
were reported inconsistently. On page 2 of the relevant Study Report (E12, 1970) it is stated that 
animals received aspartame at dose-levels of 400, 800, 1200 and 1600 mg/kg bw/day. In contrast, in 
the results section, it is reported that aspartame was administered at dose-levels of 2000, 4000, 6000, 
8000 mg/kg. The Panel considered that the reported results of this study were not supported by the 
outcome of the methods applied (Appendix H).  
Aspartame was tested in a host-mediated assay with rats (E44, 1972) and was administered by gavage 
to five groups of 10 male albino rats for five consecutive days, at dose levels of 0 (control), 500, 1000, 
2000 and 4000 mg/kg bw/day, given in three equally divided doses. Following the final dose, the 
animals were inoculated with Salmonella typhimurium, G-46, by intraperitoneal injection. Three hours 
later the bacteria were recovered, and the peritoneal washing was analysed for the presence of 
mutants. No statistically significant effects on mutation frequency were noted in the treatment groups, 
as compared to the control. The Panel noted that the test system employed has not received further 
validation and it is presently considered obsolete, and therefore the results of the study were not 
included in the assessment.  
3.2.3.2.  Additional studies on genotoxicity  
In vitro studies 
Aspartame was studied in Salmonella mutagenicity tests in the absence and in the presence of 
metabolic activation (Appendix H). No mutagenicity was detected in strains TA98, TA100, TA1535, 
TA1537 or TA97 for doses up to 10 000 μg/plate (NTP, 2005). The Panel considered that the methods 
implemented were to be sufficiently robust to support the results reported (Appendix H). However, the 
Panel noted a deviation from OECD 471 (i.e. tester strains TA102 or WP2uvrA bearing AT mutation 
were not used). The authors of the study judged the small increase in mutant colonies with 30 % rat 
liver S9 as equivocal.  
Rencuzogullari et al. (2004) tested aspartame in strains TA98 and TA100 at doses ranging from 50 to 
2000 μg/plate in the presence and in the absence of metabolic activation. No mutagenicity was 
observed. However, the Panel considered that the methods implemented were not sufficiently robust to 
support the results reported, due to major deviations from the OECD guideline (i.e. only two tester 
strains were used; the highest dose-level employed was lower than 5 mg/mL).  
Bandyopadhyay et al. (2008) reported aspartame to be negative in a test with Salmonella typhimurium 
TA97 and TA100 strains (plate incorporation, with and without metabolic activation; 10, 100, 250, 
500, 1000 or 10 000  µg/plate). The Panel considered that the methods implemented were not 
sufficiently robust to support the results reported, due to major deviations from the OECD guideline 
(i.e. only two tester strains were used; the concentration intervals were too wide; no replicate 
experiment were performed).  
Aspartame was tested for DNA damaging activity in the in vitro primary rat hepatocyte/DNA repair 
assay at concentrations of 5 and 10 mM (corresponding to 1.47 and 2.94 mg/mL, respectively) (Jeffrey 
and Williams, 2000). The Panel considered that the methods implemented were sufficiently robust to 
support the results reported. Aspartame was found to be negative in this assay.  
Rencuzogullari et al. (2004) tested aspartame in vitro in a sister chromatid exchange (SCE) assay, a 
chromosomal aberration test and a micronucleus test on human lymphocytes. Dose-related and 
statistically significant increases were observed for chromosomal aberration at both 24 and 48 hours Opinion on the re-evaluation of aspartame (E951) as a food additive
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and for induction of micronuclei only at the highest dose-levels employed (2000 µg/mL). Negative 
findings were observed for SCEs. The Panel noted that the pattern of results obtained suggests an 
indirect clastogenic effect of aspartame, e.g. secondary to cytotoxicity, not related to primary DNA 
damage. The latter is usually efficiently flagged by an increased incidence of SCEs, which was not 
observed in aspartame-treated cells at any dose. The involvement of an indirect mechanism in the 
reported clastogenic effect is also suggested by the absence of electrophilic centres, potentially 
reactive toward DNA, in the molecule of aspartame. The Panel noted several flaws in this study (see 
Appendix H) which was only performed in the absence of exogenous metabolism, while aspartame 
undergoes extensive biotransformation after ingestion resulting in no significant systemic exposure to 
intact aspartame. Overall, the Panel considered the experimental findings reported in this study of 
limited relevance for aspartame risk assessment.  
In vivo studies   
In the study by Durnev  et al. (1995) which aimed at evaluating the genotoxicity of five sugar 
substitutes in mice, aspartame was investigated for induction of chromosomal aberrations in bone 
marrow cells of C57Bl/6 mice administered aspartame by oral gavage for five days at dose-levels of 
40 and 400  mg/kg bw to groups of five animals. A concurrent negative control group was also 
included. The animals were sacrificed 6 hours after the last administration of test compound. In the 
final two hours, colchicine was administered by intraperitoneal injection to accumulate cells in 
metaphase. A minimum of 100 metaphases per animal were scored. The results obtained indicate that 
aspartame did not induce any increase in the incidence of chromosomal aberrations compared with 
negative control values. However, the Panel noted that the study was poorly reported and that a 
concurrent positive control animal group to show whether the test system was functioning correctly 
had not been included. Furthermore, the sampling of bone marrow cells 6  hours after the last 
administration of test compound was not adequate for chromosomal aberration analysis and dose-
levels administered appear to be very low. On these grounds, the Panel considered that the methods 
implemented were not sufficiently robust to support the results reported.  
In a study by Mukhopadhyay et al. (2000), male Swiss Albino mice were exposed by oral gavage to a 
blend of aspartame and acesulfame K (ratio 3.5:1.5) at doses up to 350 mg aspartame/kg bw. The 
blend of the two sweeteners showed a negative outcome for chromosomal aberrations. The Panel 
noted that no evaluation of cell cycle progression (e.g. mitotic index) was performed. Given the 
limitations of the study (blend of sweeteners and no mitotic index determination), the Panel considered 
it to be of limited relevance for the evaluation of the genotoxicity of aspartame.  
An acute bone marrow micronucleus test was conducted with aspartame administered orally to male 
Fisher 344 rats at three daily doses of 0 (control), 500, 1000 or 2000 mg/kg bw. No increase in the 
number of micronucleated polychromatic erythrocytes was observed at any of the tested dose levels 
(NTP, 2005). The Panel considered that the methods implemented were sufficiently robust to support 
the results reported.  
Peripheral blood micronucleus tests were conducted in male and female transgenic mice (Tg.AC 
hemizygous, p53 haploinsufficient or Cdkn2a deficient) after 9 months of exposure to aspartame at 
doses ranging from 3.1 to 50 g/kg diet. The highest dose tested was equivalent to 7660 and 8180 mg 
aspartame/kg bw/day in males and in females, respectively (NTP, 2005). The Panel considered that the 
methods implemented were sufficiently robust to support the results reported (Appendix H; NTP, 
2005). Negative results, indicative of an absence of clastogenic activity of aspartame, were obtained in 
male and female Tg.AC hemizygous and Cdkn2a deficient mice and in male p53 haploinsufficient 
mice. In female p53 haploinsufficient mice, the results of the test were judged to be positive by the 
authors of the study, based on a trend test revealing a statistically significant 2.3-fold increased 
frequency of micronucleated erythrocytes seen in the 50 g/kg diet group (NTP, 2005). However, the 
Panel noted that the incidence of micronucleated erythrocytes in female controls was the lowest 
among the historical control values of the same laboratory; this rendered the outcome of the trend 
analysis positive. Nevertheless, the observed incidence of micronucleated erythrocytes in the highest Opinion on the re-evaluation of aspartame (E951) as a food additive
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dose group fell outside the range of the historical controls. However, the Panel also noted that the 
reported increase in micronucleated erythrocytes was observed in one gender only. Furthermore, the 
effect described was observed after 9  months of administration of a daily dose, which exceeded 
approximately 8-fold, the highest recommended dose level for genotoxicity testing according to 
OECD guideline 474. The Panel concluded that the findings were equivocal in the p53 transgenic 
strain (positive in female but not in male p53 haploinsufficient mice) but negative in the other two 
strains, and, overall, did not indicate a genotoxic potential for aspartame.  
Two studies addressing DNA damage as detectable by Comet assay are available, both following 
administration of aspartame by gavage.  
Sasaki et al. (2002) administered a single dose of aspartame (2000 mg aspartame/kg bw) to mice (four 
male/group) and analysed the stomach, colon, liver, kidney, bladder, lung, brain, bone marrow. 
Aspartame did not induce any significant increases in DNA migration. Based on these results, the 
Panel considered that aspartame was not genotoxic in the organs assayed. However, the Panel noted 
that for the 24-hour sampling time, a reduction in DNA migration (a marker for DNA cross-linking 
agents) was observed in all organs analysed, but the reduction was not significant. The Panel 
considered that the methods implemented were sufficiently robust to support the results reported.  
Bandyopadhyay et al. (2008) administered aspartame as a single dose of 0 (control), 7, 14, 28 and 
35 mg aspartame/kg bw to mice (four males/group) by oral gavage, and at the highest dose-level, 
aspartame was reported to induce DNA damage in bone-marrow cells. However, the Panel noted that 
an insufficient number of cells was scored (total of 50 cells/animal) and the evaluation of cytotoxicity 
performed (trypan blue exclusion method) is inadequate to exclude an artifactual outcome. In addition, 
sampling of bone-marrow cells performed 18 hours after administration of the test compound and not 
at the recommended time for the in vivo comet assay (2-6  hours) cannot support permanence of 
residual DNA damage due to fast DNA repair activity. Furthermore, increases of DNA damage 
evaluated (% tail DNA and tail extent) were small and no historical control values were reported and 
used to exclude possible spontaneous biological fluctuations.. Therefore, the Panel considered that the 
methods implemented were not sufficiently robust to support the results reported in the study, and that 
no conclusion could be drawn from it.  
Kamath et al. (2010) used three endpoints to assess the genotoxic potential of aspartame following 
administration of 0 (control), 250, 455, 500 and 1000 mg aspartame/kg bw by gavage to mice. The 
authors concluded that aspartame induced (a) micronuclei in bone marrow erythrocytes, (b) 
micronuclei in peripheral blood and (c) chromosome aberrations in bone marrow erythrocytes. 
However, the number of animals and the ratio of polychromatic erythrocytes to normochromatic 
erythrocytes (PCE/NCE) ratio (the authors only stated that it was changed) are not given. The Panel 
considered that the methods implemented were thought not to be sufficiently robust to support the 
results reported, and that no conclusion could be drawn from it. 
AlSuhaibani (2010) tested aspartame for its ability to induce chromosome aberrations (CA) and SCE 
in bone marrow cells of mice (five males/group; by gavage) at dose levels of 0 (control), 3.5, 35 and 
350 mg aspartame/kg bw. Based on the increase in the incidence of chromatid breaks, the authors 
concluded that aspartame induced CA at 35 and 350 mg/kg bw, but neither dose level induced SCE 
nor decreased the mitotic index (MI). The Panel noted that an insufficient number of cells were scored 
(total of 50 metaphase cells/animal for CA) and that the incidence of chromosome breaks observed in 
treated mice (4.4 % at the highest dose, compared to 2.0 % in concurrent controls) is comparable to 
the incidence found in control animals from other studies for this type of assay; therefore the increase 
of CA observed in this study was not considered of biological relevance. Furthermore, no positive 
control was included in the study to ensure that experimental system was working correctly. The Panel 
considered that the methods implemented were not sufficiently robust to support the results reported, 
and that no conclusion could be drawn from the study.  
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Other studies 
Karikas et al. (1998) reported a non-covalent interaction of excess aspartame, aspartic acid and 
phenylalanine with calf thymus DNA, inferred from the altered chromatographic profile of DNA. This 
effect was attributed to the electrostatic interaction of amino groups and the negatively charged 
phosphate in naked DNA. The Panel considered these findings, obtained in an acellular system in 
presence of excess aspartame, of minimal relevance for the evaluation of the genotoxic potential of 
aspartame.  
Meier et al. (1990) investigated the kinetics of formation, stability and reactivity of nitrosation 
products of aspartic acid, aspartame, and glycine ethyl ester. Nitrosation products were obtained in 
vitro, with incubation of 40 mM substrate and nitrite at pH 2.5 for varying times. The nitrosation 
products displayed an ‘alkylating’ activity in vitro, as indicated by the reactivity with the nucleophilic 
scavenger 4-(4-nitrobenzyl)pyridine, measured with a colorimetric method. In the same study, co-
administration of glycine ethyl ester and nitrite to rats did not result in the formation of detectable 
DNA adducts in rat stomach.  
The issue of nitrosation was also addressed by Shephard et al. (1993). Aspartame and several naturally 
occurring dipeptides were nitrosated in vitro at low pH (3.5) in the presence of 40 mM nitrite and 
tested for mutagenicity in Salmonella typhimurium TA100. The nitrosation products of some 
dipeptides (Trp-Trp, Trp-Gly) and aspartame exhibited a direct mutagenic activity, which was related 
by the study authors to the nitrosation of their primary amino groups.  
Concerning the studies of Meier et al. (1990) and Shephard et al. (1993), the Panel noted the harsh 
conditions utilised for the in vitro nitrosation of substrates and considered the results of doubtful 
relevance for the assessment of the genotoxic risk posed by the dietary intake of aspartame or other 
natural amino acids and dipeptides.  
3.2.3.3.  Conclusion on the genotoxicity of aspartame 
The Panel concluded that the in vitro genotoxicity data on bacterial reverse mutation exhibited some 
limitations (e.g. absence of TA102 and WP2 uvrA Escherichia coli). However, the Panel considered 
the weight-of-evidence was sufficient to conclude that aspartame was not mutagenic in bacterial 
systems. Concerning mammalian systems in vitro, the Panel concluded that, apart from the valid UDS 
study that was negative, no conclusion could be drawn at the gene and chromosomal level because no 
studies dealing with these endpoints were available.  
In vivo, the majority of investigations on systemic genotoxicity reported negative findings. Equivocal 
positive findings were only described in a NTP study, positive in female but not in male p53 
haploinsufficient mice; in two other transgenic mouse strains the results were negative.  
Concerning the possible site of first contact effects in vivo, limited data are available. However, the 
available in vitro data do not indicate a direct genotoxic activity of aspartame that might predispose to 
a site of first contact effect in vivo.  
Overall, the Panel concluded that the available data do not indicate a genotoxic concern for aspartame. 
Summary tables on the genotoxicity of aspartame are presented in Appendix H.  
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3.2.4.  Chronic toxicity and carcinogenicity of aspartame 
3.2.4.1.  Studies on chronic toxicity and carcinogenicity received following a public call for data 
which were available at the time of the previous JECFA and SCF evaluations 
In these chronic toxicity and carcinogenicity studies, aspartame was administered in the diet. Although 
the purity of aspartame used in these studies was considered to be 100 %, it was reported in the studies 
that the content of DKP varied from 0.2 % to 1.5 % per batch.  
Mice 
Aspartame (DKP content varied from 0.8 % to 1.2 % per batch) was administered in the diet to groups 
of 36 male and 36 female ICR Swiss mice (approximately 28 days of age) at dose levels amounting to 
0 (control), 1000, 2000 and 4000 mg/kg bw/day for 104 weeks (E75, 1974). Criteria evaluated were 
physical appearance, behaviour, body weight gain, feed consumption, survival, clinical chemistry, eye 
examination, organ weights, tumour incidence and gross and histopathology. There was no effect on 
the physical appearance and behaviour of the animals. Body weight gain for the male mice at all dose 
levels was significantly lower than that for the male controls but this was accompanied by reduced 
total feed consumption during the first year for the males at the low and high dose levels. At week 52 
differences between control and treated male group body weight values did not exceed 3 % and these 
differences were not considered biologically meaningful. Mean terminal body weights were 
unremarkable for each of the male and female treatment groups. Survival in all treated groups was 
comparable to that of the controls. Haematological and blood chemistry analyses revealed no 
compound-related alterations at any exposure level compared to the control. Random fluctuations 
reaching statistical significance were observed occasionally but, according to the authors of the report, 
the values were within the range of historical control data. Gross observations at necropsy did not 
reveal compound-related changes in any organs or tissues. Relative organ weights were unaffected 
except for the relative heart weight in females that was increased at the high dose level and the relative 
thyroid weight that was increased in females at the low dose level only. In males, the relative thyroid 
weight was increased at the low dose level only and the relative prostate weight was decreased at the 
low and mid dose but not at the high dose. Histopathological examination was performed on all gross 
lesions from all animals at each treatment level, and on 20-27 grossly unremarkable organs from 
control and high dose level animals, as well as from roughly two-thirds and one-third of the animals in 
the mid and low dose level. Detailed histopathological evaluations were performed on brain and 
urinary bladder from all mice in the control and the three treatment groups. The incidence of tumours 
was not reported to be significantly higher than that in controls for any type of tumour in either sex at 
any dose. Histopathological examination revealed no evidence for any treatment-related non-
neoplastic changes in any organ or tissue. The authors concluded that aspartame, administered to the 
mouse for 104 weeks in the diet at dose levels of 1000, 2000 and 4000 mg/kg bw/day exhibited no 
adverse effects regarding survival rate, and that there was no evidence of an effect with respect to the 
incidence of neoplasms or with regard to non-neoplastic changes in any organ or tissue. The Panel 
agreed with this evaluation and identified a NOAEL for this study of 4000 mg/kg bw/day, the highest 
dose level tested.  
Rats 
Aspartame (DKP content varied from 0 % to 1.5 % per batch) was administered in the diet to groups 
of 40 male (initial body weight of 75-108 g) and 40 female (initial body weight of 80-102 g) Charles 
River Albino rats at dose levels of 0 (control), 1000, 2000, 4000, and 8000  mg/kg bw/day for 
104  weeks (E33-34, 1973). The highest dose was 6000  mg/kg bw/day from week 0 to week 16, 
7000 mg/kg bw/day from week 16 to week 44, and 8000 mg/kg bw/day in week 44 through week 104. 
There was no evidence that the administration of aspartame resulted in any effect on the physical 
appearance and behaviour of the animals. Growth rates at 8000  mg/kg bw/day were significantly 
lower than that of controls, but this could be related to the significantly lower values for feed 
consumption for the first 52 weeks for the male and female rats in the 8000 mg/kg bw/day group and Opinion on the re-evaluation of aspartame (E951) as a food additive
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for the females in the 4000 mg/kg bw/day group. Survival after 104 weeks was comparable to controls 
for all treated groups except for the females of the 8000 mg/kg bw/day group that showed statistically 
significant lower survival rates. Evaluation of the clinical chemistry data revealed no consistent 
statistically significant alterations outside the normal range of values. The results from 
ophthalmoscopic examinations revealed no indication of a compound-related effect. Changes in 
relative organ weights were not accompanied by gross nor histopathological changes and were 
therefore considered by the authors to be without biological significance. Histopathological 
examination was performed on all gross lesions from all animals at all treatment levels and on 20-25 
grossly unremarkable organs from the groups at 0, 4000 and 8000 mg/kg bw/day and from roughly 
25  % of the animals at the 1000 and 2000  mg/kg bw/day groups. Urinary bladder received more 
extensive examination since four intermittent transverse bladder sections were examined 
microscopically from each rat in the study. Tumour incidence for the types of tumours analysed was 
not statistically significantly higher than in the controls in any of the dose groups of either sex. 
Histopathological examination revealed no treatment-related changes in brain, pituitary, spinal cord, 
peripheral nerve, thyroid, adrenal, salivary gland, skin, skeletal muscle, heart, liver, mesenteric lymph 
node, bone marrow, stomach, small intestine, large intestine, uterus, vagina, mammary gland, testis 
and urinary bladder. In lungs, pneumocyte hyperplasia was slightly increased in the 8000  mg/kg 
bw/day group females. Effects on ovaries were unremarkable except for an increased incidence of 
cystic follicles at all treatment levels, probably related to an unusually low incidence in the controls. 
Seminal vesicle atrophy of slight to moderate degree was inconsistently present, with a slightly 
increased incidence observed in the 4000 and 8000 mg/kg bw/day groups (2/23, 4/23 and 6/21 in 
control, 4000 and 8000 mg/kg bw/day groups, respectively). Acute and chronic prostatitis was also 
observed somewhat more frequently in treated animals but no dose-relationship was observed. An 
increased incidence of focal pancreatic fibrosis and mild atrophy was inconsistently observed in 
treated groups, affecting primarily the animals in the 8000 mg/kg bw/day group. Nodular hyperplasia 
of the pancreas was also observed more often in females at this high dose level (3/60 in controls versus 
11/40 in the high dose groups) than in males (1/60 in controls versus 1/40 in the high dose group). 
Since there was no increased incidence of pancreatic tumours, the Panel considered the toxicological 
relevance of the slight increase in incidence of nodular hyperplasia in the pancreas of the female high 
dose group unremarkable. The authors indicated that all the changes in lungs, ovaries, seminal 
vesicles, prostate, pancreas were inconsistently present and lacked clear dose-response relationships. A 
renal pigment deposit (identified as iron-containing haemosiderin) was present in tubular and pelvic 
epithelial cells with increased incidence in male rats at 8000 mg/kg bw/day. Females and low dose 
males were not affected. Focal hyperplasia of the renal pelvic epithelium was also present with 
increased incidence in the 8000 mg/kg bw/day group in males. Tubular degeneration was increased in 
the 8000 mg/kg bw/day group in males. The authors concluded that administration of aspartame to rats 
for two years did not result in adverse effects or an increased incidence of neoplasms, and produced no 
evidence of treatment-related non-neoplastic lesions in any organ examined except for the renal 
changes in males at 8000 mg/kg bw/day. Based on these observations the Panel identified a NOAEL 
of 4000 mg aspartame/kg bw/day in this study.  
In a chronic toxicity study in the rat, aspartame (DKP content varied from 0.8 % to 1.2 % per batch) 
was administered in the diet to groups of male and female Charles River albino rats at dose levels of 0 
(control; 60  males/60  females), 2000 (40  males/40  females)  and  4000  (40 males/40 females) mg/kg 
bw/day for 104 weeks post-weaning (E70, 1974). These treated rats were obtained as F1 weanlings 
from parental animals which had been pre-treated with aspartame at the same levels for 60 days prior 
to mating and continued to receive the test material during mating and throughout the gestation and 
nursing periods. Endpoints evaluated were physical appearance, behaviour, eye examination, growth, 
feed consumption, survival, clinical chemistry, organ weights, tumour incidence and gross and 
microscopic pathology. There was no effect on the physical appearance and behaviour of the animals. 
Growth rates for the exposed animals were comparable to growth rates of the controls except for the 
high dose in males for which growth rates were significantly lower than for controls, this was 
accompanied by a significantly lower feed consumption. Survival at 104 weeks was comparable to 
controls for both treatment groups. Clinical chemistry data revealed no consistent statistically 
significant alterations outside the normal range. The results from ophthalmoscopic examinations Opinion on the re-evaluation of aspartame (E951) as a food additive
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revealed no indication of a compound-related effect. Gross observations at necropsy revealed no 
compound-related changes in any organs or tissues. Some statistically significant changes in relative 
organ weights were reported but these were not accompanied by histopathological alterations and 
these were therefore considered by the authors to be of no biological significance. Histopathological 
examination was performed on all gross lesions from all animals at all treatment levels and on 20-25 
grossly unremarkable organs (see below) from all control and treated animals. Microscopic evaluation 
of eight coronal sections representing all major neuroanatomic areas of the brain was performed for 
each control and treated rat. Urinary bladder also received more extended examination, since four 
intermittent transverse bladder sections were examined microscopically from each rat in the study. 
Incidences for the types of tumours analysed was not statistically significantly higher in any dose 
group compared to the control group. Histopathology revealed that at all levels administered, there 
were no effects on brain, spinal cord, eye, salivary gland, thyroid, lung, small intestine, large intestine, 
lymph nodes, peripheral nerve, skin, testis, prostate, seminal vesicle, vagina, bone, bone marrow, and 
mammary gland. For the stomach, the incidence of focal gastritis, mucosal ulceration, and 
pigmentation was slightly increased in the treated females, but these effects were considered by the 
authors to be of little biological relevance. Pancreatic focal acinar hypertrophy occurred more 
frequently among low dose male rats than among control animals but was considered by the authors to 
be spontaneous in nature. Likewise, an increased incidence of ovary atrophy among the high dose 
animals and a higher incidence of endometritis in low dose survivors and high dose non-survivors 
were considered by the authors to be unrelated to treatment. Pituitary chromophobe hyperplasia and 
cysts involving the pars distalis were observed in higher numbers of treated animals, but because of 
the overall low incidence of these findings, the authors did not consider them compound-related. The 
incidence of nodular hyperplasia of the adrenal cortex was somewhat higher for the treated males and 
angiectasis of the adrenal was more frequently noted for the treated females than for the respective 
controls. However, the authors indicated that these findings were not common to both sexes and the 
differences were not considered significant. The incidence of renal cortical pigmentation among 
treated male and female survivors and focal mineralisation among only the treated females was 
slightly increased as compared to the controls but the authors indicated that there was no meaningful 
difference between findings for the control and treated groups. The incidence of parenchymal 
hyperplastic nodules was higher in the livers of treated females (3/23 in the 2000 mg/kg bw/day and 
1/20 in the 4000 mg/kg bw/day group) when compared with controls (0/28), whereas the incidence 
was similar between control (2/35) and treated males (1/20 in the 2000 mg/kg bw/day and 1/18 in the 
4000 mg/kg bw/day group). This finding among the treated females was not considered by the authors 
as compound-related since the incidence for the control females was low compared to the historical 
control data of this strain, for studies conducted in their laboratories and since there was no evidence 
of a dose-response relationship. The only other notable finding for this organ was a slightly increased 
incidence of pericholangitis among the high dose male non-survivors. The authors concluded that rats 
treated with 2000 or 4000 mg aspartame/kg bw/day throughout the prenatal period, during weaning 
and post-weaning for 104  weeks by direct dietary administration, exhibited no adverse effects 
regarding survival rates or incidence of neoplasms, nor did they exhibit evidence of treatment- related 
non-neoplastic changes in any organ or tissue of either sex. The Panel agreed with this evaluation and 
identified a NOAEL for this study of 4000 mg/kg bw/day, the highest dose level tested.  
In an additional study (E87, 1973), a supplemental histopathological examination of all brains from 
these two chronic rat carcinogenicity studies (E33-34, 1973 and E70, 1974) was performed (since the 
initial post-mortem assessment only involved two coronal sections of brains from each rat in the high 
dose and concurrent control groups with additional examination restricted to rats that exhibited gross 
evidence of brain lesion(s)). In the E33-34 studies, 440 animals were examined from the 104-week 
study (120 control and 320 treated animals), 12 neoplasms involving the brain were discovered in rats 
from treated groups. Their type and distribution are presented in Table 19. 
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Table 19:   Intracranial neoplasms as reported in rats in the 104 week oral toxicity study on aspartame 
(E33-34; E87) 
Intracranial 
neoplasms 
 
 
 
Male (Dose  
mg aspartame/kg bw/day) 
  
 
 
 
Female (Dose  
mg aspartame/kg bw/day) 
 
   Cont 1000  2000 4000 8000  Cont  1000 2000 4000 8000 
Survivors  23/60 18/40 21/40  23/40 21/40 26/60  23/40 20/40 14/40 10/40 
Astrocytoma 0/60*  1/40 0/40  0/40 0/40 0/60  1/40 0/40 0/40 0/40 
Astrocytoma + 
Ependymal 
components  0/60 1/40 1/40  1/40 0/40 0/60  1/40 0/40 0/40 0/40 
Oligodendroglioma  0/60 0/40 0/40  1/40 0/40 0/60  0/40 0/40 0/40 0/40 
Ependymoma    0/60 0/40 0/40  2/40 0/40 0/60  0/40 0/40 1/40 0/40 
Meningeal  Sarcoma 0/60 0/40 0/40  0/40 0/40 0/60  0/40 0/40 0/40 1/40 
Glioma  unclassified 0/60 0/40 0/40  0/40 0/40 0/60  0/40 0/40 0/40 1/40 
*   In the authentication review of selected materials submitted to the Food and Drug Administration relative to application 
     of Searle Laboratories to market aspartame (E102a, b, c) the number of animals with neoplasm (intracranial tumour) in 
    the control group was reported as 1 instead of 0 (as reported in E33-34 and E87). 
In the second rat study (E70, 1974), the tumourigenic potential of aspartame was assessed after 
treatment throughout the prenatal period, during weaning and post-weaning for 104 weeks by dietary 
administration. The parents of the rats in this study were also pre-treated with aspartame for 60 days 
prior to mating. Nine neoplasms involving the brain were identified in the 280 animals in this study. 
Their type and distribution are presented in Table 20. 
Table 20:   Intracranial neoplasms in rats exposed to aspartame in a lifetime toxicity study (E70, 
1974; E87, 1973) 
Histopathological 
lesions  
Male (Dose  
mg aspartame/kg bw/day) 
  
 
Female (Dose  
mg aspartame/kg bw/day) 
  
   Control 2000  4000  Control  2000  4000 
Astrocytoma 3/60  1/40  1/40  1/60 1/40 0/40 
Ependymoma    0/60  1/40  0/40  0/60 0/40 0/40 
Meningeoma    0/60  0/40  0/40  0/60 0/40 1/40 
These results indicated a random occurrence of intracranial neoplasms, unrelated to treatment.  
Based on the results of these two studies, the Panel concluded that evidence of an intracranial 
tumourigenic effect was not demonstrated. The Panel noted that in treated animals of the first 104-
week study, more brain tumours originating from different tissues (astrocytoma, oligodendroglioma, 
ependymoma and meningeoma) were observed. However, there was no dose-relationship and males of 
the high dose group did not show any brain tumours. Moreover, with the exception of males in the 
4000 mg/kg bw/day group, only one or two animals per group exhibited a brain tumour and the overall 
incidence of intracranial neoplasms in the 104-week toxicity study (2.7  %) was lower than the 
incidence in the control group of the lifetime carcinogenicity study (3.3  %). The incidence of 
spontaneous brain tumours in Sprague-Dawley-derived rats has been reported by Ward and Rice 
(1982) to vary from 0 % up to 3.3 %. A similar incidence was reported by Weisburger et al. (1981).  Opinion on the re-evaluation of aspartame (E951) as a food additive
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JECFA also evaluated these data and concluded that neither the overall incidence nor the appearance 
of any particular neoplasm was associated with aspartame exposure. Therefore, JECFA concluded that 
aspartame did not cause brain tumours in rats (JECFA, 1980).  
An additional 2-year chronic toxicity and carcinogenicity study was conducted in Wistar rats (Ishii et 
al., 1981; Ishii, 1981). Wistar rats (86  males and 86  females) were administered aspartame (DKP 
content up to 1 %) at dose levels of 0 (control), 1000, 2000 and 4000 mg/kg bw/day in the diet for up 
to 104 weeks; an additional group was fed 4000 mg/kg bw/day aspartame plus DKP (3:1) for up to 
104 weeks. There was a dose-dependent depression of body weight gain at 2000 and 4000 mg/kg 
bw/day and at 4000 mg/kg aspartame plus DKP (3:1) in males, and at all dose levels in females. This 
effect was associated with decreased feed consumption. Survival was not consistently affected. In 
males, but not females, there was a trend for decreasing body weight in all groups including controls 
after one year. There were no effects on liver weight throughout the study. Clinical biochemistry and 
organ pathology were unremarkable and any significant changes observed were not treatment-related. 
Subsequent detailed analysis for brain tumours showed no evidence for increased incidence of brain 
tumours (Ishii, 1981). One atypical astrocytoma was found in a female control rat, and two 
astrocytomas, two oligodendrogliomas and one ependymoma were found in the treated groups, with 
no statistical difference in incidence between the groups. There was no evidence of a treatment-related 
effect on the incidence of non-neoplastic changes other than a dose-related increase in focal 
mineralisation of the renal pelvis in both males and females (incidences in males: control, 1/57; 
1000 mg aspartame/kg bw/day, 5/55; 2000 mg aspartame/kg bw/day, 10/60; 4000 mg aspartame/kg 
bw/day, 15/59; incidences in females: control, 16/59; 1000 mg aspartame/kg bw/day, 23/59; 2000 mg 
aspartame/kg bw/day, 30/59; 4000 mg aspartame/kg bw/day, 46/60) associated with a dose-related 
increase in urinary calcium (Ishii et al., 1981; JECFA, 1981; EFSA, 2006). The authors attributed this 
lesion to irritation caused by the mineral deposition and considered it to be of minimal toxicological 
significance. The Panel noted that mineralisation in the kidney is a common finding in rats, the 
aetiology being associated with mineral imbalance (Lord and Newberne, 1990). Thus, there was no 
evidence for toxicity of aspartame alone or in combination with its degradation product DKP, over 
2 years in rats. The Panel identified from this study a NOAEL of 4000 mg aspartame/kg bw/day. In 
addition, the Panel noted that the study provided information on the lack of toxicity of aspartame when 
administered in conjunction with DKP.  
A re-evaluation of all neoplastic and non-neoplastic lesions of the Ishii  et al. (1981) study was 
reported (Iwata, 2006). No significant differences between controls and treated animals were identified 
and it was concluded that all the tumours observed could have occurred spontaneously. Increased 
mineralisation of the renal pelvis (as reported in Ishii et al., 1981) was observed in males at 2000 and 
4000 mg/kg bw/day and in females at 4000 mg/kg bw/day. The original study report (Ishii et al., 1981) 
stated that this was not related to pelvic epithelial hyperplasia or pelvic inflammatory reactions, 
although the follow-up study reported an increase in transitional-cell hyperplasia in males at 
4000  mg/kg bw/day. This was attributed to irritation caused by the mineral deposition and was 
considered by the authors of the re-evaluation to be of negligible, if any, toxicological relevance. The 
Panel agreed with this conclusion.  
Hamsters 
The JECFA evaluation (JECFA, 1980) also described a chronic toxicity study in hamsters. In this 
study groups consisting of five male and five female hamsters were fed aspartame (containing < 1% 
DKP) at dietary levels of 1000, 2000, 4000 and 12 000 mg/kg bw/day for 46 weeks (E27, 1972; E35-
36; 1972).  
The Panel noted the inadequacies of this study due to the short duration of the study, the limited 
number of animals per group and the presence of infection in the animals. The Panel agreed that this 
study cannot be used for the present evaluation.  
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Dogs 
5-month_old Beagle dogs (5 animals/sex/group) were exposed to aspartame (a content of DKP up to 
1 %) via dietary administration for 106 weeks at dose levels that amounted to 0 (control), 1000, 2000 
and 4000 mg/kg bw/day (E28, 1972). Physical examinations were performed at 4-week intervals and 
ophthalmoscopic evaluations at 24, 52, 78 and 104  weeks of treatment. Haematology, clinical 
chemistry and urinalysis were performed periodically for all dogs. After necropsy, representative 
tissues from control and all treated animals were processed for microscopic examination. Survival 
rates were 100 % in all groups. No compound-related variations in feed consumption and body weight 
gain were observed. Physical examination findings were unremarkable. No changes in motor 
behaviour activity or in general physical appearance were noted. Periodic ophthalmoscopic 
examination did not reveal any treatment-related changes. Haematology and clinical chemistry 
findings revealed no biologically meaningful treatment-related alterations, although transient sporadic 
significant differences were reported in several of the parameters. However, most values remained 
within physiological limits and no dose-related pattern was evident. A significant increase in excretion 
of urinary phenylketones was observed in some high dose dogs at week 2, 4 and 26 of treatment, but 
not at all other time intervals. There was no increase in plasma L-phenylalanine levels during the 106-
week treatment period. Gross and microscopic findings and organ weight data were unremarkable. An 
extended histopathological examination of the brain tissue did not reveal any lesions (E86, 1973). The 
authors concluded that continuous dietary administration of aspartame at daily intake levels of 1000, 
2000 and 4000 mg/kg bw/day in Beagle dogs of both sexes for 106 weeks causes no biologically 
meaningful alterations in body weight, feed consumption, physical examination, clinical chemistry 
examinations or gross and microscopic findings. The Panel agreed with this evaluation. This study has 
the advantage of providing data on systemic toxicity in a non-rodent species. However, the duration of 
the study is only 2 years and the number of animals involved is only 5/sex/group, which limits the 
power of the statistical analysis. The Panel concluded that the NOAEL in this study was 4000 mg/kg 
bw/day.  
Monkeys  
The only study addressing the chronic effects of aspartame on primates is a 52-week oral toxicity 
study in neonatal rhesus monkeys (Macaca mulatta) (E32, 1972). Starting in infancy, rhesus monkeys 
were dosed with aspartame (containing 0.2-1.0 % DKP), which was mixed with Similac milk formula 
and administered four times daily. Following gradual increases in the doses administered, mean daily 
doses of aspartame of 970  mg/kg bw/day (planned dose 1000  mg/kg bw/day; 1 male/1 female), 
3010 mg/kg bw/day (planned dose 3000 mg/kg bw/day; 2 males/1 female) and 3620 mg/kg bw/day 
(planned dose 4000-6000 mg/kg bw/day; 2 males) were attained. The actual duration of dosing ranged 
from 210-363 days. 
Survival was 100 % in all except the high dose group; one monkey in this group died after 300 days of 
treatment; the cause of death was unknown. Feed intake and growth rate were mildly reduced by 
treatment with aspartame. One low dose monkey, which had an apparent congenital abnormality, was 
kept in the study but had reduced weight gain compared with other monkeys in the study. 
Haematology and clinical chemistry parameters were generally unremarkable in treated animals 
except for increased plasma phenylalanine and tyrosine levels, associated with increased urinary 
phenylketone levels, in medium and high dose groups after six months.  
The main adverse effect observed in this study was that animals in both the mid and high dose groups 
started to experience grand mal seizures, the first such event occurring on day 218. Occurrence of 
seizures was associated with high plasma phenylalanine levels (Median dose: mean peak of 
420  µmol/100 ml at 28  weeks; high dose: mean peak of 480  µmol/100  ml at 36  weeks); similar 
convulsions occurred in monkeys fed L-phenylalanine in equimolar quantities. In the low dose group 
no increase in plasma phenylalanine levels was observed and no seizures occurred. Intermittent 
seizures occurred thereafter for the remainder of the study, usually occurring during handling. Opinion on the re-evaluation of aspartame (E951) as a food additive
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Treatment was withdrawn for the last three months of the study; no convulsions were observed during 
this period.  
All the mid dose and high dose monkeys in this study developed Shigella infections during this study, 
and the data reassurance programme conducted by Searle rejected the study on this basis (Rust, 1976). 
It should also be noted that the study included no control group; historical control data were relied 
upon for comparison.  
In summary, treatment of rhesus monkeys with high doses of aspartame for the first year of life did not 
have any significant effect on biochemical parameters, but animals treated with aspartame at doses 
above 3000  mg/kg bw/day experienced grand mal seizures, beginning after about 30  weeks of 
treatment. The significance of this finding is not clear, because all the monkeys manifesting grand mal 
seizures were also affected by a Shigella infection during the study. The Panel concluded that the 
study provided insufficient information to conclude on chronic effects of aspartame in monkeys.  
3.2.4.2.  Additional long-term carcinogenicity studies  
Since the last evaluation of aspartame by the SCF, two new long-term carcinogenicity studies on 
aspartame in rats (Soffritti et al., 2006, 2007; Chiozzotto et al., 2011) and one in mice (Soffritti et al., 
2010) have been reported. All three studies were performed by the European Ramazzini Foundation 
(ERF).  
In the Soffriti et al. (2006) study, Sprague Dawley rats (100-150 animals/sex/group) from the in-bred 
colony of the ERF were exposed to 0, 80, 400, 2000, 10 000, 50 000 or 100 000 mg aspartame/kg in 
the diet, equivalent to 0, 4, 20, 100, 500, 2500 or 5000 mg aspartame/kg bw/day, from eight weeks of 
age until natural death. A range of inflammatory changes was observed in a variety of organs and 
tissues particularly in the lungs and kidneys, in both males and females. Furthermore, an increased 
incidence of lymphomas/leukaemias in female rats, with a positive significant trend in both male and 
female rats was reported by the authors. Additional effects included an increased incidence of 
transitional-cell carcinomas of the renal pelvis and ureter and their precursors (dysplasias), with a 
positive significant trend in female rats, an increased incidence of malignant Schwannomas of 
peripheral nerves, with a positive significant trend in male rats and an increased incidence of 
malignant tumour-bearing animals, with a positive significant trend in both sexes.  
In 2007, Soffriti et al. (2007) published a follow-up study in which groups of 70–95 male and female 
Sprague-Dawley rats were exposed to 0, 400 or 2000 mg aspartame/kg in the diet, equivalent to 0, 20 
or 100 mg aspartame/kg bw/day from the 12
th day of fetal life until natural death. The authors of the 
study reported a significant, dose-related increase in the incidence of malignant tumour-bearing 
animals in males and a dose-related increased incidence in lymphomas/leukaemias in females, and an 
increased incidence of lymphomas/leukaemias in treated males and females at the high dose group. 
Furthermore, a dose-related increased incidence of mammary gland carcinomas, in females and a 
significantly higher incidence of these carcinomas in females exposed to the high dose was reported 
(Soffritti et al., 2007; Chiozzotto et al., 2011).  
The two rat studies have already been evaluated by the former AFC Panel (EFSA, 2006) and the ANS 
Panel (EFSA, 2009a, 2009b), respectively. Both Panels considered that the two ERF rat studies had 
flaws that bring into question the validity of the findings, as interpreted by the ERF. In particular, the 
high background incidence of chronic inflammatory changes in the lungs and other vital organs and 
tissues, and the uncertainty regarding the correctness of the diagnoses of some tumour types were 
major confounding factors in the interpretation of the findings of the study. The ANS Panel also noted 
that the increase in incidence of mammary carcinomas was not considered indicative of a carcinogenic 
potential of aspartame since the incidence of mammary tumours in female rats is rather high and varies 
considerably between carcinogenicity studies. The ANS Panel noted that the only consistent findings 
reported by the authors in the two rat studies were an increased incidence of lymphomas/leukaemias in 
female rats and an increased incidence of lymphomas/leukaemias in treated males and females of the Opinion on the re-evaluation of aspartame (E951) as a food additive
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high dose group (EFSA, 2009a). A full evaluation of the ERF studies, including an assessment of the 
malignant schwannomas and the hyperplastic and neoplastic lesions of the epithelium of the renal 
pelvis, ureter and urinary bladder, has been published elsewhere (EFSA, 2006; EFSA, 2009a, 2009b). 
In the present evaluation, the ANS Panel noted that an NTP review of selected ERF studies (conducted 
between 1974 and 1993) had found evidence of high rates of infection in the animals at the ERF 
institute (NTP-EPA, 2011). Furthermore, the NTP evaluation included a review of original 
histopathological slides. The review noted that there was no formal quality assessment process for 
pathology diagnoses, and that in a significant number of cases the NTP reviewers did not confirm 
malignancy as diagnosed by ERF pathologists. In view of these methodological concerns, given the 
consistency of findings in the studies reviewed, the Panel considered that these would apply to other 
studies carried out by Soffritti and co-authors at the ERF including the aspartame studies. The COC in 
2006 also evaluated the Soffritti et al. (2006) study on aspartame (COC, 2006). In light of the 
limitation in the design of this study and the use of animals with a high infection rate, the COC 
considered that no valid conclusions could be derived from it (COC, 2006).  
In the mouse study (Soffritti et al., 2010) groups of 62–122 male and female Swiss mice were treated 
with aspartame in the feed at doses of 0, 2000, 8000, 16 000 or 32 000 mg/kg feed, equivalent to 0, 
250, 1000, 2000 or 4000 mg/kg bw/day, from prenatal life (12 days of gestation) until death. The 
authors of the study reported a dose-related increase in hepatocellular carcinomas in the two highest 
dose male mice groups, and an increase in the incidence of alveolar/bronchiolar carcinomas in males 
of the high dose group, whereas no compound-attributed carcinogenic effects were reported in female 
mice at any of the doses tested.  
The ANS Panel (EFSA ANS Panel, 2011) and EFSA (EFSA, 2011a) concluded that the hepatic and 
pulmonary tumour incidences reported by Soffritti et al. (2010) all fall within their own historical 
control ranges for spontaneous tumours. It was also noted that Swiss mice are known to have a high 
background incidence of spontaneous hepatic and pulmonary tumours (Prejean et al., 1973; Fox et al., 
2006).  
Based on these data, the Panel concluded that the results of the studies performed by Soffritti et al. 
(2010) do not provide evidence for a carcinogenic effect of aspartame in mice.  
Since the evaluations by the SCF and JECFA, the US National Toxicology Program (NTP) has carried 
out several 9-month carcinogenicity studies with aspartame in genetically modified mouse models 
(NTP, 2005). Fifteen male and fifteen female transgenic mice/group of three strains (Tg.AC 
hemizygous, p53 haploinsufficient and Cdkn2a deficient) were exposed to aspartame in the diet at 
doses ranging from 0, 3.1 to 50 g/kg diet for 9 months. The high dose tested was equivalent to 7660 
and 8180 mg aspartame/kg bw/day in males and in females, respectively (Tg.AC hemizygous); 7280 
and 9620 mg aspartame/kg bw/day in males and in females, respectively (p53 haploinsufficient); 7400 
and 9560 mg aspartame/kg bw/day in males and in females, respectively (Cdkn2a deficient) (NTP 
2005). According to the NTP, there was no evidence of treatment-related neoplastic or non-neoplastic 
lesions in any of these studies. The former AFC Panel evaluated these studies and agreed with this 
conclusion. The overall number of animals with primary neoplasms, with benign neoplasms or with 
malignant neoplasms in aspartame-exposed groups of both sexes was not significantly increased 
compared to the respective controls (EFSA, 2006). The Panel agreed with these conclusions.  
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3.2.5.  Reproductive and developmental toxicity of aspartame 
3.2.5.1.  Studies on reproductive and developmental toxicity received following a public call for 
data which were available at the time of the previous JECFA and SCF evaluations 
In the reproductive and developmental toxicity studies evaluated, aspartame was either administered in 
the diet or given by gavage (rabbit studies only).  
3.2.5.1.1. Reproductive studies 
Rats 
A two-generation reproduction toxicity study was performed in Charles River albino rats (12 male and 
24 female animals per group) that received aspartame (assumed to be 100 % pure) in the diet at dose 
levels of 0 (control), 2000 and 4000 mg/kg bw/day (E11, 1971). The results of this study were not 
reported in detail. Dietary administration was conducted through two parental generations and one-
litter per generation. Parameters evaluated included survival, body weights, feed consumption, 
physical appearance, and behaviour of the parental generations; indices of fertility, gestation, live birth 
and lactation; the litter size, appearance, behaviour, body weights and growth of offspring; and results 
of gross necropsy on selected weanlings. All parameters were comparable between the control and test 
groups with the exception of body weight suppression at weaning among the high dose pups which 
was evident during both the first (F1) and second (F2) generation litters. Statistical analysis performed 
on the F1 and F2 litters revealed the body weights at the end of weaning of both sexes at the high dose 
level to be statistically significantly lower (F1: 41 g and 38 g in males and females, respectively; F2: 
43 g and 41 g, in males and females, respectively) than those of the controls (F1: 48 g for both sexes; 
F2: 52 g for both sexes). Growth among the low dose pups was comparable to the controls during both 
reproduction phases. The high dose pups were noted to be generally smaller than the control and low- 
dose pups. The effect on haematological and biochemical parameters and on tissue morphology was 
examined in F2 pups from 1 up to 21 days of age. The results of this part of the study were described in 
more detail in another report below (E9, 1972).  
Forty pups, 20 males and 20 females (of the F2 generation from the study described above), offspring 
from the maternal groups that received aspartame at dose levels of 0 (control), 2000, or 4000 mg/kg 
bw/day, were used (E9, 1972). At 24 hours and at 5, 15, and 21 days postpartum 10 pups from each 
group (5 pups/sex) were sacrificed and haematology, clinical chemistry and histopathology of selected 
tissues were performed. The appearance and behaviour of the pups during the study was comparable 
between control and test groups. Results of haematology and clinical chemistry (measured at days 5, 
15 and 21 postpartum) were unchanged at both dose levels. Microscopic examination of sections of 
heart, liver, stomach, kidney and urinary bladder revealed no apparent compound-related effects. In 
the kidney, minimal to slight hypertrophy and vesiculation of nuclei in cells of tubules in the inner 
cortex was noted primarily in the 15 and 21-day 4000 mg/kg bw/day males and females. Minimal 
changes were also seen in two 21-day 2000 mg/kg bw/day females. The authors noted that features of 
this same condition were also observed in a 15-day control male, but microscopic examination of renal 
tissue from weanlings aged 28-30 days revealed that such changes were not present in either control or 
treated rats of this age. The authors concluded that these changes were treatment-related but of a 
transient nature. A treatment-related effect at 2000 mg/kg bw/day at 21 days was equivocal, since the 
control group was not negative throughout. Such changes were not present in the treated rats at 28-
30 days of age. The Panel noted that the histological changes observed in the kidney seemed to be 
consistent with normal histological processes during postnatal development. There was evidence of a 
treatment-related effect at 15 and 21 days of age, but this was transient and appeared to have resolved 
by 28-30 days of age. The Panel identified a NOAEL from these studies of 2000 mg/kg bw/day, based 
on the lower pup weights at weaning in both generations (E9, 1972; E11, 1971).  
In study E10 (1972), aspartame (DKP content 0.3  %) (0, 2000 or 4000  mg/kg bw/day) was 
administered in the diet to Charles River rats (12 males and 48 females in the control group and 
40 females in the aspartame groups) for 64 days (males) or 14 days (females) prior to mating, followed Opinion on the re-evaluation of aspartame (E951) as a food additive
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by a further dosing period until the end of lactation (female rats). During the pre-mating period, rats in 
the male groups ingested a mean daily dose of 1950 and 3867 mg/kg bw, respectively. In females the 
mean daily doses were 2017 and 4430 mg/kg bw during the pre-mating period, 1988 and 4100 mg/kg 
bw/ during gestation, 2375 and 4925 mg/kg bw during the first 14 days of lactation and 2700 and 
5900 mg/kg bw during the last 14 days of lactation. Aspartame had no significant effect on maternal 
sexual behaviour or fertility. Female body weights were slightly but significantly decreased in the high 
dose group at pre-mating day 7, GD 18 and postpartum day 7. The authors also reported that the pups 
from aspartame-treated groups did not differ from controls in growth, survival or subsequent 
reproductive performance. The Panel agreed with this conclusion and identified a NOAEL of 
4000  mg/kg bw/day (actual ingested doses ranged from 4100  mg/kg bw/day during gestation to 
5900 mg/kg bw/day during the last 14 days of lactation), this being the highest dose level tested.  
In study E39 (1973), the effect of aspartame on peri and postnatal development was studied in female 
rats (30 animals per dose group). Aspartame (with a content of DKP of 0.5 %) was administered in the 
diet at intended dose levels of 0 (control), 2000 or 4000 mg/kg bw/day. The recorded dose levels were 
0, 2000 or 4000 mg/kg bw/day during gestation, increasing to 0, 3500 and 6800 mg/kg bw/day during 
lactation. The number of viable pups per litter at birth and pup survival until weaning was significantly 
decreased in the high dose group. Despite the reduced number of pups no effect on pup body weight 
(through to postpartum day 21) was recorded. There was no difference in feed consumption between 
the groups throughout the experiment. Maternal body weights were comparable between control and 
treated groups during gestation, except for GD 21, where the low and high dose groups showed a 5 
and 9  % reduction in body weight, respectively. During lactation, maternal body weights were 
comparable between the control and low dose groups, whereas in the high dose group mean body 
weight was significantly lower at postpartum day 21 (approximately 12 %). According to the authors, 
the NOAEL in this study was 2000 mg/kg bw/day (recorded doses were 2000 mg/kg bw/day during 
gestation and 3500 mg/kg bw/day during lactation). The Panel agreed with the author’s conclusion on 
the NOAEL but noted that, considering the poor survival of control pups, the health status of all the 
animals in the study might have been compromised.  
Monkeys 
A report summarising fragmentary data from a monkey study with aspartame was also submitted to 
EFSA following the public call for data (E88, 1975). The incompleteness of the data, however, 
severely limited the usefulness of this study. In summary, administration of aspartame to eight 
pregnant monkeys at dose levels up to 3800 mg/kg bw/day did not alter maternal appetite or body 
weight and did not induce seizure. There were no malformations observed in the fetuses at term. In 
addition, plasma phenylalanine levels in pregnant monkeys were not significantly increased, and the 
two abortions reported were spontaneous. However, no information on the reproductive capabilities, 
the reproductive status at the time of mating, the identity and reproductive history of the mate, 
evidence of actual establishment of the pregnancy or assessment of the gestational status of pregnant 
animals or experimental conditions of the animals were provided. The Panel concluded that the study 
provided insufficient information to evaluate reproductive and developmental effects of aspartame in 
monkeys.  
3.2.5.1.2. Developmental studies 
Mice 
The developmental toxicity of aspartame was investigated in Charles River CD-1 mice (E89, 1975) 
(Appendix I). Aspartame (DKP content 0.29 %) was administered in the diet to mated mice (four 
groups of 36 pregnant female) for 10 days from GD 6 to 15 at the intended dose levels equating to 0 
(control), 1000 (1400)
19, 2000 (2700), 4000 (5700)  mg/kg bw/day. On GD  18, all females were 
sacrificed and necropsied. Fetuses were examined for external, soft tissue and skeletal abnormalities. 
                                                      
19   The doses in brackets refer to the actual average doses to which the animals were exposed to based on feed  
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The treatment had no effect on maternal survival and conception rates, maternal body weight changes, 
feed consumption, incidence of abortions and premature deliveries, proportion of litters that consisted 
of fetuses only, of both fetuses and resorption sites, or of resorption sites only, mean litter size, mean 
number of resorptions per litter, mean male and female fetal body weights and crown-rump distances, 
and the number of major malformations and skeletal variants, when compared to controls on a fetal 
incidence and a litter incidence basis. According to the Panel, the NOAEL for developmental toxicity 
in this study was 5700 mg/kg bw/day, the highest dose level tested.  
Rats 
Three segment III studies were performed in rats (peri- and postnatal development: E47, 1973; E48, 
1973; E 49, 1973).  
In two studies on peri- and postnatal development (E47, 1973 and E48, 1973), aspartame (DKP 
content 0.2 and 0.5 %, respectively) was administered to rats (24 female rats per group in E47 and 
30 female rats per group in E48) at the intended doses of 0, 2000 or 4000 mg/kg bw/day. In E47, the 
rats received 2500 and 4400 mg/kg bw/day during gestation and 3600 and 6800 mg/kg bw/day during 
lactation, whereas in E48, the actual doses were 1800 and 4000 mg/kg bw/day during gestation and 
3700 and 7000  mg/kg bw/day during lactation. The authors reported significant body weight 
suppression of the pups at birth at the high dose (E47, E48) and weaning (at postpartum day 21) in 
females at both low and high doses (E47, E48) and in males at the high dose (E48). In the high dose 
group a significant decrease in survival at weaning was observed (E47, E48) and incomplete eyelid 
opening in 5/164 pups (E47) and 2/79 pups (E48). The mothers exposed to the high dose showed 
decreased feed intake at postpartum day 21 and reduced body weight at postpartum day 21 and during 
lactation (5-16 %). Based on the results reported in these studies, the Panel identified a NOAEL of 
2000 mg/kg bw/day (E47:2500 mg/kg bw/day during gestation, 3600 mg/kg bw/day during lactation; 
E48: 1800 mg/kg bw/day during gestation, 3700 mg/kg bw/day during lactation).  
In a further segment III study (E49, 1973) in rats (30 females per group), the effects of aspartame 
(DKP content 0.5 %) (0 or 4000 mg/kg bw/day in the diet) on peri and postnatal development were 
compared with those of L-phenylalanine (1800  mg/kg bw/day) or L-aspartic acid (1700  mg/kg 
bw/day) or the combination of L-phenylalanine and L-aspartic acid (2100 and 1800 mg/kg bw/day). 
The actual doses that the rats received were 4000  mg aspartame/kg bw/day, 1800  mg L-
phenylalanine/kg bw/day, 1700  mg L-aspartic acid/kg bw/day or 2100  +  1800  mg L-
phenylalanine + L-aspartic  acid/kg  bw/day  during gestation and 7800  mg aspartame/kg bw/day, 
4200  mg L-phenylalanine/kg bw/day, 4000  mg L-aspartic acid/kg bw/day or 4600  +  3900 mg L-
phenylalanine + L-aspartic acid/kg bw/day during lactation. The authors of the study reported that feed 
consumption was comparable between all groups but noted a significant decrease in body weight in 
the aspartame, L-phenylalanine and L-phenylalanine  + L-aspartic acid groups as compared to the 
control group at postpartum days 7, 14 and 21. For example, at postpartum day 21, mean maternal 
weights recorded were 369.2  +  6.5  g for controls, 327.7  +  5.8  g for the aspartame group, 
318.4 + 10.8 g for the L-phenylalanine group and 316.4 + 9.6 g for the L-phenylalanine + L-aspartic 
acid group. No differences in litter size were found, but at postpartum day 21, L-phenylalanine and L-
phenylalanine + L-aspartic acid group pup weights were notably lower (28.4 + 3.3 g and 28.0 + 2.3 g 
for male pups and 26.9 + 3.1 g and 28.5 + 2.3 g for female pups) (statistically not significant) and 
significantly decreased in the aspartame group (25.9 + 1.5 g for male pups and 25.9 + 1.3 g for female 
pups) compared to controls (34.2 + 2.5 g for male pups and 33.4 + 2.0 g for female pups). Pup survival 
was comparable between all the groups except for the L-phenylalanine  +  L-aspartic acid group 
(30.7  % versus 49.5  % in controls), where it was significantly lower. The authors of the study 
concluded that L-phenylalanine on its own or in combination with aspartic acid decreased maternal 
and pup body weight, which reproduced the observed effects of aspartame on these endpoints. The 
Panel agreed with the author’s conclusion but noted the poor survival of control pups.  
The developmental toxicity of aspartame (was evaluated in a segment II study using dietary 
administration to pregnant albino rats (30 animals per group) from GD 6 to 15 inclusive (E5, 1970). Opinion on the re-evaluation of aspartame (E951) as a food additive
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Dose levels were 0 (control), 2000 and 4000 mg/kg bw/day. Parameters evaluated included maternal 
mortality, body weight, feed consumption, necropsy findings of the reproductive organs, in utero litter 
size (viable fetuses), resorptions, non-viable fetuses and fetal sex distribution; fetal size, gross 
appearance and examination of the fetal visceral and skeletal systems. Maternal mortality, body 
weight changes and necropsy findings were comparable between both aspartame-treated groups and 
the control. Mean feed consumption throughout gestation was comparable in the control and low dose 
groups, but was decreased by 15 % at the beginning of the treatment period at the high dose level. 
Feed consumption in the latter group gradually recovered and reached control values by the time 
compound administration was discontinued. No evidence of treatment induced fetopathological effects 
was observed in the 47 treated litters (589 term fetuses) examined. The Panel identified a NOAEL of 
4000 mg aspartame/kg bw/day for developmental and maternal toxicity.  
The Panel considered that, the two-generation reproductive toxicity study (E11, 1971) was not 
reported according to current standards but taken together with the segment I study (E10, 1972) and 
segment III studies (E47, 1973; E48, 1973) the available data were sufficient to conclude on 
reproductive toxicity. In summary, the results of the reproductive and developmental toxicity studies 
in rats indicate NOAELs that ranged from 2000 mg aspartame/kg bw/day (E11, 1971; E39, 1973; E47, 
1973; E48, 1973) to 4000 mg/kg bw/day (E5, 1970; E9, 1972; E10, 1972).  
Rabbits 
In several studies aspartame was administered in the diet at dose levels of 0 (control), 2000, or 
4000 mg/kg bw/day (E53, 1973; E54, 1974; E55, 1973) or 0 (control), 1000, or 2000 mg/kg bw/day 
(E62, 1973) from GD 6 to GD 17-19, or 0 (control), 1400, or 2400 mg/kg bw/day (E63, 1973) from 
GD 6 to GD 18. The Panel noted that the actual dose to which the rabbits were exposed did not exceed 
1880  mg/kg bw/day (range 1160-1880  mg/kg bw/day) when the intended dose was 4000  mg/kg 
bw/day (administered as 4.8 % (w/w) aspartame in the diet). This was a result of the considerable 
decrease in feed intake observed in the pregnant rabbits (32-62 % decrease) in this dose group. The 
decrease in feed intake was much less pronounced in the 2000 mg/kg bw/day groups than in the 
4000 mg/kg bw/day groups; as such the Panel noted that the actual aspartame doses in the low and 
high aspartame dose groups were often comparable.  
For example in E54 (1974), aspartame (DKP content 0.1 %) was administered in the diet from GD 6 to 
19 to 16 pregnant female rabbits per dose group. The actual aspartame doses were reported to be 1880 
and 1870  mg/kg bw/day for the intended 2000 and 4000  mg/kg bw/day groups, respectively. The 
Panel noted that a significant decrease in fetal body weight and skeletal anomalies were reported for 
the 4000 mg/kg bw/day group but not for the 2000 mg/kg bw/day group even though both groups 
received the same dose of aspartame based on feed intake. Thus, the Panel concluded from these 
observations that the developmental effects on body weight and skeletal development reported in the 
aspartame feeding studies may be caused by the significant depression of feed consumption in the high 
dose group.  
In study E63 (1973) artificially inseminated rabbits (n = 26 per group) received aspartame (with a 
DKP content of 1-4 % as analysed in the diets) in a commercially-prepared pellet diet at a level of 3.4 
or 6.7 % w/w from GD 6 to 18 resulting in a dose of 1400 and 2400 mg/kg bw/day. The control group 
was pair-fed (GD 6 to 24). There were no deaths in the pair-fed control group, two deaths in the 
1400 mg/kg bw group and three deaths in the 2400 mg/kg bw group. One female in the high dose 
group had an early delivery. Conception rates were 96, 81 and 77  % in the control, 1400 and 
2400 mg/kg bw groups, respectively. During gestation (GD 6 to 24), there were similar increases in 
body weight (9 and 7 %) in both aspartame-treated groups and an increase of 3 % in the pair-fed 
controls. Increases in body weight during the entire gestation period were 5, 2, and 2 % in these same 
groups. The feed consumption during treatment and post-treatment as compared to pre-treatment, 
decreased by 6 and 19  %, respectively for the 1400  mg/kg bw group, increased by 3 and 2  %, 
respectively for the 2400 mg/kg group and decreased by 21 and 33 %, respectively for the pair-fed 
control. The Panel noted that the feed consumption was lower in the pair-fed controls than in the Opinion on the re-evaluation of aspartame (E951) as a food additive
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treated animals. Uterine and litter data for the pregnant females sacrificed at term showed no evidence 
of compound-related effect. All fetuses were examined for external abnormalities and half of the 
fetuses were examined for skeletal or visceral examination. The total incidence of major 
malformations was 5 of 153 fetuses (3 of 21 litters) in the pair-fed control group, 2 of 100 fetuses (2 of 
13 litters) in the 1400 mg/kg bw group and 4 of 121 fetuses (3 of 17 litters) in the 2400 mg/kg group.  
In another series of prenatal developmental studies, rabbits were exposed to aspartame (at doses up to 
2000 mg/kg bw/day) using administration by gavage from GD 6 to 18. Most of these studies were 
confounded by poor health of the animals, and, in many cases, by a number of deaths in the treated 
groups, possibly related to the misdosing (E51, 1973; E52, 1973; E79, 1974).  
In study E51 (1973), artificially inseminated rabbits (36) received a daily dose of 2000  mg 
aspartame/kg bw/day (with a content of DKP of 1 %) suspended in an aqueous solution of Tween-80 
and methylcellulose by gavage twice daily as equal doses from GD 6 through 18. Twelve control 
rabbits received the equivalent volume of vehicle as the treated animals. The study was confounded by 
poor health of the animals and the gavage technique issues. As a result, maternal mortality was high. 
The administration of aspartame was associated with depression of feed consumption by up to 40 %. 
The controls were pair-fed to match the aspartame-treated animals with the lowest feed intake, but 
feed intake was noted to be lower still in control animals. The authors concluded that no embryotoxic 
or teratogenic effects were observed.  
Study E52 (1973) also suffered from maternal mortality due to poor health and the gavage technique 
issues. The study involved 24 control and 72 treated animals receiving a daily dose of 2000  mg 
aspartame/kg bw/day (DKP content up to 2 %) suspended in an aqueous solution of Tween-80 and 
methylcellulose that was administered twice daily as equal doses. The control rabbits received the 
equivalent volume of vehicle. The control animals were pair-fed to compensate for the decrease in 
feed intake caused by aspartame. The control animals were pair-fed to match the aspartame-treated 
animals with the lowest feed intake, but feed intake was noted to be lower still in control animals. The 
authors concluded that no embryotoxic or teratogenic effects were observed.  
In study E79 (1974) artificially inseminated rabbits received a daily dose of 750 (37 animals) or 
2000 mg aspartame/kg bw/day (with a content of DKP up to 2 %) (95 animals) in suspension in an 
aqueous solution of Tween-80 and methylcellulose and administered by gavage twice daily as equal 
doses to artificially inseminated rabbits from post-insemination day 6 through day 18. Control rabbits 
(32 animals) received the same volume of vehicle as the treated animals. The study was confounded 
by poor health of the animals and the misdosing. As a result, maternal mortality was high. The 
administration of aspartame was associated with decreased feed consumption by up to 36 %. The 
control animals were pair-fed to match the aspartame-treated animals with the lowest feed intake. 
However, especially aspartame-treated animals with a very restricted feed consumption died and the 
aspartame-treated animals with a more normal food consumption survived. As a result, the food 
consumption in the pair-fed control animals was noted to be lower than the food consumption of the 
aspartame-treated animals. The authors concluded that no embryotoxic or teratogenic effects were 
observed. However, the Panel considered the study not to be adequate to reach such a conclusion.  
Overall, the Panel considered that the data from the studies described above were confounded by the 
decrease in feed intake (when aspartame was administered via the diet or by gavage), the poor health 
of the animals, and, in many cases, by a number of deaths of pregnant rabbits in the treated groups, 
most possibly related to misdosing.  
In a separate study in pregnant rabbits (E90, 1975), which contained a sufficient number of animals for 
the evaluation of developmental toxicity, aspartame (DKP content 0.29 %) suspended in an aqueous 
solution of Tween-80 and methylcellulose was administered by gavage twice daily to artificially 
inseminated rabbits from GD 6 up to 18. The doses of aspartame were 0 (control), 500, 1000 and 
2000  mg/kg bw/day. The controls received the same volume of vehicle per kg bw as the treated 
animals. The study included two additional groups, one that received L-phenylalanine (820 mg/kg Opinion on the re-evaluation of aspartame (E951) as a food additive
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bw/day) and one that received L-aspartic acid (1100 mg/kg bw/day), which, on a molar basis, were 
levels equivalent to 75 % and 134 % of the amount of the same amino acids theoretically available 
from 2000 mg/kg bw aspartame. Each treatment group consisted of 50 inseminated rabbits. On GD 28 
all surviving females were sacrificed and necropsied. Fetuses were removed by hysterectomy and 
examined, weighed, measured and preserved for either soft tissue or skeletal examination. Parameters 
evaluated included: maternal survival rates; maternal conception rates; incidences of abortion or of 
premature delivery; maternal body weights, feed consumption incidences of litters consisting of 
fetuses only, of both fetuses and resorptions, or of resorptions only; mean litter sizes; mean number of 
resorption sites per litter; mean fetal body weights and crown-rump distances; incidences of major and 
minor malformations on a per litter or per fetus basis. A number of animals died spontaneously during 
the study (4/control; 4/500  mg/kg bw/day; 1/1000  mg/kg bw/day; 4/2000  mg/kg bw/day; 
5/phenylalanine; 2/aspartic acid), mainly due to misdosing. Eight control females, 4 low and mid dose 
females and 13 high dose females were non-pregnant. No abortions were detected in the control, mid 
dose and L-aspartic acid groups, two abortions in the low dose aspartame group and 24 abortions were 
observed in the high dose aspartame group (a significant increase compared to controls) and four in 
the L-phenylalanine group. An approximately 65 % decrease in mean feed consumption was observed 
in the 2000  mg/kg bw/day group animals, beginning on the first day of treatment (GD  6) and 
continuing throughout the treatment period (GD  18). Similarly, feed consumption for the L-
phenylalanine group females from gestation days  6 through 18 was significantly decreased by 
approximately 40 % as compared to the controls. The decrease in feed consumption in the high dose 
aspartame group was followed by body weight loss, first apparent on day 10. These body weight 
losses were statistically significant (P < 0.05) in the high dose group beginning on GD 13, and were 
more marked in those females that ultimately aborted, which comprised well over one-half of the 
pregnant high dose females. Feed consumption was lower in those high dose animals that 
subsequently aborted than in those that maintained their pregnancies to GD  28. In view of the 
statistically significant decrease in feed consumption and the high-incidence of abortions, the authors 
of the report subdivided the data from the high dose animals into two groups for further analysis: those 
from animals surviving until sacrificed on gestation day 28 and retaining their litter (no abortions); and 
those from animals surviving until day 28 but aborting their litter. This analysis showed that females 
in the high dose group having aborted had statistically significantly lower body weights (p < 0.05) 
compared to controls and to non-aborting females, starting at gestation days 13 and 18, respectively. 
Females in the high dose group having retained their litter (non-aborting) did not show any statistically 
significant difference in body weight as compared to controls or to aborting females during the entire 
duration of the study (28 days). Since the decrease in body weight started several days before (13 and 
18 days) the abortions (28 days), the authors concluded that abortion was a consequence of significant 
and rapid body weight loss caused by decreased feed consumption.  
At Caesarean section, only 11 pregnant females of the high dose group were available for evaluation 
versus 36 control, 41 low dose and 44 mid dose pregnant females. The mean number of resorptions in 
the high dose group was increased although not statistically significant due to the low numbers and 
large variability between these litters. However, the mean number of resorptions was significantly 
(P  <  0.05) increased in the L-phenylalanine group. Mean fetal body weight and length were 
significantly reduced in both the 2000 mg/kg bw/day group and the L-phenylalanine group (mean 
body weights (ig) for male fetuses 23.5 (aspartame) and 28.2 (L-phenylalanine) vs. 33.2 in controls; 
for female fetuses 23.3 (aspartame) and 27.1 (phenylalanine) vs. 32.0 in controls). The decrease was 
approximately proportional to the reduction in feed consumption. The number of tarsal and metacarpal 
ossification centres, an indicator of normal fetal growth, was significantly (p < 0.05) reduced in the 
rabbit fetuses of the 2000 mg/kg bw/day and phenylalanine groups. Additionally, a significant increase 
in the incidence of an extra (13
th) pair of ribs and a reduction in sternebral ossification centres were 
observed in high dose aspartame group. Comparisons based on either fetal incidence or litter incidence 
revealed a significantly higher rate of total (major and minor) malformations in the 2000  mg/kg 
bw/day group animals, as compared to the concurrent control group. The increases in major 
malformations were due primarily to three instances of cleft palate in two litters in the high dose 
aspartame group and five instances of umbilical hernia or omphalocele in five separate litters in the L-
phenylalanine group. The increases in minor malformations were due, in large part, to various Opinion on the re-evaluation of aspartame (E951) as a food additive
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vertebral defects and fused or split sternebrae. The authors indicated that all the above reported effects, 
observed at 2000 mg/kg bw/day and to a lesser extent in the L-phenylalanine group, appeared to be 
produced by a severe reduction of nutrient intake.  
Aborting female rabbits from the high dose group in study E90 (1975) manifested body weight loss 
and decreased to negligible feed consumption compared to those that maintained their pregnancies. 
The authors suggested that the effects on dams and fetus were due to a reduced nutrient intake.  
In summary, the results of the reproductive and developmental toxicity studies in rats indicate 
NOAELs that ranged from 2000 mg aspartame/kg bw/day (E11, 1971; E39, 1973; E47, 1973; E48, 
1973) to 4000  mg/kg bw/day (E5, 1970; E9, 1972; E10, 1972). The highest NOAEL for 
developmental toxicity in rabbits of 2400 mg aspartame/kg bw/day was identified by the Panel in 
study E63 (1973), in which the test compound was administered in the diet. The NOAEL in the study 
in rabbits dosed by gavage (E90) was 1000 mg aspartame/kg bw/day, based on maternal toxicity in the 
2000 mg/kg bw/day group, which was accompanied by a severe decrease in mean feed intake. The 
Panel noted that the severely decreased feed intake could have a negative effect on the nutritional 
status of these females and the observed adverse effects could result from gastrointestinal disturbances 
as well as from the potential effect of phenylalanine.  
The overview of the reproduction and developmental studies is presented in Appendix I. 
3.2.5.2.  Additional studies on reproductive and developmental toxicity  
3.2.5.2.1. Reproductive studies 
Rats  
The effect of aspartame on reproduction was investigated in Sprague Dawley rats by Brunner et al. 
(1979). Rats (total number not stated) were fed diets containing 0, 2, 4 or 6 % aspartame (w/w) during 
pre-breeding, gestation and lactation and post-weaning. Feed consumption measurements suggest that 
the animals were exposed to doses of aspartame of approximately 0, 1600, 3500 and 5000 mg/kg 
bw/day during pre-breeding and gestation, 0, 4000, 7000 and 9600 mg/kg bw/day during lactation and 
0, 3000, 6000 and 9000 mg/kg bw/day post-weaning. Another group of rats received phenylalanine in 
the diet (3  %) (approximately 2500  mg/kg bw/day during pre-breeding and gestation, 4600  mg/kg 
bw/day during lactation). Breeding pairs were enrolled in the study until 18 litters were available for 
each group. There was no effect on pre-breeding body weights or on maternal weight gain during 
gestation, but rats exposed to the highest aspartame dose during lactation lost more weight than the 
other dietary groups (9  % of decrease from Day  1 to Day  21). Increased offspring mortality was 
observed in rats fed the highest aspartame dose and in the phenylalanine-exposed animals. Gestation 
length and litter size were not affected by aspartame or phenylalanine; however, pups fed 6  % 
aspartame weighed significantly less than controls after 30 days and remained lighter throughout the 
study. Eye opening was delayed by one day in pups in the 6 % aspartame and 3 % phenylalanine diet 
groups, but timing of pinnae detachment and incisor eruption were not affected. The Panel agreed with 
the conclusion of the authors.  
Potential post-coital fertility was assessed in Charles River rats (6  animals/group) following 
administration of 300 mg aspartame/kg bw/day in corn oil by gavage for seven days after mating 
(Lennon et al., 1980). Controls received corn oil. There were no differences noted in the number of 
rats that became pregnant. The Panel noted that the number of animals used in these studies was small.  
Hamsters 
Potential post-coital fertility was also assessed in a similar experiment in female hamsters with a 
control group of 15 animals treated with corn oil and a group of five animals given daily doses of 
300 mg aspartame/kg bw in corn oil by gavage for seven days after mating (Lennon et al., 1980). No Opinion on the re-evaluation of aspartame (E951) as a food additive
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differences were reported in implantation and regression of corpora lutea. The Panel noted that the 
number of animals used in these studies was small.  
3.2.5.2.2. Developmental studies 
Mice 
Mahalik and Gautieri (1984) reported a study in pregnant CF-1 mice (number not reported) which 
were administered aspartame by gavage at doses of 1000 mg/kg bw/day and 4000 mg/kg bw/day from 
GD 15 to 18. There were no significant differences between control and treated animals in negative 
geotaxis, surface or air righting. However, the achievement age for visual placing was significantly 
delayed, in a dose-dependent manner, in both groups of treated animals (22  ±  0.7 at 1000  mg/kg 
bw/day and 24.4  ±  0.7 at 4000  mg/kg bw/day vs. 20  ±  0.9 in controls). The Panel noted that 
uncontrolled litter size and pup weight were not taken into consideration and performance of the 
offspring was assessed only the last day of achievement for the entire litter.  
In a similar study by McAnulty et al. (1989), CF-1 pregnant mice (20/group) were administered 
aspartame by gavage at doses of 0, 500, 1000, 2000, and 4000 mg/kg bw/day from GD 15 to 18. 
Maternal body weight, feed consumption, gestation length, reproductive indices, and litter size were 
not affected by the treatment. In the pups, there were no changes in body weights, negative geotaxis, 
surface and midair righting reflexes. In addition, reflex pupil closure, and ophthalmoscopic 
examination in the offspring were not altered by the treatment. Time of eye opening was statistically 
significantly later than control at the lowest and highest doses (14.3  ±  0.15 for both doses vs. 
14.8  ±  0.15 in controls), as well as the development of the visual placing which was statistically 
significantly lower than control at the lowest dose of 500 mg aspartame/kg bw/day (18.8 0.28 vs. 
20.5 ± 0.40 in controls). The authors considered these findings as isolated points that may vary in 
either direction. They were not dose-related and as such, the results were not considered to be 
biologically meaningful. The authors concluded that in utero exposure to aspartame in CF-1 mice did 
not affect the physical and functional development of the visual system of the pups. The Panel agreed 
with the conclusion of the authors.  
Rats 
Holder (1989) studied the effects of aspartame administered in the drinking water to rats from 12 days 
prior to conception until the pups were 38 days old. Adult Sprague-Dawley rats (10/group) were given 
either water or water containing aspartame (0.007 %, 0.036 %, 0.18 % or 0.9 % w/v) or phenylalanine 
(0.45  % w/v). The authors reported that adult rats consumed an average of 14, 68, 347, and 
1614  mg/kg bw/day of aspartame respectively, and 835  mg/kg bw/day of phenylalanine. After 
weaning, the pups (4/sex/litter) were given the same treatment as the adult rats, and consumed an 
average of 32, 154, 836, and 3566 mg/kg bw/day of aspartame respectively, and 1795 mg/kg bw/day 
of phenylalanine. The two parameters of morphological development, latency of pinnae detachment 
and eye opening, as well as the two parameters of reflex development, latencies for surface righting 
reflex (which decreased in a dose-dependent manner with aspartame treatment) and negative geotaxis 
were not statistically significantly affected by aspartame or phenylalanine. There were no differences 
on the performance of spatial memory in the radial-arm maze or in the milk maze. Moreover, the 
latency of mothers to retrieve their pups was not affected by either treatment. The authors concluded 
that exposure in utero and later directly of the pups did not affect reflex development, morphological 
development and spatial memory. The Panel agreed with the conclusion of the authors.  
Monkeys 
In a postnatal developmental study, monkeys were fed with 0, 1000, 2000, or 2500-2700  mg 
aspartame/kg bw/day for 9  months. No effects on body weight gain, crown-heel length, teething, 
vocalization, alertness, or general behaviour were observed. No effects on haematological, plasma 
chemistry and urinalysis parameters or on ECG were observed. Aspartame exposure had no effects on Opinion on the re-evaluation of aspartame (E951) as a food additive
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learning performance and hearing ability. The NOAEL was 2500-2700 mg aspartame/kg bw/day, the 
highest dose of aspartame tested (NTP-CERHR Report, 2003). 
3.2.5.2.3. Other studies 
Mice 
Collison et al. (2012a) investigated the effects of neonatal exposure to monosodium glutamate (MSG), 
aspartame or a combination of both, on glucose and insulin homeostasis in C57BL/6J mice chronically 
exposed to these food additives starting in utero. Mouse offspring (12 to 18/sex/group) were bred, 
weaned and maintained on the following diet groups for 17 weeks: standard diet (control), standard 
diet with MSG (120 mg/kg bw/day) alone, standard diet with aspartame (approximately 50 mg/kg 
bw/day) alone, standard diet with MSG and aspartame (at the same doses as when the compounds 
were administered separately). Aspartame alone caused a 1.6-fold increase in fasting blood glucose 
and reduced insulin sensitivity. MSG alone decreased blood triglyceride and total cholesterol levels. 
The combination of MSG and aspartame increased body weight, and caused a further 2.3-fold increase 
in fasting blood glucose compared to control diets. Total cholesterol levels were reduced in both 
aspartame-containing diets in both sexes. A positive correlation between aspartame intake and body 
weight at 6 weeks and 17 weeks, and aspartame intake and fasting blood glucose levels at 17 weeks 
was also noted. The authors concluded that aspartame exposure might promote hyperglycaemia and 
insulin intolerance, and MSG might interact with aspartame to impair further glucose homeostasis.  
The authors attributed indirectly the increases in fasting blood glucose and reduced insulin sensitivity 
observed in their study to an elevated level of aspartame-derived phenylalanine that could potentially 
accumulate in the brain leading to changes in the regional brain concentrations of neurotransmitters 
and a dose-dependent reduction in dopamine, serotonin and noradrenalin levels. The Panel noted that 
the mouse strain used in this study is known to harbour a dominant trait showing a high susceptibility 
to diet-induced type-2 diabetes, as well as obesity and atherosclerosis (JAX Mice Database). The 
Panel also noted that no dose-response was assessed in this study and that other authors (Berglund et 
al., 2008) have reported higher insulin and glucose basal levels in the C57BL/6J mice strain 
suggesting that those parameters vary in that mice strain. The Panel also noted that phenylalanine and 
glutamate can also arise from the protein content of the diet and thus the actual contribution of 
aspartame to the total phenylalanine and glutamate amino acids pool should be clearly defined to be 
able to attribute exclusively an increment in fetal amino acid pool to aspartame intake. Finally, the 
Panel also observed that short term preliminary interventional trials undertaken in human volunteers 
suggest that test meals containing aspartame significantly reduce postprandial glucose levels and 
insulin levels compared to a test meal containing sucrose (Anton et al., 2010). 
In another study Collison et al. (2012b) investigated the effects of neonatal exposure to aspartame, 
commencing  in utero, on changes in blood glucose parameters, spatial learning and memory in 
C57BL/6J mice (numbers of animals not clearly reported but according to the tables published they 
are between 12 and 18 per group depending on the parameter measured) that were administered 
standard diet (control) or standard diet with aspartame (approximately 50  mg/kg bw/day) for 
17 weeks. Increased weight gain, increased fasting glucose levels and decreased insulin sensitivity was 
observed in treated male mice compared to controls. These effects were less apparent in females, 
which did however show significantly raised fasting glucose levels. The escape latencies used in the 
Morris Water Maze to test spatial learning and memory were consistently higher in treated male mice 
than in controls, as well as the thigmotactic behaviour and time spent floating directionless. Spatial 
learning of female-treated mice was not significantly different from controls. Reference memory was 
changed in both sexes, and the aspartame-fed mice spent significantly less time searching for the 
former location of the platform. Visceral fat deposition positively correlated with non-spatial search 
strategies (i.e. floating and thigmotaxis), and negatively with time spent in the target quadrant and 
swimming across the location of the escape platform. Overall, the authors of the study concluded that 
lifetime exposure to aspartame, commencing in utero, might affect spatial cognition and glucose 
homeostasis in C57BL/6J mice, particularly in males.  Opinion on the re-evaluation of aspartame (E951) as a food additive
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The Panel noted that the selection method of pups for several tests was not clearly reported by 
Collison et al. and that only one dose was used thus rendering any assessment of dose-response 
relationship impossible.  
The Panel noted that the findings in mice reported by Collison et al. (2012 b) might not apply to other 
species, since in a large study on Sprague-Dawley rats (Holder, 1989) performances on radial-maze 
and milk maze was similar for rat pups given aspartame at doses from 14 to 1614 mg/kg bw/day or 
phenylalanine at a dose of 835 mg/kg bw/day compared to controls. These findings indicated to the 
authors that spatial memories, as well as motor and visual components of these tasks were not affected 
by perinatal exposure to aspartame.  
Although the study by Collison et al. (2012b) is an in-utero-derived study in mice, the authors do not 
report the initial number of parent females, the number of litters used for each group, nor any litter 
data such as litter size, birth weight and male/female ratio. As these parameters may influence 
nutritional and metabolic parameters associated with fat accretion the observed changes cannot be 
unequivocally attributed to aspartame feeding. The Panel was concerned about the statistical 
procedures used. Based on the study description in Collison et al. (2012a) more than one pup/sex/litter 
was apparently used. In this case a nested evaluation should have been done, calculating group means 
from within-litter-means, instead of treating all pups as unrelated entities.  
In contrast, in the rat study by Holder (1989) the litter data were provided and also the correct 
statistical procedures were applied to account for testing of more than one pup/sex/litter. Thus the rat 
study was considered by the Panel to be more reliable than the mouse study. The Panel concluded that 
the rat study also overruled the results of the mouse study because the rat study had multiple dose 
groups whereas the mouse study had one dose group and a control group only. The Panel considered 
that studies which employ multiple doses and show a trend in response are intrinsically more 
powerful.  
Rats 
Lennon et al. (1980) conducted a larger experiment with 60 female Charles River rats to assess the 
effect of aspartame in the diet on lactation. After mating and delivery of pups, the dams were allocated 
in body weight matched pairs to treatment groups for a pair-feeding experiment. Groups of six dams 
were fed diets containing l, 2, 4, 7.5, or 14 % aspartame by weight for 21 days (during the lactation 
period). Pair-matched controls were fed the same amount of feed as their match consumed ad libitum 
the previous day, but without added aspartame. Feed consumption and body weights were 
significantly lower in dams fed 7.5 and 14  % aspartame diets on day one and throughout the 
experiment (e.g. body weight reduction by up to 65 %). Similar body weight losses were observed in 
the pair-fed controls; therefore, the loss of body weight was considered by the Panel to be due to the 
lower feed consumption. Based on feed consumption data, the actual doses of aspartame by the 
different groups were 0, 1870, 3680, 7120, 9110 and 8830 mg/kg bw/day. Pup body weight was also 
significantly reduced in the 9110 and 8830  mg/kg bw/day groups. Pup survival was significantly 
reduced in the highest dose group and pair-matched controls. Dams fed the highest dose of aspartame 
and pair-matched controls had a higher incidence of resting or inactive mammary glands, which were 
attributed by the authors of the study to a lack of suckling pups and severe feed restriction. The Panel 
noted that there were no effects of aspartame at doses up to 7120 mg/kg bw/day on feed consumption, 
dam and pup body weight, pup survival and mammary gland histology. Therefore, the Panel identified 
a NOAEL of 7120 mg/kg bw/day.  
Rabbits 
Ranney et al. (1975) investigated the phenylalanine and tyrosine content of maternal and fetal body 
fluid in rabbits following dietary exposure to aspartame. Thirty pregnant New Zealand female rabbits 
were fed with either a standard diet (control) or a diet containing aspartame at a level of 6  %, 
beginning from GD 6. Maternal and fetal blood samples and fetal amniotic fluid were taken up to Opinion on the re-evaluation of aspartame (E951) as a food additive
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GD 20. Maternal plasma phenylalanine and tyrosine levels significantly increased in aspartame-fed 
animals compared to controls, reaching a peak of 4.9  ±  0.3  mg/dL (Phe, 296.6  µM) and 
9.9 ± 0.6 mg/dL (Tyr, 546 µM) on GD 9. These values returned to normal on GD 20. Fetal plasma 
tyrosine was significantly higher in aspartame-fed animals compared to controls, reaching a peak of 
7.4  ±  0.2  mg/dL (408  µM) on GD  20, whereas phenylalanine was unchanged (2.5  ±  0.2  mg/dL 
(151.3 µM) in controls vs. 2.3 ± 0.2 mg/dL (139.2 µM) in aspartame-treated rabbits). This resulted in a 
significant drop in the Phe/Tyr ratio in both maternal (up to 58  %) and fetal plasma (53  %). 
Phenylalanine and tyrosine concentrations in the amniotic fluid were consistently higher in the 
aspartame -treated animals compare to controls at GD 16 and 20, with peaks at 20.4 ± 2.8 mg/dL (Phe, 
1235 µM) and 33.4 ± 2.0 mg/dL (Tyr, 1843 µM) at GD 20. The ratios of amniotic fluid/maternal and 
fetal plasma phenylalanine and tyrosine concentrations at GD 20 were higher in treated-animals 
compared to controls. Both phenylalanine and tyrosine concentrations of the supernatants from whole 
fetal homogenates at GD  16 and 20 were higher in treated-animals than in control, and, as a 
consequence, the ratio of Phe/Tyr was consistently lower than control values. The authors concluded 
that the treatment of pregnant rabbits with a high dose of aspartame did not affect the transport of 
phenylalanine and tyrosine across the placental membrane since the ratios of fetal/maternal plasma 
amino acid concentrations were unaffected by the treatment.  
3.2.6.  Other studies on aspartame 
3.2.6.1.  Neurotoxicity 
In order to investigate whether aspartic acid generated from aspartame might induce neurotoxicity, a 
study in neonatal mice was performed. Neonatal hybrid A/JAX-ICR mice aged 6-10  days (12-
18 animals of both sexes per dose group, sex ratio not specified) were dosed between PND 6 and 10 
by gavage with aspartame at single doses of 250 (n = 12 out of 3 litters), 500 (n = 19 out of 5 litters), 
1000 (n = 21 out of 3 litters), 1500 (n = 17 out of 4 litters) or 2000 (n = 5 out of 18 litters) mg/kg as a 
10 % slurry (volume, vehicle and duration of exposure not stated) (E94, year not reported). Upon 
sacrifice, brains were subjected to histopathological examination. The Panel however noted that the 
design of the study was not adequately described and no control group was included, and, therefore, 
this study was considered not relevant for the overall risk assessment.  
In another study using mice aged 6-12 days (sex and strain not specified) aspartame was dosed orally 
at 500 (27 animals), 1000 (15 animals), 1500 (17 animals) or 2000 (18 animals) mg aspartame/kg bw 
in a 10 % (w/v) slurry (volume and vehicle not stated) (Reynolds et al., 1976). The Panel noted the 
absence of control animals in the study and therefore did not take this study into consideration.  
Long Evans weanling rats (21-day-old, 32/sex/group) were given a standard diet (control) or standard 
diet supplemented with L-phenylalanine (2.5 or 5 %), or aspartame (4.5 or 9 %) for 13 weeks (E14, 
1972). For aspartame in the diet, the calculated mean daily intakes of L-phenylalanine were: 
3000  mg/kg bw/day (4.5  % aspartame) and 6100  mg/kg bw/day (9  % aspartame) in males, and 
3100 mg/kg bw/day (4.5 % aspartame) and 6800 mg/kg bw/day (9 % aspartame) in females. For L-
phenylalanine in the diet, the calculated mean daily intakes of L-phenylalanine were: 3000 mg/kg 
bw/day (2.5  % L-phenylalanine) and 6700  mg/kg bw/day (5  % L-phenylalanine) in males, and 
3200  mg/kg bw/day (2.5  % L-phenylalanine) and 6500  mg/kg bw/day (5  % L-phenylalanine) in 
females. No differences in physical condition were noted between the groups. For the low dose groups 
(2.5 % L-phenylalanine and 4.5 % aspartame), some effects were reported on occasions but they were 
transient and not dose-related. For the high dose groups (5 % phenylalanine and 9 % aspartame), 
statistically significantly impaired learning performances were reported (i.e. conditioned or 
nondiscriminated avoidance responses). The Panel concluded that L-phenylalanine administered at 
doses of 6000 mg/kg bw/day for 90 days to rats, impaired learning performances. Doses of aspartame 
providing the same dose of L-phenylalanine induced similar effects. At a lower dose (3000 mg L-
phenylalanine/kg bw/day), the effects were not reported.  Opinion on the re-evaluation of aspartame (E951) as a food additive
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Male weanling Long-Evans rats (8 animals) were dosed with aspartame (1000 mg/L in drinking water; 
actual intake not specified) for 14  weeks, after which terminal blood samples were taken for 
measurement of plasma glucose, immunoreactive insulin and leptin (Beck et al., 2002). The study 
contained a control group of 16 rats that received tap water. Epididymal, perirenal and subcutaneous 
fat pads were dissected and the liver, spleen and heart were also taken. Frozen sections of brain 
(300 µm) were cut and individual brain regions were sampled by micropunching for the analysis of 
neuropeptide Y. The authors of the study reported that feed and fluid intakes were similar between 
treated and control groups, but aspartame treated rats gained less body weight than controls, with fat 
pads weighing less than controls (34.86  + 1.39 g  vs.  27.59 + 1.89 g;  p < 0.02).  Whereas  terminal 
plasma insulin and glucose levels did not differ between groups, the level of hypothalamic 
neuropeptide Y in the arcuate nucleus (but not in other parts of the brain) was significantly lower in 
aspartame-treated rats than in controls by 23.2 % (p < 0.02). The author reported that the reasons for 
the neuropeptide Y decrease were not clear and further analysis of other neuropeptides in the arcuate 
nucleus plus further histological controls will contribute to elucidate if the observed effects are 
physiological or treatment-related. The panel agreed with these observations.  
Christian et al. (2004) reported effects of chronic aspartame treatment on the T-maze performance in 
rats and on brain muscarinic cholinergic receptors and Na
+,K
+-ATPase, potentially related to learning 
and memory processes. Twelve male rats were exposed to aspartame (250 mg/kg bw/day) for 120 days 
through drinking water and compared to a control group of the same size which received regular tap 
water. Learning was unimpaired and during the first 60 days both groups exhibited similar latencies to 
get the reward, a piece of chocolate placed in the same arm of the maze for all trials. From day 90 
onward, latencies of the aspartame group increased which the authors interpreted as a sign of memory 
loss. The aspartame group also showed an increase of midbrain Na
+,K
+-ATPase activity and of 
muscarinic receptors in various brain regions. However, no association with regions specifically 
involved with memory functions was apparent. Moreover, the change in brain Na
+,K
+-ATPase activity 
restricted to midbrain would indicate a difference in motivation rather than a memory problem (Shen 
and Johnson, 1998). The Panel noted that a sweet reward may have held a much higher attractiveness 
for control animals given unsweetened drinking water than for animals given aspartame in drinking 
water. The Panel concluded that this study is insufficient to ascertain an effect of aspartame on 
memory functions.  
Rabbits (3 months old) and Wistar rats (30 days old) were dosed with aspartame (2000 mg/kg bw/day 
in diet slurry) for 30 days (Puica et al., 2008, 2009). No vehicle or sham-gavaged control group is 
mentioned and the frequency of dosing is not stated. At the end of 30 days of dosing, animals were 
decapitated and the brains prepared for EM. Ultrastructural damage, described as ‘selective 
degeneration of all subcellular neurons ultrastructures both in CA1 pyramidal neurons of the 
hippocampus and ventromedial area of the hypothalamus’ was reported in both species, and the 
authors conclude that juvenile rats and rabbits are particularly susceptible to neurotoxic effects 
induced by aspartame. However, the Panel noted that the interpretation of these studies was not 
possible because of the lack of experimental details, the absence of appropriate control animals and of 
statistical analysis of the data.  
The potential neurotoxic effects of high doses of aspartame were also examined in monkeys (E104, 
1979; Reynolds et al., 1980; E105, year not reported). Macaques aged 1-22 days (species Macaca 
mulatta,  Macaca fascicularis and  Macaca arctoides) weighing 280-820  g were administered by 
gavage a single dose of either vehicle (2-5  ml water/animal; 2  males and 3  females), aspartame 
(2000 mg/kg bw; 2 males and 6 females) or a combination of aspartame and monosodium glutamate 
(MSG) (2000 + 1000 mg/kg bw; 3 males and 3 females) as a 10 % (w/v) slurry. For aspartame, the 
dose was calculated to correspond to 6-11 ml administered/animal. The Panel noted that this dosing 
volume was higher than that received by controls. The study also included an untreated control group 
of five males and one female. Blood samples were taken up to 4-5 hours after dosing and the animals 
were then sacrificed. Light and electron microscopic examination of the brain sections revealed no 
significant abnormalities in response to aspartame or aspartame + MSG treatments. Measurements of 
plasma amino acid levels showed that aspartic acid reached a peak concentration of 230 ± 330 µM at Opinion on the re-evaluation of aspartame (E951) as a food additive
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60 min (p < 0.0001) and that phenylalanine reached a peak concentration of 950 ± 590 µM at 90 min. 
Basal levels (0 minute time point) for aspartic acid and phenylalanine were 0.69  + 0.43 µM  and 
5.93 + 2.81 µM, respectively. The Panel noted that the design of the study is inappropriate to evaluate 
effectively any potential neurotoxic effects of aspartame.  
The Panel is aware that the neurotoxicity of aspartame was also reviewed by Magnuson et al. (2007) 
and subsequently by the National Expert meeting of the EFSA Advisory Forum (EFSA, 2010). 
Magnuson et al. (2007) concluded that the data obtained from the extensive investigations of the 
potential neurotoxic effects due to aspartame consumption, did not support the hypothesis that 
aspartame present in the human diet would cause any impairment of the neuronal function, learning or 
behaviour. Likewise, the National Expert Meeting of the EFSA Advisory Forum (EFSA, 2010) 
concluded that no new data were identified which reported a link between aspartame intake and 
enhanced susceptibility to seizures, behaviour, mood and cognitive function (EFSA, 2010). These 
conclusions were in line with the SCF conclusions in 2002 (SCF, 2002). The Panel agreed with their 
conclusions.  
3.2.6.2.  Studies on the effect of aspartame administration on xenobiotic metabolising enzymes 
An early study (E15, 1972) indicated that the oral administration of aspartame to male Charles River 
rats (2000-4000  mg/kg) for four days had no acute effect on hepatic cytochrome P450 (CYP)-
mediated xenobiotic metabolism, as measured as aminopyrine N-demethylation, p-nitroanisole N-
demethylation, hexobarbital sleeping time or zoxazolamine paralysis time. Two studies subsequently 
showed that aspartame administration (≤ 4000 mg/kg bw/day for up to 90 days) had small effects on 
hepatic Phase 1 and Phase 2 metabolism in rodents after 45 days treatment but not after 90 days 
treatment (Tutelyan et al., 1990). In a more recent study (Vences-Mejia et al., 2006), male Wistar rats 
were dosed with aspartame (75 or 125 mg/kg bw/day) daily for 30 days. Using hepatic microsomal 
samples from liver, cerebrum (pooled) and cerebellum (pooled), the authors investigated CYPs by 
immunoblotting (CYPs 1A1, 1A2, 2B, 3A2 and 2E1) and enzymatic activity measurement 
(ethoxyresorufin O-deethylase, methoxyresorufin O-demethylase, pentoxyresorufin O-depentylase, 
benzyloxyresorufin O-debenzylase, 4-nitrophenol hydroxylase and erythromycin-N-demethylase). No 
effect of aspartame treatment was observed in the liver samples. However, bands corresponding to 
CYPs 1A1, 1A2, 2B, 3A2 were detectable in the cerebrum and cerebellum samples brain samples after 
aspartame treatment (but not in the control samples) and increases in all the enzyme activities were 
reported. The Panel noted that the findings have minimal relevance for human risk assessment.  
3.2.6.3.  Miscellaneous studies on aspartame 
Alleva et al. (2011) evaluated the ability of aspartame to induce angiogenesis in an in vitro model 
which used human endothelial cells (HUVEC) co-cultured in a matrix of human fibroblasts (IMR-90) 
following treatment with aspartame at concentrations of 20-100 μM in culture medium. The formation 
of blood vessels was associated with a transient release of the inflammatory cytokine IL-6 and the 
growth factor VEGF-A into the medium. Transient increases in the inflammatory cytokine IL-6 and 
the growth factor VEGF-A were also observed in the HUVEC cells following treatment with 
aspartame. This increase coincided with a temporary induction of ROS in HUVEC cells but not in 
IMR-90 fibroblasts thus concluding that generation of ROS is related to the target. The Panel noted 
that production of ROS could not be attributed to specific cell types but rather a general phenomenon. 
Furthermore, the authors did not evaluate the fate of aspartame in culture medium ascertaining 
whether it was hydrolysed to its usual metabolites or remained intact. For induction of angiogenesis, 
no positive and negative controls were reported. Therefore, the findings reported might be ascribed 
specifically to the conditions of the study. For these reasons, the Panel considered that this study was 
not relevant for the risk assessment of aspartame.  
Haque and Mozaffar (1993) reported the effect of aspartame on acetylcholinesterase activity in the 
brain of Swiss Wistar mice. Forty-two males and forty-two females at the age of 22, 32 and 52 days, 
were fed with a formulated diet containing 1 % aspartame for 30 days. Brain filtrates were analysed 
for acetylcholine (ACh) levels and acetylcholine esterase (AChE) activity. No effect on ACh protein Opinion on the re-evaluation of aspartame (E951) as a food additive
 
 
EFSA Journal 2013;11(12):3496  85
was reported. Aspartame did not influence AChE activity except in the oldest female group where a 
10 % decrease of the activity was observed. The authors calculated that for a mean body weight of 
35 g for female animals, the daily consumption of aspartame was 286 mg/kg bw. The study authors 
concluded that aspartame does not affect AChE activity. The Panel noted that there was an error in 
authors’ calculation of aspartame daily consumption dose, because applying EFSA’s conversion factor 
(EFSA Scientific Committee, 2012) gives a daily dose of 2150 and 1690 mg/kg bw for females and for 
males respectively.  
The effect of aspartame on AChE activity was investigated in an in vitro system by Simintzi et al. 
(2007a, b). Aspartame metabolites were tested on AChE pure enzyme or on AChE extracted from the 
frontal cortex (Simintzi et al., 2007a) or hippocampus (Simintzi et al., 2007b) of albino Wistar rats (21 
days of age). Four mixes of methanol, aspartic acid and phenylalanine were tested, simulating the 
assumed concentrations of these metabolites in the cerebrospinal fluid (CSF) of humans after ingestion 
of aspartame at different doses: 10 mg/kg bw (mix 1), 34 mg/kg bw (mix 2), 150 mg/kg bw (mix 3) 
and 200 mg/kg bw (mix 4). According to the authors, mixes 3 and 4 represented doses that could be 
ingested by accident. The results showed a significant reduction of AChE activity from the frontal 
cortex and of AChE pure enzyme after incubation with mix 3 and 4. Mix 2 caused a significant 
reduction only of the AChE activity from the frontal cortex (Simintzi et al., 2007a). Mix 3 and 4 
induced a similar reduction of AChE activity from hippocampal protein extract (Simintzi et al., 
2007b).  
The authors of the study also described the effect of each aspartame metabolite on the activity of both 
AChE pure enzyme and AChE from frontal cortex homogenates (Simintzi et al., 2007a) or from 
hippocampal homogenates (Simintzi et al., 2007b). The enzyme activity was measured after a 1-hour 
incubation with each aspartame metabolite, separately, at the concentration expected in CSF 
corresponding to the aspartame intake of 10, 34, 150 or 200 mg/kg. The results indicated that the 
incubation with metabolites corresponding to 10  mg aspartame/kg bw (methanol 0, aspartic acid 
0.05 mM, phenylalanine 0.012 mM) did not affect AChE activity (both with pure enzyme and with 
enzyme present in frontal cortex homogenates). At the aspartame dose of 34 mg/kg bw, only aspartic 
acid (0.16  mM) reduced the activity of both AChE from frontal cortex and AChE pure enzyme. 
Methanol (0.14  mM) reduced the activity only of AChE from frontal cortex while phenylalanine 
(0.023 mM) did not affect the enzyme activity (Simintzi et al., 2007a). The incubation with methanol, 
phenylalanine or aspartic acid at concentrations corresponding to an aspartame intake of 150 or 
200  mg/kg bw reduced the activity of both AChE pure enzyme and AChE from frontal cortex 
(Simintzi et al., 2007a) or from hippocampal homogenates (Simintzi et al., 2007b).  
According to the authors, aspartame metabolites can reach the cerebrospinal fluid and brain tissues. 
The authors suggest that phenylalanine could inhibit AChE activity through a direct interaction with 
the positively charged sites of the enzyme or with an oxidative effect. Another mechanism is the 
saturation of the blood-brain barrier transport system by a large excess of phenylalanine. As 
hypothesised for PKU patients, a high phenylalanine concentration could saturate the transport system 
excluding other amino acids, e.g. tyrosine and tryptophan from entry into the brain. As a consequence, 
phenylalanine would interfere with the conversion of tyrosine to biogenic amines (dopamine, 
adrenaline, serotonin) and possibly affecting AChE activity. Aspartic acid could reduce AChE activity 
inducing a membrane lipid peroxidation affecting the function of membrane AChE. Methanol could 
affect AChE activity through its interaction with lipids or proteins.  
From these in vitro experiments, the authors concluded that AChE activity could be reduced by 
aspartame metabolites after ingestion of very high amounts of aspartame. Metabolites derived from a 
realistic beverage consumption of aspartame does not affect AChE activity. The Panel, noting the 
unrealistic high doses of aspartame metabolites assumed to be present in CSF and several assumptions 
and speculations that were applied to explain the effect on AChE activity, considered that no 
conclusions can be drawn from these studies. The Panel concluded that these studies are of no 
relevance for aspartame risk assessment under realistic use conditions.  Opinion on the re-evaluation of aspartame (E951) as a food additive
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Aspartame was administered to zebrafish (70 per dose group) in the diet (50 g/kg diet) for 14 days 
(Kim et al., 2011). No effect of aspartame on survival was observed.  
Following a public call for data, preliminary investigations on a wide range of potential 
pharmacological and endocrine effects of aspartame, summarised in two data compendia (E1, 1972; 
E19, year not provided), were received. The compendia did not report any adverse effects.  
3.2.7.  Human studies of aspartame 
3.2.7.1.  Epidemiological studies  
Epidemiological data on aspartame were previously reviewed by SCF (2002). The Panel considered 
and agreed with the conclusions of SCF that there was no evidence for adverse effects of aspartame in 
the human population. New epidemiology studies, published since the SCF opinion, are described 
below. 
3.2.7.1.1. Recent epidemiological studies on artificially sweetened drinks and pre-term delivery 
A large prospective cohort study (Halldorsson et al., 2010) based on data from the Danish National 
Birth Cohort investigated associations between consumption of artificially sweetened and sugar- 
sweetened soft drinks during pregnancy and subsequent pre-term delivery. Recruitment of the cohort 
of participants occurred between January 1996 and October 2002.  
The reasons cited by the authors for undertaking the analysis were: 
a) Both artificially and sugar-sweetened soft drinks might be associated with hypertension which is a 
known risk factor for pre-term delivery.  
b) Intake of sugar-sweetened soft drinks has been related to the metabolic syndrome and type 2 
diabetes mellitus. High blood glucose concentrations have been linked to a shorter duration of 
gestation.  
c) Methanol is a metabolite of aspartame. Low dose methanol exposure has been linked to a shorter 
duration of gestation.  
The study population included 91  827 pregnant women from all over Denmark, equating to 
approximately 35 % of all deliveries in Denmark during the study period. Of these, 59 334 (64.6 %) 
women were analysed in this study, the main reason for attrition being failure to provide the required 
dietary information during pregnancy. Since the events leading to exclusion occurred before the 
outcome of pregnancy was known, they would not be expected to have given rise to bias. Analysis 
was restricted to each woman’s first singleton pregnancy registered during the study period. This 
restriction appears appropriate, since multiple pregnancies are a significant factor in pre-term birth. It 
would not be expected to produce bias.  
Dietary exposures were obtained at about week 25 of gestation by a food frequency questionnaire 
(FFQ) covering the past month. Among other things, questions were asked about frequency of 
consumption (in servings) of each of: sugar-sweetened carbonated drinks; sugar-sweetened 
uncarbonated drinks; sugar-free carbonated drinks; and sugar-free uncarbonated drinks. It appears that 
no attempt was made to analyse exposures to other more important dietary sources of methanol such 
as fruit and vegetables. A subsample of 103 women completed a repeat FFQ at 33-35 weeks gestation. 
Spearman’s correlation coefficients for the soft drink exposure variables in paired questionnaires were 
about 0.7. Due to the prospective design, any misclassification of exposures would be expected to bias 
risk estimates towards the null rather than to produce spurious associations between exposure and 
health outcome. It should be noted that the exposure assessment was for sweeteners in general and not 
specific for aspartame. Furthermore, the exposure assessment did not consider other dietary sources of 
sweeteners (e.g. sweeteners added to coffee, tea or other food products).  Opinion on the re-evaluation of aspartame (E951) as a food additive
 
 
EFSA Journal 2013;11(12):3496  87
Pre-term delivery was defined as delivery occurring before week 37 of gestation. Data on date of 
delivery and type of delivery (spontaneous or induced) were obtained from the Medical Birth Registry. 
Data on expected date of delivery were obtained from mothers at approximately week 12 of gestation 
(43 % of pregnancies) or week 30 of gestation (56 %), or from the Medical Birth Registry (1 %).  
Statistical analysis was by logistic regression and apparently did not adjust for year of delivery. This 
could have produced bias if both consumption of soft drinks and thresholds for induction of delivery 
pre-term changed over the course of the study period. However, as the study period was only seven 
years, it is highly unlikely that any such bias would have been large. Analyses were adjusted for seven 
non-dietary factors that were known to predispose to pre-term delivery: maternal age, maternal height, 
pre-pregnancy BMI, cohabitant status, parity, smoking during pregnancy, and familial socioeconomic 
status. This information was ascertained in prenatal telephone interviews conducted at around 
weeks 12 and 30 of gestation.  
Statistically significant trends were found in the risk of pre-term delivery with increasing consumption 
of artificially sweetened drinks (both carbonated and non-carbonated), but not for sugar-sweetened 
drinks. In the highest exposure groups (≥ 4 servings/day) the odds ratios relative to non-consumption 
were 1.78 (95 % CI 1.19-2.66) and 1.29 (95 % CI 1.05-1.59) respectively for carbonated and non-
carbonated artificially sweetened drinks. The associations with different categories of soft drinks were 
not mutually confounded, and the associations with consumption of artificially sweetened carbonated 
drinks did not differ demonstrably according to whether delivery was very early (< 32 weeks) or only 
moderately or late pre-term.  
A notable finding was that the trend in risk for artificially sweetened carbonated drinks was strongest 
for medically induced pre-term deliveries, and was not clearly apparent for spontaneous pre-term 
deliveries. No analysis was made by reason for pre-term delivery (data on which may not have been 
available).  
The Panel noted that the prospective design and large size of the study sample were major strengths, 
and there were no important flaws in the methods used. However, risk estimates may have been 
inflated by residual confounding (including by year of delivery). No account was taken of other 
dietary sources of methanol, and use of aspartame specifically was not distinguished from that of other 
artificial sweeteners). Therefore, given these limitations, the Panel agreed with the authors who 
concluded that replication of their findings in another setting was warranted.  
Another study (Englund-Ögge et al., 2012) investigated the relation between consumption of 
artificially sweetened and sugar-sweetened soft drinks during the first 4-5 months of pregnancy and 
subsequent pre-term delivery in a large cohort of Norwegian women.  
The authors used data from a prospective cohort study of 90 700 pregnant women recruited during 
1999-2008 (comprising 38.5 % of those invited to participate), which they analysed retrospectively. 
After exclusions for various specified reasons (e.g. not a singleton pregnancy, incomplete data on 
covariates, baby not born alive between gestational weeks 22 and 41), analysis was based on 60 761 
women. The exclusions are unlikely to have been an important source of bias. In particular, where data 
were missing on covariates (6630 women), this occurred before the outcome of pregnancy was known.  
Dietary exposures were ascertained at about week  22 of gestation by a semi-quantitative food 
frequency questionnaire covering the first 4-5 months of pregnancy. Among other things, six questions 
were asked about frequency of consumption (in 250 ml servings) of artificially and sugar-sweetened 
carbonated drinks (carbonated cola and other carbonated drinks) and non-carbonated drinks. From this 
information, total intakes of artificially sweetened and sugar-sweetened soft drinks were calculated.  
Pre-term delivery was defined as occurring before week  37 of gestation. Gestational age was 
determined by ultrasonography at gestational weeks 17-18. This information, and that about pregnancy 
outcome, was obtained from a national birth registry.  Opinion on the re-evaluation of aspartame (E951) as a food additive
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Statistical analysis was by logistic regression. Analyses were carried out with and without adjustment 
for eight co-variates known to be associated with pre-term delivery: maternal history of previous pre-
term delivery, maternal age at delivery, maternal pre-pregnancy BMI (calculated from self-report of 
weight and height), marital status, parity, smoking during pregnancy, maternal education, and total 
energy intake during the first half of pregnancy. The result of adjusting for co-variates was generally a 
reduction of the risk estimates. Some analyses also adjusted for consumption of the other type of 
beverage (sugar-sweetened or artificially sweetened), and this increased risk estimates slightly.  
No significant trends were found in the risk of pre-term delivery with increasing consumption either of 
artificially sweetened drinks or of sugar-sweetened drinks. Small elevations of risk were observed with 
higher consumption of artificially sweetened soft drinks, but after adjustment for covariates, these 
reached statistical significance only when categories of consumption were aggregated to four levels, 
and then the odds ratio for the highest category (≥ 1 serving/day) was only 1.11 (95 % CI 1.00-1.24) in 
comparison with non-consumption. This was driven by an increase in spontaneous but not medically-
induced pre-term delivery. Associations with sugar-sweetened soft drinks tended to be somewhat 
stronger, with an adjusted odds ratio of 1.25 (95 % CI 1.08-1.45) for consumption of at least one 
serving per day.  
This pattern of results contrasts with that reported by Halldorsson et al. The association of pre-term 
delivery with artificially sweetened soft drinks was much weaker and barely discernible, applied more 
to spontaneous than medically induced deliveries, and was exceeded by an association with 
consumption of sugar-sweetened soft drinks. The Panel noted that effects may have been 
underestimated because of non-differential inaccuracies in the assessment of dietary exposures, but the 
method was similar to that used by Halldorsson et al., and the same for sugar-sweetened as for 
artificially sweetened soft drinks.  
Both Halldorsson et al. (2010) and Englund-Ögge et al. (2012) studies appear to have been well 
designed and conducted. Noting this, the Panel concluded that even at high levels of exposure to 
artificially sweetened soft drinks the risk of pre-term delivery is likely to be small, if any. The 
observed associations could be a consequence of uncontrolled residual confounding, and the 
inconsistencies in the patterns of association reinforce this uncertainty.  
La Vecchia (2013) performed a meta-analysis of findings from the studies by Halldorsson et al. (2010) 
and Englund-Ögge et al. (2012). The methods used were described as ‘standard’, but were not reported 
in detail. The analysis indicated similarly elevated risks of pre-term delivery with higher consumption 
both of sugar-sweetened and of artificially sweetened drinks. This lack of specificity in the 
associations again points to possible residual confounding.  
Overall, currently available epidemiological data do not suggest that consumption of artificially 
sweetened soft drinks is a cause of pre-term delivery. 
3.2.7.1.2 Epidemiological study on artificially sweetened drinks and allergy 
Maslova et al. (2013) explored how intake of artificially sweetened beverages during pregnancy 
related to asthma and allergic rhinitis in children at 18 months and 7 years of age. Analysis was based 
on 60 466 pregnant women who enrolled in the prospective longitudinal Danish National Birth Cohort 
between 1996 and 2002. 
Maternal diet was assessed by a food frequency questionnaire completed at around gestation week 25. 
Mothers were subsequently interviewed about their child’s health and medical diagnoses since birth 
when the child was 18 months old, and 7 years of age. At the 7 year follow-up, the study authors also 
ascertained diagnoses of asthma and treatment for asthma through two national registries: the Danish 
National Patient Registry (DNPR) and Register of Medicinal Product Statistics (RMPS).  
Logistic regression was used to assess an association between mother’s intake of artificially-sweetened 
drinks during pregnancy and allergic disease in the children. Various potential confounding factors Opinion on the re-evaluation of aspartame (E951) as a food additive
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were taken into account: maternal age, smoking, parity, pre-pregnancy BMI, physical activity, 
breastfeeding, socioeconomic status, child’ sex, maternal and paternal history of asthma and allergies, 
and maternal energy intake during pregnancy. Cases of asthma in the children were identified using 
four alternative definitions (mother reported doctor’s diagnosis at age 18 months; a positive response 
at age 7 years to the standardised International Study of Asthma and Allergies in Childhood questions 
on doctor-diagnosed asthma and wheezing symptoms; ever hospital admission for asthma by age 7 
years (through the Danish National Patient Registry); and at least two prescriptions of certain drugs for 
obstructive airways disease by age 7 years (through the Register of Medicinal Product Statistics)). The 
study authors indicated that data from both registries were limited to children with self-reported 
diagnosis, in order to avoid discordance in findings due to differences in study populations. In 
addition, previous occurrence of allergic rhinitis was defined by a reported doctor’s diagnosis of hay 
fever by age 7 years. This method to identify allergic rhinitis would not include all cases of allergic 
rhinitis, but it would reduce the chance of false positive diagnosis. 
In comparison with no consumption of artificially sweetened non-carbonated soft drinks during 
pregnancy, consumption of at least one serving per day was associated with an increased risk of 
asthma by three of the four case definitions (odds ratios up to 1.23, 95% CI 1.13-1.33 for asthma at 18 
months), but there was no consistent exposure-response relationship across lower frequencies of 
consumption. In a corresponding analysis for artificially sweetened carbonated soft drinks, elevated 
odds ratios were observed for all four case definitions with the highest odds ratios of 1.30, 95% CI 
1.01 – 1.66 for asthma at 7 years of age identified through the Danish National Patient Registry, but 
again without clear exposure-response relationships. Allergic rhinitis was non-significantly associated 
with daily consumption of artificially sweetened carbonated soft drinks (OR 1.31, 95% CI 0.98-1.74); 
no association was observed with daily consumption of artificially sweetened non-carbonated drinks 
(odds ratios of 1.03, 95% CI 0.86-1.24). 
Although the study distinguished between carbonated and non-carbonated soft drinks, the exposure 
assessment was for sweeteners in general and not specific for aspartame.  
Because in epidemiological terms, the elevations of risk were only small and inconsistent, the findings 
from this study can only be considered weakly suggestive of hazard i.e. an association between the 
consumption of artificially sweetened beverages during pregnancy and the diagnosis of asthma or 
allergic rhinitis in children. Before a final conclusion can be reached with regard to aspartame, the 
findings need to be explored further with more detailed assessment of exposure to specific artificial 
sweeteners. 
3.2.7.1.3. Epidemiological studies of aspartame and cancer  
In a Swedish case-control study 209 patients with brain tumour were compared with 425 controls, who 
were selected from the Swedish Population Register (Hardell et al., 2001) and matched to the cases for 
sex, age and region of residence. The focus of the study was exposure to ionising radiation and cellular 
telephones, but information was also collected about consumption of low-calorie drinks, most of 
which contained aspartame. Non-significant elevations of risk were observed for consumption of such 
drinks in relation to brain tumours overall (OR 1.24, 95 % CI 0.72-2.14) and malignant brain tumours 
specifically (OR 1.70, 95 % CI 0.84-3.44).  
The study had a high response rate, but was limited by its relatively small size, the basic assessment of 
exposure (low-calorie drinks were the only source of aspartame investigated in this study), and the 
potential for recall bias (because cases knew that they had a brain tumour) all of which could have led 
to spurious inflation of risk estimates.  
A US case-control study included 315 children with medulloblastoma/primitive neuroectodermal 
tumour diagnosed before the age of 6  years, and 315 control children (selected from the general 
population by random digit dialling) (Bunin et al., 2005). Their mothers were interviewed 
retrospectively (on the telephone by trained interviewers) about their diet before (to ascertain the Opinion on the re-evaluation of aspartame (E951) as a food additive
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periconception period) and during pregnancy (second trimester). This was assessed by a modified food 
frequency questionnaire covering 112 items. 
In an unadjusted analysis, a significant trend of increasing risk was observed with more frequent 
consumption of low-calorie carbonated drinks (diet soda) in the pre-conception period. However, this 
was attenuated after adjustment for potential confounders, with an adjusted odds ratio of 1.3 (95 % CI 
0.7-2.5 for ≥ 2/day versus < 1/month). There were no significant associations with reported frequency 
of consuming diet soda during midpregnancy.  
Response rates were reasonable, but the assessment of exposure to diet soda required recall after an 
interval of several years and therefore may not have been reliable. Furthermore, it served only as a 
proxy for exposure to aspartame (which at the time was the most widely used sweetener in soft 
drinks), and other possible sources of aspartame were not evaluated.  
The authors concluded that their results generally did not support an association with aspartame, but 
the above limitations, and also the low statistical power, restrict the conclusions that can be drawn 
from this study.  
A paper by Gallus et al. (2006) reports a linked set of case-control studies carried out in Italy between 
1991 and 2004 to assess the association of artificial sweeteners with nine types of cancer. Patients with 
incident, histologically confirmed cancers of the oral cavity and pharynx (598), oesophagus (304), 
colon (1225), rectum (728), larynx (460), breast (2569), ovary (1031), prostate (1294) and kidney 
(767) were compared with 7028 controls admitted to the same hospitals for acute, non-neoplastic 
disorders. Odds ratios for consumption of sweeteners other than saccharin (mainly aspartame) ranged 
from 0.71 to 1.62, and their upper 95 % confidence limits from 1.00 to 3.14. The highest lower 95 % 
confidence limit was 0.86 (prostate cancer).  
Dietary exposures were ascertained in an interview in hospital, which included a food frequency 
questionnaire with 78 items. Assessment of dietary exposure was restricted to usual diet in only the 
past two years, and did not cover all possible sources of artificial sweeteners (only sachets or tablets). 
However, the authors state that dietetic soft drinks had only recently been introduced in Italy, and that 
they were therefore unlikely to have contributed to the cancers in the age groups investigated.  
It seems likely that any misclassification of exposures will have been non-differential (i.e. similar for 
cases and controls), in which case the effect will have been to bias risk estimates towards the null. 
Thus, while the results do not suggest a hazard for the cancers studied, on their own they provide only 
limited reassurance of safety. 
In an extension to this series of studies, the possible associations of artificial sweeteners with three 
additional types of cancer were further explored (Bosetti et al. 2009).  
The cases were 230 patients with histologically confirmed stomach cancer, 326 patients with 
pancreatic cancer and 454 patients with endometrial cancer. These were compared with 547, 652 and 
908 controls, frequency matched by age, sex and study centre. Cases and controls were interviewed 
during their hospital stay. A food frequency questionnaire was used to investigate the patient’s usual 
diet in the 2 years before diagnosis (or hospital admission for controls), and included questions on 
weekly consumption of sugar, saccharin and other low-calorie sweeteners (mainly aspartame). Odds 
ratios (ORs) and corresponding 95 % CIs for consumption of sweeteners and of sugar were derived by 
logistic regression with adjustment for age, sex, study centre, year of interview, education, body max 
index, tobacco smoking, history of diabetes, consumption of hot beverages and total energy intake. 
ORs for ever use of low-calorie sweeteners versus non-use were 0.80 (95 % CI, 0.45-1.43) for gastric 
cancer, 0.62 (95 % CI, 0.37-1.04) for pancreatic cancer, and 0.96 (95% CI, 0.67-1.40) for endometrial 
cancer. Corresponding ORs for saccharin were 0.65 (95 % CI, 0.25-1.68), 0.19 (95 % CI, 0.08-0.46), Opinion on the re-evaluation of aspartame (E951) as a food additive
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and 0.71 (95 % CI, 0.36-1.38), and for other sweeteners were 0.86 (95 % CI, 0.45-1.67), 1.16 (95 % 
CI, 0.66-2.04), and 1.07 (95 % CI, 0.71-1.61). 
Again, the findings do not suggest a hazard, but because exposures to aspartame specifically were not 
distinguished, and because of possible non-differential misclassification of exposures, on their own 
they provide only limited evidence of safety. 
A case-control study (Andreatta et al., 2008) was carried out between 1999 and 2006 in Còrdoba 
(Argentina) to investigate the relation between urinary tract tumours (UTT) and the use of artificial 
sweeteners as sugar substitutes in infusions (e.g. tea, coffee, matè). A cohort of 197 patients with 
incident histopathologically confirmed transitional-cell UTTs were recruited (response rate almost 80 
%), along with 397 controls from the same area who had no history of cancer, and had been admitted 
to hospital with acute non-urinary tract diseases. It is unclear from the report how potential controls 
were identified, or what response rate was obtained form those invited to take part.  
A food frequency questionnaire was administered at interview to assess the intake of artificial 
sweeteners before diagnosis or hospitalisation. Subjects were classified according to their duration of 
exposure to artificial sweeteners as non-consumers, short-term consumers (1 to 9 years) or long-term 
consumers (10 or more years). In addition, subjects were further classified according to the types of 
artificial sweeteners they had used: saccharin/cyclamate or aspartame/acesulfame-K. 
The use of artificial sweeteners was more frequent in cases than in controls. For short-term consumers, 
no association with UTT was observed, but a positive association was found between long-term use of 
artificial sweeteners and risk of UTT (OR 2.18, 95 % CI: 1.22 – 3.89, adjusted for age, sex, body max 
index, social status, and years of tobacco use).  
The Panel noted that the analysis of exposure data was limited to the use of artificial sweeteners in 
infusions, and that other dietary sources of sweeteners were not considered. Moreover, approximately 
80 % of both cases and controls who consumed artificial sweeteners, used saccharin and/or cyclamate. 
Thus, the study provided little information about possible risks from aspartame. 
A prospective cohort study by Lim et al. (2006) was based on data from the NIH-AARP Diet and 
Health Study. The analysis included 285 079 men and 188 905 women aged 50 to 71 years at entry to 
the cohort, which was drawn from members of the American Association of Retired Persons in 8 study 
areas in the US. In this cohort, risk of haematopoietic cancer (1888 cases) and malignant glioma 
(315 cases) during five years of follow-up (1995-2000) was examined in relation to daily intake of 
aspartame assessed at baseline. For haematopoietic cancer, intake of ≥ 600 mg aspartame per day 
carried no elevation of risk (RR 0.98, 95 % CI 0.76-1.27), and there was no association between 
glioma and consumption of aspartame (RR 0.73, 95 % CI 0.46-1.10). Assessment of exposure to 
aspartame was through a food frequency questionnaire. The authors concluded that their prospective 
study suggested that aspartame consumption derived from its main source, aspartame-containing 
beverages, does not raise the risk of haematopoietic or brain malignancies.  
The Panel noted that major strengths of this investigation were its prospective longitudinal design, the 
large number of cases, and that exposures were assessed at baseline and therefore unbiased by 
knowledge of disease outcome. Ascertainment of cancers was reliable. Confounding is unlikely to 
have been a major problem, although there was no adjustment for socio-economic status (which has 
shown some relation with brain cancer). Assessment of exposure to aspartame covered aspartame-
containing drinks as well as addition of aspartame to coffee and tea, but it was limited to one point in 
time, and usage in the years before the study may have been lower. This would have limited the ability 
of the study to detect effects that occurred with a long latency.  
In a small pilot case-control study of brain cancer conducted in southern France, 122 incident adult 
cases were compared to 122 controls with other neurological diagnoses (Cabaniols et al., 2011). There 
was no association with aspartame consumption during the past five years of at least once per week 
(OR 1.02, 95 % CI 0.57-1.85). However, information on the method of dietary assessment is limited, 
and there was no attempt to control for potential confounding factors other than sex and age. In view Opinion on the re-evaluation of aspartame (E951) as a food additive
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of this, and the low statistical power of the study (reflected in the confidence interval), the non-
positive finding provides little reassurance of an absence of hazard.  
The risk of lymphatic and haematopoietic cancers in relation to consumption of diet soda and 
aspartame sweeteners added at the table was examined in two US cohorts (one of 77 218 female 
registered nurses and one of 47 810 male health professionals) followed prospectively from 1984 and 
1986 to 2006 (Schernhammer et al., 2012).  
Exposure to aspartame through consumption of diet soda and packets used at table was assessed by 
semi-quantitative food frequency questionnaires repeated at four-yearly intervals, and at each point in 
follow-up was characterised by the average from all questionnaires that the participant had completed 
up to that time. Various potential confounding factors (e.g. weight, smoking habits, physical activity) 
were also assessed through repeated questionnaires. Cancer outcomes were ascertained from biennial 
questionnaires, state tumour registries and death records, and where possible, diagnoses were verified 
using medical records. Analysis was by Cox regression.  
During follow-up, 1,324 subjects developed non-Hodgkin lymphoma (NHL), 285 multiple myeloma, 
and 339 leukaemia (mostly myeloid leukaemia). After adjustment for potential confounders, the 
highest category of aspartame intake defined by the authors (≥ 143 mg/day) was associated with a 
significantly elevated relative risk of NHL (1.64, 95 % CI 1.17-2.29) and of multiple myeloma (3.36, 
95 % CI 1.38-8.19) in men. However, there was no consistent trend in risk with increasing exposure, 
and there were no corresponding elevations in risk in women. No clear association with leukaemia was 
apparent in either men or women. The authors speculated that the differential findings for men and 
women might reflect differences in the activity of alcohol dehydrogenase type 1, which converts 
methanol (a metabolite of aspartame) to formaldehyde.  
Major strengths of this study are its prospective design, the substantial number of cancer cases, the 
repeated assessment of dietary intake and the fact that various potential confounders were addressed. 
However, the positive findings can be given little weight, given their limitation to men, the small 
relative risks observed, and the lack of clear dose-response relationships. The authors’ proposed 
explanation for the differential associations in men and women is unconvincing in the absence of data 
on other more important dietary sources of methanol.  
Overall, the Panel considered that the results of these epidemiological studies do not suggest an 
increased risk associated with aspartame consumption for the types of cancer examined.  
3.2.7.2.  Single dose studies in humans 
A number of single dose studies on the kinetics of aspartame in human subjects have been carried out; 
these are described in Section 3.1.  
In one study, single loading doses of aspartame (34  mg/kg bw) and, two weeks later, of L-
phenylalanine (19  mg/kg bw) were administered in orange juice to two female adolescents (E66, 
1973). The authors of the study reported that the two subjects tolerated the doses well. In another 
study (E110, 1979), six subjects who claimed to be sensitive to monosodium glutamate (Chinese 
Restaurant Syndrome) were given a loading dose of 34 mg aspartame/kg bw or 1000 mg sucrose/kg 
bw in a cross-over study. The test doses were dissolved in orange juice. Although one subject reported 
slight nausea after aspartame, no symptoms of Chinese Restaurant Syndrome were reported.  
3.2.7.3.  Repeat dose studies in humans 
A number of repeat dose studies on the kinetics of aspartame in human subjects have been carried out, 
and some of them are described in Section 3.1.  
Several repeat dose studies in healthy non-obese human subjects have been performed with aspartame. 
In preliminary studies (E23, 1972) 31 men and 38 non-pregnant women (age 21-45  years) were Opinion on the re-evaluation of aspartame (E951) as a food additive
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administered aspartame under double blind conditions in capsules containing placebo, 200  mg 
aspartame or 300 mg aspartame. The subjects took an appropriate number of capsules per day to 
deliver increasing doses of aspartame (or placebo) over a six-week period (600, 1200, 2400, 4500, 
6300 and 8100 mg/day in a weekly dose-escalation protocol) followed by a one week period with no 
treatment. Standard clinical chemistry profiles were analysed together with methanol, determined by 
gas chromatography in serum and urine at weeks 4 and 6. All 69 subjects completed the study, and 
there were no obvious physical or biochemical differences between the aspartame and placebo groups 
before, during or at the end of the study. No significant differences in glucose and insulin homeostasis 
were identified at weeks 0 or 6, or during follow up (week  7). There was no accumulation of 
phenylalanine or tyrosine in subjects taking aspartame; phenylalanine was not detected in urine in 
weeks 0, 3, 6 or 7. The only symptoms reported were mild and often contradictory (loose 
stools/constipation, increased/decreased appetite and headache).  
A similar short-term (6-week) study was conducted in obese adults (ages 21-70  years; weight 
exceeding more than 20 % of the mean normal weight for height, sex, frame and age) (E24, 1972). Of 
the 95 subjects entering the study, 84 successfully completed the 6  weeks of treatment (44 on 
aspartame and 40 on placebo). The dose regime was the same as that described in E23 (1972), as were 
the biochemical analyses. As with the normal adults, no obvious physical or biochemical differences 
between the aspartame and placebo group were reported before, during or at the end of the study. 
According to the authors, few complaints were reported during the study and none were serious (e.g. 
loose stools, constipation, decreased appetite, increased appetite, headache). The incidence of these 
complaints was slightly greater among females than males, and among the aspartame users than 
placebo subjects. Subjects in both groups lost a significant amount of weight between the initial 
weighing and the end of the study, but the difference in weight loss between two groups was not 
significant.  
A follow up study (E60, 1973) was conducted in subjects who agreed to continue from the study 
described above (E23, 1972) together with a number of new recruits. This follow up study ran for 
21 weeks, so continuing subjects received aspartame for a total of 27 weeks and the new recruits were 
dosed for 21 weeks. Subjects from the previous study stayed on the same preparation (either aspartame 
or placebo) as they had received during the short-term study, but all the new recruits received 
aspartame. All subjects were dosed at 1800 mg aspartame/day (2 x 300 mg capsules, 3 times daily). 
Laboratory tests conducted during weeks 6, 12, 20 and 21 revealed some variability in results, but this 
was not associated with consumption of aspartame. There were no consistent differences in glucose 
and insulin homeostasis between aspartame and placebo groups and, despite fluctuations in plasma 
phenylalanine and tyrosine levels, there was no accumulation of either amino acid in male or female 
subjects. No phenylpyruvic acid was detected in urine. No changes in weight and no product-related 
side effects were reported; the symptoms that were reported were of a similar nature to those in the 
previous study.  
Aspartame tolerance was also evaluated in a 13-week double-blind study in children and adolescents, 
aged 2-20 years (E61, 1972). Five groups of children (ages 2-3, 4-6, 7-9, 10-12 and 13-20 years) were 
randomly assigned to receive sucrose or aspartame at doses of 39.5–58.1  mg/kg/day, and older 
subjects (ages 13-20 years) also took aspartame capsules (200 mg, 3 times daily). Subjects returned for 
evaluation at the end of weeks 1, 3, 5, 7, 9, 11 and 13. Clinical chemistry profiles indicated some 
minor differences between aspartame and placebo groups, but all were considered clinically trivial and 
none persisted. No compound-related differences in profiles were detected at the end of the study. 
Both groups exhibited a slight decline in plasma phenylalanine levels during the study but tyrosine 
levels remained unchanged and there were no trends in phenylalanine/tyrosine ratios. Urinary 
phenylpyruvic acid measurements were negative and both serum and urinary methanol levels (in 
33 subjects selected at random) were below the limit of detection at all times. There was slight weight 
gain during the study in all groups, consistent with the age of the participants. No severe adverse 
effects were reported and the minor complaints received were similar for aspartame and placebo 
groups. Hives and rashes were observed in four individuals but these were not related to aspartame 
consumption. No eye abnormalities or changes in acne incidence or severity were observed.  Opinion on the re-evaluation of aspartame (E951) as a food additive
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A metabolic study was designed to evaluate the effect of added monosodium glutamate (MSG) plus 
aspartame upon plasma amino acid levels (E95, 1977). Three male and three female subjects were 
given, in a cross-over manner, a test meal or the same test meal containing aspartame at 34 mg/kg and 
MSG at 34 mg/kg. Blood samples were collected up to 8 hours. The addition of aspartame (34 mg/kg) 
to the meal increased the phenylalanine content from 43 to 64 mg/kg. The addition of aspartame plus 
MSG had no effects upon the plasma glutamate curves, the plasma amino acid levels, and the plasma 
aspartate levels. The plasma levels of phenylalanine and tyrosine after ingestion of MSG and 
aspartame were only slightly higher than those noted after the ingestion of the test meal alone, and all 
levels were within the normal postprandial limits.  
Leon et al. (1989) conducted a study of the effects of aspartame involving 101 subjects (ages 18-
62  years). This was a randomised, double-blind, placebo-controlled, parallel-group design. 
Participants included 57 women and 51 men, randomly assigned to either the aspartame (n = 53) or 
placebo (n = 55) groups. Exclusion criteria were well-defined and included body weight greater than 
20 % above normal range. Subjects consumed three capsules per day containing either 300  mg 
aspartame or 300 mg microcrystalline cellulose plus 0.9 mg silicon dioxide for 24 weeks. Compliance 
was verified by counting capsules and subjects were asked to avoid additional sources of aspartame. 
The approximate dose of aspartame was 75  mg/kg bw/day. No treatment-related haematological 
changes, consistent alterations in clinical chemistry and analyses or urinary abnormalities were 
observed and no significant differences in vital signs or body weight were noted. In addition, no 
differences were observed in relation to blood formate or methanol; urinary Ca
2+ or formate; serum 
folate; or serum lipids. There were no significant changes in amino acid profiles and no evidence of 
accumulation of phenylalanine or tyrosine. Various adverse events were reported which were all 
considered by the authors as frequently occurring minor ailments and mild in nature.  
In a controlled diet study (Porikos and Van Italie, 1983) in which 21 men (aged 24-45; 15 obese, 6 
non-obese) were given a baseline diet (25-30 % of calories from sucrose) alternating with a calorie-
restricted diet (25-30 % of calories from sucrose (days 1-6 and 19-30, sweetness being replaced with 
aspartame on days  7-18, so volunteers ate significantly less calories on days of aspartame 
consumption) for 12 days at a time, the ALT and AST levels in serum were elevated (but remained 
within the normal range) on the baseline diet, fell on the aspartame-containing diet then rose again 
when the baseline diet was reintroduced. There were also small increases in blood urea nitrogen 
(BUN) levels in subjects on the aspartame containing diet, but renal function remained within normal 
parameters. Serum triglycerides decreased by 33  % on the aspartame diet (from 130  mg/dL to 
87 mg/dL). The Panel noted that the dose of aspartame was not specified and that there were other 
changes in the diet, including changes in its caloric content.  
A short-term tolerance study was conducted in adult PKU heterozygotes (parents of homozygote 
children) in three different laboratories (E25, 1972). A total of 65 subjects (men and women between 
the ages of 21 and 45) were administered under double-blind conditions capsules containing placebo, 
200 mg aspartame or 300 mg aspartame. The subjects took an appropriate number of capsules per day 
to deliver increasing doses of aspartame (or placebo) over a six-week period (600, 1200, 2400, 4500, 
6300 and 8100 mg/day in a weekly dose escalation protocol) followed by one week with no treatment. 
Total daily phenylalanine from aspartame was 340, 670, 1350, 2530, 3540, 4550 mg/day, respectively. 
All 65 subjects completed the study and there were no biochemical differences between the aspartame 
and placebo group either initially or at the end of the study in two out of the three groups. However, in 
one of the laboratories, a significantly higher mean initial value on BUN was reported in the placebo 
group, which was not detected at the end of the study. This laboratory also reported a significantly 
higher mean value in haematocrit in the aspartame group at the end of the study; this value was 
however within the normal range. No significant differences in glucose and insulin levels were 
identified at weeks 0 or 6, or during follow-up (week  7). There were no changes in serum 
phenylalanine, tyrosine levels (mean levels were below the 8 mg set as the upper limit for women) or 
in the ratio phenylalanine/tyrosine in subjects taking aspartame after fasting overnight and without 
preceding aspartame intake for more than 12  hours. No abnormal findings were reported on the Opinion on the re-evaluation of aspartame (E951) as a food additive
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urinary phenylalanine metabolites. The only complaints reported were a feeling of fullness and some 
unusual bowel movements.  
Long-term tolerance studies were also conducted in adult PKU heterozygotes. In a double-blind study 
a total of 52 subjects (men and women between the ages of 21 and 45) were randomly assigned to be 
dosed at 1.8 g aspartame/day (2 x 300 mg capsules, 3 times daily) or placebo for 21 weeks (E67, 
1973). Laboratory tests (complete blood count, urinanalysis, partial thromboplastin, prothrombin time, 
BUN, thyroxine, bilirubin, SGOT, alkaline phosphatise, uric acid, creatinine, cholesterol, 
triglycerides) conducted during weeks 6, 12, 16, 20 and 21 revealed no differences between the groups 
in the final laboratory values as well as in the final serum glucose and insulin levels. The only 
significant difference between the treatment groups occurred in the phenylalanine levels at week 16. 
No abnormal findings on the phenylalanine metabolism were observed in any subject.  
In another study, six healthy adult subjects (3  males and 3  females) and five females clinically 
identified by the authors as PKU heterozygous subjects were administered aspartame at 100 mg/kg bw 
dissolved in orange juice (E109, 1978). The PKU heterozygous subjects were selected after detection 
of a significant difference in plasma phenylalanine levels following loading with phenylalanine. 
Plasma and erythrocyte samples were collected up to 8 hours after the load. Plasma aspartate levels 
were not significantly affected by aspartame administration in either normal subjects or presumed 
PKU heterozygous subjects. Levels for glutamate, asparagine and glutamine were also unchanged 
after aspartame loading in the two groups. Plasma phenylalanine levels increased significantly after 
aspartame loading in both normal subjects and PKU heterozygous subjects. The plasma phenylalanine 
levels in PKU heterozygous subjects ingesting aspartame at 100  mg/kg bw were similar to those 
observed in normal subjects ingesting aspartame at 200 mg/kg bw. In the normal subjects plasma 
phenylalanine levels increased from fasting levels of 5.6 ± 1.2 µM to values in the normal postprandial 
range of 11.1  ±  2.49  µM and returned to baseline by 8  hours. In heterozygous subjects, the 
postprandial levels were higher; 16.0  ±  2.25  µM. Plasma tyrosine levels increased after aspartame 
loading in both groups, with higher levels in normal subjects. Levels of aspartate in erythrocytes were 
unchanged after aspartame administration in both groups, whereas phenylalanine and tyrosine levels in 
erythrocytes increased significantly over baseline.  
Another study (E26, 1972) assessed the tolerance of loading doses of aspartame by PKU homozygous 
children. Two 14-year-old PKU homozygous boys were given a loading dose of 34  mg/kg bw 
aspartame in orange juice and 2  weeks later they were given a molecular equivalent amount of 
phenylalanine (19 mg/kg bw) in orange juice. One of the boys was on a liberalized Lofenalac diet 
(infant powder formula to replace milk in the diet of PKU suffers) with an allowable phenylalanine 
dietary intake of 70 mg/kg/day; the other boy was on a well-controlled Lofenalac diet (phenylalanine 
intake of 17 mg/kg/day). The subject on a liberalised diet received a total amount of 3228 mg of 
phenylalanine (total dietary intake/occasion: 2539 mg plus phenylalanine added from loading dose: 
689 mg), which was well within his permitted phenylalanine range during the loading study. The 
subject on a restricted diet received a total amount of 2037  mg of phenylalanine (total dietary 
intake/occasion: 965 mg plus phenylalanine added from loading dose: 1072 mg), which far exceeded 
his dietary limitation. The patient on a liberalised diet was excreting phenylalanine metabolites in 
large quantities, whereas the patient on a restricted diet did not excrete phenylpyruvic acid after either 
loading. The serum analysis indicated that the loading dosages of aspartame and phenylalanine did not 
cause any significant increase in either phenylalanine or tyrosine levels.  
Overall, the Panel concluded that no significant adverse effects were observed following repeated 
administration of aspartame for different durations and at different dose levels of aspartame either in 
healthy (adults, adolescents and infants) or in PKU heterozygous subjects.  
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3.2.7.4.  Effect of Aspartame on behaviour and cognition 
Children 
Kruesi et al. (1987) investigated the effect of sugar and aspartame consumption on behaviour in 30 
preschool boys (ages 2 to 6 years), of which 18 were described as 'sugar responders' because their 
parents reported a history of behavioural change following ingestion of sugar. The study was a double-
blind cross-over challenge with aspartame (30 mg/kg bw), sucrose (1.75 g/kg bw), saccharin (amount 
not specified) and glucose (1.75 g/kg bw). The sweeteners were given in lemon-flavoured carbonated 
drinks on four separate challenge days, with a 5-7-day washout period between challenges. The 
subjects were scored for behavioural effects, including aggression and activity. There was no 
significant difference in scores of aggression or observers’ ratings of behaviour between the sugar-
responsive and age-matched control boys following any of the four treatments. Lower but not 
significantly different activity was scored during the aspartame challenges in both sugar-responsive 
and the age-matched control children (recorded by means of an actometer) but the differences were 
not apparent to the observers.  
In a double-blind controlled cross-over study (Wolraich et al., 1994), 25 normal preschool children (3 
to 5 years of age) and 23 primary school-age children (6 to 10 years of age) described by their parents 
to respond adversely to sugar were recruited. Over three consecutive 3-week periods, they received in 
a randomised distribution the following diets: 
-  diets containing aspartame (38 + 13 mg/kg bw/day for the preschool children and 32 + 8.9  mg/kg 
bw/day for the school-age children) or, 
-  diets containing sucrose (5600 + 2100 mg/kg bw/day for the preschool children and 4500 + 1200  
mg/kg bw/day for the school-age children) or, 
-  diets containing saccharin (as placebo) (12 + 4.5 mg/kg bw/day for the preschool children and 
9.9 + 3.9  mg/kg bw/day for the school-age children). 
The children were scored for 31 (preschool children) or 39 (school-age children) behavioural and 
cognitive variables. There were no significant differences in any of the 39 behavioural and cognitive 
variables among the school-age children receiving any of the three diets. For the preschool children 
statistically significant differences were measured in 4 (Parents’ ratings of cognition, grooved 
pegboard, dominant hand, nondominant hand) of the 31 measures; however, no consistent pattern in 
behavioural and cognitive differences was observed amongst the three diets. Wolraich et al. (1994) 
concluded that ‘neither dietary sucrose nor aspartame affects children’s behaviour or cognitive 
function’.  
In another randomised, double blind, and placebo-controlled crossover trial (Shaywitz et al., 1994a), 
the effect of large doses of aspartame on behaviour, cognitive function and monoamine metabolism in 
15 children with attention deficit disorder (11 boys and 4 girls, 5-13 years of age) was investigated. 
The trial consisted of two 2-week periods that were identical except for the administration of either 
aspartame (34 mg/kg bw/day) or placebo (microcrystalline cellulose). Aspartame or placebo were 
administered. each morning in a single capsule. All children were on an aspartame-free diet 
throughout the trial. The children were scored in behavioural and cognitive tests. Blood samples were 
collected for biochemical and haematological tests and urine was analysed for catecholamine and 
monoamine metabolite excretion. The authors did not observe any significant effect of aspartame 
administration on cognitive, attentive or behavioural testing. Likewise, the biochemical and 
haematological parameters were not altered by aspartame ingestion except that plasma phenylalanine 
levels increased by approximately 40 % two hours following aspartame administration. The authors 
considered this increase as within the normal postprandial range. The Panel noted that the changes in 
plasma phenylalanine levels were consistent with the toxicokinetic studies.  
The study of Roshon and Hagen (1989) examined the effect of sucrose consumption on the behaviour 
of 12 preschool children (6 boys and 6 girls, age 3-5) and did not find any significant difference in Opinion on the re-evaluation of aspartame (E951) as a food additive
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locomotion, task orientation and learning in participants exposed to either sucrose or placebo (9 mg 
aspartame/kg bw).  
The study by Saravis et al. (1990) showed that a single dose of aspartame (9.7 or 34 mg/kg bw) did not 
have a detrimental effect on learning, behaviour and mood in children. 
The Panel noted that no effects of aspartame on behaviour and cognition were observed in children in 
these studies. 
Adults 
Lapierre et al. (1990) reported a double-blind randomised crossover study on 10 healthy adult 
volunteers (6 men, 4 women, aged 21–36 years) who received a single dose of aspartame (15 mg/kg 
bw) or placebo capsules. No significant differences between aspartame and placebo were found in 
measures of sedation, hunger, headache, reaction-time, cognition or memory during the study. The 
authors stated that plasma phenylalanine levels rose within thirty minutes of administration of 
aspartame.  
In another study (Ryan-Harshman et al., 1987), healthy males age 20 to 35 years (n = 13/group) were 
given capsules containing phenylalanine (0.8, 2.5, 5 and 10 g) or aspartame (5 or 10 g) as a single dose 
in a randomised crossover design to investigate their neurobehavioral effects on energy and 
macronutrient selection and on subjective feelings of hunger, mood and arousal. Neither phenylalanine 
nor aspartame altered mean energy intakes or macronutrient selection nor caused any behavioural 
effects.  
Pivonka and Grunewald (1990) studied the effect on mood and well-being in 120 young women of 18 
to 30 years of age receiving water, aspartame-sweetened or sugar-sweetened beverages. The only 
observed effect was increased sleepiness following the consumption of sugar-sweetened beverages as 
compared to the consumption of aspartame or water. 
In a double-blind study (Stokes et al., 1991), 12 healthy certified active pilots (four females and eight 
males) were given trial placebo capsules, aspartame (50 mg/kg bw) or ethanol (positive control, dose 
not reported but estimated to raise plasma alcohol to 0.1 %). Each subject performed the SPARTANS 
cognitive test battery of aviation-relevant information-processing tasks on 5 occasions, with at least 
1 week between treatments that were given in random order among the 12 participants. The tests 
included an initial pre-test at week 1 and a final post-test at week 5. The authors reported that no 
detectable performance decrements were associated with the exposure to aspartame, but decrements in 
psychomotor and spatial abilities were detected following ethanol administration.  
The follow up study (Stokes et al., 1994) was undertaken in 12 subjects (college students, sex not 
reported) in order to examine the effects of double-blind repeated dosing of aspartame on performance 
in aviation-relevant cognitive tasks. The subjects received placebo capsules or aspartame capsules 
(50 mg/kg bw/day) for 9 days, or an acute dose of ethanol to achieve 0.1 % blood ethanol levels. On 
the last day of treatment periods and 90 min after administration of the capsules, plasma phenylalanine 
levels averaged 59 µM following placebo treatments and 121.5 µM following aspartame consumption. 
Forty-seven task variables were measured using the SPARTANS 2.0 cognitive test battery and no 
significantly impaired performance on flight-relevant cognitive tasks were observed by the authors. 
Instead, in the case of three tasks, the consumption of aspartame was associated with an apparent 
improvement in performance and a significant correlation between blood phenylalanine levels and 
performance on the scheduled task was noted.  
The study by Walton et al. (1993) was designed to test whether subjects with mood disorders were 
sensitive to adverse effects caused by aspartame. The initial study design required the recruitment of 
40 adult patients with unipolar depression and a similar number of adult subjects without a psychiatric 
history. Some of the latter group considered themselves to be sensitive to aspartame; however, no Opinion on the re-evaluation of aspartame (E951) as a food additive
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information on possible intolerance to aspartame among the patients with depression was provided by 
the authors. The participants were given aspartame (30  mg/kg bw/day) or placebo (sucrose) in 
capsules for a period of 7 days with two 3-day washout periods using a double-blind cross-over study 
design. Subjects monitored themselves and self-scored the severity of a list of symptoms, including 
headache, nervousness, dizziness, nausea, feeling 'blue' or depressed, temper outbursts. After eight 
adult patients (five women and three men; age range, 24-60 years) undergoing treatment for 
depression and five non-depressed controls (three men and two women; age range, 24-56 years; three 
self-assessed as sensitive to aspartame (headaches)) had completed the study. The project was stopped 
because of reactions experienced by three subjects within the group of patients. One patient suffered 
retinal detachment during the placebo week and another patient experienced a conjunctival 
haemorrhage during the aspartame week. It was not clear what kind of reaction the third subject 
experienced and whether it occurred during the placebo or the aspartame phase. The authors reported 
that despite the small number of subjects, there was a significant difference in the number and severity 
of self-scored symptoms between aspartame and placebo in the patient group while there was no noted 
difference in the non-depressed volunteer group.  
Using a randomised double-blind placebo-controlled 3-way crossover study design, a group of 48 
healthy volunteers (24 men, 24 women, ages 18–34 years) were exposed after an initial one-month 
aspartame-free period, to aspartame, sucrose or placebo administered for 20 days each (Spiers et al., 
1998). Twenty-four participants were given a high dose of aspartame (45 mg/kg bw/day) and the 
remaining received a low dose of aspartame (15 mg/kg bw/day). The dose of sucrose was 90 g/day for 
all subjects. Administration of aspartame or placebo (microcrystalline cellulose) was in the form of 
capsules and for sucrose, a beverage. Effects were evaluated on day 10 and 20 of each treatment, with 
testing starting 90 minutes after consumption of test material. Plasma phenylalanine levels increased 
dose-dependently with aspartame consumption from 56 µM (placebo) to 79 µM (high dose), but no 
neuropsychologic, neurophysiologic and behavioural effects linked to aspartame consumption were 
observed.  
The Panel noted the limited number of participants, the short duration and the inconsistency of the 
reporting of the results in all these adult human studies. These limitations apply to both positive and 
negative studies.  
Overall, the Panel concluded that there was no evidence that aspartame affects behaviour or cognitive 
function in children or adults.  
3.2.7.5.  Effects of aspartame on seizures 
A double-blind study was undertaken in eight girls and two boys (age range, 5.1 to 14.6 years) 
recently diagnosed with generalised absence seizures or also called petit mal seizures to investigate 
whether aspartame, might exacerbate the occurrence of such seizures (Camfield et al., 1992). The day 
before the study and during the study, children were allowed to eat as they wished, except any food or 
beverages containing aspartame. No information was provided regarding the diet. The children ate 
their normal breakfast on the morning prior to starting the study. Following 1-hour baseline recordings 
of the number and length of spike-wave bursts (determined using an ambulatory cassette EEG 
recorder), the children were given 250 ml orange juice sweetened with either aspartame (40 mg/kg 
bw) or sucrose (1 g sucrose for every 25 mg aspartame to achieve similar sweetness) (assigned in a 
random way) and the EEG recordings were continued for a further six hours. Each child was tested 
once with each substance. The authors reported that following the consumption of aspartame but not 
of sucrose, the total duration of spike-wave discharge per hour was significantly increased and 
concluded that aspartame appeared to exacerbate the amount of EEG spike wave in children with 
absence seizures. The Panel noted that the combination of the two parameters (number and length of 
spike-wave bursts) into a single measure was not adequately explained, and lack of control of food and 
drink intake before and after dosing may have affected the results. The Panel further noted that 
aspartame was given in a single dose at the ADI. Opinion on the re-evaluation of aspartame (E951) as a food additive
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In a randomised double-blind placebo-controlled, crossover study (Shaywitz et al., 1994b) aspartame 
(34 mg/kg bw) was administered to epileptic children (5 boys, 5 girls, ages 5-13 years) for two weeks 
to investigate the induction of seizures following aspartame consumption. Measurements and 
parameters tested included EEG, Subjects Treatment Emergent Symptoms Scale (STESS), routine 
haematology, plasma levels of amino acids, methanol, formate and glucose, liver function tests, urine 
analysis, and plasma and urinary monoamines and their metabolites. Children were requested to eat a 
normal diet that was free of aspartame. Nine children completed the study and it was reported that 
there was no difference in the occurrence of seizures between aspartame and placebo exposure. The 
plasma levels of phenylalanine increased from 60 µM to 82 µM by one hour post aspartame 
administration. The possibility that aspartame provokes seizures in self-reported aspartame-sensitive 
individuals was further investigated in a randomised double-blind placebo-controlled crossover study 
by Rowan et al. (1995). In this trial, subjects (sixteen adults and two children) who claimed to have 
experienced epileptic seizures reportedly due to aspartame were given capsules either containing 
microcrystalline cellulose (placebo) or aspartame (total dose of 50 mg/kg bw). This dose was divided 
into three portions and administered in the morning at two-hour intervals. All meals were uniformly 
standardised on treatment days. The authors reported no seizures or other adverse effects from 
aspartame ingestion. Mean plasma phenylalanine levels increased from 52 µM (after placebo) to 84 
µM two hours after the first two doses aspartame. 
The Panel noted that the changes in the plasma phenylalanine levels in the studies described above 
(Shaywitz et al., 1994b; Rowan et al., 1995) were consistent with those in the toxicokinetic studies. 
Overall the Panel concluded that the available data do not provide evidence for a relationship between 
aspartame consumption and seizures.  
3.2.7.6.  Effect of aspartame on headaches  
Schiffman et al. (1987) reported a randomised double-blind crossover trial with aspartame on 40 
subjects with a history of headache and related neurologic symptoms within 24h of aspartame 
consumption. The subjects (12 males and 28 females; age range, 19–69 years) were given aspartame 
(30 mg/kg bw) or placebo (microcrystalline cellulose) in capsules; the dose was divided into three 
doses administered in the morning at two-hour intervals. The treatment days were interposed by a 
washout day. The authors reported that the incidence rate of headache after consumption of aspartame 
(35 %) was not significantly different from that after placebo (45 %).  
In a controlled thirteen-week, double-blind, randomised cross-over study, Koehler and Glaros (1988) 
comparing the effect of aspartame to that of a matched placebo on the frequency and intensity of 
migraine headache. The subjects (two males, eight females; ages 18 to 47 years) who had medical 
diagnosis of migraine, consumed aspartame (1200 mg/person) or placebo (microcrystalline cellulose) 
in capsules and during two four-week experimental phases (separated by a 1-week washout phase) and 
submitted self-their diet and headache charts each week during the study. According to the study 
authors, the statistical analysis indicated a significant increase in the frequency of migraine headaches 
from the placebo to the aspartame treatment (mean number of migraines per subject: 1.72 (baseline 
phase), 1.55 (placebo phase), and 3.55 (aspartame phase)). No differences were reported in the 
intensity or duration of migraine headaches. The high drop-out rate, from 25 to 11 participants in this 
study was not due to increased frequency or intensity of migraines. The Panel noted that the high inter 
individual variability in the response of the remaining volunteers makes interpretation unreliable.  
In the study by Lipton et al. (1989) 171 patients at a headache unit completed a survey in which 
alcohol, aspartame, or carbohydrates intake were felt to be triggers of their headaches. About 8 % 
reported aspartame as a trigger of headaches compared to 2.3 % for carbohydrates, and to about 50 % 
for alcohol. The Panel considered that having only listed possible triggers of headaches, was a major 
limitation of this study.  Opinion on the re-evaluation of aspartame (E951) as a food additive
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Van den Eeden et al. (1994) conducted a double-blind randomised cross-over trial with subjects self-
diagnosed as sensitive to aspartame. Of the 32 subjects recruited and randomised to receive aspartame 
(in capsules given three times/day to give a daily dose of 30  mg/kg bw/day for seven days) and 
placebo (microcrystalline cellulose in capsules given three times/day), only 18 participants completed 
the full study. The authors stated several reasons for the dropouts, including adverse effects. The 
participants reported headaches on 33 % of the days during aspartame intake, compared with 24 % on 
placebo treatment (p = 0.04). However, no significant difference in the length or intensity of 
headaches or in the occurrence of side effects associated with the headaches was observed between 
treatments. The authors concluded that a small subset of the population may be susceptible to 
headaches induced by aspartame. 
The possible effect of aspartame on headaches has been investigated in various studies, which reported 
conflicting results, ranging from no effect to the suggestion that a small subset of the population may 
be susceptible to aspartame-induced headaches. The number of existing studies was small, and several 
had high participant drop-out rates, both under placebo and aspartame treatment. Overall, the Panel 
noted that because of the limitations of the studies it is not possible to conclude on a relationship 
between aspartame consumption and headaches. 
3.2.7.7.  Effects of aspartame on eating behaviour 
The Panel is aware that a number of studies have focused on the effects of aspartame on appetite, 
hunger and food intake.  
The Panel considered that these studies of the effect of aspartame (or other low calorie sweeteners) on 
eating behaviour were not relevant for the assessment of the safety of aspartame and that risk benefit 
assessment of aspartame are outwith the term of reference and the remit of the Panel. 
3.2.7.8.  Allergenicity of aspartame 
In studies reported by Szucs et al. (1986) aspartame did not affect IgE-mediated histamine release 
from mast cells in vitro. However, mast cells cultured in the presence of aspartame for periods of up to 
9 days showed enhanced proliferation and decreased responsiveness to releasing stimuli. The authors 
concluded that the effect of aspartame on proliferation of cells in culture could be ascribed to a non-
specific enhancing effect of its constituent amino acids. Aspartame did not stimulate mast cell or 
basophil in vivo as assessed by skin testing. 
Kulczycki (1986) reported a case of aspartame induced urticaria confirmed by double blind challenge 
in a 23 year old woman with no history of allergic disease. A second case in a 42 year old woman was 
also briefly reported in the same paper. 
Garriga et al. (1991) attempted to identify subjects with hypersensitivity reactions to aspartame with 
blinded challenge procedures. A total of 61 self-referrals and physician referrals were screened, with 
20 referrals evaluated in the clinic. Twelve patients underwent single- and double-blind challenge with 
up to 2000 mg of aspartame. At the end of the study, no subject with a clearly reproducible adverse 
reaction to aspartame was identified. The authors concluded that subjects who believed themselves to 
be allergic to aspartame did not have reproducible reactions. 
Geha et al. (1993) conducted a multi-centre placebo-controlled clinical study to evaluate individuals 
who had experienced urticaria and/or angioedema associated with ingestion of food containing 
aspartame. In a double-blind crossover study, 21 recruited subjects with a self reported history of 
hypersensitivity to aspartame were exposed to aspartame and placebo. Conversion products of 
aspartame, aspartyl-phenylalanine diketopiperazine and beta-aspartame, were also included in the 
study. Patients received, on different days, increasing doses of aspartame (50, 300, 600  mg) and 
placebo. Four urticaria reactions were observed, two followed aspartame ingestion and two followed 
placebo ingestion. The authors concluded that aspartame and its conversion products were no more Opinion on the re-evaluation of aspartame (E951) as a food additive
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likely than placebo to cause allergic symptoms in subjects with a history consistent with 
hypersensitivity to aspartame.  
In a letter to the editor, Kulczycki (1995) considered that in the Geha et al. (1993) study, several 
aspects in subject recruitment method, convenience, compensation and safety for subjects, as well as 
inclusion and exclusion criteria and challenge may limit the conclusions of their study. 
Butchko et al. (2002) reviewed all published papers from 1980 onwards reporting allergic-type 
reactions and attributed to aspartame exposure. In an evaluation of consumer complaints related to 
aspartame by the Centers for Disease Control and Prevention (CDC, 1984) approximately 15 % of the 
anecdotal complaints were assigned to allergic-dermatologic reactions attributed to aspartame 
ingestion, such as rashes, sore throat/mouth, swelling and itching.  
Cases of urticaria (Kulczycki, 1986) and granulomatous panniculitis (Novick, 1985, McCauliffe and 
Poitras, 1991) thought to be related to aspartame were reported. The SCF (2002) noted that studies on 
allergic-like reactions in individuals who themselves reported such reactions to aspartame have not 
confirmed the occurrence when later studied under control conditions.  
Very few cases of presumed systemic allergic dermatitis in patients with contact sensitivity to 
formaldehyde, apparently caused by the intake of aspartame in artificial sweeteners, have been 
described. The four patients described in the literature all had eyelid dermatitis (as cited in Veien et al, 
2012).  
The Panel noted that the studies available were performed on a limited number of participants.  
Overall, taking into account the limited data currently available, the Panel considered that the weight-
of-evidence does not suggest that aspartame is associated with allergic-type reactions in experimental 
models or in humans. However, the Panel cannot exclude the possibility that in rare instances 
individuals could be susceptible to allergic reactions following aspartame ingestion.  
3.2.7.9.  Anecdotal reports on aspartame 
Whilst acknowledging that these data exist, the Panel noted that the data do not meet the pre-specified 
inclusion/exclusion criteria. To ensure a comprehensive risk assessment the Panel examined the recent 
assessment of anecdotal reports by the EFSA National Expert Group (EFSA, 2010).  
The EFSA National Expert Group assessed anecdotal data of spontaneous reports of cases with 
symptoms imputed to be related to aspartame (EFSA, 2010). The anecdotal reports explored were 
largely self-reported, and the information was not structured and was without medical confirmation. 
This resulted in an incomplete database with limited possibilities to carry out meaningful analyses. 
The total number of cases considered was 1135. The number of cases where symptoms were classified 
was 1059. The case reports consisted of reports published in peer reviewed journals and reports 
compiled by Dr H.J. Roberts and published under the title ‘Aspartame Disease – An ignored 
Epidemic’ (Roberts, 2001). Of the total number of reports from the latter book entered in the database, 
689 were female, 299 were male and 77 were unclassified (the gender was not specified). Forty-three 
cases were children and an additional 154 cases were documented with the index case (i.e. friends and 
relatives).  
The total number of symptoms reported from all sources was 4281, as most cases reported more than 
one symptom. Headache was the most frequently reported adverse effect (28.5  %), followed by 
dizziness and giddiness (19.2 %). Although the results of a questionnaire-based study (Lipton et al., 
1989) and two double-blind out-patient investigations (Koehler and Glaros, 1988; Van den Eeden et 
al., 1994) employing daily doses of up to 30 mg/kg bw/day indicated a potential association between 
aspartame intakes and headache, it is still not possible to deduce causality, as the effect of diet has not 
been adequately controlled for and the interpretation of the data was complicated by a high dropout 
rate and a limited experimental design.  Opinion on the re-evaluation of aspartame (E951) as a food additive
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The Panel noted that the number of cases is low when compared with the widespread use and that the 
effects were mild to moderate.  
4.  Discussion of aspartame toxicity database 
This section discusses the toxicity database on aspartame and undertakes a hazard identification and 
characterisation of key end points, critical studies and points of departure for derivation of the ADI. It 
also provides a rationale for the description of the toxicity databases on methanol and DKP, which 
summarise relevant data and a hazard identification, and characterisation for their integration into the 
risk characterisation in Section 13.  
Aspartame is the methyl ester of the dipeptide of the amino acids aspartic acid and the essential amino 
acid phenylalanine. After oral ingestion, aspartame is fully hydrolysed, either within the lumen of the 
gastro-intestinal (GI) tract, or within the mucosal cells lining the inside of the GI-tract. The products 
that result from these reactions are methanol and the amino acids aspartic acid and phenylalanine. 
Hydrolysis of aspartame releases a corresponding 10  % by weight of methanol. Due to the very 
efficient hydrolysis in the gastro-intestinal tract the amount of aspartame that enters the bloodstream 
has been reported as undetectable in several studies conducted among others in rats, dogs, monkeys 
and humans (Oppermann, 1984; Burgert et al., 1991). Further studies conducted in monkeys and pigs 
have shown that also the potential intermediate metabolite phenylalanine methyl ester is rapidly 
broken down to phenylalanine and methanol in the intestinal lumen (Burton et al., 1984; Burgert et al., 
1991).  
The Panel concluded that the products formed following hydrolysis of aspartame are normal 
constituents of the diet and are metabolised by endogenous metabolic pathways. The Panel noted that 
there were acute intravenous toxicity studies in rat and dog at doses of 100 mg aspartame (equivalent 
to approximately 500 mg/kg bw in a 200 g rat and 10 mg/kg in a 10 kg beagle dog) with no effects. 
The Panel concluded that these data would provide reassurance over potential systemic exposure to 
aspartame if it was possible to administer doses of aspartame that were not fully hydrolysed in the 
gastrointestinal tract (complete breakdown has been observed with no detectable plasma aspartame at 
doses up to the highest tested of 200 mg/kg bw).  
Overall, the Panel noted that no unchanged aspartame was identified in body fluids or in tissues from 
experimental animals or humans in any of the studies. Therefore, the Panel concluded that after oral 
ingestion, aspartame was hydrolysed in the gastrointestinal tract to yield aspartic acid, phenylalanine 
and methanol. These metabolites are then absorbed and enter normal endogenous metabolic pathways. 
In humans, individuals heterozygous for phenylalanine hydroxylase mutations showed a somewhat 
reduced capacity compared to normal individuals to metabolise phenylalanine including that derived 
from the aspartame molecule. Individuals homozygous for phenylalanine hydroxylase mutations (PKU 
patients) have a markedly reduced capacity for phenylalanine metabolism.  
Several acute and sub-chronic toxicity, genetic toxicity, chronic toxicity and carcinogenicity and 
reproductive and developmental toxicity studies were made available for re-evaluation to EFSA 
following a public call for data that was launched in 2011 (see 
http://www.efsa.europa.eu/en/dataclosed/call/110601.htm). The Panel was aware that many of these 
reports would have been available at the time of the JECFA and SCF evaluations. The present 
evaluation by the Panel of the biological and toxicological data includes the assessment of all these 
unpublished studies, together with the published literature identified up to the end of November 2012. 
The Panel noted that the majority of these studies were performed in the period 1970-1978 and thus 
not performed according to Good Laboratory Practice (GLP) and OECD guidelines 
(http://www.oecd.org/chemicalsafety/testingofchemicals/oecdseriesonprinciplesofgoodlaboratorypract
iceglpandcompliancemonitoring.htm). However, the Panel concluded that although the studies were 
old and were not performed according to current standards, they should not per se be disqualified and 
should be included in the risk assessment of aspartame. As long as the design of such studies and the 
report of the data were appropriate, the Panel agreed that the studies should be considered in the re-Opinion on the re-evaluation of aspartame (E951) as a food additive
 
 
EFSA Journal 2013;11(12):3496  103
evaluation of the sweetener. These studies appeared to be the basis for deriving the ADI by JECFA 
and SCF, using the NOAELs of 4000 mg/kg bw/day identified in the chronic and carcinogenicity 
studies in rats and applying an uncertainty factor of 100. Due to perceived concerns over the safety of 
aspartame, the Panel regarded aspartame as a special case and looked again at the studies available to 
JECFA and the SCF.  
The acute toxicity of aspartame was tested in mice, rats, rabbits and dogs and was found to be very 
low. Similarly, sub-acute and sub-chronic studies did not indicate any significant toxic effects in rats, 
mice or dogs over dosing periods up to 9 weeks.  
Abhilash et al., (2011, 2013) treated male Wistar rats with aspartame in water by gavage, daily for 
6 months. They found slight increases (1.50, 1.84, 1.11 and 4.03-fold increase, respectively) in serum 
liver enzyme (ALAT, ASAT, ALP and γGT) levels in animals exposed to 1000 mg/kg bw/day. The 
Panel considered these increases as relatively low and likely to be within the normal historical range 
seen in many laboratories. Therefore, they were not considered to be of biological relevance. 
Furthermore, the Panel considered the focal infiltration of the liver by inflammatory cells, which is 
generally also present in the liver of control animals, as normal background pathology. Moreover, 
these effects were not reported in the chronic toxicity and carcinogenicity studies in both rats and 
mice, which were performed with much higher doses (up to 8000 mg/kg bw/day).  
Aspartame has been tested for genotoxicity in a number of in vitro and in vivo studies. The Panel 
concluded that the in vitro genotoxicity data on bacterial reverse mutation exhibited some limitations 
(e.g. absence of TA102 and WP2 uvrA Escherichia coli). However, the Panel considered the weight-
of-evidence was sufficient to conclude that aspartame was not mutagenic in bacterial systems. 
Concerning mammalian systems in vitro, the Panel concluded that, apart from the valid UDS study 
that was negative, no conclusion could be drawn at the gene and chromosomal level because no 
studies dealing with these endpoints were available.  
In vivo, the majority of investigations on systemic genotoxicity reported negative findings. Equivocal 
findings were described only in one NTP study, positive in female but not in male p53 
haploinsufficient mice; in two other transgenic mouse strains the results were negative.  
Concerning the possible site of first contact effects in vivo, limited data are available. However, the 
available in vitro data do not indicate a direct genotoxic activity of aspartame that might predispose to 
a site of first contact effect in vivo.  
Overall, the Panel concluded that the available data do not indicate a genotoxic concern for aspartame.  
The results from three chronic toxicity and carcinogenicity studies in rats (E33-34, 1973; E70, 1974; 
Ishii et al., 1981) and in mice (E75, 1974) revealed no compound-related increase in neoplasms at all 
doses. In the rat study E33-34 (1973), in which the highest dose tested was 8000 mg/kg bw/day renal 
changes (pigment deposits, focal tubular degeneration and focal tubular hyperplasia) were recorded in 
males. In an additional two-year chronic toxicity and carcinogenicity study in Wistar rats (Ishii et al., 
1981; Ishii, 1981) there was a dose-dependent depression of body weight gain at 2000 and 4000 mg/kg 
bw/day, and this effect was correlated with decreased feed consumption. Furthermore a dose-related 
increase in focal mineralisation of the renal pelvis in both males and females, associated with a dose-
related increase in urinary calcium was recorded but this common lesion in rats attributable to mineral 
imbalance was considered by the Panel to be of minimal toxicological significance. The Panel derived 
a NOAEL of 4000 mg/kg bw/day in these four studies (E33-34, 1973; E70, 1974; E75, 1974; Ishii et 
al., 1981), which was the highest dose level tested in three out of the four studies (E70, 1974; E75, 
1974; Ishii et al., 1981).  
The results of the three studies in rats did not provide any consistent evidence of an intracranial 
tumourigenic effect, but showed a study-to-study variability in the incidence of such neoplasms in 
controls. The incidences of spontaneous brain tumours in Sprague-Dawley derived rats have been Opinion on the re-evaluation of aspartame (E951) as a food additive
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reported by Ward and Rice (1982) to vary from 0 % up to 3.3 %. A similar incidence was reported by 
Weisburger et al. (1981). The Panel noted that the incidences observed in the studies with aspartame 
were within the range of spontaneous brain tumours observed in CD-rats. JECFA also evaluated these 
data and reported that no particular type of neoplasm or the general incidence of intracranial 
neoplasms seemed to predominate in any treated group. Therefore, JECFA concluded that aspartame 
did not cause brain tumours in rats (JECFA, 1980). The Panel agreed with this conclusion.  
The NTP carried out several 9-month carcinogenicity studies with aspartame in genetically modified 
Tg.AC hemizygous, p53 haploinsufficient and Cdkn2a deficient mice (NTP, 2005). According to 
NTP, there was no evidence of treatment-related neoplastic or non-neoplastic lesions in any of these 
studies. The former AFC Panel independently evaluated these studies and agreed with this conclusion 
(EFSA, 2006). The Panel also agreed with these conclusions but noted that the three mouse models 
remain at an experimental stage and had not been formally validated as experimental models for 
carcinogenicity testing. Therefore, the Panel did not use the results from the NTP study to derive a 
NOAEL.  
Since the last evaluation of aspartame by the SCF, Soffritti and co-workers reported new long-term 
carcinogenicity studies on aspartame in both rats (Soffritti et al., 2006, 2007) and mice (Soffritti et al., 
2010). The two rat studies have already been evaluated by the former AFC Panel (EFSA, 2006) and 
the ANS Panel (EFSA, 2009a), respectively. Both Panels considered that the two ERF rat studies had 
flaws that brought into question the validity of the findings, as interpreted by the ERF. In particular, 
the high background incidence of chronic inflammatory changes in the lungs and other vital organs 
and tissues and the uncertainty regarding diagnosis of some tumour types were major confounding 
factors in the interpretation of the study. The ANS Panel also noted that the increase in incidence of 
mammary carcinoma was not considered indicative of a carcinogenic potential of aspartame since the 
incidence of mammary tumours in female rats is rather high and varies considerably between 
carcinogenicity studies. The ANS Panel noted that the only consistent findings reported by the authors 
in the two rat studies were an increased incidence of lymphomas/leukaemias in female rats and an 
increased trend or incidence of lymphomas/leukaemias in treated males and females at the high dose 
group (EFSA, 2009a).  
In the mouse study (Soffritti  et al., 2010) Swiss mice were given aspartame (up to 4000  mg/kg 
bw/day) in the feed from prenatal life (12 days of gestation) until death. The authors of the study 
reported a dose-related increase in the incidence of hepatocellular carcinomas in male mice, and an 
increase in the incidence of alveolar/bronchiolar carcinomas in males of the highest dose group, 
whereas no compound-attributed carcinogenic effects were reported in female mice. The former ANS 
Panel (EFSA ANS Panel, 2011) and EFSA (EFSA, 2011a) observed that the hepatic and pulmonary 
tumour incidences reported by Soffritti et al. (2010) all fall within their own historical control ranges 
for spontaneous tumours. It was also noted that Swiss mice are known to have a high background 
incidence of spontaneous hepatic and pulmonary tumours (Prejean et al., 1973; Fox et al., 2006).  
The validity of the ERF studies has been questioned by several investigators, and more recently in an 
US EPA (US Environmental Protection Agency) commissioned NTP report (NTP-EPA, 2011). For 
instance, Cruzan (2009) argued that lung infections probably played a role in the development of what 
Soffritti et al. (2002) referred to as lympho-immunoblastic lymphomas. The Panel noted that the same 
arguments are applicable to the Soffritti et al. (2006) and Soffritti et al. (2007) studies and considered 
it plausible that lung infections might have played a role in the development of neoplastic changes that 
originated from mediastinal lymph nodes. Similarly, Schoeb et al. (2009) and Schoeb and McConnell 
(2011) assessed the likelihood that lifetime cancer bioassays of aspartame, methanol, and methyl 
tertiary butyl ether conducted with conventional (not specific pathogen-free) Sprague-Dawley rats 
were compromised by Mycoplasma pulmonis disease. The authors concluded, based on published 
reproductions of the lesions (Belpoggi et al., 1999, Soffritti et al., 2005), that the accumulation of 
lymphocytes, plasma cells and neutrophils in the lungs of the rats used in these studies was more 
plausibly due to M. pulmonis, possibly with contributions by other pathogens, than to a rare cellular 
type of lymphoma having an organ distribution uncharacteristic of recognised forms of lymphoma in Opinion on the re-evaluation of aspartame (E951) as a food additive
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rats (Schoeb  et al., 2009). The Committee on Carcinogenicity of Chemicals in Food Consumer 
Products and the Environment (COC) also evaluated the Soffritti et al. (2006) study on aspartame 
(COC, 2006). In light of the limitations in the design of this study and the use of animals with a high 
infection rate, the COC considered that no valid conclusions could be drawn from this study. Schoeb 
and McConnell (2011) subsequently confirmed the occurrence of inflammatory lesions in not only the 
respiratory tract but also lymph nodes, thymus, pleura and brain, suggesting the involvement of other 
pathogens in addition to M. pulmonis. They furthermore stated that upon screening of the ERF animal 
colony, antibodies to ‘mycoplasma’ had been found. Overall, Schoeb and McConnell (2011) 
concluded that the reported development of lymphomas in the ERF studies performed with Sprague-
Dawley rats should not be taken into account in cancer risk assessments. The Panel agreed with the 
above conclusions.  
Finally, the ANS Panel noted that an NTP review of ERF studies on methanol, methyl‐t‐butyl‐ether, 
ethyl‐t‐butyl‐ether, acrylonitrile and vinyl chloride had been performed following a request by US 
EPA (NTP-EPA, 2011). In the case of the methanol study (Soffritti et al., 2002), the NTP pathologists 
did not confirm the diagnosis of malignancy and reported fewer lymphoid neoplasms, mainly of the 
respiratory tract. They also observed fewer neoplasms of the inner ear and cranium and noted that 
there was chronic inflammation of the nasal cavity, ear canal, trachea, and lung, indicating infection of 
the animals by one or more respiratory pathogens. EPA concluded that many of the malignant 
neoplasms and the lymphoid dysplasias diagnosed by the ERF pathologists were cases of hyperplasia 
related to chronic infection (NTP-EPA, 2011).  
The reproductive and developmental toxicity studies on aspartame comprised an embryotoxicity and 
teratogenicity study performed in the mouse, a two-generation reproduction toxicity study in the rat, 
five peri- and postnatal developmental studies in the rat, a reproductive performance and 
developmental study in the rat and an embryotoxicity and teratogenicity study in the rat. In addition, 
eight embryotoxicity and teratogenicity studies were performed in the rabbit, four with administration 
of aspartame by diet and four by gavage.  
The Panel identified a NOAEL for developmental toxicity in the mouse (E89, 1975) of 5700 mg/kg 
bw/day, the highest dose level tested. In the case of the rat, the two-generation reproduction toxicity 
study was reported with limited details. However, the Panel considered this study (E11, 1971) together 
with other segment I and segment III studies that included a full examination of the F2A pups from the 
two-generation reproduction toxicity study (E9, 1972) sufficient to fulfil the requirements of a two-
generation reproduction toxicity study. The animals received aspartame in the diet at dose levels of 0 
(control), 2000 and 4000 mg/kg bw/day. Statistically significant pup body weight suppression and 
smaller size at weaning were recorded in the 4000 mg/kg bw/day. The Panel identified a NOAEL from 
these studies of 2000 mg/kg bw/day based on the lower pup weights at weaning in both generations 
(E9, 1972; E11, 1971).  
Further rat studies included a male and female fertility study (E10, 1972) and three segment peri and 
postnatal developmental studies (E39, 1973; E47, 1973; E48, 1973). In all these studies, the route of 
aspartame administration was via the diet at dose levels of 0 (control), 2000, or 4000 mg/kg bw/day. 
The effects on the pups were depressed body weights at birth and a decreased survival rate, which 
were observed at the high dose only. For all these studies the Panel derived a NOAEL of 2000 mg/kg 
bw/day. In an embryotoxicity and teratogenicity study (E5, 1970), no evidence of treatment-induced 
fetopathological effects was observed, and the Panel derived from this study a NOAEL of 4000 mg 
aspartame/kg bw/day for developmental and maternal toxicity, the highest dose level tested.  
In a peri- and postnatal development study in rats (E49, 1973), the effects of aspartame (4000 mg/kg 
bw/day) were compared with those of L-phenylalanine (1800  mg/kg bw/day) or L-aspartic acid 
(1700  mg/kg bw/day) or the combination of L-phenylalanine and L-aspartic acid (2100 and 
1800 mg/kg bw/day). The intention of the study was to have equimolar doses of each substance in the 
diet. The authors of the study reported a significant depression in body weight in the aspartame, L-
phenylalanine and L-phenylalanine + L-aspartic acid groups as compared to the control group and Opinion on the re-evaluation of aspartame (E951) as a food additive
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concluded that L-phenylalanine on its own or in combination with aspartic acid decreased maternal 
and pup body weight and therefore duplicated the observed effects of aspartame on these endpoints. 
The Panel agreed with the author’s conclusion but noted the poor survival of control pups.  
The Panel noted that the two-generation reproduction toxicity study (E11, 1971) was not reported 
according to current standards. However, when taken together with the segment I study (E10, 1972) 
and segment III studies (E47, 1973; E48, 1973) the Panel considered the available data sufficient to 
conclude on reproductive toxicity. In summary, the results of the reproductive and developmental 
toxicity studies in rats indicate NOAELs that ranged from 2000 mg aspartame/kg bw/day (E11, 1971; 
E39, 1973; E47, 1973; E48, 1973) to 4000 mg/kg bw/day (E5, 1970; E9, 1972; E10, 1972). The Panel 
noted that where developmental changes in pup body weight were observed at birth in studies at the 
dose of 4000 mg/kg bw/day, these could be attributed to a combination of malnutrition and nutritional 
imbalance due to excessive exposure to phenylalanine from metabolism of aspartame. In support of 
this hypothesis, the Panel noted that administration of a dose of L-phenylalanine (1800 mg/kg bw/day) 
that was equimolar to 4000 mg aspartame/kg bw/day led to a similar decrease in maternal and pup 
body weight as observed in a concurrent aspartame group (E49, 1973). Furthermore, supplementation 
of the diet with L-phenylalanine (5-7 %) (Kerr and Waisman, 1967) or the combination of 3 % L-
phenylalanine and 0.5 % α-methylphenylalanine (Brass et al., 1982) has been shown to result in severe 
nutritional imbalance in rats (Kerr and Waisman, 1967) and to lead to a reduction in pup body weight 
at birth (Brass  et al., 1982). In addition, milk production in mothers exposed to excessive L-
phenylalanine intake has been reported to be decreased, which could further contribute to malnutrition 
of the pups during weaning and result in pup mortality (Boggs and Waisman, 1962; Kerr and 
Waisman, 1967).  
The Panel considered that the depression in pup body weight in the high dose groups might be 
accounted for by the effect of high exposure to phenylalanine from metabolism of aspartame and it 
should be regarded as an (indirect) effect related to the test compound. The Panel noted that milk 
quality in the rat could be adversely affected by high levels of plasma phenylalanine and that body 
weights of pups could have been adversely affected (decreased) by decreased milk quality. This might 
provide a plausible explanation for the effects of aspartame on pup body weight at weaning.  
In several reproductive and developmental toxicity studies, aspartame was administered to rabbits via 
the diet (E53, 1973; E54, 1974; E55, 1973; E62, 1973; E63, 1973). The Panel noted that the actual 
doses of aspartame to which the rabbits were exposed did not exceed 1880 mg/kg bw/day (range 
1160–1870  mg/kg bw/day when the intended dose was 4000  mg aspartame/kg bw/day; 670–
1880  mg/kg bw/day when the intended dose was 2000  mg aspartame/kg bw/day) due to the 
considerable decrease in feed intake observed in the does (by 32-62 %) in this dose group. In another 
series of prenatal developmental studies, rabbits were exposed to aspartame (at doses up to 
2000 mg/kg bw/day) by gavage (E51, 1973; E52, 1973; E79, 1974). Overall, the Panel considered that 
the data from the studies described above were confounded both by the decrease in feed intake (when 
aspartame was administered via the diet or by gavage), the poor health of the animals, and, in many 
cases, by a number of deaths of pregnant rabbits in the treated groups, possibly related to misdosing 
via the gavage technique.  
In a separate study, pregnant rabbits were dosed by gavage at levels of 0 (control), 500, 1000 and 
2000 mg/kg bw/day (E90, 1975). This study also included L-phenylalanine and L-aspartic acid groups 
at dose levels equimolar to the top dose of 2000 mg aspartame/kg bw. An approximately 65 % and 
40 % decrease in feed consumption was observed in the 2000 mg aspartame/kg bw/day group and the 
L-phenylalanine treated animals, respectively, which in the high dose aspartame group was 
accompanied by a significant body weight loss. Twenty-four abortions were observed in the high dose 
aspartame group compared to no abortions in controls and four in the L-phenylalanine group. Mean 
fetal body weight and length were significantly reduced in both the 2000 mg/kg bw/day group and the 
L-phenylalanine group animals and a significantly higher rate of total (major and minor) 
malformations in the 2000 mg aspartame/kg bw/day group animals compared to the concurrent control 
group was reported. The authors of the study suggested that the effects observed at 2000  mg/kg Opinion on the re-evaluation of aspartame (E951) as a food additive
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bw/day and to a lesser extent in the L-phenylalanine group appeared to be produced by a severe 
reduction of nutrient intake.  
The Panel concluded that despite this plausible explanation, a direct toxic effect of treatment could not 
be ruled out. Although pregnant female rabbits from the high dose group in study E90 (1975) 
manifested body weight loss and decreased to negligible feed consumption, the Panel was unable to 
determine that the reported developmental effects on fetus were due to a reduced nutrient intake by the 
mother, as suggested by the authors. The Panel also considered the possibility that exposure to high 
levels of phenylalanine resulting from metabolism of aspartame may be in part or wholly responsible 
for these effects in the high dose aspartame group because similar effects, although less severe, were 
seen in the phenylalanine group. However, the Panel noted that the dose of L-phenylalanine 
administered was 25 % lower than the animals would have received as phenylalanine from the high 
dose of 2000 mg aspartame/kg bw/day.  
The Panel agreed that the results in developmental rabbit studies with aspartame may have been 
influenced by the nutritional status of the female rabbits as a result of gastrointestinal disturbances and 
the potential effect of phenylalanine from metabolism of the test compound. Gastrointestinal 
disturbances have also been reported in pregnant rabbits following administration of sucralose (SCF, 
2000), steviol glycosides (EFSA ANS Panel, 2010) and neotame (EFSA, 2007).  
Rabbits are known to be susceptible to disturbances of the gastrointestinal tract (Otabe et al., 2011). 
Gastrointestinal disturbances and lower feed intake in the rabbits may result from administering high 
levels of test preparation by gavage and may lead to disturbed clinical appearance, death or abortions.  
Matsuzawa et al. (1981) reported that pregnant rabbits restricted to 20 or 60 g feed/day from gestation 
days  6 to 20 showed statistical significantly higher fetal losses than pregnant rabbits fed 150  g 
feed/day and control group. 
Cappon et al. (2005) studied the effects of feed restriction on reproductive performance and 
development of the fetuses in rabbits. Groups of 15 New Zealand White rabbits were offered 150 
(control), 110, 75, 55, 35, and 15  g feed/day from GD 7-19. An increased number of abortions 
associated with an impairment of body weight gain were observed after feed restriction to 15  g 
feed/day. Feed restriction to 75  g feed/day was associated with reduced ossification of the fetal 
skeleton whereas reduced fetal weight and increased incidence of fetuses with reduced ossification of 
the skeleton were noted at feed consumption of less 75 g feed/day. Cappon reported no association of 
fetal malformation with up to 90 % feed restriction. The author concluded that the weight-of-evidence 
suggested that restricting rabbit feed during pregnancy, and the associated impairment of maternal 
gestational body weight gain could cause abortion, and fetal growth retardation exhibited by reduced 
fetal body weight and reduced skeletal ossification, but induced, remarkably, few (or no) 
malformations. Based on the available descriptions of the developmental rabbit studies the Panel was 
unable to ascertain whether the gastrointestinal disturbances were a cause of or a consequence of the 
reproductive and developmental effects seen. The Panel further noted that the gastrointestinal effects 
in the rabbit studies may be species specific and would therefore not be relevant for humans. Overall, 
the Panel concluded that the rabbit studies should not be considered as pivotal in the safety evaluation 
of aspartame because of the confounding factors affecting these studies. 
The Panel noted that there were limitations and deficiencies in the reproductive and developmental 
toxicity database in rats and rabbits. In many cases, these were likely to be attributable to study 
methodology and reporting requirements at the time when the studies were conducted. The Panel 
recognised the difficulty to evaluate retrospectively whether the reported effects would account for the 
toxicity of aspartame and thus be of toxicological relevance. The Panel considered whether this could 
be resolved by performing reproductive and developmental toxicity studies according to current 
guidelines. The Panel noted that this would require doses equivalent to, if not higher than, those used 
in the earlier studies. For animal welfare reasons, modern studies would not generally be conducted at 
doses greater than the lower end of the dose range identified to cause maternal toxicity, and/or Opinion on the re-evaluation of aspartame (E951) as a food additive
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associated with a severe decrease in feed consumption; the Panel therefore concluded that it was 
unlikely that a definitive modern study would be possible or ethical.  
The Panel considered that the attribution of effects to phenylalanine was both plausible and supported 
by the data on metabolism and kinetics of aspartame. Developmental toxicity studies, in which 
phenylalanine instead of aspartame was administered to rabbits, showed that phenylalanine induced 
maternal toxicity and effects in pups that were similar to those observed with aspartame. Therefore, 
the Panel considered that data on adverse effects of elevated plasma phenylalanine on pregnancy 
outcomes in phenylketonuria sufferers could be helpful. The Panel considered that combining these 
data with information on toxicokinetics of phenylalanine derived from aspartame might allow a mode 
of action approach to assess the reproductive and developmental effects of aspartame.  
Epidemiological studies have explored possible associations of aspartame, or artificial sweeteners 
more broadly, with pre-term delivery and various cancers. The epidemiological data on aspartame 
were previously reviewed by SCF (2002). The Panel considered and agreed with the conclusions of 
SCF that there was no evidence for adverse effects of aspartame in the human population. The new 
epidemiology studies, published since the SCF opinion, are described below.  
A large and well conducted prospective cohort study in Denmark found a significantly elevated risk of 
pre-term delivery (particularly medically induced pre-term delivery) in women with higher reported 
consumption of artificially sweetened drinks (but not aspartame specifically) at about 25  weeks 
gestation (Halldorsson et al., 2010). However, even in the highest exposure category (≥ 4 servings per 
day), odds ratios were less than two, and in the absence of any identified plausible underlying toxic 
mechanism or of independent replication in other studies, it is possible that the finding resulted from a 
combination of uncontrolled residual confounding and chance.  
To explore whether the findings of the Danish study could be replicated, another prospective study in 
Norway investigated the relation between consumption of artificially sweetened and sugar-sweetened 
soft drinks during the first 4-5 months of pregnancy and subsequent pre-term delivery in a large cohort 
of Norwegian women (Englund-Ögge et al., 2012). No significant trends were found in the risk of pre-
term delivery with increasing consumption either of artificially sweetened drinks or of sugar-
sweetened drinks. Small elevations of risk were observed with higher consumption of artificially 
sweetened soft drinks, but after adjustment for covariates, these reached statistical significance only 
when categories of consumption were aggregated to four levels, and then the odds ratio for the highest 
category (≥ 1 serving/day) was only 1.11 (95 % CI 1.00-1.24) in comparison with never consumption. 
This was driven by an increase in spontaneous but not medically induced pre-term delivery. 
Associations with sugar-sweetened soft drinks tended to be somewhat stronger, with an adjusted odds 
ratio of 1.25 (95 % CI 1.08-1.45) for consumption of at least one serving per day.  
This pattern of results contrasts with that reported by the Danish study. The association of pre-term 
delivery with artificially sweetened soft drinks was much weaker and barely discernible, applied more 
to spontaneous than medically induced deliveries, and was exceeded by an association with 
consumption of sugar-sweetened soft drinks. The Panel noted that effects may have been 
underestimated because of non-differential inaccuracies in the assessment of dietary exposures, but the 
method was similar to that used by the Danish study, and the same for sugar-sweetened as for 
artificially sweetened soft drinks. 
When findings from the two studies are considered together, as recently done in a meta-analysis of the 
data from both studies (La Vecchia, 2013), they do not point clearly to a hazard. In summary, both 
studies appear to have been well designed and conducted. Noting this, the Panel concluded that even at 
high level of exposure to artificially sweetened soft drinks the risk of pre-term delivery is likely to be 
small if it exists at all. This small potential risk could be a consequence of uncontrolled residual 
confounding, and the inconsistencies in the patterns of association reinforce this uncertainty. The 
Panel noted that the studies only allowed conclusion on artificially sweetened soft drinks and not on 
aspartame specifically. Opinion on the re-evaluation of aspartame (E951) as a food additive
 
 
EFSA Journal 2013;11(12):3496  109
The study by Schernhammer et al. (2012) examined the risk of lymphatic and haematopoietic cancers 
in relation to consumption of diet soda and aspartame sweeteners added at the table was examined, in 
two US cohorts. The authors reported that the category of highest aspartame intake (≥ 143 mg/day) 
was associated with a significantly elevated relative risk of non-Hodgkin Lymphoma (NHL) (1.64, 
95 % CI 1.17-2.29) and of multiple myeloma (3.36, 95 % CI 1.38-8.19) in men. However, there was 
no consistent trend in risk with increasing exposure, and there were no corresponding elevations in 
risk in women. No clear association with leukaemia was apparent in either men or women. The Panel 
noted that the positive findings could be given little weight, given their limitation to men, the small 
relative risks observed, and the lack of clear dose-response relationships. The authors’ proposed 
explanation for the differential associations in men and women is unconvincing in the absence of data 
on other more important dietary sources of methanol.  
A Swedish case-control study of malignant brain tumours suggested a possible link with consumption 
of low-calorie drinks, most of which contained aspartame (Hardell et al., 2001). However, the 
association was not statistically significant, and a more rigorous prospective cohort study in the United 
States found that risk of malignant glioma was significantly lower in subjects with higher intakes of 
aspartame at baseline. Moreover, a case-control study of children with medulloblastoma/primitive 
neuroectodermal tumour, also in the United States, found only a weak and statistically non-significant 
association with mothers’ recalled consumption of low-calorie carbonated drinks during pregnancy 
(Bunin et al., 2005). 
A cohort study of haematopoietic cancer in the United States showed no relation to consumption of 
aspartame, and in a set of linked case-control studies in Italy (Gallus et al., 2006), associations 
between consumption of sweeteners other than saccharin (mostly aspartame) and cancers of the oral 
cavity and pharynx, oesophagus, colon, rectum, larynx, breast, ovary, prostate and kidney were 
unremarkable.  
In a small pilot case-control study on brain cancer in adults conducted in southern France, 122 cases 
were compared to 122 controls with other neurological diagnoses (Cabaniols et al., 2011). There was 
no association with aspartame consumption during the past five years of at least once per week 
(OR 1.02, 95 % CI 0.57-1.85). However, the Panel noted that, due to different study limitations, the 
non-positive finding provides little reassurance of an absence of hazard.  
Overall, the reassurance of safety that is provided by non-positive findings in these epidemiological 
investigations is limited by (sometimes unavoidable) shortcomings in their design, and particularly in 
their assessment of exposures. At the same time, the studies do not point strongly to any hazard, and 
do not provide a suitable point of departure for derivation of a toxicological reference value.  
Magnuson et al. (2007) and Weihrauch and Diehl (2004) reviewed strengths and weaknesses of these 
four cancer epidemiological studies and concluded that there was no evidence that aspartame posed a 
carcinogenic risk. The National Expert meeting of the EFSA Advisory Forum (EFSA, 2010) also 
concluded that there was no evidence to support an association between aspartame and the prevalence 
of brain, haematopoietic or other tumours. The Panel agreed with these conclusions.  
5.  Biological and toxicological data on methanol 
The section contains summarised information on methanol metabolism and kinetics and a few detailed 
descriptions of the studies on release of methanol from aspartame.  
5.1.  Absorption, distribution, metabolism and excretion of methanol 
Methanol is converted to formaldehyde through one of at least four pathways, involving alcohol 
dehydrogenase, catalase, CYP2E1 or a Fenton-like system (Fe(II)/H2O2) (Dikalova  et al., 2001; 
Sweeting et al., 2010; MacAllister et al., 2011). Primates, including humans, metabolise methanol 
primarily using the alcohol dehydrogenase pathway whereas rodents appear to use all four pathways. 
In monkeys, about 25  % of the 
14C from [
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formylation biosynthetic reactions (E92, 1976). Formaldehyde is converted to formate by a specific 
formaldehyde dehydrogenase, and formate is converted to carbon dioxide. In monkeys, about 70 % of 
the 
14C from [
14C-methyl]-aspartame follows this path to carbon dioxide (E92, 1976). Formate can 
enter the one-carbon metabolic pool by formylating tetrahydrofolic acid to N5,N10-methylene-
tetrahydrofolate.  
In mammals, methanol is readily absorbed following ingestion, inhalation and dermal exposure (COT, 
2011). Methanol can readily enter the total body water and has a volume of distribution of 0.6-0.7 l/kg 
bw. Methanol is subject to a significant first pass metabolism. The overall metabolism of methanol 
proceeds by stepwise oxidation via formaldehyde to formate and then to carbon dioxide. The 
metabolism of formaldehyde is very efficient. Even after intravenous infusion, it was difficult to detect 
formaldehyde in blood, in which formaldehyde has been reported to display a half-life of about 
1 minute (McMartin et al., 1979; Tephly and McMartin, 1984). The oxidation of formate to carbon 
dioxide varies between species, the rate of formate elimination in humans and non-human primates 
being half of that in rats (Kavet and Nauss, 1990). In rodents, formate is converted to carbon dioxide 
through a folate-dependent enzyme system and a catalase-dependent pathway (Dikalova et al., 2001) 
whereas in humans metabolism occurs exclusively through the folate-dependent pathway (Hanzlik et 
al., 2005). Studies in humans have shown that approximately 80  % of an oral [
14C]formate dose 
(administered as a single dose of 3.9 g calcium formate) is exhaled as 
14CO2, 2-7 % excreted in urine 
and approximately 10 % is metabolically incorporated (Hanzlik et al., 2005). 
Formaldehyde is an intermediate in the formation of formic acid from methanol. Even after 
intravenous infusion of formaldehyde in dogs, cats, rabbits, guinea pigs and rats, it was difficult to find 
this substance in the blood, because of a very short half-life (~ 1 minute). Formaldehyde formation 
was studied in older publications on acute toxicity of methanol, but this intermediate could not be 
detected in animals or in humans (Tephly and McMartin, 1984). In monkeys given methanol orally via 
a nasogastric tube [3  g/kg bw as a 20  % (w/v) solution of [C
14]methanol (1300  dpm/µmol of 
methanol)], formaldehyde could be detected in the blood at a level of 27-45 μM over the period up to 
18 hours following dosing with methanol. No formaldehyde could be found in liver, kidney, urine or 
several neural tissues (LOD 25  μM; ~  0.75  mg/L or 0.75  mg/kg tissue). Formic acid was readily 
detected in all tissues and body fluids studied, in particular in urine, liver, blood and kidney 
(McMartin et al., 1979).  
When 
14C-methanol or [
14C-methyl]-aspartame were given orally to rats or monkeys in equimolar 
doses, in both species, the radioactivity was rapidly eliminated via exhaled air (~ 60 % of the dose in 
rats; ~  70  % in monkeys) within 8  hours post dosing. With methanol, a slightly higher rate of 
exhalation was observed, probably because hydrolysis and absorption are required when the 
radioactivity was administered as labelled aspartame. Virtually no radioactivity appeared in the faeces 
and 2-5 % of the dose was eliminated via urine. In rats, about 40 % and in monkeys about 30 % of the 
dose was not accounted for, but it is noted that residual radioactivity in the carcass from incorporation 
through the 1-carbon cycle was not studied. These studies were undertaken with dose levels of 10 to 
20 mg aspartame/kg bw (Oppermann, 1984).  
In a recent study (Lu et al., 2012) formaldehyde hydroxymethyl DNA adducts have been measured 
after administration of labelled [
13CD4]-methanol to rats (500 and 2000 mg/kg bw/day for 5 days) in 
multiple tissues in a dose dependent manner. This finding is in line with the known metabolism of 
methanol.  
The half-life for the systemic clearance of methanol has been reported to be 2.5-3 hours following oral 
doses of less than 100 mg/kg bw methanol given to human volunteers, increasing to 24 hours or more 
for doses greater than 1000 mg/kg (WHO, 1997). Stegink et al. (1981b) reported a human volunteer 
study in which methanol cleared with a half life of 2.5 to 3 hours after administration for a dose of 
80 mg aspartame/kg bw.  Opinion on the re-evaluation of aspartame (E951) as a food additive
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5.2.  Toxicological data of methanol 
5.2.1.  Acute oral toxicity  
A limited number of studies have assessed the acute oral toxicity of methanol. The LD50 reported were 
7300 mg/kg bw in mice, 5628 mg/kg bw in rats and 7000 mg/kg bw in monkeys (Lewis, 1992).  
5.2.2.  Short-term and sub-chronic toxicity  
In a 90-day study, Sprague-Dawley rats (30/sex/group) were administered 0, 100, 500, or 2500 mg 
methanol/kg bw/day by gavage for 6 weeks until the day of the interim necroscopy. After the interim 
sacrifice, all surviving rats were dosed daily until the end of the experiment (EPA, 1986). No 
differences in body weight gain, food consumption, gross or microscopic examinations were reported 
between treated animals and controls. Serum alanine transaminase (ALT)
 
and serum alkaline 
phosphatase (ALP) of the high dose group’s males (p ≤ 0.05) and females were approximately 30 % 
and 40 % higher respectively than those of the control group at the end of the experiment. Blood Urea 
Nitrogen (BUN) averages in the high dose group were 17 % and 12 %, respectively lower than control 
groups (p ≤ 0.05). Mean Corpuscular Haemoglobin (MCH) averages in the high dose group females 
were also significantly lower than controls (p ≤ 0.001) as well as Mean Cell Volume (MCV) averages 
were lower in the mid dose and low dose females groups (p ≤ 0.05). Brain weights of high dose group 
males and females were significantly decreased compared to the control group at the end of the 
treatment. The authors considered these differences to be treatment-related but very small, and not 
associated with any histological lesion. A higher incidence of colloid in the hypophyseal cleft of the 
pituitary gland was also observed in the high dose group (24/40) compared to the controls (3/40). The 
authors identified a NOAEL from this study of 500 mg/kg day. 
5.2.3.  Genotoxicity of methanol 
The genotoxicity of methanol has been studied in bacterial and mammalian in vitro tests and in some 
in vivo tests. A brief description of the studies found in the literature, is given below and summarised 
in Appendix H.  
In vitro studies 
De Flora et al. (1984) published a survey of 71 drinking water contaminants and their capacity to 
induce gene reversion in the Ames test with Salmonella typhimurium strains TA98, 100, 1535, 1537, 
and 1538 and found methanol to be negative. De Flora et al. (1984) also reported methanol to be 
negative for induction of DNA repair in Escherichia coli strains WP2, WP2 (uvrA-, polA-), and 
CM871 (uvrA-, recA-, lexA-), both when tested in the presence or absence of metabolic activation. The 
Panel considered these studies as providing insufficient information and therefore, were not taken into 
further consideration.  
Griffiths (1981) reported a genotoxicity study of methanol using fungi, and reported methanol to be 
negative for the induction of aneuploidy in Neurospora Crassa. The Panel considered that the methods 
implemented were thought not to be sufficiently robust to support the results reported.  
Simmon  et al. (1977) listed methanol as one of 45 chemicals that gave negative results with 
Salmonella typhimurium strains TA98, 100, 1535, 1537 and 1538, tested with or without metabolic 
activation. However, for the reasons explained in detail in Appendix H, the Panel considered this study 
provided insufficient details and therefore, was not taken into further consideration.  
Abbondandolo et al. (1980) used a ade6-60/rad10-198,h
- strain of Schizosaccharomyces pombe (P1 
strain) to determine the capacity of methanol to induce forward mutations. Negative results were 
obtained for methanol, both without and with metabolic activation. In contrast to this finding, weakly 
positive results for methanol were obtained for the induction of chromosomal malsegregation in the 
diploid strain P1 of Aspergillus nidulans (Crebelli  et al., 1989). The disturbance of chromosome 
segregation by methanol was attributed by the study authors to the non-specific damage of cell Opinion on the re-evaluation of aspartame (E951) as a food additive
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membranes induced at high doses by methanol and other aliphatic alcohols. The Panel noted that the 
fungal systems are not considered relevant for chromosomal malsegregation induction in mammalian 
cells. The Panel considered that the methods implemented were sufficiently robust to support the 
results reported.  
Methanol was studied in a Salmonella mutagenicity test in the presence or in the absence of metabolic 
activation. No mutagenicity was detected in strains TA98, 100, 1535, 1537, 1538 in 5 doses up to 
3.6 mg/plate (Gocke et al., 1981). The bacterial reverse mutation assay followed a standard protocol of 
that time. However, no detailed results for methanol were reported. Furthermore, TA102 and 
Escherichia coli were not included in the study and the maximal concentration tested (3.6 mg/plate) 
was lower than recommended in current guidelines. The Panel considered the bacterial reverse 
mutation assays, which were part of the screening study by Gocke  et al. (1981), as providing 
insufficient information for further consideration.  
NEDO (1987) reported methanol to be negative for gene mutation in Salmonella typhimurium TA98, 
100, 1535, 1537, 1538; Escherichia coli WP2 uvvA (Pre-incubation, absence and presence of S9; 10, 
50, 100, 500, 1000, 5000  µg/plate). The Panel considered that the methods implemented were 
sufficiently robust to support the results reported.  
NEDO (1987) also used Chinese hamster lung cells to monitor the capacity of methanol to induce (a) 
forward mutations to azaguanine, 6-thioguanine, and ouabain resistance (15.8, 31.7, 47.4, 
63.3  mg/mL), (b) chromosomal aberrations (7.1, 14.3, 28.5  mg/mL) and (c) SCEs (7.1, 14.3, 
28.5 mg/mL). Methanol was negative in tests for gene mutation and CA, but displayed some capacity 
to induce SCE in Chinese hamster lung cells, since the incidence of these lesions at the highest 
concentration (28.5 mg/mL) was significantly greater than in controls (9.41 ± 0.416 vs. 6.42 ± 0.227) 
expressed as mean ± SE per 100 cells. The Panel noted that this concentration of methanol exceeded 
the maximum concentration recommended for in vitro studies (i.e. 5 mg/mL or 5 µL/mLor 10 mM, 
whichever is the lowest) (OECD test guidelines 473 and 487.) The Panel considered that the methods 
implemented were not sufficiently robust to support the results reported.  
In a test for forward mutation in Escherichia coli SA500, methanol concentrations above 23 % were 
cytotoxic, reducing survival of the cells to less than 40 %. A 23 % methanol solution produced no 
mutagenic effects; cell survival was 53 % (Hayes et al., 1990). However, the assay was performed 
with one Escherichia coli strain (SA500) as well as in the absence of metabolic activation only. The 
Panel considered that the methods implemented were not sufficiently robust to support the results 
reported.  
Ohno et al. (2005) developed a genotoxicity test system based on p53R2 gene expression in human 
cells. The assay was based on examination of the chemical activation of the p53R2 gene, which was 
assessed by the incorporation of a p53R2-dependent luciferase reporter gene into two human cell lines, 
MCF-7 and HepG2. The Panel considered that the methods implemented were sufficiently robust to 
support the results reported, but not adequate for the present evaluation, because the endpoint used 
was not relevant for the mechanism of action of non-radiomimetic chemical compounds.  
McGregor  et al. (1988) aimed to define the optimal conditions for the metabolic activation of 
chemicals to mutagens in the L5178Y/TK+/- Mouse Lymphoma Assay using different pro-mutagenic 
compounds. Methanol was assessed for its mutagenicity at 5-50  μL/mL (approximately 3.95-
39.5 mg/mL). In the presence of 2.5 mg S9/mL, 10 μL methanol/mL exhibited a mutagenic effect, 
relative total growth (RTG) was reduced to less than 30 %. Furthermore, increasing the concentration 
of the S9 mix to 7.5 mg/mL reduced RTG to about 15 % but increased the mutant fraction from 60 in 
the control to 650 mutants/10
6 at 5  μL methanol/mL. However, the Panel noted that the lowest 
concentration tested (5 µL/mL) exceeded in terms of molarity (13.4 M) the maximum concentration 
recommended in OECD guideline 476 (5  mg/mL, 5  µL/mL, or 0.01  M, whichever is the lowest). 
Therefore, indirect effects due to non-physiological culture conditions at all concentrations tested Opinion on the re-evaluation of aspartame (E951) as a food additive
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cannot be excluded. The Panel considered that the methods implemented were not sufficiently robust 
to support the results reported.  
DeMarini et al. (1991) examined methanol in two independent microscreen prophage-induction assays 
with Escherichia coli WP2 (λ). Five methanol concentrations ranging from 0.15 up to 5 % (i.e. from 
37 mM to 1.23 M; assuming the concentrations are expressed as %, v/v), which included toxic levels, 
did not result in prophage-induction, without and with metabolic activation. The Panel considered that 
the methods implemented were sufficiently robust to support the results reported.  
Hamada et al. (1988) examined methanol (2-8 %; 0.49-1.97 M)) for induction of gene mutations in 
Saccharomyces cerevisiae ATCC26422 as a control culture within a study which aimed at elucidating 
the effects of ethidium bromide. Methanol did not induce gene mutations, but was only tested without 
a metabolic activation system. The Panel considered that the methods implemented were not 
sufficiently robust to support the results reported.  
In a survey by Shimizu  et al. (1985) which aimed to investigate the genotoxicity of forty-three 
industrial chemicals, methanol was assessed for its mutagenic potential in the Ames test with the 
Salmonella typhimurium tester strains TA1535, TA1537, TA1538, TA98, TA100 and Escherichia coli 
WP2 uvr A, using the preincubation method, both in the absence and presence of rat liver S9 
metabolism. Dose-levels of 5, 10, 50, 100, 500, 1000, 5000 µg/plate were used. The Panel considered 
that the methods implemented were sufficiently robust to support the results reported. Methanol was 
not mutagenic in this test system either in the absence or in the presence of S9 metabolic activation 
system.  
In the study by Lasne et al. (1984) which aimed to compare the sensitivity of the SCEs and in vitro 
micronucleus test assays to detect cytogenetic effects induced by different chemical agents, methanol 
was assessed for its potential clastogenicity for the induction of micronuclei in Chinese hamster V-79 
cells at a single dose-level of 50 µL/mL for 48 hours in the absence of S9 metabolism only. Results 
obtained indicate that methanol did not induce micronuclei, under the reported experimental condition. 
However, the Panel noted that the treatment time used was exceedingly long compared to the 1.5-
2  cell-cycle length recommended by the OECD test guideline 487 for the testing of chemicals. 
Furthermore, the dose-level administered was 10 times greater than the maximum recommended dose-
level to be used in in vitro studies (i.e. 5 µL/mL) to keep culture physiological conditions. On these 
grounds, the Panel considered that the methods implemented were not sufficiently robust to support 
the results reported.  
In vivo studies 
Pregnant CD-mice were administered by gavage twice daily with 2500 mg methanol/kg bw on GD 6-
GD 10 (Fu et al., 1996). No evidence of methanol-induced formation of micronuclei in the blood of 
fetuses or mothers was found. However, the Panel noted that blood samples were collected eight days 
after last administration of the compound. Normal procedures indicate sampling not later than 
72 hours, Therefore this study was not taken into further consideration (Appendix H).  
NEDO (1987) carried out an in vivo micronucleus test in 6 male SPF mice/group who received a 
single gavage dose of 1050, 2110, 4210, and 8410 mg methanol/kg bw. Twenty-four hours later, 1000 
cells were counted for micronuclei in bone marrow smears. The Panel considered that the methods 
implemented were sufficiently robust to support the results reported. At any dose level, methanol did 
not induce micronuclei significantly compared with the vehicle control (i.e. sterilized distilled water).  
In a recent study, DNA adducts were measured in several organs after oral administration to rats by 
gavage of the stable isotope methanol ([
13CD4]-methanol) in doses of 500 mg/kg bw and 2000 mg/kg 
bw per day for 5 days (Lu et al., 2012). The method can distinguish between adducts formed by 
endogenous substances and exogenous agents. It has already been used to study formaldehyde adducts 
in the nose and at distant sites after inhalation exposure to rats (Lu et al., 2010; Lu et al., 2011) and to Opinion on the re-evaluation of aspartame (E951) as a food additive
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cynomolgus macaques (Moeller et al., 2011). The data of the study (Lu et al., 2012) show that labelled 
formaldehyde arising from [
13CD4]-methanol induced N2-hydroxymethyl-dG DNA adducts in 
increasing numbers with increasing dose in all tissues, including liver, but in particular in the bone-
marrow. The number of exogenous DNA adducts was lower than the number of endogenous 
hydroxymethyl-dG adducts in all tissues of rats. The ratio of exogenous/endogenous dG adducts was 
0.18 and 0.45 in bone-marrow and 0.056 and 0.2 in the liver after doses of 500  mg/kg bw and 
2000  mg/kg bw of stable isotope methanol respectively after adjusting for isotopic effects in the 
metabolism of [
13CD4]-methanol.  
The Panel identified some concerns about the lower number of exogenous hydroxymethyl DNA 
adducts measured in the analysed tissues of rats following administration of [
13CD4]-methanol at 
500 mg/kg bw for 5 days compared to the number of endogenous hydroxymethyl DNA adducts. A 
previous study has shown a slower metabolic conversion of deuterium-labelled methanol compared to 
the unlabelled one (Brooks and Shore, 1971; Kraus and Simon, 1975). The Panel noted that the 
isotope effect factor employed was the mean of several widely varied published values. Furthermore, 
the measurements of N-hydroxymethyl-dG and dA adducts was not direct but required an in vitro 
reduction process with NaCNBH3 to the corresponding N-methyl derivative. Based on the authors’ 
comments, this procedure appeared not to be quantitative as the rate of reduction was in the range of 
65-85 %. Furthermore, deuterium could have been exchanged by the hydride during the reduction 
steps, which would have allowed for depletion of the labelled material and therefore led to an 
underestimation of the number of exogenous DNA adducts. The Panel noted that the measurements of 
endogenous N-hydroxymethyl-dA adducts in the untreated animal group and in methanol treated 
group at 500 mg/kg bw for 5 days were rather variable especially in the case of white blood cells, 
bone-marrow and brain cells.  
Furthermore, the Panel noted that adduct formation is a biomarker of exposure of organs and tissues to 
methanol and that a second step is necessary between DNA adduct formation and mutagenic events 
(Swenberg et al., 2008; Jarabek et al., 2009). Moreover, the Panel noted that doses applied in the study 
were in the lethal range for humans. Therefore, the Panel considered that the methods implemented 
were not sufficiently robust to support the results reported, and that no conclusion could be drawn 
from the study.  
No increase in sex-linked lethal mutations in either the wild type or the Basc strain of Drosophila 
melanogaster was found after methanol feeding (1000 mM) (Gocke et al., 1981).  
Pereira et al. (1982) reported that ‘the oral administration in mice of methanol (1000 mg/kg), increased 
the incidence of chromosomal aberrations particularly aneuploidy and exchanges and the micronuclei 
of polychromatic erythrocytes’.The study was available as an abstract only, without data to support the 
statement of the authors. Therefore the Panel was not able to reach a conclusion.  
Ward  et al. (1983) reported an increase in chromosome aberrations (exchanges (Robertsonian 
translocation), aneuploidy) in male B6C3F1 mice upon a single dose of 1000 mg methanol/kg bw). 
However, the Panel noted that the concurrent vehicle control showed 10 exchanges out 665 cells 
scored. Since chromatid and chromosome exchanges are not expected in healthy animals from this 
strain the Panel considered that the methods implemented were not sufficiently robust to support the 
results reported.  
In vivo studies by other routes of exposure (inhalation and intraperitoneal administration) 
Although the Panel noted that inhalation studies and intraperitoneal administration provide routes of 
exposure that are different from oral exposure, once methanol is absorbed, it is rapidly distributed to 
all organs and the tissue/blood concentration ratios should be similar (Cruzan, 2009). Therefore, 
similar effects from all three routes of exposure can be expected. Consequently, four in vivo reports 
using inhalation or the intraperitoneal route of administration (Gocke et al., 1981; Campbell et al., Opinion on the re-evaluation of aspartame (E951) as a food additive
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1991; McCallum et al., 2011a; 2011b) were considered by the Panel as valid studies and useful for a 
weight-of-evidence (WOE) approach in the assessment of the genotoxic potential of methanol.  
Gocke  et al. (1981) examined the potency of methanol to induce micronuclei formation in bone 
marrow upon intraperitoneal injection. Two male and two female NMRI mice were given 1920, 3200 
or 4480 mg methanol/kg bw as single intraperitoneal injections. No significant increase in the number 
of micronucleated polychromatic erythrocytes was observed. The Panel considered that the methods 
implemented were sufficiently robust to support the results reported.  
In the study by Campbell et al. (1991), ten male C57BL/6J mice/group were exposed by inhalation to 
0, 800, or 4000 ppm (0, 1048, and 5242 mg/m
3) methanol, six hours/day, for five days. At sacrifice, 
blood cells were examined for the formation of micronuclei. In addition, primary lung cells cultures 
established following perfusion of lung with 0.13  % trypsin, 0.01  % EDTA and 50  U of 
collagenase/mL, were examined for SCEs, CA and micronuclei. Furthermore, the synaptonemal 
complex damage in meiotic prophase nuclei obtained from teasing seminiferous tubules and 
subsequent fixation of cells was analysed. All endpoints studied gave negative results. However, the 
Panel noted that cytogenetic analyses in primary lung cultures are not validated procedures and, more 
specifically, the spontaneous incidences of micronuclei, SCEs and chromosomal aberrations were 
unexpectedly very high for primary cell cultures (23.2 %, 11.2 % and 6.9 % respectively in experiment 
1). Furthermore, the absence of a concurrent positive control strongly biased the negative outcome of 
the study. The Panel considered that the methods implemented were sufficiently robust to support the 
results reported.  
Groups of 10 male Swiss-Webster mice which had been kept on either a normal or a folate-deficient 
diet for 9  weeks before dosing, were given intraperitoneal methanol doses of 300, 600, 1200 or 
2500 mg/kg bw on 4 consecutive days. 24 hours after the last dose, the incidence of micronuclei in the 
RNA-positive erythrocytes of the animals was determined. The treatment with methanol did not 
significantly increase the incidence of micronuclei above the control values (O’Loughlin et al., 1992).  
McCallum  et al. (2011a; 2011b) investigated the potential indirect DNA-damaging activity of 
methanol by a reactive oxygen species-mediated mechanism. Male CD-1 mice (9-13 weeks old), New 
Zealand white rabbits (5  months old) and cynomolgus monkeys (3.4-5.7  years) received 2000  mg 
methanol/kg bw by intraperitoneal injection. Tissue oxidative DNA damage was assessed 6 hours 
post-dose, measured as 8-hydroxy-2’-deoxyguanosine (8-oxodG) by HPLC with electrochemical 
detection. The results obtained showed no methanol-dependent increases in 8-oxodG in bone marrow 
or spleen (McCallum et al., 2011a) or lung, liver or kidney (McCallum et al., 2011b) in any species. 
Chronic treatment of CD-1 male mice with 2000  mg/kg bw of methanol daily by intraperitoneal 
injection for 15 days also did not increase 8-oxodG levels in bone marrow or spleen (McCallum et al., 
2011a) or lung, liver or kidney (McCallum et al., 2011b). To further assess the possibility that the 
formation of 8-oxodG could have been enhanced by methanol, but rapidly removed via excision 
repair, DNA repair-deficient mice lacking oxoguanine glycosylase 1 (Ogg1-deficient mice) were 
treated with methanol at 2000 mg/kg once by intraperitoneal injection and tissues and organs collected 
6 and 24  hours later and analysed for oxidative DNA damage. The results obtained indicated an 
accumulation of 8-oxodG levels in the untreated Ogg1-deficient mice compared to the wild type mice, 
but no evidence for methanol-induced oxidative DNA damage was observed in lung, liver or kidney 
despite increases in 8-oxodG levels by the positive control potassium bromate (McCallum  et al., 
2011b) or in bone marrow or spleen (McCallum et al., 2011a). In the study by McCallum  et al. 
(2011b), the potential induction of 8-oxodG formation by methanol was further assessed in fibroblasts 
from Ogg1-deficient mice treated with methanol in vitro. The results obtained indicated an 
accumulation of 8-oxodG levels following a 3-hour treatment with the renal carcinogen potassium 
bromate (2.0  mM); however, the fibroblasts did not accumulate 8-oxodG following exposure to 
125  mM methanol for 6  hours. The Panel noted that in this in vitro assessment, methanol was 
administered at a dose-level far exceeding the recommended maximum dose-level of 10 mM to keep 
physiological treatment conditions (OECD test guidelines 483 and 487) In addition, free radical-
mediated hydroxynonenal-histidine protein adducts were reported not to be enhanced by methanol in Opinion on the re-evaluation of aspartame (E951) as a food additive
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primate bone marrow or spleen, or in rabbit bone marrow or mouse spleen, although modest increases 
were observed in rabbit spleen and mouse bone marrow. The authors concluded that taken together 
these observations suggest that methanol exposure did not promote the accumulation of oxidative 
DNA damage in lung, kidney or liver (McCallum  et al., 2011a) or in bone marrow and spleen 
(McCallum  et al., 2011b) in any species investigated including Ogg1–deficient mice. The Panel 
considered that the methods implemented were sufficiently robust to support the results reported and 
agreed with the conclusions of the authors.  
5.2.3.1.  Conclusion on the genotoxicity of methanol 
The in vitro genotoxicity data on methanol which were considered as relevant for the evaluation 
comprise a negative bacterial reverse mutation test, a negative gene mutation test with 
Schizosaccharomyces pombe and a negative prophage induction test with Escherichia coli WP2(λ).  
The in vivo genotoxicity data upon oral uptake on methanol considered as relevant for the evaluation 
comprise a negative mouse micronucleus test in bone marrow. In addition, in studies following intra 
peritoneal application or inhalation exposure of mice, rabbits or monkeys, no evidence of induction of 
DNA-damage (8-oxodG) formation, micronuclei and SCE was found.  
In a weight-of-evidence approach, the Panel also considered in vivo studies with inhalation and 
intraperitoneal applications. Taken together the Panel concluded that the data set is limited but that the 
available reliable in vitro and in vivo data did not indicate a genotoxic potential of methanol.  
Overall, the Panel concluded that available data do not indicate a genotoxic concern for methanol.  
Summary tables on the genotoxicity of methanol are presented in the Appendix H.  
5.2.4.  Chronic toxicity and carcinogenicity of methanol 
Methanol is a breakdown product of aspartame and was considered by the SCF in its safety assessment 
of aspartame (SCF 1985; 2002). The SCF concluded that there was no reason of concern regarding the 
chronic toxicity and carcinogenicity over the amounts of methanol likely to be produced by the 
metabolism of aspartame when compared with those present naturally in food (SCF, 1985). However, 
Soffritti and co-workers in their study recently proposed a role for methanol in the potential 
carcinogenic effects of aspartame (Soffritti et al., 2010). Although the ANS Panel had previously 
concluded that the results of Soffritti did not provide evidence for a carcinogenic effect of aspartame 
in mice, the Panel decided to present a more detailed analysis of the suggested chronic toxicity and 
carcinogenicity of methanol (EFSA ANS Panel, 2011). Only oral chronic and carcinogenicity studies 
of methanol have been considered for this evaluation.  
The oral studies on chronic toxicity and carcinogenicity of methanol are limited to a mouse study 
reported by Apaja (1980) and a rat study reported by Soffritti et al. (2002). 
The study by Apaja (1980) is part of a PhD thesis that investigated the effect of malonaldehyde bis-
dimethylacetal that decomposes to malonaldehyde and methanol and aimed at studying the 
carcinogenic effect of malonaldehyde. The study design contained groups dosed with methanol but no 
concurrent unexposed controls. In the study, male and female Eppley Swiss Webster mice 
(25/sex/dose group; 8 weeks old at study initiation) were exposed 6 days per week until natural death 
to 0.222 %, 0.444 % and 0.889 % methanol in drinking water (Apaja, 1980). Although no unexposed 
control group was included in the study, the author provided pathology data from historical records of 
untreated Swiss mice of the Eppley colony used in two separate chronic studies, one involving 100 
untreated males and 100 untreated females (Toth et al., 1977) and the other involving 100 untreated 
females histopathological analyzed by Apaja (Apaja, 1980). Mice were housed five per plastic cage 
and fed Wayne Lab-Blox pelleted diet. Water was available ad libitum throughout life. Liquid 
consumption per animal was measured 3 times a week. The methanol doses in the drinking water 
study were reported as 22.6, 40.8 and 84.5 mg/day (560, 1000 and 2100 mg/kg bw/day) for females, Opinion on the re-evaluation of aspartame (E951) as a food additive
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and 24.6, 43.5 and 82.7 mg/day (550, 970, and 1800 mg/kg bw/day) for males, 6 days/week. The 
animals were checked daily and body weights were monitored weekly. Test animals were sacrificed 
and necropsied when moribund. The experiment ended at 120 weeks with the death of the last animal.  
The author reported that survival of the methanol-exposed females in the drinking water study was 
lower than that of untreated historical controls (p < 0.05), but no significant differences in survival 
were noted for males. An increase in liver parenchymal cell necrosis was reported in the male and 
female high dose groups, with the incidence in females (8 %) being significant (p < 0.01) relative to 
untreated historical controls. Incidence of acute pancreatitis was higher in high dose males (p < 0.001), 
but did not appear to be dose-related in females, increasing at the mid (p < 0.0001) and low doses 
(p < 0.01) when compared to historical controls but not appearing at all in the high dose females. 
Significant increases relative to untreated historical controls were noted in amyloidosis of the spleen, 
nephropathy and pneumonia, but the increases did not appear to be dose-related.  
The author reported incidences of malignant lymphomas in females of 560, 1000, and 2100 mg/kg 
bw/day of 4/25 (16 %), 9/25 (36 %), and 10/25 (40 %), respectively. Males from the drinking water 
study had incidences of malignant lymphoma of 1/25 (4 %), 6/25 (24 %), and 4/25 (16 %) at 550, 970, 
and 1800  mg/kg bw/day respectively. The lymphomas were classified according to Rappaport’s 
classification (Rappaport, 1966), but it was not clear from the paper whether the lymphomas were 
generalised or whether they were restricted to one organ. The author indicated that the incidences in 
both males and females were ‘within the normal range of occurrence of malignant lymphomas in 
Eppley Swiss mice’. However, elsewhere in the document, Apaja states that ‘there was an increased 
(p < 0.05 in both) occurrence of malignant lymphomas (40.0 % and 24.0 % of the effective animals 
respectively) compared to historical data of untreated controls (Table 9)’. The latter table reports the 
historical control values of Toth et al. (1977).  
The Panel noted the lack of a concurrent control group and the small number of animals used per dose 
group. In particular, the Panel noted that even though the incidence of malignant lymphomas in the 
high dose group appears higher than the historical data reported by Apaja (1980), a comparison with 
other contemporary control groups from the same institute and from the same colony of mice (e.g. 
Cabral et al., 1979) shows that the background lymphoma incidence in untreated animals can be as 
high as 26 % for male and 43 % for female mice. Furthermore, the study was inadequately described 
in that tumour nomenclature and description were poorly defined, and there was a lack of individual 
animal results regarding tumour incidence and time of death. Finally, the Panel noted that the animals 
were not maintained under pathogen-free conditions and this is reflected by an overall incidence rate 
of pneumonia of approximately 22 % (Apaja, 1980). Overall, the Panel concluded that the study by 
Apaja is inadequate for the assessment of the carcinogenic potential of methanol.  
Soffritti et al. (2002) reported a chronic study in which methanol was given to 100 Sprague-Dawley 
rats/sex/group ad libitum in drinking water at concentrations of 0, 500, 5000, and 20 000 ppm (v/v). 
The study was published as a non-peer-reviewed paper. The animals were 8 weeks old at the onset of 
the study. All rats were exposed for up to 104  weeks, and after that maintained until they died 
naturally. The experiment ended at 153 weeks with the death of the last animal. Mean daily drinking 
water, feed consumption, and body weights were monitored weekly for the first 13  weeks, every 
2 weeks thereafter for 104 weeks, then every 8 weeks until the end of the experiment. Clinical signs 
were monitored 3 times/day, and the occurrence of gross changes was evaluated every 2 weeks. All 
rats were necropsied at death and underwent histopathological examination of organs and tissues.  
No substantial dose-related differences in survival were observed, although the data were not 
provided. Body weight, water and feed consumption were monitored in the study, but the data were 
not documented in the published report. However, average doses of 0, 55, 542 and 1840 mg/kg bw/day 
in males and 0, 67, 630 and 2250 mg/kg bw/day in females were calculated by Cruzan (2009) from 
drinking water concentrations of 0, 500, 5000, and 20 000 ppm and data made public by the ERF.  Opinion on the re-evaluation of aspartame (E951) as a food additive
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Water consumption in high dose females was reduced compared to controls between 8 and 56 weeks 
and the mean body weight in high dose males tended to be higher than that of control males. Overall, 
there was no pattern of compound-related clinical signs of toxicity, and the available data did not 
provide any indication that the control group was not concurrent with the treated group (Cruzan, 
2009). Soffritti  et al.  (2002) further reported that there were no compound-related signs of gross 
pathology or histopathological lesions indicative of non-cancer toxicological effects in response to 
methanol.  
The study reported a number of oncogenic responses to methanol including haemolymphoreticular 
neoplasms, the majority of which were reported to be lympho-immunoblastic lymphomas (Table 21). 
In the ERF bioassays, including this methanol study, haemolymphoreticular neoplasms are generally 
divided into specific histological types (lymphoblastic lymphoma, lymphoblastic leukaemia, 
lymphocytic lymphoma, lympho-immunoblastic lymphoma, myeloid leukaemia, histocytic sarcoma, 
and monocytic leukaemia) for identification purposes. According to Soffritti et al. (2007), the overall 
incidence of haemolymphoreticular tumours (lymphomas/leukaemias) in ERF studies is 13.3  % 
(range, 4.0–25.0 %) in female historical controls (2274 rats) and 20.6 % (range, 8.0–30.9 %) in male 
historical controls (2265 rats). The high dose responses, reported in the methanol study amounted to 
28  % (p  <  0.05) and 40  % (not significant) for females and males, respectively. The study also 
suggested a significant increase in the incidence of ear duct carcinoma.  
In 2010, US Environmental Protection Agency (EPA) proposed that the chronic cancer study on 
methanol performed in rats by Soffritti et al. (2010) should be subjected to an independent pathology 
review following discrepancies in the diagnosis identified during a site visit to ERF by pathologists 
from NTP conducted in 2010. The EPA commissioned the NTP to conduct this pathology review. The 
NTP pathologists diagnosed fewer lymphoid neoplasms, mainly of the respiratory tract, and fewer 
neoplasms of the inner ear and cranium and noted that there was chronic inflammation of the nasal 
cavity, ear canal, trachea, and lung, indicating infection of the animals by one or more respiratory 
pathogens. EPA concluded that many of the malignant neoplasms and the lymphoid dysplasias 
diagnosed by the ERF pathologists were cases of hyperplasia related to chronic infection (Table 21, 
NTP-EPA, 2011).  
In view of the concerns identified by EPA, the Panel did not support the validity of the conclusions in 
studies reported by Soffritti and colleagues.  
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Table 21:   Summary Incidences of Malignant Lymphoma or Leukaemia in Male and Female Rats 
 0  ppm
c  500 ppm  5000 ppm  20 000 ppm 
MALES 
Number of animals per 
group 
100 100  100  98-100 
 ERF  PWG ERF  PWG  ERF  PWG  ERF  PWG 
Lung only  7  0  10  0  13  1  13  0 
Multiple tissues  19  13  21 11 22  12  26  8 
Total rats with 
Lymphoma
a/Leukaemia
b 
26  13  31 11 35  13  39  8 
FEMALES 
Number of animals per 
group 
100 100  100  99-100 
 ERF  PWG ERF  PWG  ERF  PWG  ERF  PWG 
Lung  only  3  3  5 0 6  0  7  0 
Multiple tissues  9  5  16  4  16  7  18  6 
Total rats with 
Lymphoma/Leukaemia 
12 8  21  4  22  7  25  6 
ERF = European Ramazzini Foundation study diagnosis; PWG = Pathology Working Group EPA Panel consensus 
a ‘Lymphoma’ includes lymphoblastic lymphoma, lymphocytic lymphoma, lymphoimmunoblastic lymphoma for the ERF 
diagnoses. For QA pathologist and PWG, all lymphoma sub types were diagnosed as malignant lymphoma. 
b ‘Leukaemia’ includes lymphoblastic leukaemia and myeloid leukaemia for SD diagnoses and for QA pathologist and PWG, 
includes myeloid leukaemia and mononuclear cell leukaemia. 
c Average doses of 0, 55, 542 and 1840 mg/kg bw/day in males and 0, 67, 630 and 2250 mg/kg bw/day in females were 
calculated by Cruzan (2009) from drinking water concentrations of 0, 500, 5000, and 20 000 ppm and data made public by 
the ERF. 
5.2.5.  Reproductive and developmental toxicity of methanol 
A few studies on oral reproductive and developmental toxicity of methanol were reported. In most of 
the studies, especially in the rat, limitations were observed (maternal toxicity not described, limited 
number of animals and dose levels tested, time of dosing).  
Four studies were identified on the reproductive and developmental toxicity of methanol in mice via 
the oral route.  
5.2.5.1.  Reproductive toxicity 
Mice 
Four month old male B6C3F1 mice were dosed by gavage with 0 (n  =  5) or 1000 (n  =  10)  mg/kg 
bw/day methanol in water for 5 days (Ward et al., 1984). An increase in the number of mice with 
‘banana-type’ sperm morphology was reported. The total number of sperm abnormalities was not 
significantly increased in the methanol group. The Panel noted that these effects were considered of 
unknown biological significance as fertility (by mating of the animals) was not tested and general 
toxicity was not described.  
5.2.5.2.  Developmental toxicity 
Mice 
In mice, one prenatal toxicity study by inhalation, in which also one high oral dose was tested, and two 
oral prenatal developmental studies at high dose levels were identified and are summarised below.  
Rogers et al. (1993) dosed pregnant CD-1 mice (n= 70, 26, 41, 40, 15, 11, 6) with 0, 1000, 2000, 5000, 
7500, 10 000 and 15 000 ppm (equivalent to approximately 0, 1300, 2600, 6500, 9750, 13 000 and 19 Opinion on the re-evaluation of aspartame (E951) as a food additive
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500 mg methanol/m
3 ) by inhalation on GD 6-15 for 7 hours/day. Increased incidences of exencephaly 
and cleft palate were found in the offspring at 6500 mg/m
3 (5000 ppm) or higher. There was increased 
embryo/fetal death at 9750  mg/m
3 (7500  ppm) or higher and an increased incidence of full-litter 
resorptions. Reduced fetal weight was observed at 13  000 and 19  500  mg/m
3 (10  000 and 15  000 
ppm). A dose-related increase in cervical ribs was significant at doses > 2600 mg/m
3 (2000 ppm). The 
no observed adverse effect concentration (NOAEC) for developmental toxicity was 1300  mg/m
3 
(1000  ppm) methanol. There was no evidence of maternal toxicity at methanol exposure 
concentrations below 9750 mg/m
3 (7500 ppm). To evaluate the significance of route of exposure, a 
study was conducted in which pregnant mice were dosed twice a day with 2 g methanol/kg bw/day (4 
g daily) by oral gavage. Plasma methanol levels on GD 6 and GD 15 were comparable in the 10 000 
ppm inhalation group and the 4000  mg/kg bw/day oral group. Incidences of resorptions, external 
defects including cleft palate, and decreases in fetal weight were similar to those found in the 13 000 
mg/m
3 (10 000 ppm) inhalation exposure group, presumably due to the greater rate of respiration of 
the mouse. The Panel considered the NOAEC of 1000  ppm based on the cervical rib effects as 
conservative as these effects tend to disappear as the pups grow and are often observed in inhalation 
studies. From this concentration, an oral dose of approximately 560 mg/kg bw/day was calculated by 
the Panel according to the method of Alexander et al., 2008
20. 
Both Fu et al. (1996) and Sakanashi et al. (1996) studied the influence of dietary folic acid on the 
developmental toxicity of methanol.  
In the study of Fu et al. (1996), virgin female CD-1 mice were fed a standard diet (containing 
1200 nmol folic acid (FA)/kg) or diet deficient in FA (400 nmol FA/kg referred to as ‘marginal’). Both 
of these diets contained 1 % succinylsulfathiazole (to prevent endogenous synthesis of folate by the 
intestinal flora). The animals were fed these diets for 5 weeks prior to mating and throughout breeding 
and gestation. From GD  6-10 dams were given by gavage deionised, distilled water or methanol 
(MeOH, 15.65 % Optima HPLC grade MeOH) at 2.5 g/kg body weight, twice daily. On GD 18, mice 
were weighed and killed and the liver, kidneys, and gravid uteri removed and weighed (21-24 
litters/group). Implantation sites, live and dead fetuses, and resorptions were counted; fetuses were 
weighed individually and examined for cleft palate and exencephaly. The marginal FA dietary supply 
alone resulted in low maternal liver (50  % reduction) and red cell folate (30  % reduction) 
concentrations, as well as low fetal tissue folate concentrations (60 to 70 % reduction) relative to the 
standard FA diet groups. In addition, marginal FA supply alone resulted in cleft palate in 13 % of the 
litters; there were no litters affected with cleft palate in the standard FA diet group. Marginal FA-
MeOH treatment resulted in a further increase in the litters affected by cleft palate (72 % of litters 
affected). The percentage of litters affected by exencephaly was highest in the marginal FA-MeOH 
group. The authors considered that the results show that marginal folate deficiency in pregnant dams 
significantly increases the teratogenicity of MeOH.  
Sakanashi et al. (1996) fed Crl: CD-1 mice a purified, amino acid-based folic acid-free diet fortified 
with either 400, 600, or 1200  nmol/kg diet folic acid commencing 5  weeks prior to mating and 
throughout breeding and gestation. All diets contained 1  % succinylsulfathiazole to prevent 
endogenous synthesis of folate by intestinal flora. On GD 6-15, mice were gavaged twice daily with 
water or methanol (purity not specified) in water at 2000 or 2500 mg/kg bw for a total daily dose of 0, 
4000 or 5000 mg/kg bw. On GD 18, dams were weighed and killed and the liver, kidneys, and gravid 
uteri removed and weighed. Implantation sites, live and dead fetuses, and resorptions were counted; 
fetuses were weighed individually and examined for cleft palate and exencephaly. One third of the 
fetuses in each litter were examined for skeletal morphology. Twelve to 29 litters were examined per 
group; in the low folate/2000 mg methanol group only 3 litters were examined. Methanol treatment 
decreased gestational weight gain in groups fed diets containing 600 or 1200 nmol folic acid/kg diet; 
these effects were not seen in the 400  nmol/kg group. Methanol did not affect pregnancy or 
implantation rate. There was no consistent effect of methanol exposure on haematocrit or liver folate 
                                                      
20   Definition extracted from Alexander et al. (2008). Daily dose [mg/kg bw]= 0.608* Concentration [mg/L]* Duration  
 [minutes]/BW
 0.148 [kg]; 1000 ppm (1.32 g/m
3)= 0.608*1.32*7*60/0.035 
0.148 = 562 mg/kg bw Opinion on the re-evaluation of aspartame (E951) as a food additive
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level; plasma folate was increased in mice from the 1200 nmol/kg group that received 5000 mg/kg/day 
methanol. Methanol decreased fetal body weight in each of the folic acid dietary groups. An increase 
in the litter incidence of cleft palate was seen with methanol treatment in all dietary groups; the 
incidence was exacerbated in the 400  nmol/kg group. The litter incidence of exencephaly was 
increased by exposure to methanol in the 400 nmol folic acid/kg group. Methanol increased anomalies 
affecting the cervical region, although the incidence tended to decrease in dietary groups receiving 
larger amounts of folic acid. The authors concluded that the developmental toxicity of methanol was 
enhanced when maternal folic acid stores were low.  
The Panel concluded from the latter two studies, that the effects found on developmental toxicity were 
related to methanol. However, it is not proven that the enhancement of the developmental effect was 
due to the deficiency in folate as the effect described can also be related to malnutrition as also 
described in the NTP-CERHR 2003.  
Rats 
In rats, one study by inhalation and three oral prenatal developmental toxicity studies were identified 
and are summarised below.  
In the study by Nelson et al. (1985), the inhalation of methanol by pregnant Sprague-Dawley rats 
(n=15-16) throughout the period of embryogenesis induced a wide range of concentration-dependent 
teratogenic and embryo lethal effects. Treatment–related malformations, predominantly extra or 
rudimentary cervical ribs and urinary or cardiovascular defects, were found in fetuses of rats exposed 
7 hours/day to 26 000 mg/m
3 (20 000 ppm) methanol during GD 7-15. Maternal toxicity (decreased 
weight gain and feed intake) during the first week of exposure was found at this exposure level. No 
adverse effects to the mother of offspring were found in animals exposed to 6500 mg/m
3 (5000 ppm) 
7 hours/day from GD 1-19. The authors considered this dose as the NOAEC in this study (Nelson et 
al., 1985). The Panel agreed with this conclusion. From this concentration, an oral dose of 
approximately 2070 mg/kg bw/day was calculated by the Panel according to the method of Alexander 
et al., 2008. 
The reproductive toxicity of methanol was studied by Infurna and Weiss (1986) in an experiment 
where Long-Evans rats were divided into 3 groups of 10 animals. Two of the groups consumed 
drinking solutions of 2 % v/v methanol, one from GD 15-17 and the other from GD 17-19. The control 
group received distilled water. No maternal toxicity was apparent, as measured by weight gain, 
gestational duration, and daily fluid intake. To assess maternal and fetal toxicity the following 
variables were recorded during gestation and throughout the pre-weaning period: weight gained during 
the 3
rd week of gestation, daily fluid intake during this period, duration gestation, birth weight and 
body weight on postnatal days 0, 7, 14, and 20, day of eye opening, maternal behaviour following 
parturition, and litter size. Postnatal behavioural evaluations began the day after birth by testing the 
suckling behaviour of rat pups from all 3 groups on day 1 and nest seeking behaviour on day 10. The 
only observed effect, in methanol-dosed groups, was a significant impairment in suckling behaviour 
measured as mean latency of attachment to the nipple during a 2-minute test. This was the only 
observed effect but the authors concluded that these data suggest that prenatal methanol exposure 
induces behavioural abnormalities early in life, since no other signs of toxicity was apparent either in 
the mothers or the offspring (Infurna and Weiss, 1986). The Panel did not agree with this conclusion 
because of the limited usefulness of this test in isolation.  
Cummings (1993) demonstrated that in the rat (n = 8), 3.2 g methanol/kg bw/day administered by 
gavage from day 1 to day 8 of gestation was associated with a range of maternal toxic effects and 
fetotoxic effects. The maternal toxicity was characterized by a reduction in uterine weight on GD 9 
that represents an inhibition of the growth of decidualized tissue in the treated animals. At 
3.2  g/kg/day, the number of atypical sites (defined as implantation sites, often small, exhibitimg 
adjacent extravasation of blood) was significantly increased at GD 9 but not at GD 11 and GD 20. 
When dams were killed on GD  20, there was no evidence of fetal resorptions and no effects on Opinion on the re-evaluation of aspartame (E951) as a food additive
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maternal ovary weight and corpora lutea were observed. Methanol did not affect either uterine weight 
or maternal body weight on GD 20.  
Long-Evans rats (n  =  10-13/group) received by gavage a single dose of methanol of 1.3, 2.6, or 
5.2 ml/kg bw (corresponding to 1023, 2045, or 4090 mg/kg bw/day according to CERHR calculation) 
on GD 10 (Youssef et al., 1997). Signs of maternal toxicity were only seen in the highest dose group 
and included decreased body weight gain and feed intake. Fetal body weights were significantly 
reduced in all treatment groups, but not in a dose-dependent manner. Dose related-anomalies were 
undescended testes and eye defects, which reached statistical significance in the high dose group, and 
facial haemorrhage and dilated renal pelvis. The Panel considered this study to be of limited relevance 
due to the timing of the single dose, which was not at what is considered the most sensitive period for 
developmental toxicity of methanol.  
The Panel noted that the design of the oral rat studies was inadequate. In one study (Youssef et al., 
1997) rats were only administered once and not during the most sensitive period for induction of 
developmental effects. In two other studies in rats the duration of the administration period (GD 15-17 
and GD 17-19 or GD 1-8) did not cover the period of organogenesis (Infurna and Weiss, 1986 and 
Cummings, 1993).  
Monkeys 
In a study by Burbacher et al. (2004), Macaque monkeys (11-12 females per dose group) were 
exposed to 0, 200, 600 or 1800  ppm methanol vapour for 2.5  hours/day for 7  days a week 
(corresponding to oral doses of 0, 21, 61 and 185 mg/kg bw/day (Alexander et al., 2008)) prior to 
breeding and throughout pregnancy (approximately 120 days). The mothers remained healthy during 
the study and tests to evaluate motor incoordination, vision loss, and/or respiratory effects were 
negative. Methanol exposure did not affect menstrual cycles, number of matings to conception or 
conception rate. The mean length of pregnancy was significantly reduced by 6-8  days in treated 
animals compared to controls but the reduction was not dose-related. In addition, although not 
statistically significant, five methanol treated females (in different dose groups) were Caesarean-
sectioned due to pregnancy complications. No methanol-related effects were apparent on the birth 
weight or health of the offspring (Burbacher et al., 2004). The Panel considered that it was not 
possible to identify an effect level from this study.  
The Panel concluded that mice were more sensitive than rats to the developmental toxic effects of 
methanol by inhalation, as was found by Rogers et al. (1993). A contributing factor to this species 
difference may be the difference in their respiratory frequencies. Blood levels reported in the studies 
of Nelson et al. (1985) in rats were lower than those reported for mice at the same exposure levels and 
regimen. Oral studies were only performed at high dose levels of 4000 or 5000 mg/kg bw/day and no 
NOAELs could be derived from these studies. Therefore, a NOAEL for oral exposure was calculated 
from the studies as described by Alexander et al. (2008). The Panel considered 1000 ppm as the 
NOAEC in mice in the study of Rogers et al. (1993), and 5000 ppm as a NOAEC in rats in the study 
of Nelson et al. (1985). From these exposure concentrations by inhalation, oral dose levels of 560 and 
2070 mg/kg bw/day respectively, were calculated by the Panel. The overall NOAEL of 560 mg/kg 
bw/day is considered as conservative by the Panel. 
6.  Discussion of methanol toxicity database 
When ingested, methanol is subject to a significant first pass metabolism. Principally, methanol 
(CH3OH) metabolism proceeds by stepwise oxidation via formaldehyde (HCHO) to formate 
(HCOOH), and then to carbon dioxide (CO2 )via different metabolic pathways.  
Formaldehyde and formate can also enter the one carbon metabolic pool through tetrahydrofolic acid 
and from there, may contribute to the biosynthesis of purines and pyrimidines (Figures 3 and 4). 
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The oral studies on chronic toxicity and carcinogenicity of methanol are limited to a mouse study 
reported by Apaja (1980) and a rat study performed by the ERF and reported by Soffritti et al. (2002). 
The Panel noted that the experimental design of the poorly reported study by Apaja (1980) is flawed 
due to the lack of a concurrent control group, the small number of animals used per dose group that 
were not maintained under pathogen-free conditions resulting in a high incidence rate of pneumonia. 
Therefore, the Panel concluded that the study by Apaja (1980) was inadequate for the assessment of 
the carcinogenic potential of methanol.  
The rat study on methanol (Soffritti et al., 2002) demonstrated a statistically significant increased 
incidence of haemolymphoreticular tumours (lymphomas/leukaemias) but only in females at the 
highest dose level.  
As already discussed above, the validity of the ERF study on methanol has recently been criticised 
(Cruzan, 2009; Schoeb et al., 2009; Schoeb and McConnell, 2011; NTP-EPA, 2011). The ANS Panel 
concurred with the concerns identified by EPA and others, and did not support the validity of the 
conclusions in the study on methanol as reported by Soffritti et al. (2002). The Panel concluded that 
the ERF rat study was not a suitable for the cancer risk assessment of methanol.  
No adequate animal studies on the effects of methanol on fertility and reproductive performance were 
described.  
The database on developmental toxicity of methanol is limited.  
In mice, one prenatal developmental toxicity study by inhalation in which one group was also dosed 
orally and two oral prenatal developmental studies at high dose levels were available. The Panel 
derived a NOAEC by inhalation for prenatal developmental toxicity in mice of 1000 ppm from the 
study of Rogers et al. (1993) and calculated a NOAEL for oral exposure of approximately 560 mg/kg 
bw/day. The Panel considered the NOAEC of 1000  ppm based on the cervical rib effects as 
conservative as these effects tend to disappear as the pups grow and are often observed in inhalation 
studies.  
The design of oral prenatal studies in rats was inadequate. In one study (Youssef et al., 1997), rats 
were administered methanol only once and not during the most sensitive period for induction of 
developmental effects. In two other studies in rats the duration of the administration period (GD 15-17 
and GD  17-19 or GD  1-8) did not cover the period of organogenesis (Infurna and Weis, 1986; 
Cummings, 1993). In the study of Nelson et al. (1985), pregnant females were exposed by inhalation 
during organogenesis and a NOAEC of 5000  ppm was found. The Panel calculated from this 
concentration a corresponding oral NOAEL of approximately 2070 mg/kg bw/day.  
In a study by Burbacher et al. (2004), Macaque monkeys were exposed to 0, 200, 600 or 1800 ppm 
methanol vapour for 2.5 hours/day for 7 days a week (estimated doses of 0, 21, 61 and 185 mg/kg 
bw/day (Alexander et al, 2008)) prior to breeding and throughout pregnancy (approximately 
120 days). No methanol-related effects were apparent on the birth weight or health of the offspring.  
The Panel noted that there is 140-515-fold difference between the calculated NOAELs in mice and 
rats, respectively, and the amount of methanol released from aspartame consumed at the ADI.  
The Panel noted that for average consumers of aspartame, the contribution to the overall exposure to 
methanol ranged from 1 % up to 10 % across the EU general population. In this estimate, the Panel 
also noted that exposure to methanol from natural sources is a minor contributor compared to exposure 
from endogenous pathways (less than 10 %). The Panel noted that the exposure from aspartame-
derived methanol is similar to methanol exposure from natural sources.  Opinion on the re-evaluation of aspartame (E951) as a food additive
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The Panel concluded that there is no safety concern from the levels of methanol released from 
aspartame under the current uses and permitted use levels.  
The Panel also considered the metabolite of methanol, formaldehyde, in its risk assessment. IARC 
classified formaldehyde as a known human and animal carcinogen in 2006 that causes nasopharyngeal 
cancer in humans and squamous cell carcinomas in the nasal passages of rats (IARC, 2006). The 
recent evaluation of formaldehyde by NTP (2011) and its re-evaluation by IARC in 2012 confirmed it 
to be a human and animal nasal carcinogen following exposure by inhalation (NTP, 2011; IARC 
2012). Some epidemiological studies have identified an association between formaldehyde exposure 
by inhalation and the induction of leukaemia in professional and industrial workers, however other 
studies have not demonstrated this association (NTP, 2011; IARC, 2012). The epidemiological 
evidence was recently criticised by the US National Academy of Sciences (NRC, 2011). The Panel 
considered that the epidemiological evidence for leukaemia from occupational exposure was 
inconsistent. Moreover, a recent analysis of DNA adducts in rats and cynomolgus macaques caused by 
inhaled formaldehyde revealed not only the existence of high levels of endogenous formaldehyde 
adducts in all tissues examined, including bone marrow, but also that DNA adducts and DNA-DNA 
cross-links from inhaled formaldehyde only occurred in the nasal mucosa and not in sites remote from 
the portal of entry (Lu et al., 2010, 2011; Moeller et al., 2011). The Panel noted that the distribution of 
DNA adducts from inhaled formaldehyde did not support systemic effects of formaldehyde or a causal 
association with leukaemia in humans from occupational exposure.  
As previously concluded by EFSA (2006), the carcinogenicity of formaldehyde is only observed under 
occupational exposure by inhalation and oral exposure is not linked to cancer in animals (Til et al., 
1989).  
To further consider any potential for DNA adduct formation after oral aspartame exposure in humans, 
the Panel estimated the steady state plasma levels of formaldehyde likely to be generated from 
aspartame exposure at current ADI. The Panel also assessed the potential for DNA adduct formation at 
the Cmax if aspartame were given in 3 equal doses equivalent in total to the ADI (40 mg/kg bw/day) 
over the day.  
Methanol released from aspartame in the gut, is absorbed and enters the body. The released methanol 
is 10 % (by weight) of aspartame and therefore the amount of methanol formed at an aspartame dose 
of 40 mg/kg bw/day (current ADI) is 4  mg/kg bw/day. Using this dose, the plasma steady state 
concentration that could arise maximally from aspartame-derived methanol can be calculated using the 
following equation: 
Css = f x D/Cl x tau 
 
Where: 
Css = plasma steady state concentration 
f = fraction absorbed (=1.0 for methanol) 
D = dose (4 mg/kg bw = 280 mg) 
Cl = total body clearance (= 0.500 L/min) 
tau = dosing interval (=1 day =1440 min) 
Using this approach, the plasma steady state concentration that could arise maximally from aspartame-
derived methanol is calculated to be 12 µM. Peak concentrations of methanol after three divided doses 
of aspartame at the current ADI of 40 mg/kg bw are calculated to be about 60 µM.  
According to the COT report (2011), methanol is oxidised sequentially to formaldehyde, then to 
formic acid or formate (depending on the pH) and finally to carbon dioxide (see above). In humans 
and non-human primates, the oxidation of methanol to formaldehyde is mediated by alcohol 
dehydrogenase (ADH). In non-primate mammals, the reaction is primarily mediated by a catalase-Opinion on the re-evaluation of aspartame (E951) as a food additive
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peroxidative system, but the conversion rates are similar. The oxidation of formaldehyde to formate is 
mediated by several enzyme systems including formaldehyde dehydrogenase. Formate is then oxidised 
to carbon dioxide through the action of formyl-THF synthetase, whereby formic acid combines with 
tetrahydrofolic acid (THF) to form 10-formyl-THF which is subsequently converted to carbon dioxide 
by formyl-THF dehydrogenase (COT, 2011). 
At the tissue level, formaldehyde is reported to be present as formaldehyde acetal (CH2(OH)2): 
HCHO + H2O → CH2(OH)2 
before undergoing conjugation with glutathione (GSH): 
CH2(OH)2 + GSH → HO-CH2 – SG + H2O 
which is a substrate for enzymatic transformation to formic acid by formaldehyde dehydrogenase 
(Andersen et al., 2010): 
HO-CH2 – SG + NAD
+ + H2O → HCOOH + GSH + NADH + H
+ 
Thus, a concentration of 12 µM methanol will produce at most, a steady state concentration of 12 µM 
formaldehyde/formaldehyde acetal. The maximum concentration (Cmax) of formaldehyde was 
estimated to be about 60 µM. In nasal tissue, Andersen et al. (2010) have shown that in the nasal cells 
the amount of GSH will remain stable as long as the tissue concentration of formaldehyde acetal does 
not increase above 500  µM. The nasal intracellular baseline formaldehyde acetal concentration is 
400 µM (Andersen et al., 2010, based on data by Casanova and Heck, 1987 and Casanova et al., 
1994). Increase in formaldehyde bound to DNA was not measurable for concentrations below 400 µM 
in the experiments done by Casanova et al. (1994) used for the modelling by Andersen et al. (2010). It 
is acknowledged that the nasal tissue and other tissues such as the bone marrow may vary in terms of 
absolute concentrations of GSH present, however, Esmali et al. (2012) demonstrated that bone marrow 
cells are well equipped with GSH. The increase in formaldehyde acetal associated with an exposure to 
aspartame at the maximal ADI (and if ingested as a single dose), even if all the methanol liberated 
from aspartame was converted into formaldehyde, which then formed a formaldehyde acetal with 
water, would be less than 3 % (for the steady state level) and less than 15 % (for the peak level) of the 
normal intracellular endogenous levels. It can be used to make an estimate of the additional burden of 
formaldehyde acetal associated with the intake of aspartame at the level of the ADI. Such an 
additional burden should be evaluated in the light of the naturally occurring inter-species and intra-
species variation in the internal level of methanol, formaldehyde and formaldehyde acetal which by far 
exceed the difference between internal concentration of these endogenous substances and the 
additional exposure by oral intake of aspartame at the current ADI level. Kleinnijenhuis et al. (2013) 
using a sensitive and specific method have measured a formaldehyde concentration in blood of 2.25 ± 
0.67 mg/L in rats. This corresponds to a coefficient of variation of 30 % in endogenous formaldehyde 
blood levels in rats. 
Thus, the Panel concluded the additional methanol and formaldehyde arising from aspartame at the 
ADI does not constitute a significant additional risk above the risk from naturally occurring 
endogenous methanol and formaldehyde, given the fact that worst case assumptions have been used. 
7.  Biological and toxicological data on DKP 
A public call was launched by EFSA in 2011 and 2012. The present evaluation of the biological and 
toxicological data is based on the evaluation of unpublished and published studies following this call 
together with additional studies identified from the published literature up to the end of November 
2012.  Opinion on the re-evaluation of aspartame (E951) as a food additive
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7.1.  Absorption, distribution, metabolism and excretion of DKP 
7.1.1.  Studies on absorption, distribution, metabolism and excretion of DKP received 
following a public call for data and which were available at the time of the previous 
JECFA and SCF evaluations 
The toxicokinetic properties of DKP have been studied extensively and are summarised below. Studies 
in the rat, rabbit, monkey and man (E15, E18, 1972) have shown that [
14C(U)-Phe]-DKP (20-30 mg/kg 
bw) did not enter the normal metabolic pathways of phenylalanine and was not well absorbed from the 
gut. Radioactivity was recovered in the faeces, primarily as unchanged DKP. Following oral 
administration of DKP metabolism to phenylacetic acid occurs in the gastro-intestinal tract, 
phenylacetic acid can then be absorbed and is rapidly excreted in the urine as phenylacetic acid and 
following conjugation with glutamate to phenylacetylglutamine (E80, 1974). The urinary excretion of 
phenylacetic acid and phenylacetylglutamine accounts for 20 % (rat) to 50 % (monkey and man) of the 
orally administered DKP.
  Phenylacetylglutamine is a naturally occurring compound that is also 
generated during the metabolism of phenylalanine. It was not observed following direct intravenous 
administration of DKP in monkeys, suggesting that it was generated by bacterial metabolism in the gut 
rather than by endogenous metabolism following absorption.  
When [
14C(U)-Phe]-DKP was administered orally to monkeys (E80, 1974), the distribution curve was 
biphasic, with an early phase representing absorption and distribution among tissues while the second 
phase represented the appearance in the circulation of phenylacetylglutamine. Thus, the major 
metabolite of DKP, was the major form excreted via the urine in monkeys following oral 
administration of DKP. It has also been identified in human urine following administration of [
14C(U)-
Phe]-DKP (E80, 1974).  
Additional studies were carried out to characterise the biotransformation of DKP by intestinal flora 
(E80, 1974). The urinary metabolites of DKP were compared in conventional rats with normal 
microflora and in germ-free rats following dosing with [
14C(U)-Phe]-DKP. In the absence of gut flora, 
89 % of urinary 
14C was present as DKP itself whereas in conventional rats only 24 % of the urinary 
label was in this form with most of the urinary radioactivity recovered as phenylacetylglutamine. 
When the germ-free rats were populated with microflora, the pattern of metabolism was converted to 
that seen in conventional rats. It appeared, therefore, that the primary metabolites of DKP arose as a 
result of bacterial biotransformation.  
Cho et al. (1987) measured plasma and urinary concentrations of DKP in samples obtained from six 
normal adult subjects ingesting 2.2 mg DKP/kg bw as part of a dose of 200 mg aspartame/kg bw. DKP 
concentrations were measured by HPLC in plasma (0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 
24 hours) and urine (0-4, 4-8, 8-24 hours) for 24 hours. In plasma, DKP concentrations were always 
below the detection limit (less than 1 μg/mL). In urine, DKP was measurable in all collected samples. 
Mean total urinary DKP excreted during the first 24-hour period after dosing was 6.68 + 1.30 mg 
(corresponding to 4.83  % of the ingested DKP dose). Approximately 44  % of the total urinary 
excretion of DKP occurred in the first 4 hours after dosing. 
Another study reported the effect of repeated ingestion of beverages containing DKP on amino acid 
and DKP concentrations in plasma and urine of normal healthy subjects (UN05, 1987) and in PKU 
heterozygous subjects (UN06, 1987). Six normal healthy adult and six healthy adult PKU 
heterozygotes received a dose of 150 mg of DKP every hour for eight hours. Blood and urine samples 
were collected up to 24  hours. DKP administration produced a small increase in plasma DKP 
concentration that reached a plateau after four doses in both normal and PKU subjects. DKP was 
detectable in the urine during the 24-hour period following ingestion, and amounted to 5 % or 2 % of 
the total dose in normal or PKU heterozygous subjects, respectively. DKP had no significant effect on 
plasma amino acids concentrations, on blood formate and methanol, on urinary formate 
concentrations, on the plasma LNAA ratios in both normal and PKU subjects.  Opinion on the re-evaluation of aspartame (E951) as a food additive
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7.2.  Toxicological data of DKP 
7.2.1.  Acute oral toxicity of DKP 
The acute toxicity of the DKP was studied in mice, rats and rabbits (E45, 1973). DKP was 
administered by gavage (as 15-17.5 % suspension in 1 % Tween 80, or an aqueous 2 % suspension for 
low doses) at doses up to 5000 mg/kg bw. Male Sprague Dawley rats (n = 6) were dosed at 2191 or 
5000 mg/kg bw and male Schmidt Ha/ICR mice (n = 6) were dosed at 3710 or 5000 mg/kg bw. Male 
New Zealand White Luenberg rabbits were dosed at 2000, 2500 or 3200 mg/kg bw (n = 1) and 4000 or 
5000 mg/kg bw (n = 3). The animals were observed intermittently during the 7 day post-treatment 
period and no remarkable motor or behavioural activites were noted. No mortalities were observed in 
the experimental period.  
In the same report, the acute toxicity of DKP was also studied by i.p. injection (E45, 1973). Male 
Sprague Dawley rats (n  =  6) were dosed at 1562  mg/kg bw and male Schmidt Ha/ICR mice at 
1577  mg/kg bw (n  =  6). Motor and behavioural activites were unremarkable and no deaths were 
recorded during the study period.  
As for aspartame, the authors concluded for DKP that ‘it can be assumed that the LD50 values are in 
excess of the highest doses administered to each species by the routes employed’.  
The overview of these studies is presented in Appendix F.  
7.2.2.  Short-term and sub-chronic toxicity of DKP 
7.2.2.1.  Studies on short-term and sub-chronic toxicity received following a public call for data 
which were available at the time of the previous JECFA and SCF evaluations 
DKP was administered daily for 2  weeks to Charles River CD rats by gavage (as 5  % aqueous 
suspension) (E7, 1971). The daily dosage was 1000 mg/kg bw. The young adult rats (11 weeks) were 
randomly assigned, 5 males and 5 females to the control and treatment groups. Survival of the animals 
was 100 %, no effects on body weight, or physical or behavioural changes were noted during the study 
period. In addition, no treament-related changes in haematoloy, clinical chemistry, urinalysis or 
histopathology were reported.  
Groups of 10 Ha/ICR mice (4 weeks old; sex unspecified) were administered 1000 mg/kg bw DKP or 
an equal volume of vehicle only by gavage (as 5 % aqueous suspension) daily for 2 weeks (E6, 1971). 
Survival of the animals was 100 %, no effects on body weight, or physical or behavioural changes 
were noted during the study period, nor were any treament-related changes in haematology, clinical 
chemistry, urinalysis or pathological changes reported.  
Groups of eight-week-old male and female Charles River CD rats (n = 5) were randomly assigned to 
study groups (E8, 1972). DKP was administered in diet to result in dose levels of 0, 2000, 4000 and 
6000 mg/kg bw/day; actual consumption resulted in dosing within 5 % of these doses. A moderate 
(statistically significant at sacrifice) decrease was noted in the body weight of the female rats in the 
highest dose group and was attributed to a proportional decrease in feed intake. All animals survived 
the experimental period and no physical or behavioural changes were noted. There were no treament-
related changes in haematology, clinical chemistry, urinalysis or histopathology, but several 
incidences of non-treatment-related disease were observed.  
The overview of these studies is presented in Appendix G.  
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7.2.3.  Genotoxicity of DKP 
7.2.3.1.  Studies on genotoxicity of DKP received following a public call for data which were 
available at the time of the previous JECFA and SCF evaluations 
In vitro studies 
DKP was tested in two bacterial reverse mutation assays with Salmonella typhimurium strains 
TA1535, TA1537, TA1538, TA98 and TA100, both plate incorporation without and with metabolic 
activation, (a) 10 to 5000 µg/plate (E98, 1978) and (b) 50 to 10 000 µg/plate (E106, 1978) revealed no 
evidence for mutagenicity of DKP (Appendix H). The Panel considered that the methods implemented 
were sufficiently robust to support the results reported.  
Negative results were also reported in a study in which DKP was tested in the Ames test with 
Salmonella typhimurium strains TA1535, TA1537, TA1538, TA98 and TA100 at 870 and 
4370 µg/mL both in the absence and presence of S9 and in limited test for reversion/mitotic crossing-
over in the yeast D7, only without metabolic activation (Tateo et al., 1989). The Panel noted that the 
study lacks TA102 strain and that only two dose levels were tested.  
In vivo studies 
DKP was tested for the induction of chromosome aberrations in bone marrow cells in rats 
(10  males/group) following administration of 0 (control), 250, 500, 1000 and 2000  mg DKP/kg 
bw/day by gavage for 5 consecutive days, given in three equally divided daily doses (E30, 1972). No 
evidence for CA-induction was found, the Panel considered that the methods implemented were 
sufficiently robust to support the results reported (Appendix H).  
DKP was studied for mutagenicity by host-mediated assay in rats (E31, 1972). Rats were treated with 
0 (control), 250, 500, 1000, 2000 mg DKP/kg bw/day by gavage, divided equally in three doses for 
five consecutive days (E31, 1972). 30 minutes after the final dose, the animals were inoculated with 
Salmonella typhimurium, G-46, by intraperitoneal injection. Three hours later the bacteria were 
recovered and the peritoneal washing was evaluated for the presence of mutants. In rats, the host-
mediated assay revealed no evidence for mutagenicity of DKP. However, the Panel noted that the test-
system employed has not received further validation.  
DKP was studied for mutagenicity by a host-mediated assay in mice (E82, 1974). Mice were treated 
orally with 0 (control), 1000, 2000, 4000 or 8000 mg DKP/kg bw/day, given in three equally divided 
doses at two-hour intervals for five consecutive days. The authors concluded that the study did not 
provide evidence for mutagenicity of DKP. However, for the reasons given in Appendix H, the Panel 
considered that the methods implemented were not sufficiently robust to support the results reported.  
For a dominant lethal assay, rats were treated by gavage with 1000 mg DKP/kg bw/day, given in two 
equally divided doses on a single day (E42, 1973). Each male was mated with two sexually mature 
virgin females weekly for eight consecutive weeks. On GD 14 these mated females were sacrificed for 
ovarian and uterine examinations. The Panel considered that the methods implemented were 
sufficiently robust to support the results reported. DKP did not affect paternal growth, maternal 
pregnancy rate, corpora lutea and implantation sites.  
7.2.3.2.  Conclusion on the genotoxicity of DKP 
The genotoxicity data on bacterial reverse mutation exhibit some limitations (e.g. absence of TA102 
and WP2 uvrA Escherichia coli) but were considered sufficient to conclude that DKP was not 
mutagenic in bacterial systems. The in vivo studies on genotoxicity of DKP comprise chromosome 
aberration in bone marrow erythrocytes and dominant lethal assays, all of which gave negative results. 
Taken together, the Panel considered that the data available in vitro and in vivo did not indicate a 
genotoxic potential of DKP.  Opinion on the re-evaluation of aspartame (E951) as a food additive
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Overall, the Panel concluded that available data do not indicate a genotoxic concern for DKP.  
Summary tables on the genotoxicity of DKP are presented in the Appendix H.  
7.2.4.  Chronic toxicity and carcinogenicity of DKP 
7.2.4.1.  Studies on chronic toxicity and carcinogenicity received following a public call for data 
which were available at the time of the previous JECFA and SCF evaluations 
The chronic toxicity of DKP was investigated in mice (E76, 1974) and rat (E77-78, 1974).  
Mice 
DKP was administered in the diet to groups of 36 male and 36 female ICR Swiss albino mice at dose 
levels equating to 0 (control), 250, 500, and 1000 mg/kg bw/day for 110 weeks (E76, 1974). Another 
group of 72 males and 72 females served as controls. Criteria evaluated were physical appearance, 
behaviour, body weight gain, feed consumption, survival, clinical chemistry, eye examination, organ 
weights, tumour incidence and gross and microscopic pathology. Histopathological examination was 
performed on all gross lesions from all animals at each treatment level, and on 20-27 grossly 
unremarkable organs from control and high dose level animals, as well as from roughly two-thirds and 
one-third of the animals in the mid and low dose groups. Detailed histopathological evaluations were 
performed on brain and urinary bladder from all mice in the control and the three treatment groups. 
There was no effect on the physical appearance and behaviour of the animals. Mean terminal body 
weights were significantly increased only for the low dose males. No significant differences in body 
weight gain during the first year were noted despite significantly reduced feed consumption in males 
at all three doses of DKP. Mean survival was significantly decreased for the mid dose females 
(16.7  %  ±  6.3  %) compared to the controls (33.9  %  ±  5.7  %). However, this finding was not 
considered treatment-related with respect to mean survival time. Mean survival to week 108 was 
20-39 %. No consistent treatment-related haematology/clinical chemistry and urinalysis findings were 
noted. Random fluctuations reaching statistical significance were occasionally observed but the values 
remained within historical control data. No compound-related effects in ocular examinations were 
reported. Gross observations at necropsy did not reveal compound-related changes in any organs or 
tissues. Relative organ weights were unaffected, except for relative thyroid weight, that was increased 
in females at the mid and high doses. In no instance was the adjusted tumour incidence of any of the 
analysed tumour types significantly higher than that of the respective controls. No unusual tumours 
were encountered. One primary brain tumour (i.e. meningioma) was identified in a control female. 
Secondary lymphoreticular tumours were detected in brain and urinary bladder from small numbers of 
mice at all dose levels and controls. No consistent non-neoplastic alterations attributable to compound 
treatment were observed. The authors concluded that when DKP was administered to the mouse for 
110 weeks in the diet at dose levels up to 1000 mg/kg bw/day there was no evidence of an effect, with 
respect to the incidence of neoplasms, or with regard to non-neoplastic changes in any organ or tissue. 
The Panel agreed with this evaluation and identified a NOAEL for this study of 1000 mg/kg bw/day, 
the highest dose level tested.  
Rats 
DKP was administered in the diet to groups of 36 male and 36 female Charles River CD rats at dose 
levels of 0 (control), 750, 1500, 3000 mg/kg bw/day for 115 weeks (E77-78. 1974). Another group of 
72 males and 72 females served as controls. Histopathological examination was performed on 
available tissues from all animals in the study; also, all usual and unusual gross lesions and tissue 
masses were examined microscopically. Microscopic examinations of the brains, including seven 
coronal sections from each brain representing all major neuroanatomical areas, and bladder were also 
performed. There was no evidence that the administration of DKP at any level resulted in any effect on 
the physical appearance and behaviour of the animals. Two transient unidentified infectious diseases 
occurred during the study; these affected control and treated rats equally. One arose in weeks 12-14 of 
the study and was diagnosed as a putative viral infection of the salivary and Harderian glands. The Opinion on the re-evaluation of aspartame (E951) as a food additive
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other arose during weeks 48-52 and was assumed to be bacterial; rats were treated with penicillin G in 
an attempt to control this infection. No compound-related decrease in survival rates was observed in 
any of the group. Body weights were significantly reduced in the high dose groups of both sexes in 
later stages, and periodically at lower doses. Feed intake was not consistently affected except for an 
increase in the mid-study in the high dose male group. Statistically significant changes in haematology 
or clinical chemistry and urinalysis were limited to a mild but significant decrease in serum cholesterol 
in high dose animals from day 42 (female) and 92 (male) onwards, and decreased urinary pH in all 
treated female groups, which was statistically significant at the high dose level. This effect was 
thought to be associated with the presence of acidic DKP metabolites in urine. No compound-related 
effects in ocular examination were noted. No biologically meaningful compound-related variation in 
organ weights was observed. There was no treatment-related non-neoplastic histopathology in any 
organ or tissue, and no unusual non-neoplastic lesions were observed. The adjusted tumour incidence 
of the analysed tumour types was not significantly higher than that of the respective controls. No 
unusual tumours were encountered. The authors concluded that the dietary administration of DKP to 
rats for 115 weeks at dose levels up to 3000 mg/kg bw/day indicated no evidence of an effect with 
respect to the survival rate, rate of body weight gain, physical examination and haematology findings, 
and incidence of neoplasms or non-neoplastic changes in any organ or tissue. DKP produced a 
significant decrease in urinary pH in the high dose female group, which was attributed to acidic 
metabolites of DKP in the urine, and a mild but significant decrease in serum cholesterol at the high 
dose level only. In addition, a significant increase in uterine polyps (benign tumours) was also found 
in females treated with the mid and high doses of DKP (1/69, 1/34, 4/34, 6/33, in control, 750, 1500, 
3000 mg/kg bw/day, respectively). Based on these last observations, and in agreement with the JECFA 
monograph (JECFA, 1980) and the SCF evaluation (1989), the Panel identified a NOAEL for this 
study of 750 mg DKP/kg bw/day.  
7.2.4.2.  Additional chronic toxicity and carcinogenicity studies  
An additional 2-year chronic toxicity and carcinogenicity study on aspartame was conducted in Wistar 
rats (Ishii et al., 1981; Ishii, 1981). This study is described in section 3.2.4.1. This study also included 
a group of rats that was fed 4000 mg/kg bw/day aspartame + DKP (3:1) for up to 104 weeks. There 
was a dose-dependent depression of body weight gain at 4000 mg/kg aspartame + DKP in males and 
females. This effect was correlated with decreased feed consumption. There was no evidence of a 
treatment-related effect on incidence of neoplastic and non-neoplastic changes other than an increase 
in focal mineralisation of the renal pelvis in both males and females (incidences in males: control, 
1/57; aspartame  +  DKP, 13/59; incidences in females: control, 16/59; aspartame  +  DKP, 38/60) 
associated with a dose-related increase in urinary calcium (Ishii et al., 1981; JECFA, 1981; EFSA, 
2006). In addition, medullary mineralisation was observed in females (control, 23/59; 
aspartame  +  DKP, 36/60). The authors attributed these effects to irritation caused by the mineral 
deposition and considered to be of minimal toxicological significance. The Panel noted that 
mineralisation in the kidney is a common finding in rats, the aetiology being associated with mineral 
imbalance (Lord and Newberne, 1990). Thus, there was no evidence for toxicity of aspartame with its 
degradation product DKP over 2 years in rats. The Panel noted that this study provided information on 
the lack of toxicity of aspartame when administered in conjunction with DKP.  
7.2.5.  Reproductive and developmental toxicity of DKP 
7.2.5.1.  Studies on reproductive and developmental toxicity received following a public call for 
data which were available at the time of the previous JECFA and SCF evaluations 
Rats 
The available data were a segment I study (male and female fertility study; E37, 1973), a segment II 
study (embryotoxicity and teratogenicity; E38, 1973) and a segment III study (peri- and postnatal 
development; E13, 1972) in rats. In addition, there was a segment II study in rats given a mixture of 
aspartame and DKP (3:1) (E56, 1972). The route of administration was via the diet. Animals were fed 
the test material from 17 days prior mating through gestation and lactation (E37, 1973), from GD 6 to Opinion on the re-evaluation of aspartame (E951) as a food additive
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15 (E38, 1973), from GD 14 through weaning (E13, 1972), and from GD 6 to 14 (E56, 1972). None of 
the endpoints studied showed a difference between treated groups and controls and therefore, the 
lowest NOAEL observed in these studies was 2000 mg DKP/kg bw/day (E37, 1973; E38, 1973), 
corresponding to the highest dose tested. In the segment II study with a mixture of aspartame and DKP 
(E56, 1972), the NOAEL was 3040 mg/kg bw/day, the highest dose tested.  
Rabbits 
The rabbit studies included two developmental toxicity studies, which were confounded by poor health 
of the animals, and, in many cases, by a number of deaths in the treated groups, possibly related to 
misdosing due to gavage technique issues. In one study, DKP was administered to albino rabbits at 
doses of 500, 1000, and 2000 mg/kg bw/day from GD 6 to 18 (E57, 1972), whereas in a second study 
albino rabbits were administered a mixture of aspartame and DKP (3:1) at doses of 1000, 2000, and 
3000 mg/kg bw/day from GD 6 to 18 (E29, 1972). In the first study (E57, 1972), according to the 
authors the NOAEL for maternal toxicity was 1000  mg/kg bw/day, due to a large gastric bolus 
comprised of granular white material (presumed DKP) admixed with hair found at necropsy in some 
animals from the high dose group. In the second study (E29, 1972), there was a statistically significant 
decrease in live mean fetal weights at the two highest doses, therefore according to the authors the 
NOAEL for this study was 1000 mg/kg bw/day (E29, 1972).  
7.2.6.  Other Studies on DKP 
In a PhD Thesis (Bolteus, 2002), the effect of DKP treatment (0-10 mM) for 1 or 24 hours on MTT (3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) reduction in cultures of neonatal Wistar 
rat astrocytes and human astrocytes obtained from a biopsy taken during a craniotomy is described. 
There was no apparent change in MTT reduction when rat astrocytes cultures when exposed to DKP 
up to 10  mM for 1  hour or 24  hours as compared to culture medium-exposed control cultures. 
Likewise, there was no apparent change in MTT reduction when human astrocyte cultures when 
exposed to DKP up to 10 mM for 1 hour or up to 5 mM for 24 hours as compared to culture medium-
exposed control cultures. However, the author reported a 30 % increase in mean MTT reduction over 
control with 10 mM DKP. The Panel noted that the exposure to DKP was performed under serum-free 
conditions and that a 24-hour serum starvation period can be highly toxic to untransformed cells. No 
information on the effect of serum removal on MTT reduction was provided by the author except that 
a gradual removal of the serum from the culture medium over two days was necessary before the 
experiments with DKP could be initiated. The Panel further noted that MTT reduction is dependent on 
the reductive capacity of cells and, therefore, is only an indirect indicator of a change in cell viability 
and cell number, Overall, the Panel considered that based on the methods applied, the results of the 
study by Bolteus (2002) did not provide evidence for a proliferative effect of DKP in human 
astrocytes.  
8.  Discussion of DKP toxicity database 
DKP is one of the degradation products of aspartame that is formed under certain processing and 
storage conditions. The EU and JECFA specifications for aspartame set a limit for DKP levels of 
1.5 % (w/w) in aspartame as supplied (Commission Regulation (EU) No 231/2012; JECFA, 2006). 
The levels of DKP will potentially increase in aspartame-containing food and drinks during processing 
and storage. For example, it has been determined that up to 24 % of the aspartame is degraded into 
DKP in carbonate beverages (UN11, 1986; Table 3).  
The Panel noted that the content of DKP in aspartame tested in the toxicological studies, including the 
long-term studies and carcinogenicity studies ranged from 0.1 % up to 4 %.  
Some toxicological studies have been conducted on DKP.  
Studies in animals and man have shown that DKP was not well absorbed from the gut and was 
recovered in the faeces, primarily as unchanged DKP. Following oral administration of DKP Opinion on the re-evaluation of aspartame (E951) as a food additive
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metabolism to phenylacetic acid occurs in the gastrointestinal tract, phenylacetic acid can then be 
absorbed and is rapidly excreted in the urine as phenylacetic acid and following conjugation with 
glutamate to phenylacetylglutamine. The urinary excretion of phenylacetic acid and 
phenylacetylglutamine accounts for 20 % (rat) to 50 % (monkey and man) of the orally administered 
DKP.
  Phenylacetylglutamine is a naturally occurring compound that is also generated during the 
metabolism of phenylalanine.  
The available in vitro genotoxicity data on bacterial reverse mutation have some limitations (e.g. 
absence of assays with Salmonella strain TA102 and Escherichia coli strain WP2 uvrA) but were 
considered sufficient to conclude that DKP is not mutagenic in bacterial systems. The in vivo data on 
genotoxicity of DKP comprise chromosome aberration in bone-marrow erythrocytes and dominant 
lethal assay, all of which gave negative results. Taken together, the Panel considered that the data 
available from in vitro and in vivo studies did not indicate a genotoxic concern for DKP.  
DKP administration to mice for 110  weeks in the diet at dose levels up to 1000  mg/kg bw/day 
indicated neither a carcinogenic effect nor a treatment-related increase in non-neoplastic lesions at the 
doses tested (E76, 1974). The Panel considered that the NOAEL was 1000 mg DKP/kg bw/day, the 
highest dose level tested.  
In another study, DKP was administered in the diet to male and female Charles River CD rats at dose 
levels of 0 (control), 750, 1500, 3000 mg/kg bw/day for 115 weeks (E77-78, 1974). A significant 
decrease at the high dose level in feed intake (males), body weight (both sexes), urinary pH (females) 
and a mild but significant decrease in serum cholesterol (both sexes) were reported. In addition, a 
significant increase in uterine polyps (benign tumours) was also found in females treated with the mid 
and high doses of DKP. Based on these last observations, and in agreement with the JECFA 
monograph (JECFA, 1980) and the SCF evaluation (1989), the Panel identified a NOAEL for this 
study of 750 mg DKP/kg bw/day.  
Several studies were performed in rats and rabbits to assess the reproductive and developmental 
toxicity of DKP. The lowest NOAEL observed in the rat studies was 2000 mg DKP/kg bw/day (E37 
and E38), the highest doses tested. For the rabbit studies, the NOAEL was 1000 mg/kg bw/day, for 
maternal toxicity and the effects observed on fetal weight.  
9.  Summary of biological and toxicological data on phenylalanine and aspartic acid 
Both phenylalanine and aspartic acid occur naturally and are normally consumed as part of the diet.  
9.1.  Biological and toxicological data on phenylalanine 
9.1.1.  Absorption, distribution, metabolism and excretion of phenylalanine 
Phenylalanine exists as D and L enantiomers, and L-phenylalanine is an essential amino acid required 
for protein synthesis in humans (Salway, 2012). Dietary intake of L-phenylalanine along with 
endogenous recycling of amino acid stores are the major sources of L-phenylalanine in the body, while 
utilisation of L-phenylalanine occurs through integration into proteins, oxidation to tyrosine by 
phenylalanine hydroxylase (PAH) or, to a minor extent, conversion to other metabolites such as 
phenylpyruvate.  
PAH (EC 1.14.16.1) catalyses the stereospecific hydroxylation of L-phenylalanine to tyrosine in a 
reaction requiring molecular oxygen and the cofactor tetrahydrobiopterin. PAH activity is mainly 
associated with the liver, although minor activity has been demonstrated in rat kidney (Richardson et 
al., 1993). A five-fold greater rate of L-phenylalanine metabolism between rats and humans has been 
reported (Fernstrom, 1989). The human PAH gene is found on the long arm of chromosome 12 and 
contains 13 exons which encode a polypeptide of 452 amino acids. Mutations at the PAH locus result 
in phenylketonuria (PKU; MIM# 261600), an autosomal recessive inborn error of L-phenylalanine 
metabolism resulting in hyperphenylalaninaemia (HPA). Untreated PKU is associated with an Opinion on the re-evaluation of aspartame (E951) as a food additive
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abnormal phenotype including growth failure, microcephaly, seizures and intellectual impairment 
caused by the accumulation of L-phenylalanine and its by-products (see section 10). 
9.1.2.  Toxicological data on phenylalanine 
9.1.2.1.  Studies in animals 
Many studies have been conducted where rats and other experimental animals have been fed large 
amounts of L-phenylalanine in an effort to reproduce the biochemical and behavioural effects 
observed in PKU patients. The rat studies show a decrease in growth rate when fed large amounts of 
L-phenylalanine (reviewed in Harper, 1984; also Section 3.2.5.). Effects of oral administration of L-
phenylalanine in pregnant rabbits are described in Section 3.2.5.  
Additional studies on the effect of oral administration of high levels of L-phenylalanine have been 
conducted in primates. In one study (Waisman and Harlow, 1965), experimental PKU was produced in 
six infant rhesus monkeys by feeding excessive quantities of L-phenylalanine (3000 mg/kg bw/day) 
soon after birth and for up to three years. The phenylketonuric monkeys had elevated plasma levels of 
phenylalanine, and excreted almost the same phenylalanine metabolites in the urine as humans. Grand 
mal convulsions, observed in some children with phenylketonuria, were also observed in the 
experimental animals. The observed slowness in adapting to testing procedures, or even failure to 
adapt, and the inadequate performance was interpreted by the authors as an intellectual deficit induced 
by the excessive dose of L-phenylalanine. In another study conducted on nine rhesus monkeys (Gibbs 
and Smith, 1977), an intragastric preload of 1 g L-phenylalanine/kg bw, but not 1 g D-phenylalanine 
produced large reductions in food consumption. The authors proposed that L-phenylalanine releases a 
satiety signal.  
9.1.2.2.  Studies in humans 
A large number of papers have investigated the untoward effects of uncontrolled diets in subjects 
suffering from PKU and have led to a substantial understanding of the toxic effects of L-phenylalanine 
intake in humans. Some of these are briefly summarised below.  
Studies have shown that infants with PKU are particularly vulnerable to adverse effects of L-
phenylalanine if their diet is unrestricted (Smith, 1971; Giovannini et al., 2012). High levels of blood 
phenylalanine during infancy and childhood can lead to severe, permanent brain damage, but the exact 
mechanism underlying the effects on neuronal function is not yet fully understood. During childhood, 
adolescence and adulthood tolerance to dietary L-phenylalanine may increase but is often very 
variable depending on the severity of the form of PKU. Infants born to mothers with PKU have also 
been found to be very susceptible to the toxic effects of L-phenylalanine presenting a high rate of birth 
defects and developmental disabilities: congenital heart disease, mental retardation, facial 
dysmorphism and intra uterine growth retardation.  
A detailed discussion on the effect of plasma phenylalanine level management strategies on health is 
found in Section 10.  
9.2.  Biological and toxicological data on aspartic acid 
9.2.1.  Absorption, distribution, metabolism and excretion of aspartic acid 
The metabolism of orally administered L-aspartic acid has been studied in several species and is 
summarised as follows (Oppermann, 1984). The majority of radioactivity following oral 
administration of [
14C(U)]-aspartic acid to rats or monkeys is accounted to 60-70 % by 
14CO2 expired 
in the air. This rapid and high level of elimination as CO2 appears to result from both the 
decarboxylation of L-aspartate to alanine and CO2 and the transamination reaction with pyruvate to 
form alanine and oxaloacetate in the intestinal mucosal cells. The alanine and oxaloacetate formed 
then enter the tricarboxylic acid cycle to form eventually CO2. Approximately 25 % of the [
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aspartic acid dose is not accounted for in the expired air, urine or faeces but appears to be incorporated 
into normal body constituents or used for gluconeogenesis.  
9.2.2.  Toxicological data on aspartic acid 
L-Aspartic acid is among the most common amino acids found in our diet. It is an excitatory 
neurotransmitter of the central nervous system (brain, spinal cord). In contrast to L-phenylalanine, L-
aspartic acid is a nonessential amino acid.  
Excitatory amino acids are known to cause neurodegeneration when nerve cells expressing glutamate 
receptors become overstimulated following exposure to excessive levels of glutamate and L-aspartate 
(Rothman and Olney, 1995; Choi, 2001). The concentration of extracellular L-aspartate and glutamate 
in the central nervous system must therefore be controlled to prevent neuronal degeneration.  
Even though orally administered L-aspartate is rapidly metabolised and kinetic studies on aspartame 
have shown that plasma L-aspartate levels do not substantially change following bolus or repeated 
administration of aspartame (see Section 3.1), some authors (Olney, 1982; Reif-Lehrer, 1976) have 
speculated that aspartame-derived L-aspartate, especially when consumed with foods containing 
monosodium glutamate (MSG), would cause an increase in the combined plasma concentrations of L-
aspartate and L-glutamate, which might pose a risk of focal neuronal degeneration.  
9.2.2.1.  Studies in animals 
Aspartate and glutamate can cause hypothalamic neuronal death in neonatal rodents, if given orally in 
large doses (500 mg/kg bw or higher) to infant animals (Olney, 1969; Olney and Ho, 1970; Lemkey-
Johnson and Reynolds, 1974; Okaniwa et al., 1979; Finkelstein et al., 1983; Daabees et al., 1985). For 
instance, in mouse pups, which may be considered the most sensitive of all animal species, single 
doses of 1000 mg L-aspartate/kg bw caused extensive hypothalamic neuronal necrosis. In another 
study, eight-day-old mice were administered by gavage aspartate at 0, 1.88, 3.76, 4.89, 5.64 and 
7.52 mmol/kg bw (corresponding to 0, 250, 500, 650, 750 and 1000 mg L-aspartate/kg bw) and the 
degree and extent of neuronal necrosis determined. Dose-dependent hypothalamic neuronal necrosis 
was found with 4.89 mmol L-aspartate/kg bw and higher doses. The extent of neuronal necrosis was 
proportional to dose, once a neurotoxic dose of L-aspartate was reached. The authors also reported that 
the highest concentration of L-aspartate in the plasma not inducing lesions was 870 + 230 μM.  
Olney and co-workers (Olney and Sharpe, 1969; Olney et al., 1972) also reported neuronal necrosis in 
neonatal nonhuman primates administered large bolus doses of glutamate (1000-4000  mg/kg bw 
subcutaneously or orally. This observation, however, could not be reproduced by a number of other 
scientists with either glutamate or aspartame at high dosages (reviewed by Butchko et al., 2002).  
A 90-day aspartate feeding study (Tada et al., 2008) performed in Fischer 344 rats (55 males and 
55  females) was recently evaluated by EFSA (EFSA, 2008). The animals were divided into 5 
treatment groups and fed diets controlled for L-aspartic content. Dietary L-aspartic acid dosing was 0, 
0.05, 1.25, 2.5 and 5.0  %, corresponding to 0, 28.7, 715.2, 1470.2 and 2965.9  mg/kg bw/day for 
females and to 0, 26.9, 696.6, 1416.6 and 2770.2 mg/kg bw/day for males. No signs or symptoms of 
neurotoxicity were observed at any of the doses tested. A NOAEL of approximately 700  mg/kg 
bw/day for males was identified by the ANS Panel based on renal toxicity findings (an apparent dose-
related regenerative renal tubules dilation in males accompanied by inflammatory cell infiltration) 
(EFSA, 2008).  
9.2.2.2.  Studies in humans 
Numerous intervention trials have been performed in adults with different aspartate compounds 
(sodium, magnesium, potassium-magnesium, buffered aspartic acid, arginine aspartate) in doses 
ranging from 1 to 10 g/day, for time periods between one single dose and four weeks. These studies 
have previously been reviewed by the ANS Panel (EFSA, 2008). None of these studies were 
undertaken to assess toxicity of aspartate intake, however, excluding reports on plasma amino acid Opinion on the re-evaluation of aspartame (E951) as a food additive
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imbalance and soft stools/diarrhoea, no other adverse effects were reported (Colombani et al., 1999; 
Chouinard et al., 1990).  
Consumption of 15 g of arginine aspartate daily, corresponding to 6.3 g L-aspartate, over 14 days in a 
double-blind, placebo-controlled cross-over trial by 14 healthy individuals resulted in significantly 
higher plasma levels of arginine, ornithine and urea as compared to placebo. In contrast, plasma levels 
of most other amino acids, including aspartic acid, and total amino acids were reduced (Colombani et 
al., 1999).  
10.  PKU data 
PKU is an autosomal recessive disorder that leads to high levels of L-phenylalanine in the plasma and 
low level of tyrosine in the blood (Widaman, 2009; Zimmermann et al., 2012). High plasma L-
phenylalanine levels are neurotoxic, probably through its inhibitory action on the transport of other 
amino acids (leucine, isoleucine, valine, tyrosine, tryptophan, and lysine), necessary for the protein 
and neurotransmitter synthesis (e.g. serotonin) (Giovannini et al., 2012). Furthermore, the inhibition of 
L-phenylalanine metabolism to tyrosine impacts on the formation of melanin and neurotransmitters 
derived from tyrosine such as dopamine, adrenaline, noradrenaline and thyroid hormones. HPA results 
due to a number of different mutations within the PAH allele producing a spectrum of phenotypes 
including classic phenylketonuria (PKU), moderate PKU, mild PKU and mild HPA (Zimmermann et 
al., 2012). For all these PKU phenotypes, plasma L-phenylalanine levels are above 10  mg/dL 
(600 μM) when on an unrestricted diet.  
The restriction of dietary L-phenylalanine is the mainstay of PKU management. Patients with PKU 
have to avoid foods rich in protein (meat, fish, eggs, standard bread, dairy products, nuts, and seeds) 
and foods and drinks containing aspartame, flour, soya, beer or cream liqueurs. Therefore, PKU diets 
consist mainly of low-protein natural foods (vegetables, fruits and some cereals) that are modest in L-
phenylalanine (Giovannini et al., 2012). The aim of the dietary treatment is to avoid acute and chronic 
increased concentrations of L-phenylalanine in plasma and consequently in cerebral tissue, responsible 
for an important worsening of the neuronal performance and behaviour in PKU patients.  
Growth and brain development are most rapid during the first 6 months, and an infant with PKU is 
particularly vulnerable to adverse effects of L-phenylalanine if their diet is unrestricted (Smith, 1971; 
Giovannini et al., 2012). High levels of plasma L-phenylalanine during infancy and childhood lead to 
severe, permanent brain damage, but the exact mechanism of the effects on neuronal function is not 
understood. 
Inversely, excessive restriction of L-phenylalanine intake during the first year of life is also 
detrimental to health given that L-phenylalanine is an essential amino acid that cannot be synthesised 
by the body. Cases of loss of weight, vomiting, listlessness, generalized eczematous rash and mental 
retardation have been attributed to suboptimal L-phenylalanine intake.  
According to the NIH Consensus Statement on phenylketonuria, it is assumed that levels in excess of 
dietary requirement for this essential amino acid but below 10 mg/dL (600 μM) do not lead to brain 
damage.  
The reference values for plasma L-phenylalanine concentration recommended by NIH (NIH, 2000) are 
L-phenylalanine levels between 2–6 mg/dL (120-360 μM) during pregnancy and for neonates through 
12 years of age, and L-phenylalanine levels between 2–10 mg/dL (120-600 μM) after 12 years of age. 
This document recommends that L-phenylalanine levels between 120 and 360 μM are achieved at 
least 3 months before conception and that metabolic control should be achieved as soon as possible. 
Infants with PKU should start treatment to establish dietary control of their L-phenylalanine levels, 
ideally within 7–10 days of birth (NIH, 2000).  
Waisbren and co-workers (Waisbren et al., 2007) assessed the reliability of plasma phenylalanine 
levels as a predictive biomarker of clinical outcomes in the development of treatments for PKU by Opinion on the re-evaluation of aspartame (E951) as a food additive
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performing a systematic literature review and meta-analysis of published trials of PKU, which 
included L-phenylalanine level and neurological and dietary compliance outcome measures. The 
authors found that each 100 μM increase in L-phenylalanine (assessed by mean Index of Dietary 
Control during the critical childhood period or lifetime through 18 years) predicted a 1.3 to 3.9 point 
decrease in IQ for early-treated patients with PKU, over a L-phenylalanine range from 394 to 750 μM. 
A correlation was also found between concurrent L-phenylalanine level and IQ for early-treated 
patients with PKU, in which each 100 μM increase in L-phenylalanine predicted a 0.5 to 1.4 point 
reduction in IQ, over a L-phenylalanine range from 429 to 1664 μM. 
Although the maintenance of a plasma L-phenylalanine concentration within the recommended range 
is clearly important in the treatment of PKU, a recent meta-analysis of 40 studies (Anastasoaie et al., 
2008) demonstrated that the stability of plasma L-phenylalanine levels may be more important to 
cognitive functioning (FSIQ, Full Scale Intelligence Quotient) in PKU children continuously treated 
from shortly after birth than the overall exposure to L-phenylalanine. The authors of the study 
concluded that occasional increases (‘spikes’) in plasma L-phenylalanine levels of approximately 
600 µM, which occur in the majority of children with PKU, may be benign, but that it is the long-term 
variability that appears to be important in the effects of L-phenylalanine on cognitive function 
(Anastasoaie et al., 2008). Cockburn and Clark (1996) suggested that adolescents and adults should 
continue the diet with the aim to maintain phenylalanine plasma concentration no higher than 700 µM.  
In women with PKU, the most critical phase in controlling the L-phenylalanine plasma concentration 
is pregnancy. In 1980, Lenke and Levy (1980) reported results of over 500 pregnancies of women with 
PKU who were not on low-phenylalanine diets during pregnancy. Infants born to mothers with PKU 
had a high rate of birth defects and developmental disabilities: congenital heart disease, mental 
retardation, facial dysmorphism and intra uterine growth retardation (IUGR). Although these infants 
would have carried one functional PAH allele from their fathers, the exposure of the fetus to high 
levels of phenylalanine from the mother’s blood via the placenta appeared sufficient to cause prenatal 
damage. These prenatal exposure effects show a dose-response relation, with higher levels of exposure 
leading to higher levels of disability.  
Data from the prospective international Maternal PKU Collaborative (MPKUC) Study (Koch et al., 
2003a), the French survey (Feillet et al., 2004) and the United Kingdom PKU Registry (Lee et al., 
2005) have shown that many features of the maternal PKU syndrome were preventable when dietary 
L-phenylalanine intake was restricted before conception or soon afterward (Maillot et al., 2008).  
The MPKUC Study (Koch et al., 2003a) was initiated in 1984 to monitor pregnancies of women with 
PKU, to maintain mothers on a low L-phenylalanine diet throughout their pregnancies, and to study 
relations between levels of L-phenylalanine in the mothers’ blood during pregnancy and birth and 
developmental outcomes in their offspring. Women with plasma L-phenylalanine levels > 240 μM 
were enrolled; 382 women contributed to 572 pregnancies. The 413 offspring were examined at birth 
and annually. Congenital abnormalities were noted, and the focus was on the consequences of 
congenital heart disease and microcephaly on developmental outcome. To this effect, the McCarthy 
General Cognitive Index was administered at age four, followed by the Wechsler Intelligence Scale 
for Children (Revised) at age six. Microcephaly was noted in 137 offspring (33 %), and 32 (7.7 %) 
had congenital heart disease. Maternal plasma L-phenylalanine levels were higher for infants with 
congenital heart disease and microcephaly than for infants with congenital heart disease only 
(P = 0.02). Mean L-phenylalanine levels at weeks four and eight of gestation predicted congenital 
heart disease (P < 0.0001). The McCarthy General Cognitive Index score was lower with congenital 
heart disease (P = 0.005) and microcephaly (P = 0.0017), as was the Wechsler Intelligence Scale for 
Children (Revised) full-scale IQ (intelligence quotient) score (P = 0.0002 for congenital heart disease 
and P  =  0.0001 for microcephaly). Optimal birth outcomes occurred when maternal plasma L-
phenylalanine levels between 120 and 360  μM were achieved by 8 to 10  weeks of gestation and 
maintained throughout pregnancy.  Opinion on the re-evaluation of aspartame (E951) as a food additive
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Widaman and Azen (2003) modelled the relationship between prenatal exposure to L-phenylalanine 
and measures of offspring intellectual development in the offspring of the MPKUC Study (Koch et al., 
2003). From the model, a nonlinear relation between prenatal L-phenylalanine exposure and offspring 
cognitive outcomes, with damage to the developing fetus if average L-phenylalanine levels are above 
approximately 360 μM was derived. Moreover, prenatal L-phenylalanine exposure had a strong effect 
on offspring outcomes at one year of age and was the only one of the background, pregnancy-related, 
or perinatal variables to directly influence offspring outcomes at 2, 4 and 7 years of age. 
Data from a retrospective review of pregnancies from January 1977 to June 2006 showed that an L-
phenylalanine-restricted diet should start before conception to avoid malformations and congenital 
heart disease and to ensure the best possible developmental outcome for the offspring. The study 
concluded that not only was it important to aim to maintain maternal plasma L-phenylalanine 
concentrations of < 300 μM, but, also, that variations in L-phenylalanine levels should be minimized 
(Maillot et al., 2008).  
The Panel concluded that a critical threshold for the developmental and cognitive effects of L-
phenylalanine is 360 μM, which is consistent with the NIH Consensus Statement on phenylketonuria 
(NIH, 2000). This document recommends that L-phenylalanine levels between 120 and 360 μM are 
achieved at least 3 months before conception and that metabolic control should be achieved as soon as 
possible. After 12 years of age, the range for recommended L-phenylalanine levels may increase to 
120-600 μM. During pregnancy, the recommended level is 120-360 μM (NIH, 2000).  
11.  Mode of action 
The basis for the ADI of 40 mg/kg bw previously set by SCF and JECFA was not explicitly stated, but 
the Panel’s understanding of their brief reports was that it was derived from NOAELs of 4000 mg/kg 
bw/day identified in the chronic and carcinogenicity rat studies and applying an uncertainty factor of 
100. Reanalysing the data the Panel noted that the effects reported in the rat and rabbit reproductive 
and developmental toxicity studies at doses below 4000  mg aspartame/kg bw/day should not be 
ignored. As described in section 4, the Panel considered that the relationship of these effects to 
treatment could not be definitively excluded. Therefore the Panel examined the possibilities that 
aspartame or one (or more) of its metabolites could be responsible for these effects. 
The Panel noted that aspartame is the methyl ester of the dipeptide of the amino acids, L-aspartic acid 
and L-phenylalanine. After oral ingestion, aspartame is hydrolysed, either within the lumen of the 
gastrointestinal (GI) tract, or within the mucosal cells lining of the GI-tract. Hydrolysis is very 
efficient and the amount of aspartame that enters the bloodstream has been reported as undetectable in 
several studies conducted among others in rats, dogs, monkeys and humans (Oppermann, 1984; 
Burgert et al., 1991). The products that result from the hydrolysis reaction are methanol and the amino 
acids aspartic acid and phenylalanine. Hydrolysis of aspartame releases equimolar quantities of 
aspartic acid and phenylalanine, together with methanol corresponding to 10  % by weight of the 
aspartame dose. Further studies conducted in monkeys and pigs have shown that the potential 
intermediate metabolite phenylalanine methyl ester was rapidly broken down to phenylalanine and 
methanol in the intestinal lumen (Burton et al., 1984; Burgert et al., 1991). The Panel concluded that 
hydrolysis of aspartame in the gastrointestinal tract was essentially complete and that there was no 
systemic exposure to aspartame but systemic exposure to aspartic acid, phenylalanine and methanol 
did occur. The Panel considered therefore that systemic exposure to aspartame itself could not be 
responsible for the reproductive and developmental toxicity.  
11.1.  Mode of Action Approach 
Based upon their framework for assessing chemical carcinogens in experimental animals, the 
International Programme on Chemical Safety has published frameworks for assessing chemicals with 
cancer (Boobis et al., 2006) and non-cancer endpoints (Boobis et al., 2008). This type of approach 
enhances transparency and harmonisation of the risk assessment process.  Opinion on the re-evaluation of aspartame (E951) as a food additive
 
 
EFSA Journal 2013;11(12):3496  140
First, it was necessary to establish whether the weight-of-evidence from experimental observations 
was sufficient to ascertain a mode of action (MoA). Using the Bradford Hill criteria key events 
causally related to the toxic effect were identified. These key events were compared qualitatively and 
then quantitatively between experimental animals and humans. The decision tree from Boobis et al. 
(2008) was used to determine the human relevance of a MoA for toxicity observed in experimental 
animals. It must be noted that this Framework was an analytical tool that enabled a structured 
approach to assess the overall weight-of-evidence and its relevance to humans (mode of action), it was 
not designed to provide a description of the underlying events at the molecular level (mechanism of 
action). If the output from applying the Framework identified a credible and relevant MoA, this would 
become the basis for the risk characterisation.  
Application of the Framework was considered appropriate for evaluating the effects observed in 
reproductive and developmental toxicity studies after careful consideration of the weight-of-evidence 
for the observed toxicological responses following exposure to aspartame in experimental animals. 
The Panel chose to use this approach as the application of such a framework results in a transparent 
evaluation of the data; their application of the IPCS criteria are described in detail below.  
11.1.1.  Postulated Mode of Action for aspartame 
The MoA proposed by the Panel for aspartame was that the toxicological effects observed in rat and 
rabbit in pregnancy were due to the metabolite phenylalanine.  
11.1.2.  Key events 
The reproductive and developmental toxicity studies on aspartame consisted of an embryotoxicity and 
developmental study performed in the mouse, a two-generation reproduction toxicity study in the rat, 
five peri- and postnatal developmental studies in the rat, a reproductive performance and 
developmental study in the rat and an embryotoxicity and teratogenicity study in the rat. In addition, 
eight embryotoxicity and teratogenicity studies were performed in the rabbit, four of which were by 
administration of aspartame in the diet and four by gavage. Some of these studies were also conducted 
with the aspartame metabolites phenylalanine and aspartic acid. In addition, reproductive and 
developmental toxicity studies were also available following administration of methanol.  
The Panel concluded that the depression in pup body weight in the high dose groups could not be 
disregarded. The Panel noted that in earlier assessments of aspartame the observed effects were not 
considered critical for the evaluation. The published evaluations were not explicit on the rationale 
behind this decision. After the public consultation on this opinion, following a request from a peer the 
UK Food Standards Agency made available in the House of Lords library the working documents and 
correspondence from the COT evaluations in the 1990s. These documents demonstrated that detailed 
evaluation of the reproductive and developmental toxicity studies had been undertaken and the 
rationale for not considering these studies critical. 
The Panel considered the depression in pup body weight in the high dose groups might be due to high 
exposure to phenylalanine from metabolism of aspartame. This was supported by the findings in rats 
and rabbits treated with phenylalanine. The Panel further noted that although the data from study (E11, 
1975) were sparse this study together with other segment I and segment III studies was considered 
sufficient to fulfil the requirements of a two-generation reproduction toxicity study in rats and derived 
from these studies a NOAEL of 2000 mg/kg bw/day based on the lower pup weights at weaning in 
both generations.  
The Panel agreed that observed effects in the developmental rabbit studies may have resulted from the 
nutritional status as a result of gastrointestinal disturbances and the potential effect of phenylalanine; it 
was neither possible to discriminate if these acted independently or in combination, nor which was 
responsible for the effects. Overall, the Panel agreed that the rabbit studies should not be considered 
key because these confounding factors affecting the studies and the likelihood that the gastrointestinal 
effects were species specific in rabbits and would be without direct relevance to humans.  Opinion on the re-evaluation of aspartame (E951) as a food additive
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11.1.3.  Biological Plausibility 
Considering the biological plausibility of the MoA, the Panel noted that there was long established 
evidence for increased severity and frequency of adverse developmental effects with high 
phenylalanine plasma levels as found in human patients with phenylketonuria (PKU) (Prick et al., 
2012). The Panel noted that the database on PKU and particularly on effects during pregnancy had 
increased since the earlier evaluations of aspartame.  
PKU is an autosomal recessive metabolic genetic disorder characterized by mutations in the gene for 
the hepatic enzyme phenylalanine hydroxylase (PAH), decreasing or inactivating its functionality. 
This enzyme is necessary to metabolize the amino acid phenylalanine to the amino acid tyrosine. 
When PAH activity is reduced, circulating phenylalanine levels are increased.  
Maternal PKU syndrome refers to the teratogenic effects of PKU during pregnancy. These effects 
include mental retardation, microcephaly, congenital heart disease, and intrauterine growth retardation. 
In untreated pregnancies wherein the mother has classic PKU with a plasma phenylalanine level 
greater than or equivalent to 1200 µM (20 mg/dL), abnormalities in offspring occur at exceedingly 
high frequencies, approximately 75-90  % for microcephaly and mental retardation, and 15  % for 
congenital heart disease. There is a dose-response relationship with progressively lower frequencies of 
these abnormalities at lower phenylalanine levels. The pathogenesis of this syndrome is unknown; it 
may be related to inhibition by phenylalanine of large neutral amino acid transport across the placenta 
or to direct toxicity of phenylalanine and/or a phenylalanine metabolite (phenylpyruvic acid) in certain 
fetal organs. Malformations and mental retardation in the offspring of women with PKU can be 
prevented by maintaining maternal plasma phenylalanine within a target range (120-360 μM) through 
a phenylalanine-restricted diet (NIH, 2000).  
11.1.4.  Concordance of Dose-Response Relationships 
Phenylalanine is released in a direct one to one molar ratio from the metabolism of aspartame, on a 
weight basis this would be 45 % of the aspartame dose. The Panel noted that the effects observed in 
the reproductive and developmental toxicity studies in animals occurred at equivalent molar doses of 
phenylalanine following administration of either aspartame or phenylalanine.  
As described previously, PKU is an autosomal recessive disorder resulting in high levels of 
phenylalanine and low levels of tyrosine in the blood (Widaman, 2009; Zimmermann et al., 2012). 
High blood phenylalanine levels are neurotoxic, mainly due to its inhibitory action on the transport of 
free L-amino acids (leucine, isoleucine, valine, tyrosine, tryptophan, and lysine), necessary for protein 
and neurotransmitter synthesis (dopamine and serotonin) (Giovannini et al., 2012). It is recognised that 
malformations and mental retardation in the offspring of women with PKU can be prevented by 
maintaining maternal plasma phenylalanine within a target range 120-360 μM (Koch et al., 2003) (or 
below a threshold thought to be between 330 and 360 μM (Widaman and Azen, 2003)) through a 
phenylalanine-restricted diet.  
The form of the relation between prenatal phenylalanine exposure and offspring cognitive outcomes 
appears to be nonlinear, with no damage to the developing fetus until exposure passes a critical 
threshold level. The best estimate of the critical threshold of phenylalanine exposure without damage 
to the offspring occurs is 330 to 360 μM (Widaman and Azen, 2003). A critical threshold in the range 
from 330 to 360 μM is consistent with reference values indicated by the NIH Consensus Statement on 
phenylketonuria (NIH, 2000). However, in contrast to the majority of the literature the data presented 
by Lenke and Levy (1980), showed elevated rates of mental retardation even in offspring with 
maternal phenylalanine levels between 180 and 600 μM. The Panel noted that control of phenylalanine 
plasma levels in PKU patients by dietary restriction can be highly variable and occasional high 
exposures or prolonged exposures above the target range can occur, which could be responsible for 
effects observed in PKU patients controlling levels by dietary restriction. The original range between 
180 and 600 μM proposed by Lenke and Levy (1980) has been replaced by a range between 120 and Opinion on the re-evaluation of aspartame (E951) as a food additive
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360 μM (Koch et al., 2003) and the best estimate of the threshold has been defined in the range from 
330 to 360 μM (Widaman and Azen 2003).  
11.1.5.  Temporal Association 
Apart from the hydrolysis of aspartame in the gastrointestinal tract, resulting in the increased plasma 
phenylalanine levels that the Panel considered associated with the effects observed in the reproductive 
and developmental studies in animals, there is currently no further information on a step by step 
mechanistic explanation. This mechanistic explanation is lacking for animals and humans.  
11.1.6.  Strength, Consistency, and Specificity of Association of Toxicological Response with 
Key Events 
There was consistency in the observed outcomes of the reproductive and developmental toxicity 
studies on aspartame in rat and rabbit; including a two-generation reproduction toxicity study in the 
rat, five peri- and postnatal developmental studies in the rat, a reproductive performance and 
developmental study in the rat and an embryotoxicity and teratogenicity study in the rat and eight 
embryotoxicity and teratogenicity studies performed in the rabbit. Consistent observations from a 
number of studies with differences in experimental design, increases the support for the MoA. As the 
association was consistent, it was more likely that the relationship was causal. The effects observed in 
animals following aspartame exposure were reproduced if phenylalanine was given at the equivalent 
molar dose.  
11.1.7.  Other Modes of Action 
Intact aspartame per se cannot be responsible for any adverse effects observed, due to its complete 
hydrolysis within the GI tract.  
The Panel noted that the products formed following hydrolysis of aspartame were normal constituents 
of the diet (aspartic acid, phenylalanine and methanol) and were metabolised by endogenous metabolic 
pathways.  
Methanol is subject to a significant first pass metabolism. The overall metabolism of methanol 
proceeds by stepwise oxidation via formaldehyde to formate, and then to carbon dioxide. 
Formaldehyde and formate enter the one carbon metabolic pool through tetrahydrofolic acid and from 
there, may contribute to the biosynthesis of purines, pyrimidines and amino acids. The metabolism of 
formaldehyde to formate is very efficient with a half-life of about one minute (McMartin et al., 1979; 
Tephly and McMartin, 1984). The oxidation of formate to carbon dioxide varies between species, the 
rate of formate elimination in humans and non-human primates being half of that in rats (Kavet and 
Nauss, 1990). In rodents, formate is converted to carbon dioxide through a folate-dependent enzyme 
system and a catalase-dependent pathway (Dikalova  et al., 2001) whereas in humans metabolism 
occurs exclusively through the folate-dependent pathway (Hanzlik et al., 2005).  
The Panel noted that the methanol released from aspartame may enter the general circulation. 
However, on a weight basis the amount released would be one tenth of the aspartame dose.  
In studies on the reproductive and developmental toxicity of methanol marked effects were observed 
at oral methanol doses greater than 2000 mg/kg bw/day, no lower doses were tested orally. From 
inhalation studies a NOAEL equivalent to an oral methanol dose of 560 mg/kg bw/day was derived. 
The Panel noted that a similar exposure to methanol from aspartame ingestion would occur at an oral 
dose of aspartame of 5600 mg/kg bw/day. In studies on aspartame, effects were seen at doses of 1000-
2000 mg aspartame /kg bw/day or higher. At these aspartame doses the maximum amount of methanol 
would be 100-200 mg methanol /kg bw/day respectively which is below the NOAEL derived by the 
Panel for reproductive and developmental toxicity of methanol. The Panel therefore considered that 
the effects observed following aspartame ingestion could not be due to methanol.  Opinion on the re-evaluation of aspartame (E951) as a food additive
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The Panel noted that no effects were observed in reproductive and developmental toxicity studies with 
aspartic acid even when administered at an equivalent molar dose to the dose of aspartame that gave 
rise to adverse effects in animals (Table 22). The Panel therefore considered that the effects observed 
following aspartame ingestion could not be due to aspartic acid. 
During the public consultation the possibility was raised that rather than a single metabolite being 
responsible for the reproductive and developmental effects in animals following aspartame exposure, 
the mixture of some or all of the three metabolites could act together to generate the effects. The Panel 
considered this is unlikely based on the following observations: 
•  reproductive and developmental effects observed with either phenylalanine or aspartame were 
similar 
•  these effects observed with phenylalanine and aspartame were seen at equivalent molar doses 
•  no effects were observed with aspartic acid administered alone 
•  co-administration of aspartic acid with phenylalanine did not add to the effect of 
phenylalanine alone. The respective administered doses of aspartic acid and phenylalanine 
were equivalent to an aspartame dose causing reproductive and developmental effects  
•  although similar reproductive and developmental effects were observed with methanol as with 
aspartame and phenylalanine, the doses of methanol causing these effects were 10-fold greater 
than the doses of aspartame or phenylalanine. 
If one disregards these observations and assume that methanol and phenylalanine could interact 
following aspartame ingestion, based on the dose response data for all three compounds (aspartame, 
phenylalanine, methanol) and using conservative dose addition assumptions, the Panel considered that 
combined administration of methanol and phenylalanine (either from aspartame or with co- 
administration at equivalent amounts) could add at most 10% to the activity of phenylalanine alone 
(Table 22). 
Table 22:   Doses of aspartame metabolites having molar equivalence to aspartame from the critical 
studies E90 (rabbit) and Rogers et al., 1993 (mouse) 
  Dose (of the substance as used in the study) or equivalent dose (mg/kg 
bw/day) 
Aspartame  2000*  1464 2444  20  000 
Phenylalanine  1120  820*  - - 
Aspartic acid  900  -  1100*  - 
Methanol  200  - -  2000** 
Doses in bold in the table were effect levels with the exception of aspartic acid for which 1100 mg/kg bw/day was the highest 
dose tested 
*   Data from E90 study 
**  Data from Rogers et al., 1993  
11.2.  Assessment of postulated Mode of Action 
The Panel evaluated the plausibility and human relevance of the proposed mode of action using the 
criteria developed by Boobis et al., 2008. 
11.2.1.  Life stage considerations 
The key effects observed in rats and rabbit reproductive studies related to a specific life stage 
acknowledged to be critical in both species observed and to humans, thus the effects were considered 
as relevant for risk assessment. A spectrum of effects was observed in the experimental species, 
particularly maternal toxicity and growth restriction of the offspring. The latter effect was recognised 
as an important outcome in humans because it was associated with an increased risk of perinatal 
mortality and morbidity, including perinatal asphyxia (Barker, 2001). Moreover, there was 
epidemiological evidence that human fetal growth restriction correlates with adverse effects in Opinion on the re-evaluation of aspartame (E951) as a food additive
 
 
EFSA Journal 2013;11(12):3496  144
adulthood. For example, affected individuals have an increased incidence of metabolic syndrome, 
manifesting as obesity, hypertension, hypercholesterolemia, cardiovascular disease, and type-2 
diabetes (Barker, 1997).  
The Panel noted that neurodevelopment endpoints had not been extensively measured in the animal 
studies, acknowledging that this would have provided highly relevant information on the mental 
retardation seen in PKU children.  
11.2.2.  Human relevance 
A wealth of evidence exists from the human population (maternal PKU syndrome) showing that 
increased phenylalanine plasma levels during pregnancy result in adverse effects in the offspring, 
including mental retardation, microcephaly, congenital heart disease, and intrauterine growth 
retardation. It was highly plausible that the proposed mode of action for adverse effects observed in 
animals during pregnancy would be relevant to humans if sufficiently high aspartame exposures 
occurred.  
Lenke and Levy (1980) reported results from over 500 pregnancies of women with PKU who were not 
on low-phenylalanine diets during pregnancy. Infants born to mothers with maternal PKU syndrome 
had a high rate of birth defects and developmental disabilities: congenital heart disease, mental 
retardation, facial dysmorphism and fetal growth restriction.  
Data from the prospective international Maternal PKU Collaborative (MPKUC) Study (Koch et al., 
2003), the French Survey (Feillet et al., 2004), and the United Kingdom PKU Registry (Lee et al., 
2005) showed that many features of the maternal PKU syndrome were preventable when dietary 
phenylalanine intake was restricted before conception or soon after conception (Maillot et al., 2008; 
Prick et al., 2012).  
In contrast to these results are the findings of Teisser et al. (2012) who reported data from 115 
pregnancies in 86 women. Ninety percent of women had been informed of the risk of maternal PKU in 
the absence of a strict diet during pregnancy, 88 % of women started a phenylalanine restricted diet 
before conception, and 45 % of infants were born small for gestational age (birth length and/or weight 
≤ 2 SD). Phenylalanine intakes were lower in the group with fetal growth restriction from the fifth to 
the eighth month of pregnancy and duration of time spent at plasma phenylalanine levels ≤ 120 μM 
during pregnancy was associated with a higher risk of fetal growth restriction. However, the Panel 
noted that as phenylalanine is an essential amino acid, it was likely that the increased risk of fetal 
growth restriction observed at low phenylalanine plasma levels in this study was due to dietary over 
restriction, i.e. providing not enough phenylalanine to allow normal development of the fetus.  
11.2.3.  Conclusion on the MoA analysis 
The Panel considered that the proposed mode of action was credible and highly likely to explain the 
results seen in the animal studies with aspartame based on:  
•  the metabolic data on the complete hydrolysis of aspartame in the gastrointestinal tract 
•  the known reproductive and developmental toxicity of high phenylalanine blood 
concentrations in several species 
•  data demonstrating that administered doses of phenylalanine and aspartame (having molar 
equivalence) had similar reproductive and developmental toxicity 
•  that effects were not seen with administered doses (having molar equivalence to aspartame) of 
either aspartic acid or methanol alone 
•  the absence of additive effects of aspartame metabolites.  
Despite uncertainties from the limited animal kinetic data, and in the human dose response data, the 
Panel considered that the proposed mode of action was relevant to humans based on the data from 
PKU patients.  Opinion on the re-evaluation of aspartame (E951) as a food additive
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Therefore, for the risk characterization of aspartame for humans, the Panel decided that the 
information on effects and dose response in PKU patients and human pharmacokinetic data were more 
appropriate than the results of animal studies of reproductive and developmental toxicity.  
12.  Dose-response modelling of plasma phenylalanine levels following aspartame 
administration 
Data on the concentrations of phenylalanine in plasma after different doses  of aspartame  were 
extracted from various studies, mainly unpublished studies submitted in response to EFSA’s call for 
data. These studies were principally conducted in the 1970s as part of the original evaluations of 
aspartame; the details of the studies are described in section 3.1. The studies involved a range of dose 
levels given as a single bolus administration. The time to reach peak plasma phenylalanine 
concentration (Cmax) was comparable at all doses and varied from 30 minutes to 1 hour; thereafter 
levels fell sharply. The number of participants in each study differed, ranging from 6 to 20 (Appendix 
J).  
Studies were conducted in three subsets of the population; individuals with ‘normal’ phenylalanine 
metabolism, heterozygous for phenylalanine hydroxylase, i.e. those with one recessive allele and those 
who are homozygous, i.e. individuals with PKU syndrome. The data (Cmax values) from studies in 
normal and heterozygous individuals were used to generate a model that could be used in risk 
characterization. The data from PKU homozygotes were not used as these individuals are 
unrepresentative of the general population and specific labelling of aspartame containing products is 
required to permit these individuals to control dietary phenylalanine intake, which is a risk 
management issue.  
In specifying the modelling parameters, the Panel made various decisions. These decisions are 
described below together with the rationale for their choice, but were intended to reflect the ‘worst 
case’ scenario. Consequently, the model would be expected to incorporate an additional margin of 
safety. 
The first decision was to use data after a single bolus dose to represent the total daily aspartame intake, 
whilst acknowledging that normal consumption patterns would be in smaller quantities spread 
throughout the day. The administration of a bolus dose will overestimate the peak plasma 
concentration resulting from a daily dietary intake at the corresponding dose level. All the 
administration was as bolus doses which ranged from 4 to 200 mg/kg bw. This range included the 
current ADI of 40 mg/kg bw/day.  
The second decision was to use the measured peak plasma levels (Cmax levels) following a single bolus 
administration as a surrogate for the response at the administered dose. Phenylalanine has a short half-
life in plasma of approximately 1.7 hours (Filer and Stegink, 1991). The peak plasma levels were 
transient, and the Panel noted that these would be higher than steady state plasma levels arising from 
repeated intake at normal pattern of dietary intake of the same total daily dose.  
The third decision was to base comparisons on the mean plasma levels, which were assumed clinically 
safe for the critical endpoint (effects during pregnancy) in PKU patients. This subgroup of the 
population build up higher phenylalanine plasma levels which makes them more susceptible than the 
normal and heterozygous subgroups to adverse effects from phenylalanine during pregnancy. The 
plasma levels upon which the clinical advice is based are regarded as a threshold but the true threshold 
for adverse effects from phenylalanine would be expected to be higher. It was acknowledged by the 
Panel that it is not known whether effects seen at levels above the clinical target threshold were 
associated with the mean or peak plasma levels. The Panel noted that in PKU patients even with good 
dietary control of phenylalanine intake, plasma levels of phenylalanine can be highly variable and can 
result in either higher than targeted mean plasma levels or very high spike peak plasma levels. For 
PKU patients it is recognised that mild effects have been associated with mean plasma levels of 600-Opinion on the re-evaluation of aspartame (E951) as a food additive
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800 μM, whilst significant detrimental effects have been associated with both mean and spike peak 
plasma levels of 1100-1200 μM phenylalanine (Rouse et al., 2000; Koch et al., 2003).  
Current clinical practice guidelines recommend that PKU patients restrict their dietary intake of 
phenylalanine to keep plasma levels below 360 μM. The Panel noted that intakes of aspartame as a 
food additive could occur at the same time as other dietary phenylalanine sources. Therefore, the Panel 
considered that the threshold utilised for comparisons to the modelling should be lowered to allow for 
simultaneous intake of the food additive with meals. In toddlers it can be assumed that the mean daily 
exposure to phenylalanine from diet is taken up in five meals, in children in four meals, in 
adolescence, adults and the elderly in three meals rendering the phenylalanine intake per kg bw and 
meal into 18.6-33.4 mg/kg bw/meal (toddlers), 18.1-34.2 mg/kg bw/meal (children), 13.0–26.3 mg/kg 
bw/meal (adolescents), 11.8-19.6 mg/kg bw/meal (adults), and 10.8–13.9 mg/kg bw/meal (elderly). 
The highest mean dietary phenylalanine exposure per meal is 34.2 mg/kg bw (Table 16) and this 
corresponds to a phenylalanine plasma concentration of 120 µM (as calculated from the dose-plasma 
phenylalanine modelling carried out and considering that phenylalanine represents 56 % by weight of 
aspartame). Thus, the plasma phenylalanine from the diet (120 µM) has been subtracted from the 
current clinical guideline of 360  µM to determine the maximum safe plasma concentration of 
phenylalanine that can be derived from aspartame (240  µM). The Panel noted that this plasma 
concentration was above normal phenylalanine plasma concentrations in man and therefore represents 
an overestimation of the phenylalanine intake from the regular diet (Levy, 2003).  
The Panel initially modelled the data for normal individuals, comparing dose with the highest peak 
plasma levels of phenylalanine in individuals to determine whether it was feasible to undertake dose-
response modelling. Having considered the output from this initial model, the Panel considered that 
whilst modelling was feasible, a more sophisticated statistical model was appropriate. Subsequent 
modelling included multiple studies at several dose levels and allowed for the use of data from 
different studies and different numbers of subjects within the individual studies. The data were used in 
a model developed by the SAS Unit at EFSA and an internal report was provided to the Panel 
(Appendix K). The model enabled an estimation to be determined of the plasma levels associated with 
the mean and 95
th percentile confidence limits over the dose range studied.  
Based on the model, a plasma phenylalanine concentration of 240  µM would result from the 
administration of a bolus dose of 103 mg aspartame/kg bw (lower bound distributions: 88  mg 
aspartame/kg bw (CI 59-125) using a confidence level of 0.95) to a normal subject. For an individual 
heterozygous for PKU, the concentration would be reached by the administration of a bolus dose of 
59  mg aspartame/kg bw (lower bound distributions: 50  mg aspartame/kg bw (CI  28-69) using a 
confidence level of 0.95. The Panel considered that given the conservative assumptions, realistic 
dietary intake of aspartame and the confidence intervals provided by the modelling, the peak plasma 
phenylalanine levels would not exceed the clinical target threshold when a normal individual 
consumed aspartame at levels below the current ADI of 40 mg/kg bw/day.  
The Panel noted that studies on the effect of hourly ingestion of 600 mg aspartame over a period of 
eight hours by normal individuals have shown that plasma phenylalanine levels did not exceed the 
normal postprandial range (Stegink et al., 1989). This dose corresponded to approximately 80 mg 
aspartame/kg bw or twice the current ADI, in one day. Moreover, using a published steady state model 
to compute the effect of repeated dosing of aspartame on plasma phenylalanine levels (Stegink et al., 
1989), the Panel predicted that bolus administration of 40 mg/kg bw (the current ADI) on an hourly 
basis was required to achieve steady state plasma levels greater than 240 µM.  
The Panel therefore concluded that there would not be a risk of adverse effects on pregnancy in the 
general population including heterozygous individuals at the current ADI. The Panel noted that the use 
of a sensitive subpopulation (PKU patients) obviated the need for a toxicodynamic uncertainty factor 
(UF), for inter-individual variability. The Panel concluded that the use of the 95
th percentile 
confidence level of the lower bound estimate in the dose-response modelling of plasma phenylalanine 
concentrations from heterozygotes replaced the toxicokinetic default UF.  Opinion on the re-evaluation of aspartame (E951) as a food additive
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13.  Risk characterisation 
Based on the discussion of the aspartame toxicity database (Section 4) the Panel concluded that there 
were two key endpoints in the animal data for characterising the risk from aspartame consumption. 
These endpoints were: 1) reproductive and developmental toxicity; 2) chronic toxicity and 
carcinogenicity. The Panel concluded from the animal and human ADME data that aspartame was 
rapidly and completely hydrolysed in the GI tract to methanol and the amino acids phenylalanine and 
aspartic acid. The Panel concluded that any systemic effects following aspartame ingestion must be 
due to effects of these metabolites rather than aspartame per se.  
When considering all the genotoxicity, chronic toxicity and carcinogenicity studies on aspartame the 
Panel overall concluded that there was no convincing evidence for genotoxic or carcinogenic potential 
of aspartame in experimental animals. In the hazard identification and characterisation, the Panel has 
discussed the ERF studies performed in mice and rats and confirmed the conclusion of previous 
assessments that there were major deficiencies in these studies and as such, they were not suitable for 
hazard identification and characterisation. Based on the chronic toxicity and carcinogenicity data, the 
Panel concurred with the NOAEL of 4000 mg aspartame/kg bw/day previously identified by JECFA, 
the SCF and other assessors.  
In a Weight-of-Evidence approach, the Panel considered the database on the toxicity of methanol, 
including also in vivo studies by inhalation and intraperitoneal administration. Taken together the 
Panel concluded that the data set was limited but that the available reliable in vitro and in vivo data did 
not indicate a genotoxic potential of methanol.  
The oral studies on chronic toxicity and carcinogenicity of methanol were limited to a mouse study 
reported by Apaja (1980) and a rat study performed by the ERF and reported by Soffritti et al. (2002). 
Overall, the Panel concluded that the study by Apaja did not contribute to the assessment of the 
carcinogenic potential of methanol.  
As already discussed in section 4, the validity of the ERF study on methanol has recently been 
criticised (Cruzan, 2009; Schoeb et al., 2009; Schoeb and McConnell, 2011; NTP-EPA, 2011). The 
Panel concurred with the concerns identified by EPA and others, and did not support the validity of the 
conclusions in the study on methanol reported by Soffritti et al. (2002). The Panel concluded that the 
ERF rat study was not a suitable basis for the cancer risk assessment of methanol. 
The reproductive and developmental toxicity database on methanol was limited. As described in 
section 5 and discussed in section 6, the studies in rats and monkeys were not adequate to derive a 
NOAEL. In mice, one prenatal developmental toxicity study by inhalation (in which a high oral dose 
was also tested) and two oral prenatal developmental studies (at high dose levels) were identified. Oral 
studies on methanol performed at high dose levels (4000 or 5000 mg/kg bw/day) did not allow the 
Panel to identify a NOAEL for reproductive and developmental toxicity. Therefore the Panel 
calculated a NOAEL of approximately 560 mg/kg bw/day for oral methanol exposure from the 
NOAEC of 1300 mg methanol/m
3 from inhalation study in mice (Rogers et al., 1993). The Panel 
considered the NOAEL of 560 mg/kg bw/day as conservative because it was based on the presence of 
extra cervical ribs which are transient and disappear during further development of the pup.  
The Panel noted that the lowest calculated NOAEL for methanol by oral exposure is 140 -fold higher 
than the maximum amount of methanol that could be released when aspartame is consumed at the 
ADI.  
Overall, the Panel concluded that the data on toxicity, kinetics, reproductive and developmental 
toxicity, genotoxicity and carcinogenicity of methanol do not suggest that there was a risk from 
methanol derived from aspartame at the current exposure estimates, or at the ADI of 40 mg/kg bw/day.  Opinion on the re-evaluation of aspartame (E951) as a food additive
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The Panel noted that aspartic acid is itself a neurotransmitter and can be converted to the more potent 
neurotransmitter glutamate. The Panel did not see any convincing evidence of neurotoxicity associated 
with the consumption of aspartame. The Panel concluded that aspartic acid generated from aspartame 
was not of safety concern at the current exposure estimates, or at the ADI of 40 mg/kg bw/day.  
The Panel considered that adverse effects reported for aspartame in animal studies could be attributed 
to the metabolite phenylalanine, which was particularly the case for the rat and rabbit developmental 
toxicity studies. The Panel noted that adverse developmental effects were seen in children born to 
PKU patients and that these effects appeared to be related to maternal phenylalanine levels. The Panel 
was aware that the knowledge on effects of phenylalanine in PKU mothers and their children both 
before and after birth had developed considerably since the initial evaluation of aspartame.  
The Panel undertook a formal MoA analysis of the putative role of phenylalanine in the developmental 
toxicity seen in animal studies. This MoA analysis is described in Section 11.  
The Panel considered that the proposed MoA was plausible and relevant based on the weight-of-
evidence based on the available data summarised in the opinion. There were uncertainties from the 
limited kinetic data in animals and in the human aspartame dose-phenylalanine concentration response 
data. The Panel decided to base the risk characterisation on comparison of plasma phenylalanine levels 
following aspartame administration with plasma phenylalanine levels associated with developmental 
effects in children born from PKU mothers. The Panel decided these human data were more 
appropriate than the results of animal studies of reproductive and developmental toxicity for the risk 
characterization of aspartame.  
Having established that the MoA was plausible and relevant, the Panel reviewed the information on 
plasma levels of phenylalanine associated with adverse effects on the fetuses of PKU mothers and 
noted that current clinical guidelines recommend that plasma levels of phenylalanine should be 
maintained below an average value of 360  μM. The Panel was aware that there continues to be 
discussion and research about the actual threshold and whether this was associated with average or 
peak plasma concentrations of phenylalanine. 
The Panel modelled peak plasma concentrations of phenylalanine following a bolus administration of 
aspartame to normal and PKU heterozygous individuals. The Panel chose assumptions, which 
overestimated the plasma concentrations of phenylalanine associated with administration of 
aspartame. These are discussed in more detail in Section 12. The Panel considered that comparing 
peak plasma concentrations derived in this way should be regarded as a conservative/worst case 
scenario. In comparing these values to the plasma phenylalanine concentrations that have no effect on 
the fetuses of PKU mothers, the Panel took into account that aspartame could be consumed at the same 
time, as a meal that would contain proteins which when digested would release phenylalanine. In 
calculating a safe level of aspartame exposure (based on plasma phenylalanine concentrations), the 
Panel assumed the worst-case scenario that intake of aspartame occurs in combination with the meal 
which leads to circulating plasma phenylalanine concentrations of 120 µM (the maximum plasma 
concentration based on conservative assumptions of dietary exposure to phenylalanine). The 
concentration of plasma phenylalanine derived from aspartame was therefore set to 240  µM (i.e. 
360 µM minus 120 µM) by the Panel.  
Based on the modelling, a plasma phenylalanine concentration of 240  µM would result from the 
administration of a bolus dose of 103  mg aspartame/kg bw (lower bound distributions: 88  mg 
aspartame/kg bw, 95
th percentile, CI 59-125) to a normal subject. For a PKU heterozygous individual 
the concentration of 240  µM would be reached by the administration of a bolus dose of 59  mg 
aspartame/kg bw (lower bound distributions: 50 mg aspartame/kg bw, 95
th percentile, CI 28-69). The 
Panel considered that given the conservative assumptions and the confidence intervals provided by the 
modelling, for realistic dietary intake of aspartame, the peak plasma phenylalanine levels would not 
exceed 240 µM.  Opinion on the re-evaluation of aspartame (E951) as a food additive
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The Panel noted that in the normal population the 95
th percentile confidence interval for the lower 
bound of the dose for resulting in a peak plasma level of 240 µM following a bolus administration of 
aspartame was greater than 40 mg/kg bw (the current ADI). In the PKU heterozygous population the 
95
th percentile confidence interval for the lower bound of the dose for resulting in a peak plasma level 
of 240 µM following a bolus administration of aspartame was greater than 40 mg/kg bw (the current 
ADI) in 82  % of the simulations. The Panel considered that following bolus administration of 
aspartame of 40 mg/kg bw (the current ADI) the PKU heterozygous population would not exceed the 
current clinical guideline of 360 µM for plasma phenylalanine.  
The Panel also noted that in order to exceed the phenylalanine plasma concentration of 240  μM 
following repeated administration of aspartame in normal individuals, a bolus administration at 
40 mg/kg bw (equivalent to the current ADI) would need to be given every hour.  
The Panel considered the following: 
•  the conservative assumptions used in the modelling, which would all overestimate peak 
plasma concentrations 
•  the available information on adverse effects in development in humans with PKU 
•  the allocation of 2/3 of the current clinical guideline level of 360 µM phenylalanine in plasma 
to phenylalanine from ingested aspartame, in order to account for simultaneous ingestion of 
phenylalanine from other components of the diet 
•  results of the modelling 
•  kinetic data from repeated oral administration of aspartame in humans 
•  bolus intakes based on consumption of one litre of soft drink containing aspartame at the MPL 
of 600 mg/L by a child of 20-30 kg will not exceed 30 mg aspartame/kg bw.  
Based on these considerations and evaluations, the Panel concluded that under realistic conditions (i.e. 
not a single bolus dose of 40 mg/kg bw), phenylalanine plasma levels would not exceed 240 µM in 
normal or PKU heterozygous individuals. The Panel noted that this concentration was well below the 
concentrations at which adverse effects in the fetus were reported and was also below the current 
clinical guideline (360 µM) for prevention of effects in the fetuses of pregnant PKU patients. The 
Panel noted that in young children who did not suffer from PKU, plasma levels of phenylalanine 
resulting from aspartame ingestion at or below the ADI (as either a bolus or other aspartame 
consumption patterns) were likely to remain below 240 μM. For pregnant women, the Panel noted that 
there was no risk to the fetus from phenylalanine derived from aspartame at the current ADI 
(40 mg/kg bw/day) in normal or PKU heterozygous individuals.  
The Panel noted that it was currently not possible to include chronic endpoints in the postulated MoA. 
The Panel noted that the ADI previously derived by JECFA and the SCF of 40 mg/kg bw/day 
appeared to be based on the long-term animal studies using the default uncertainty factor of 100. The 
Panel considered that this remained appropriate for the evaluation of long-term effects of aspartame. 
The current evaluation was based on analysis of human reproductive and developmental effects of 
phenylalanine in PKU patients, who are more susceptible to dietary phenylalanine than the general and 
PKU heterozygous population. Therefore, no additional allowance for toxicodynamic variability was 
required. The modelling of the aspartame dose - phenylalanine concentration response was based on 
data from PKU heterozygous individuals who at any dose would have a higher plasma phenylalanine 
concentration than the normal population; therefore no additional allowance for toxicokinetic 
variability was required for the general population. The Panel concluded that exposures at or below the Opinion on the re-evaluation of aspartame (E951) as a food additive
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current ADI were not of safety concern for reproductive and developmental toxicity in humans 
excluding PKU homozygous individuals. 
The Panel concluded from the present assessment of aspartame that there were no safety concerns at 
the current ADI of 40 mg/kg bw/day. Therefore, there was no reason to revise the ADI for aspartame.  
The Panel emphasised that its evaluation of phenylalanine plasma levels from a dose of aspartame at 
the ensuing ADI is not applicable to PKU patients. These individuals require total control of dietary 
phenylalanine intake to manage the risk from elevated phenylalanine plasma levels. The Panel noted it 
is a requirement of EU legislation that products containing aspartame indicate through labelling that 
they contain a source of phenylalanine. 
Conservative estimates of exposure to aspartame made by the Panel for the general population were up 
to 36  mg/kg bw/day at the 95
th percentile. These were below the ADI. The Panel noted that the 
percentage of PKU heterozygous individuals with a lower bound below 36 mg would be considerably 
lower. Due to the conservatism of both the exposure assessment and the aspartame dose-phenylalanine 
concentration response modelling, the Panel considered that it was highly unlikely that any individual 
in the normal and PKU heterozygous population would have plasma levels of phenylalanine above 
240 μM following aspartame ingestion. Based on the available data, the Panel further considered that 
even in combination with diet, these aspartame intakes (either as a single or repeated dose) would not 
lead to peak plasma phenylalanine concentrations above the current clinical guideline for prevention 
of adverse effects on the fetuses of PKU mothers of 360 μM.  
The Panel noted that the current ADI for DKP is 7.5 mg/kg bw/day. Based on the current specification 
for DKP in aspartame (1.5 %), estimates of DKP exposure at the ADI for aspartame were below the 
ADI for DKP. Based on available data on DKP levels in food products following breakdown of 
aspartame (up to 24 % from soft drinks), the Panel estimated high level exposure for the general 
population as ≤ 5.5 mg DKP/kg bw/day at the 95
th percentile, which is still below the ADI for DKP.  
14.  Uncertainties, inconsistencies and data gaps 
In the postulated MoA approach, the developmental effects of aspartame mainly seen in rabbits were 
attributed to L-phenylalanine. However, the Panel acknowledged that the effects seen in rabbits 
receiving aspartame may also be due to a significant reduction in feed intake during pregnancy. The 
aborting rabbits from the high dose group manifested body weight loss and decreased to negligible 
feed consumption, compared to those that maintained their pregnancies. The Panel noted that such a 
marked reduction in feed intake may have had a negative effect on the nutritional status of these 
females as a result of gastrointestinal disturbances and the potential effect of phenylalanine. Because 
the decreased feed consumption occurred in both aspartame- and phenylalanine-dosed animals, the 
Panel was unable to determine how much of the reported effects on the maternal organism and fetus 
were due to a reduced nutrient intake, and therefore to a negative effect on the nutritional status of 
these females as a result of gastrointestinal disturbances, and how much to a direct effect of the high 
phenylalanine intake (from metabolism of aspartame).  
The Panel concluded that the high phenylalanine intake (from metabolism of aspartame) could at least 
in part be responsible for these effects in the high dose aspartame group because similar effects, 
although less severe, were seen in the phenylalanine-dosed animals.  
The Panel noted that there were no measures of plasma phenylalanine levels from the rat and rabbit 
reproductive studies with aspartame. This constituted a data gap in animals as the contemporaneous 
biochemical measures would increase confidence in the assumption that phenylalanine was 
responsible for the effects seen. However, the Panel took into consideration available human data on 
plasma phenylalanine levels from highly susceptible subpopulation showing that phenylalanine has 
concentration – related developmental effects (see section 11.2.2). Opinion on the re-evaluation of aspartame (E951) as a food additive
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Due to the limitations (in terms of dose and time points) in the kinetic data in animals, phenylalanine 
levels were not modelled. From the data available following aspartame administration, it was possible 
to model reliably the peak plasma phenylalanine levels. Although potentially these could have been 
used to predict steady state concentrations of phenylalanine, had a more comprehensive dataset been 
available steady state phenylalanine levels could have been modelled more reliably and this would 
have been undertaken. 
The Panel excluded from its evaluation PKU patients, since these individuals require total control of 
dietary phenylalanine intake to manage the risk from elevated phenylalanine plasma levels.  
The following main assumptions were made by the Panel in the present risk characterization (based on 
the MoA): 
•  Phenylalanine plasma level of 360 µM is the threshold for developmental effects. 
•  The diet results in phenylalanine plasma level not exceeding 120 µM.  
•  Peak plasma phenylalanine concentration can be used in the dose-response modelling as 
surrogate of steady-state plasma phenylalanine concentration.  
•  Bolus administration of aspartame can be used in the dose-concentration modelling of plasma 
phenylalanine to represent a more typical pattern of aspartame intake.  
•  The 95
th percentile confidence interval of the lower bound estimate of the aspartame dose-
plasma phenylalanine concentration curve provides a safe limit for plasma phenylalanine for 
the entire population (with the exception of homozygous PKU patients).  
•  The increase in plasma phenylalanine concentrations following aspartame administration will 
be the same in the general population as in individuals heterozygous for PKU. 
•  Reproductive and developmental toxicity of aspartame is solely dependent on systemic 
exposure to phenylalanine.  
•  There is no requirement for a pharmacodynamic uncertainty factor (a sensitive human 
population (PKU patients) was used to define the threshold).  
•  There is no requirement for a pharmacokinetic uncertainty factor (the aspartame plasma 
phenylalanine concentration was based on a more sensitive human sub-population (PKU 
heterozygous)). 
The Panel was not able to place a specific numerical value on the uncertainties related to these 
assumptions, but the Panel considered that these assumptions would be more likely to overestimate 
than underestimate any potential developmental risk. Therefore the Panel considered that the results of 
uncertainty analysis further support its conclusion, that there is no safety concern for aspartame at the 
current ADI in normal and heterozygous subjects. 
CONCLUSIONS 
The Panel concluded that chronic toxicity and reproductive and developmental toxicity were the 
critical endpoints in the animal database. The Panel considered that the evaluation of long-term effects 
of aspartame should continue to be based on the animal data. Based on a MoA analysis and the 
weight-of-evidence, the Panel considered that the reproductive and developmental toxicity in animals 
was due to phenylalanine released from aspartame and concluded that the basis for evaluation of the 
reproductive and developmental endpoint should be the available data in humans.  
Conservative estimates of exposure to aspartame made by the Panel for the general population were 
≤ 36 mg/kg bw/day at the 95
th percentile.  
Due to the conservatism of both the exposure assessment and the aspartame dose-phenylalanine 
concentration response modelling, the Panel considered that it was highly unlikely that any individual 
in the normal and PKU heterozygous population would have plasma levels of phenylalanine above 
240 μM following oral aspartame exposure up to the ADI of 40mg/kg bw/day. The Panel further 
considered that even in combination with diet, these aspartame intakes would not lead to peak plasma Opinion on the re-evaluation of aspartame (E951) as a food additive
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phenylalanine concentrations above 360 μM, the current clinical guideline for prevention of adverse 
effects on the fetuses of PKU mothers.  
The Panel concluded from the present assessment of aspartame that there were no safety concerns at 
the current ADI of 40 mg/kg bw/day. Therefore, there was no reason to revise the ADI for aspartame.  
The Panel emphasised that its evaluation of phenylalanine plasma levels from a dose of aspartame at 
the ensuing ADI is not applicable to PKU patients. These individuals require total control of dietary 
phenylalanine intake to manage the risk from elevated phenylalanine plasma levels.  
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1)  List of unpublished study submitted to EFSA following the public call for data.  
E1  Sc-18862: A Sweetening Agent 
1972  Ajinomoto 
and 
Nutrasweet 
E2  Sc-18862: Four Week Oral Tolerance Study In The Mouse 
1972  Ajinomoto 
and 
Nutrasweet 
E3  Sc-18862: Four Week Oral Tolerance Study In The Rat 
1972  Ajinomoto 
and 
Nutrasweet 
E4  Sc-18862: Nine Week Oral Toxicity Study In The Rat 
Not 
reported 
Ajinomoto 
and 
Nutrasweet 
E5 
Sc-18862: Evaluation Of Embryotoxic And Teratogenic Potential In The 
Rat 
1970  Ajinomoto 
and 
Nutrasweet 
E6  Sc-19192: Two Week Oral Toxicity Study In The Mouse 
1971  Ajinomoto 
and 
Nutrasweet 
E7  Sc-19192: Two Week Oral Toxicity Study In The Rat 
1971  Ajinomoto 
and 
Nutrasweet 
E8  Sc-19192: Five Week Oral Toxicity Study In The Rat 
1972  Ajinomoto 
and 
Nutrasweet 
E9  Sc-18862: Toxicological Evaluation In The Neonatal Rat (Final Report) 
1972  Ajinomoto 
and 
Nutrasweet 
E10 
Toxicological Evaluation Of Sc-18862: Evaluation Of Reproductive 
Performance. Segment I Of The Teratology-Reproduction Profile 
1972  Ajinomoto 
and 
Nutrasweet 
E11  Sc-18862: Two Generation Reproduction Study - Rats (Final Report) 
1971  Ajinomoto 
and 
Nutrasweet 
E12  Sc-18862: Mutagenic Study In Rats (Final Report) 
1970  Ajinomoto 
and 
Nutrasweet 
E13 
Sc-19192: Segment III - Perinatal Weaning Study In The Rat (Final 
Report) 
1972  Ajinomoto 
and 
Nutrasweet 
E14 
Behavioral Effects Of Chronic Feeding Of L-Phenylalanine And Sc-
18862 To Weanling Rats 
1972  Ajinomoto 
and 
Nutrasweet 
E15  The Metabolism Of Aspartame - Volume I Parts I-XIV 
1972  Ajinomoto 
and Opinion on the re-evaluation of aspartame (E951) as a food additive
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Nutrasweet 
E16  Sweetening Agents (Bibliography) 
Not 
reported 
Ajinomoto 
and 
Nutrasweet 
E17  The Metabolism of Aspartame - Volume 2 Parts XV-XIX 
1972  Ajinomoto 
and 
Nutrasweet 
E18  The Metabolism of Aspartame - Volume 3 Parts XX-XXIII 
1972  Ajinomoto 
and 
Nutrasweet 
E19  Sc-18862: A Sweetening Agent (Endocrine Studies) 
Not 
reported  
Ajinomoto 
and 
Nutrasweet 
E20  Sc-18862: 2 Month Oral Administration - Rats (Final Report) 
1969  Ajinomoto 
and 
Nutrasweet 
E21  Sc-18862: 2 Month Oral Toxicity - Dogs (Final Report) 
1969  Ajinomoto 
and 
Nutrasweet 
E22 
Chicken Embryo Study Sc-18862 Calcium Cyclamate Sucrose (Final 
Report) 
  Ajinomoto 
and 
Nutrasweet 
E23  Short Term Tolerance Of Aspartame By Normal Adults 
1972  Ajinomoto 
and 
Nutrasweet 
E24  Short Term Tolerance Of Aspartame By Obese Adults 
1972  Ajinomoto 
and 
Nutrasweet 
E25  Short Term Tolerance Of Aspartame By Adult Pku Heterozygotes 
1972  Ajinomoto 
and 
Nutrasweet 
E26 
Tolerance Of Loading Doses Of Aspartame By Phenylketonuric (Pku) 
Homozygous Children 
1972  Ajinomoto 
and 
Nutrasweet 
E27  Sc-18862: 46 Week Oral Toxicity Study In The Hamster 
1972  Ajinomoto 
and 
Nutrasweet 
E28  Sc-18862: 106 Week Oral Toxicity Study In The Dog 
1972  Ajinomoto 
and 
Nutrasweet 
E29 
Sc-18862 and 19192 (3:1 Ratio): Segment II Teratology Study In The 
Rabbit (Final Report) 
1972  Ajinomoto 
and 
Nutrasweet 
E30 
Sc-19192: An Evaluation Of Mutagenic Potential Employing The In vivo 
Cytogenetics Method In The Rat (Final Report) 
1972  Ajinomoto 
and 
Nutrasweet 
E31 
Sc-19192: An Evaluation Of Mutagenic Potential Employing The Host-
Mediated Assay In The Rat (Final Report) 
1972  Ajinomoto 
and 
Nutrasweet 
E32  Sc-18862: 52 Week Oral Toxicity Study In The Infant Monkey 
1972  Ajinomoto 
and 
Nutrasweet 
E33  Sc-18862: Two Year Toxicity Study In The Rat (Annex) 
1973  Ajinomoto 
and 
Nutrasweet 
E34  Sc-18862: Two Year Toxicity Study In The Rat (Final Report) 
1973  Ajinomoto 
and 
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E35 
Sc-18862: 46 Week Oral Toxicity Study In The Hamster (Supplement 
N°1 Microscopy For Biological Research, Ltd Histopathology Report - 
Part I) 
1972  Ajinomoto 
and 
Nutrasweet 
E36 
Sc-18862: 46 Week Oral Toxicity Study In The Hamster (Supplement 
N°1 Microscopy For Biological Research, Ltd Histopathology Report - 
Part II) 
1972  Ajinomoto 
and 
Nutrasweet 
E37 
Sc-19192: Evaluation Of Reproductive Performance In The Rat - 
Segment I Of The Teratology - Reproduction Profile 
1973  Ajinomoto 
and 
Nutrasweet 
E38 
Sc-19192: An Evaluation Of The Embryotoxic And Teratogenic 
Potential In The Rat - Segment II Of The Teratology-Reproduction 
Profile 
1973  Ajinomoto 
and 
Nutrasweet 
E39 
Sc-18862: A Study Of The Pregnant And Lactating Rat And Of Her 
Offspring - Segment III Of The Teratology Reproduction Profile 
1973  Ajinomoto 
and 
Nutrasweet 
E40 
Sc-18862: An Evaluation Of The Mutagenic Potential In The Rat 
Employing The Dominant Lethal Assay 
1973  Ajinomoto 
and 
Nutrasweet 
E41 
Sc-18862: An Evaluation Of The Mutagenic Potential In The Rat 
Employing The Dominant Lethal Assay 
1973  Ajinomoto 
and 
Nutrasweet 
E42 
Sc-19192: An Evaluation Of The Mutagenic Potential In The Rat 
Employing The Dominant Lethal Assay 
1973  Ajinomoto 
and 
Nutrasweet 
E43 
Sc-18862: An Evaluation Of Mutagenic Potential Employing The In vivo 
Cytogenetics Method in The Rat (Final Report) 
1972  Ajinomoto 
and 
Nutrasweet 
E44 
Sc-18862: An Evaluation Of Mutagenic Potential Employing The Host 
Mediated Assay In The Rat (Final Report) 
1972  Ajinomoto 
and 
Nutrasweet 
E45  Sc-19192: Acute Toxicity Studies In The Rat, Mouse And Rabbit 
1973  Ajinomoto 
and 
Nutrasweet 
E46  Sc-18862: Acute Toxicity Studies In The Rat, Mouse And Rabbit 
1973  Ajinomoto 
and 
Nutrasweet 
E47 
Sc-18862: A Study Of The Pregnant And Lactating Rat And Of Her 
Offspring - A Segment III Study 
1973  Ajinomoto 
and 
Nutrasweet 
E48 
Sc-18862: A Study Of The Pregnant And Lactating Rat And Of Her 
Offspring - Segment III Of The Teratology Reproduction Profile 
1973  Ajinomoto 
and 
Nutrasweet 
E49 
Sc-18862: A Study Of The Pregnant And Lactating Rat And Of Her 
Offspring (Comparison By Feeding Of Equimolar Quantities Of L-
Phenylalanine And/Or L-Aspartic Acid) 
1973  Ajinomoto 
and 
Nutrasweet 
E50  A Study Of The Possible Reaction Of DKP With Aqueous Nitrous Acid 
Not 
reported 
Ajinomoto 
and 
Nutrasweet 
E51 
Sc-18862: An Evaluation Of The Embryotoxic And Teratogenic 
Potential In The Rabbit - A Segment II Study 
1973  Ajinomoto 
and 
Nutrasweet 
E52 
Sc-18862: Segment II - An Evaluation Of The Teratogenic Potential In 
The Rabbit (Final Report) 
1973  Ajinomoto 
and 
Nutrasweet Opinion on the re-evaluation of aspartame (E951) as a food additive
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E53 
Sc-18862: An Evaluation Of The Embryotoxic And Teratogenic 
Potential In The Rabbit - Segment II Of The Teratology Reproduction 
Profile 
1973  Ajinomoto 
and 
Nutrasweet 
E54 
Sc-18862: An Evaluation Of The Embryotoxic And Teratogenic 
Potential In The Rabbit - A Segment II Study 
1974  Ajinomoto 
and 
Nutrasweet 
E55  Sc-18862: Segment II - Teratology Study In The Rabbit (Final Report) 
1973  Ajinomoto 
and 
Nutrasweet 
E56 
Sc-18862 And 19192 (3:1 Ratio): Segment II Teratology Study In The 
Rat (Final Report) 
1972  Ajinomoto 
and 
Nutrasweet 
E57  Sc-19192: Segment II Teratology Study In The Rabbit (Final Report) 
1972  Ajinomoto 
and 
Nutrasweet 
E58 
Sc-18862: A 26 Week Urinary Bladder Tumorigenicity Study In The 
Mouse By The Intravesical Pellet Implant Technique (Final Report) 
1973  Ajinomoto 
and 
Nutrasweet 
E59 
Sc-19192: A 26 Week Urinary Bladder Tumorigenicity Study In The 
Mouse By The Intravesical Pellet Implant Technique (Status Report) 
1973  Ajinomoto 
and 
Nutrasweet 
E60  Long Term Tolerance Of Aspartame By Normal Adults 
1973  Ajinomoto 
and 
Nutrasweet 
E61 
Long Term Tolerance Of Aspartame By Normal Children And 
Adolescents 
1972  Ajinomoto 
and 
Nutrasweet 
E62 
Sc-18862: An Evaluation Of The Embryotoxic And Teratogenic 
Potential In The Rabbit - A Segment II Study 
1973  Ajinomoto 
and 
Nutrasweet 
E63 
Sc-18862: Segment II An Evaluation Of The Teratogenic Potential In 
The Rabbit (Final Report) 
1973  Ajinomoto 
and 
Nutrasweet 
E64 
Plan For Phase B: Long Term Study Of The Effects On Aspartyl 
Phenylalanine Methyl Ester (Aspartame) On Obese Adults 
1972  Ajinomoto 
and 
Nutrasweet 
E65  Tolerance Of Aspartame By Diabetic Subjects 
1972  Ajinomoto 
and 
Nutrasweet 
E66  Tolerance Of Loading Doses Of Aspartame By Normal Adolescents 
1973  Ajinomoto 
and 
Nutrasweet 
E67  Long Term Tolerance Of Aspartame By Adult Pku Heterozygotes 
1973  Ajinomoto 
and 
Nutrasweet 
E68 
The Metabolism Of Aspartame - Further Studies Of Nitrosation 
Formation 
1973  Ajinomoto 
and 
Nutrasweet 
E69  The Effect Of Acid Hydrolysis On Sc-18862 - Sc-19192 
Not 
reported 
Ajinomoto 
and 
Nutrasweet 
E70  Sc-18862: Lifetime Toxicity Study In The Rat (Final Report) 
1974  Ajinomoto 
and 
Nutrasweet 
E71 
Study Of Possible Nitrosamide Formation From APM And DKP Under 
Simulated Physiological Conditions 
Not 
reported 
Ajinomoto 
and 
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E72 
Sc-18862: A 56 Week Urinary Bladder Tumorigenicity Study In The 
Mouse By The Intravesical Pellet Implant Technique And Addendum To 
A 26 Week Urinary Bladder Tumorigenicity Study In The Mouse By The 
Intravesical Pellet Implant Technique (Final Report) 
1974 
Ajinomoto 
and 
Nutrasweet 
E73 
Sc-19192: A 56 Week Urinary Bladder Tumorigenicity Study In The 
Mouse By The Intravesical Pellet Implant Technique And Addendum To 
Sc-19192: A 26 Week Urinary Bladder Tumorigenicity Study In The 
Mouse By The Intravesical Pellet Implant Technique (Final Report) 
1974 
Ajinomoto 
and 
Nutrasweet 
E74  Effects Of Sc-18862 On Lactation In Rats 
1973  Ajinomoto 
and 
Nutrasweet 
E75  Sc-18862: 104 Week Toxicity Study In The Mouse (Final Report) 
1974  Ajinomoto 
and 
Nutrasweet 
E76  Sc-19192: 110 Week Toxicity Study In The Mouse (Final Report) 
1974  Ajinomoto 
and 
Nutrasweet 
E77  Sc-19192: 115 Week Oral Tumorigenicity Study In The Rat Volume I 
1974  Ajinomoto 
and 
Nutrasweet 
E78 
Sc-19192: 115 Week Oral Tumorigenicity Study In The Rat Volume II 
Postmortem Evaluation 
1974  Ajinomoto 
and 
Nutrasweet 
E79 
Sc-18862: Segment II An Evaluation Of The Teratogenic Potential In 
The Rabbit (Final Report) 
1974  Ajinomoto 
and 
Nutrasweet 
E80  The Metabolism Of Aspartame Volume 4 Parts XXIV - XXXI 
1974  Ajinomoto 
and 
Nutrasweet 
E81 
Sc-18862: An Evaluation Of Mutagenic Potential Employing The Host- 
Mediated Assay In The Mouse 
1974  Ajinomoto 
and 
Nutrasweet 
E82 
Sc-19192: An Evaluation Of Mutagenic Potential Employing The Host-
Mediated Assay In The Mouse 
1974  Ajinomoto 
and 
Nutrasweet 
E83 
Sc-18862 Placebo: An Evaluation Of Embryotoxic And Teratogenic 
Potential Of Specially Prepared Pelleted Diet In The Rabbit 
1974  Ajinomoto 
and 
Nutrasweet 
E84  Sc-18862: Acute Intravenous Toxicity Study In The Rat 
1974  Ajinomoto 
and 
Nutrasweet 
E85  Sc-18862: Acute Intravenous Toxicity Study In The Dog 
1974  Ajinomoto 
and 
Nutrasweet 
E86 
Sc-18862: A Supplemental Study Of Dog Brains From A 106 Week Oral 
Toxicity Study 
1973  Ajinomoto 
and 
Nutrasweet 
E87 
Sc-18862 (Aspartame): A Supplemental Study Of Rat Brains From Two 
Tumorigenicity Studies  
1973  Ajinomoto 
and 
Nutrasweet 
E88 
Sc-18862: Experiments In Mated And Pregnant Rhesus Monkeys - A 
Compilation Of Available Fragmentary Data 
1975  Ajinomoto 
and 
Nutrasweet 
E89 
Sc-18862: An Evaluation Of Embryotoxic And Teratogenic Potential In 
The Mouse 
1975  Ajinomoto 
and 
Nutrasweet Opinion on the re-evaluation of aspartame (E951) as a food additive
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E90 
Sc-18862: An Evaluation Of Embryotoxic And Teratogenic Potential In 
The Rabbit 
1975  Ajinomoto 
and 
Nutrasweet 
E91 
Table of Contents 
Section I: A. Introduction; B. Pivotal Animal Safety Studies; C. 
Overview of Data Reassurance Activities 
Section II: Review Of Metabolism Studies 
Section III: Progress Report On Aspartame Studies (University Of Iowa) 
Section IV:Conclusion 
1976 
Ajinomoto 
and 
Nutrasweet 
E92  The Metabolism Of The Methyl Moiety Of Aspartame 
1976  Ajinomoto 
and 
Nutrasweet 
E93 
Final Report On Aspartame Studies - Effect Of Aspartame Loading Upon 
Plasma And Erythrocyte Free Amino Acid Levels In Normal Adult 
Subjects 
1977  Ajinomoto 
and 
Nutrasweet 
E94 
Damage In The Neonatal Mouse Brain Following Ingestion Of 
Aspartame 
Not 
reported 
Ajinomoto 
and 
Nutrasweet 
E95 
Metabolic Studies Of Aspartame And MSG Ingested As A Meal 
Component (Final Report) 
1977  Ajinomoto 
and 
Nutrasweet 
E96 
Plasma Aminograms Of Infants And Adults Fed An Identical High 
Protein Meal (Final Report) 
1977  Ajinomoto 
and 
Nutrasweet 
E97 
Sc-18862: An Evaluation Of Mutagenic Potential Employing The Ames 
Salmonella/Microsome Assay 
1978  Ajinomoto 
and 
Nutrasweet 
E98 
Sc-19192: An Evaluation Of Mutagenic Potential Employing The Ames 
Salmonella/Microsome Assay (Report Release) 
1978  Ajinomoto 
and 
Nutrasweet 
E99  The Metabolism Of The Aspartyl Moiety Of Aspartame 
1978  Ajinomoto 
and 
Nutrasweet 
E100  The Metabolism Of Aspartate In Infant And Adult Mice 
1978  Ajinomoto 
and 
Nutrasweet 
E101 
An Evaluation Of The Mutagenic Potential of Sc-18862 Employing The 
Ames Salmonella/Microsome Assay (Report Release) 
1978  Ajinomoto 
and 
Nutrasweet 
E102a 
Authentication Review Of Selected Materials Submitted To The Food 
And Drug Administration Relative To Application Of Searle 
Laboratories To Market Aspartame Volume N°1 Chapter I, II, III 
1978 
Ajinomoto 
and 
Nutrasweet 
E102b 
Authentication Review Of Selected Materials Submitted To The Food 
And Drug Administration Relative To Application Of Searle 
Laboratories To Market Aspartame Volume N°2 Chapter IV, V, VI 
1978 
Nutrasweet 
E102c 
Authentication Review Of Selected Materials Submitted To The Food 
And Drug Administration Relative To Application Of Searle 
Laboratories To Market Aspartame Volume N°3 From Chapter VII To 
Chapter XIV 
1978 
Nutrasweet 
E103 
Effects Of Aspartame (Sc-18862) On Gonadotropin Secretion In Rats 
(Biology Document Review And Approval Sign-Off) 
1978  Ajinomoto 
and 
Nutrasweet 
E104 
Developmental Assessment Of Infant Macaques Receiving Dietary 
Aspartame Or Phenylalanine (Final Report) 
1979  Ajinomoto 
and Opinion on the re-evaluation of aspartame (E951) as a food additive
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Nutrasweet 
E105 
Aspartame Administration To The Infant Monkey: Hypothalamic 
Morphology And Blood Amino Acid Levels (Final Report) 
Not 
reported 
Ajinomoto 
and 
Nutrasweet 
E106 
An Evaluation Of The Mutagenic Potential Of Sc-19192 Employing The 
Ames Salmonella/Microsome Assay (Release Of Report) 
1978  Ajinomoto 
and 
Nutrasweet 
E107 
Effect Of Aspartame Loading Upon Plasma And Erythrocyte Free Amino 
Acid Levels And Blood Methanol Levels In Normal One Year Old 
Children 
1977  Ajinomoto 
and 
Nutrasweet 
E108 
Effect Of Aspartame On Plasma And Red Cell Amino Acids Of 
Apparently Healthy Female Adults And On Presumed Phenylketonuric 
Heterozygotes 
1978  Ajinomoto 
and 
Nutrasweet 
E109 
Effect Of Aspartame Loading At 100 Mg Per kg Body Weight Upon 
Plasma And Erythrocyte Levels Of Free Amino Acids In Normal 
Subjects And Subjects Presumed To Be Heterozygous For 
Phenylketonuria (Final Report) 
1978 
Ajinomoto 
and 
Nutrasweet 
E110 
Effect Of Aspartame Loading In Subjects Who Report Symptoms Of 
Chinese Restaurant Syndrome After Glutamate Ingestion 
1979  Ajinomoto 
and 
Nutrasweet 
E111 
Metabolic Studies Of Aspartame And Monosodium Glutamate When 
Ingested Together As Part Of A Soup Beverage Meal 
1979  Ajinomoto 
and 
Nutrasweet 
E112 
Metabolic Studies Of Aspartame And Monosodium Glutamate Ingested 
As Components Of A Hamburger - Milk Shake Meal System In Normal 
Adult Subjects 
1979  Ajinomoto 
and 
Nutrasweet 
E169 
Pharmacokintetics and metabolism of [
14C]-SC-19129 and [
14C]-SC-
19200, its free acid, in the dog 
1987 
Nutrasweet 
E170 
Pharmacokinteics and metabolism of [
14C]-SC-19129 and [
14C]-SC-
19200, its free acid, in the rabbit. 
1986 
Nutrasweet 
E171 
Pharmacokinetics and metabolism of [
14C]-SC-19129 in the Rhesus 
monkeys 
1985 
Nutrasweet 
E172 
A Pharmacokinetic Study of [
14C]-SC-19129 ([
14C]Beta-aspartame in 
man. 
1987 
Nutrasweet 
E173 
Pharmacokinetics and metabolism of [14C]-Beta-Aspartame in Healthy 
Subjects 
1988 
Nutrasweet 
UA01 
Report Of The Scientific Committee For Food On Sweeteners 
 
1984 
Ajinomoto 
UA02 
Opinion Of An Expert Panel On The Safety Status Of Aspartame As A 
Non-Nutritive Sweetener (Final) 
 
2006 
Ajinomoto 
UA03 
Food Additive Approval Process By FDA Followed For Aspartame 
(GAO Report To Senator Metzenbaum) 
 
1987 
Ajinomoto Opinion on the re-evaluation of aspartame (E951) as a food additive
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UA04 
Histopathological Examination In A Carcinogenecity Study Of Sc-18862 
In Slc: Wistar Rats (Final Report) 
 
2006 
Ajinomoto 
UN01 
Final Clinical Research Report. Effects Of Aspartame Ingestion Without 
Food On Serum Glucose, Insulin, And Glucagon Concentrations In 
Normal Subjects And Subjects With Diabetes 
 
1988 
Nutrasweet 
UN02 
Aspartame, Brain Amino Acids And Neurochemical Mediators. IlSI 
International Aspartame Workshop, November 17-21, 1986, Marbella, 
Spain.  
 
1986 
Nutrasweet 
UN03 
Toxicology Studies Done With Beta-Aspartame (Revised). IlSI 
International Aspartame Workshop, November 17-21, 1986, Marbella, 
Spain. 
 
1986 
Nutrasweet 
UN04 
Clinical Studies To Evaluate Seizures In Children And Adults Allegedly 
Due To Aspartame Consumption (N15-85-02-109 And N16-85-02-110) 
 
1991 
Nutrasweet 
UN05 
Effect Of Repeated Ingestion Of Beverage Containing Aspartame Or 
Diketopiperazine On Amino Acid Or Diketopiperazine Concentrations In 
Plasma And Urine Of Normal Healthy Subjects (N02-84-02-075). 
 
1987 
Nutrasweet 
UN06 
Effect Of Repeated Ingestion Of Beverage Containing Aspartame Or 
Diketopiperazine On Amino Acid Or Diketopiperazine Concentrations In 
Subjects Heterozygous For Phenylketonuria (N12-85-02-054). 
 
1987 
Nutrasweet 
UN07 
Multi-Center Clinical Study To Evaluate Allergic Reactions Allegedly 
Due To Aspartame Consumption (N22-86-02-002) 
 
1992 
Nutrasweet 
UN08 
Safety Of Long-Term Aspartame Administration In Normal Subjects 
(N07-84-02-093). 
 
1988 
Nutrasweet 
UN09 
A Study Of The Clinical And Biochemical Effects Of Aspartame In 
Subjects With Chronic Stable Alcoholic Liver Disease (N23-87-02-001) 
 
1991 
Nutrasweet 
UN10 
A Randomised, Double-Blind, Placebo-Controlled Approach To 
Evaluate The Potential Of Chronic High Dose Aspartame Consumption 
To Influence Psychometric Performance And Mood In Normal Healthy 
Volunteers (Pcr 0195). Vol I, II, III, IV. 
 
1993 
Nutrasweet 
UN11  Study of aspartame in carbonated beverages  1986  Nutrasweet 
UN12 
Nutrasweet’s response to FDA following a communication dated April 
25, 1989 requesting additional information on the use of encapsulated 
aspartame in baked good 
1990  Nutrasweet 
UN13  Use of aspartame as flavor enhancer in beer containing less than 3% 
alcohol by volume    Nutrasweet 
UN14  Asparatame in breakfast cereals  1987  Nutrasweet Opinion on the re-evaluation of aspartame (E951) as a food additive
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UN15  Aspartame in soft candy. Appendix III  1987  Nutrasweet 
2)  The list of published studies submitted to EFSA following the public call for data is published 
on the EFSA website (http://www.efsa.europa.eu/en/dataclosed/call/110601.htm). 
3)  Additional information submitted to EFSA following the public call for data: 
Ajinomoto, 2012a. Clarification on the manufacturing process. Ajinomoto communication to EFSA on 
26
th April 2012 a follow up of letter sent on 3
rd April 2012. 
Ajinomoto, 2012b. Ajinomoto aspartame technical booklet. Available at: http://www.aji-
aspartame.com/products/pdf/Ajinomoto_technical_booklet.pdf 
Burdock Group, 2006. Opinion of an expert panel on the safety status of aspartame as a non-nutritive 
sweetener. (confidential report). 
Cyprus, 2012. Analytical data on levels of DKP in soft drinks sold in the Cyprus market. 
FDE (Food Drink Europe), 2011. Additive E951 Aspartame concentration. November 2011.  
ICGA (International Chewing Gum Association), 2011. Additive concentration data. November 2011.  
ISA (International Sweeteners’ Association), 2011. Additive concentration data. December 2011. 
ISA (International Sweeteners’ Association), 2012. Additive concentration updated data, November 
2012.  
Nutrasweet, 2012. Clarification on the manufacturing process. NutraSweet communication to EFSA 
on 24
th April 2012 a follow up of letter sent on 3
rd April 2012. 
ProDulce, 2012. Data on usage level on aspartame. September 2012. Opinion on the re-evaluation of aspartame (E951) as a food additive
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APPENDICES 
Appendix A.   Identification and selection criteria for scientific data consideration for the re-
evaluation of aspartame  
For the risk assessment of aspartame, the Panel applied the general principles of the risk assessment 
procedure as follows: 
-  The potential health effects of aspartame or its metabolites and degradation products identified 
and characterised on the basis of the available scientific studies and literature (hazard 
identification and characterisation). 
-  An exposure assessment for aspartame and its degradation products performed in order to 
compute the current level of intake of the aspartame, its metabolites and degradation products 
in the population. 
The principles stated in the following EFSA publications were applied in the various steps of the 
process: 
-  EFSA, 2009. Guidance of the Scientific Committee on transparency in the scientific aspects of 
risk assessments carried out by EFSA. Part 2: General principles. The EFSA Journal 1051, 1-
22. 
-  EFSA Scientific Committee, 2011. Scientific opinion on genotoxicity testing strategies 
applicable to food and feed safety assessment. EFSA Journal 2011;9(9):2379. 
-  EFSA, 2011. Overview of the procedures currently used at EFSA for the assessment of dietary 
exposure to different chemical substances. EFSA Journal 2011;9(12):2490. 
-  EFSA Scientific Committee, 2012. Guidance on selected default values to be used by the 
EFSA Scientific Committee, Scientific Panels and Units in the absence of actual measured 
data. EFSA Journal 2012;10(3):2579. 
-  EFSA Scientific Committee, 2012. Scientific Opinion on Risk Assessment Terminology. 
EFSA Journal 2012;10(5):2664. 
-  EFSA, 2010. Strategy of the ANS Panel for the re-evaluation of food additives. Available 
online: http://www.efsa.europa.eu/en/events/event/ans100413-m.pdf 
The Panel considered the criteria developed by Boobis et al. (2008) in the mode of action approach.  
Identification 
The collection of the scientific information used as a basis for the aspartame risk assessment followed 
three main roots: 
-  Search in scientific databases aimed at identifying studies that have appeared in scientific 
literature such as journals, conference proceedings, editorials, letters. 
-  ‘Open call for data’ procedure adopted as a standard practice by EFSA to collect scientific 
information either unpublished or published such as study reports or case reports. 
-  Previous scientific evaluations by national agencies, national and international independent 
expert advisory committees. 
The collection of the scientific information through searching scientific literature databases was 
performed to cover the period between 1 January 1970 and 15 February 2013. In order to update the 
database, a search was conducted on a monthly basis until 15 November 2013. Opinion on the re-evaluation of aspartame (E951) as a food additive
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An exhaustive complete search strategy was used with the search terms described below, with no 
limits applied to the search. Web of Science covers over 46 million records contained in 30 000 
scholarly books, 12 000 journals and 148 000 conference proceedings while PubMed covers over 23 
million records. 
 
Search term  Search type  To capture: 
aspartame 
Major/minor 
MeSH heading 
Publications in which aspartame is a major or minor 
topic. 
Free text  Publications in which aspartame is mentioned. 
aspartam 
Major/minor 
MeSH heading 
Publications in which aspartame is a major or minor 
topic. 
Free text  Publications in which aspartame is mentioned. 
L-aspartyl-L-phenylalanine 
methyl ester  Free text  Publications in which aspartame is identified as L-
aspartyl-L-phenylalanine methyl ester. 
E951 Free  text  Publications in which aspartame is identified as 
E951. 
Sweetening agents  Major/minor 
MeSH heading 
Publications in which artificial sweetening agents 
are a major or minor topic 
(Sweeten*) and (artificial* or 
intens*)  Free text 
Publications mentioning sweeteners, sweetening, 
sweetened….. etc., together with artificial, 
artificially….. or intense, intensity, intensified….. 
etc. 
 
Using this search strategy in Web of Science and PubMed, a total of 2207 and 1149 records relevant to 
aspartame were identified, respectively.  
An open call for data entitled ‘Call for scientific data on Aspartame (E 951)’ was launched on 1 June 
2011 and closed on 30 September 2011. This call resulted in over 600 documents that were submitted 
to EFSA. These included previously unpublished scientific data, among which the 112 original studies 
on aspartame which were submitted to support the request for authorisation of aspartame in Europe in 
the early 1980s and documents identified through the search in scientific databases. The publication 
details and results of this call can be retrieved under 
http://www.efsa.europa.eu/en/dataclosed/call/110601.htm. A further call entitled ‘Call for scientific 
data on aspartame (E 951) related to 5-benzyl-3,6-dioxo-2-piperazine acetic acid (DKP) and other 
primary or secondary degradation products from aspartame’ was launched on 26 July 2012 with a 
closure date of 30 September 2012. This call resulted in the retrieval of an additional 121 documents 
which can be retrieved under http://www.efsa.europa.eu/en/dataclosed/call/120726.htm.  
In addition to the data retrieval described above, a targeted search strategy was applied to the scientific 
databases to retrieve scientific literature on metabolites and breakdown products of aspartame. The 
keywords were related to the following subjects: methanol, formaldehyde, aspartic acid, 
phenylalanine, phenylketonuria and DKP. The following aspects were included in the search: stability, 
reaction and fate in food, exposure, ADME, acute, sub-chronic and chronic toxicity, genotoxicity, 
carcinogenicity, reproductive and developmental toxicity, neurotoxicity, hypersensitivity and allergy, 
clinical and epidemiological data. For the search strategy all synonymous terms and Boolean operators 
were applied to cover the period between 1960 and 15 February 2013 using Web of Science and Opinion on the re-evaluation of aspartame (E951) as a food additive
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PubMed. These literature keyword searches were narrowed down further by manual review. In order 
to update the database, a search was conducted on a monthly basis until 15 November 2013.  
The study selection process and its results 
The selection criteria for scientific data consideration for the re-evaluation of aspartame described in 
this report were applied to the existing published and unpublished scientific literature. These criteria 
were defined a priori by the Panel and published in June 2010 (EFSA, 2010). The literature database 
retrieved included scientific peer reviewed papers and relevant non-peer reviewed papers (such as 
technical reports and published conference proceedings) identified as described above.  
 Types of studies that were considered within the criteria for inclusion in the selection process 
 
a) Experimental studies 
b) Epidemiological studies in humans 
c) Case reports supported by medical evidence 
Table 1: Source and Type of information available that may fall in these categories: 
Peer-reviewed Not  peer-reviewed 
Published papers  Unpublished study reports 
Meeting  abstracts  (conference  proceedings)  Papers in non-peer reviewed journals or non-peer 
reviewed e-papers 
Published case reports  Meeting abstracts 
  Case reports in non-peer reviewed journals 
 
Tiered Approach for the Selection Process 
Tier 1. Criteria to be used for the inclusion of scientific papers and reports in the selection process: 
1.  All studies provided by the applicants (including unpublished study reports non peer-
reviewed) with the original application dossier.  
2.  All studies on the safety and use of aspartame commissioned by national authorities. 
3.  Papers and reports that have been subject to an independent scientific peer-review process (i.e. 
process that scientific journals use to ensure that the articles to be published represent the best 
scholarship available in terms of solid scientific soundness and quality control) and have been 
subsequently published in a scientific journal. 
4.  For non independently peer reviewed papers and reports assessment based on the quality 
control procedures applied and the study designs used with reference to validated standards 
(e.g. OECD protocols and GLP Guidelines). 
Tier 2. Criteria to be used for the rejection of papers and reports in the selection process: 
1.  Insufficient details provided on the performance or outcome of the studies (EFSA, 2009).  
2.  Insufficient information to assess the methodological quality of the studies (EFSA, 2009).  
The result of the study selection process was as follows. 
-  2207 published documents and 173 unpublished documents were retrieved for aspartame. 
-  The selection of the studies for inclusion in the risk assessment of aspartame was based on 
consideration of the extent to which the study was informative and relevant to the assessment 
and general study quality considerations.  Opinion on the re-evaluation of aspartame (E951) as a food additive
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-  The further application selection process described above resulted in 147 unpublished and 365 
published studies to be considered for the final risk assessment. The references selected are 
cited in the opinion. 
-  When studies were considered of acceptable quality, irrespective of whether they yielded 
positive, negative, or null results, they were considered in assessing health effects associated 
with exposure to aspartame. 
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II.  Composition data for methanol from natural food sources  
Category   FoodEx name  min—max   mean value* 
(mg/kg) 
ANISE BRANDY  
Herb liqueur  trace—563 ppm   281.5 
Spirits trace—563  ppm    281.5 
ARCTIC BRAMBLE (Rubus 
arcticus L.)  Blackberries (Rubus fruticosus)  < 0.05 ppm in 
juice   0.05 
ARRACK   Punch  25.6—750 ppm   387.8 
BANANA (Musa sapientum 
L.) 
Bananas   15 ppm   15.0 
Dried bananas   15 ppm   15.0 
Candied fruit, Bananas  15 ppm   15.0 
Nectar, Banana  15 ppm   15.0 
Soft drink, banana flavour  15 ppm   15.0 
BEANS 
Beans, with pods  1.3 ppm  1.3 
Legumes, beans, green, without 
pods  1.3 ppm  1.3 
Beans, green, without pods   1.3 ppm  1.3 
Legumes, beans, dried  1.3 ppm  1.3 
Beans 1.3  ppm  1.3 
Broad bean   1.3 ppm  1.3 
Lima bean   1.3 ppm  1.3 
Mung bean   1.3 ppm  1.3 
Urd bean   1.3 ppm  1.3 
Black eye bean   1.3 ppm  1.3 
Horse bean   1.3 ppm  1.3 
Scarlet runner bean   1.3 ppm  1.3 
Rice bean   1.3 ppm  1.3 
Yam bean   1.3 ppm  1.3 
Castor bean   1.3 ppm  1.3 
Beans-based meals  1.3 ppm  1.3 
Beans and meat meal  1.3 ppm  1.3 
Beans and vegetables meal  1.3 ppm  1.3 
Beans, meat, and vegetables meal  1.3 ppm  1.3 
Legume (beans) soup  1.3 ppm  1.3 
Prepared legume (beans) salad  1.3 ppm  1.3 
BLACK CURRANTS (Ribes 
nigrum L.) 
Currants (red, black and white) 
(Ribes nigrum, Ribes rubrum)  4 ppm   4.0 
Jam, Currants (black) (Ribes 
nigrum)  4 ppm   4.0 
Juice, Blackcurrant  4 ppm   4.0 
Juice concentrate, Currants (black)   4 ppm   4.0 
CABBAGE (Brassica 
oleracea)  
Head cabbage (Brassica oleracea 
convar. capitata)  0.6 ppm   0.6 
Chinese cabbage   0.6 ppm   0.6 
CARROT (Daucus carota L.)  
Carrots (Daucus carota) trace—0.05  ppm    0.03 
Juice, Carrot  trace—0.05 ppm   0.03 
Apple/carrot juice  trace—0.05 ppm   0.03 
Multi-fruit-carrot juice  trace—0.05 ppm   0.03 
CIDER (APPLE WINE)   Cider  16—248 ppm   132.0 
CITRUS FRUITS  
Citrus fruits  0—213 ppm   106.5 
Juice, Orange  0—213 ppm   106.5 
Juice, Grapefruit  0—213 ppm   106.5 
Juice, Lemon  0—213 ppm   106.5 Opinion on the re-evaluation of aspartame (E951) as a food additive
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Category   FoodEx name  min—max   mean value* 
(mg/kg) 
Juice, Lime  0—213 ppm   106.5 
Juice, Mixed fruit  0—213 ppm   106.5 
Juice concentrate, Oranges   0—213 ppm   106.5 
Juice concentrate, Mandarins   0—213 ppm   106.5 
Nectar, Orange   0—213 ppm   106.5 
Juice, Orange-Grapefruit  0—213 ppm   106.5 
Juice, Mandarin-Banana  0—213 ppm   106.5 
Juice, Apricot-Orange  0—213 ppm   106.5 
Juice, Orange-Peach  0—213 ppm   106.5 
Juice, multi-fruit  0—213 ppm   106.5 
FIG (Ficus carica L.)  
Figs (Ficus carica) <  1—5  ppm    3.0 
Dried figs (Ficus carica) <  1—5  ppm    3.0 
GIN  Gin  76 ppm   76.0 
GRAPE (Vitis species)  
Vine leaves (grape leaves) (Vitis 
euvitis)  0.032—0.04 ppm   <0.04 
Table grapes (Vitis euvitis) 0.032—0.04  ppm    <0.04 
Wine grapes (Vitis euvitis) 0.032—0.04  ppm    <0.04 
Canned fruit, Table grape (Vitis 
euvitis)  0.032—0.04 ppm   <0.04 
Fruit compote, Table grape (Vitis 
euvitis)  0.032—0.04 ppm   <0.04 
grape juice (Filer and Stegink, 
1989) 
Juice, Grape  12-680 mg/L  346.0 
Juice concentrate, Grapes  12-680 mg/L  346.0 
Juice, Apple-Grape  12-680 mg/L  346.0 
Juice, Berries-Grapes  12-680 mg/L  346.0 
Fruit soft drink, Grape red  12-680 mg/L  346.0 
Fruit soft drink, Grape white  12-680 mg/L  346.0 
Soft drink, grapefruit flavour  12-680 mg/L  346.0 
LENTILS  
Lentils, green (Lens culinaris syn. 
L. esculenta)  4.4 ppm   4.4 
Lentils (Lens culinaris syn. L. 
esculenta)  4.4 ppm   4.4 
MILK and MILK 
PRODUCTS 
Milk and dairy products  < 0.009 ppm   <0.005 
Butter  < 0.009 ppm   <0.005 
Butter oil  < 0.009 ppm   <0.005 
Ghee  < 0.009 ppm   <0.005 
PASSIFLORA SPECIES 
Passion fruit (Passiflora edulis)  4 ppm   4.0 
Juice, Passion fruit  4 ppm   4.0 
PEAR BRANDY  
Fruit liqueur  4300—9300 ppm   6800.0 
Brandy 4300—9300  ppm    6800.0 
Spirits made from fruits  4300—9300 ppm   6800.0 
PEAS (Pisum sativum L.)  
Peas, with pods (Pisum sativum) 1  ppm    1.0 
Mushy peas (Pisum sativum) 1  ppm    1.0 
Peas, green, without pods (Pisum 
sativum)  1 ppm   1.0 
Peas (Pisum sativum) 1  ppm    1.0 
RASPBERRY, 
BLACKBERRY and 
BOYSENBERRY 
Boysenberry (Rubus ursinus x 
idaeus)  7—16 ppm   11.5 
Juice, Blackberry  7—16 ppm   11.5 
Fruit soft drink, Raspberry  7—16 ppm   11.5 
Soft drink, raspberry flavour  7—16 ppm   11.5 
RUM   Rum  0.08—36 ppm   18.0 Opinion on the re-evaluation of aspartame (E951) as a food additive
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Category   FoodEx name  min—max   mean value* 
(mg/kg) 
SHERRY   Sherry  31—163 ppm   97.0 
SOYBEAN (Glycine max. L. 
merr.)  
Soya beans  0.02—6 ppm   3.0 
Soya beans flour  0.02—6 ppm   3.0 
STRAWBERRY (Fragaria 
species)  
Strawberries (Fragaria × 
ananassa)  0.01—5 ppm   2.5 
Jam, Strawberries   0.01—5 ppm   2.5 
Juice concentrate, Strawberries   0.01—5 ppm   2.5 
Juice, Strawberry-Cherry  0.01—5 ppm   2.5 
TEA  
Tea (dried leaves and stalks, 
fermented or otherwise of Camellia 
sinensis) 
0.01—1.8 ppm   0.9 
Tea (dried leaves and stalks, 
fermented or otherwise of Camellia 
sinensis), decaffeinated 
0.01—1.8 ppm   0.9 
Tea (Infusion)  0.01—1.8 ppm   0.9 
TEQUILA (Agave tequilana)   Spirits made from vegetables 
(Tequila)  500—1000 ppm   750.0 
TOMATO (Lycopersicon 
esculentum Mill.)  
Tomatoes (Lycopersicum 
esculentum)  2.7—560 ppm   281.4 
Tomato purée  2.7—560 ppm   281.4 
Sun-dried tomatoes  2.7—560 ppm   281.4 
Juice, Tomato  2.7—560 ppm   281.4 
Juice, Tomato-Vegetable  2.7—560 ppm   281.4 
Juice, Tomato-Carrot  2.7—560 ppm   281.4 
Tomato ketchup  2.7—560 ppm   281.4 
Tomato chutney  2.7—560 ppm   281.4 
WHISKY   Whisky  15—160 ppm   87.5 
WINE   Wine  0.086— 30 ppm   115.0 
* mean values have been calculated by the Panel for the purpose of estimating background chronic intake of methanol from  
  natural food occurrence which is based on assumption that distribution of composition data per category (only when range  
  is expressed) is following a uniform distribution. 
Analytical values from VCF., 28th March 2012 and Filer and Stegink, 1989.   Opinion on the re-evaluation of aspartame (E951) as a food additive
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III.  Composition data for methanol from pectine degradation 
Matrix description  pectin content 
(g/100g) 
methanol 
(mg/kg) 
Vegetables and vegetable products (including fungi) 0.66 594 
Root vegetables 0.86 774 
Bulb vegetables 0.66 594 
Fruiting vegetables 0.67 603 
Brassica vegetables 0.66 594 
Leaf vegetables 0.66 594 
Legume vegetables 0.45 405 
Stem vegetables (Fresh) 0.66 594 
Vegetable products   0.66 594 
Fungi, cultivated 0.45 405 
Fungi, wild, edible  0.45 405 
Starchy roots and tubers  0.695 625.5 
Legumes, nuts and oilseeds  0.45 405 
Fruit and fruit products 0.59 531 
Citrus fruits  0.59 531 
Grapefruit (Citrus paradisi) 0.445 400.5 
Oranges (Citrus sinensis) 0.59 531 
Lemons (Citrus limon) 0.63 567 
Limes (Citrus aurantifolia) 0.63 567 
Mandarins (Citrus reticulata) 0.59 531 
Pomelo (Citrus grandis) 0.445 400.5 
Pome fruits  0.565 508.5 
Apple (Malus domesticus) 0.565 508.5 
Pear (Pyrus communis) 0.565 508.5 
Quince (Cydonia oblonga) 0.565 508.5 
Medlar (Mespilus germanica) 0.565 508.5 
Loquat (Eriobotrya japonica) 0.565 508.5 
Hawthorn (Crataegus and Rhaphiolepis) 0.565 508.5 
Rowan (Sorbus) 0.565 508.5 
Service tree (Sorbus domestica) 0.565 508.5 
Nashi pear (Pyrus pyrifolia) 0.565 508.5 
Stone fruits  0.635 571.5 
Apricots (Prunus armeniaca) 0.87 783 
Plums (Prunus domestica) 0.635 571.5 
Damson plum (Prunus domestica var institia) 0.635 571.5 
Mirabelle (Prunus domestica var syriaca) 0.635 571.5 
Greengage (Prunus domestica var italica) 0.635 571.5 
Sweet cherry (Prunus avium)   0.4 360 
Sour cherry (Prunus cerasus)   0.4 360 
Chickasaw plum (Prunus angustifolia) 0.635 571.5 
Susina (Prunus salicina) 0.635 571.5 
Sloe (Prunus spinosa)   0.635 571.5 
Peaches (Prunus persica) 0.635 571.5 
Chokecherry (Prunus virginiana) 0.4 360 
Berries and small fruits  0.55 495 
Table grapes (Vitis euvitis) 0.75 675 
Wine grapes (Vitis euvitis) 0.75 675 
Strawberries (Fragaria × ananassa) 0.47 423 
Blackberries (Rubus fruticosus) 0.55 495 
Dewberries (Rubus ceasius) 0.7 630 
Raspberries (Rubus idaeus) 0.49 441 
Boysenberry (Rubus ursinus x idaeus) 0.55 495 
Blueberries (Vaccinium corymbosum) 0.55 495 
Cranberries (Vaccinium macrocarpon) 0.55 495 
Currants (red, black and white) (Ribes nigrum, Ribes  0.55 495 
Gooseberries (Ribes uva-crispa) 0.55 495 
Rose hips (Rosa canina) 0.55 495 Opinion on the re-evaluation of aspartame (E951) as a food additive
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Matrix description  pectin content 
(g/100g) 
methanol 
(mg/kg) 
Mulberries (Morus spp.) 0.55 495 
Azarole (mediteranean medlar) (Crataegus azarolus) 0.55 495 
Elderberries (Sambucus nigra) 0.55 495 
Cloudberry (Rubus chamaemorus) 0.55 495 
Loganberry (Rubus loganobaccus) 0.55 495 
Salmonberry (Rubus spectabilis) 0.55 495 
Thimbleberry (Rubus parviflorus) 0.55 495 
Wineberry (Rubus phoenicolasius) 0.55 495 
Bearberry (Arctostaphylos spp.) 0.55 495 
Bilberry or whortleberry (Vaccinium spp.) 0.55 495 
Crowberry (Empetrum spp.) 0.55 495 
Cranberry (Vaccinium spp.) 0.55 495 
Huckleberry (Vaccinium spp.) 0.55 495 
Lingonberry (Vaccinium vitis-idaea) 0.55 495 
Strawberry Tree (Arbutus unedo), not to be confused with  0.55 495 
Jabuticaba (Brazilian grape tree) (Myrciaria cauliflora) 0.55 495 
Physalis (Physalis peruviana) 0.55 495 
Sea buckthorn (Hippophae rhamnoides) 0.55 495 
Miscellaneous fruits  0.54 486 
Dates (Phoenix dactylifera) 0.54 486 
Figs (Ficus carica) 0.54 486 
Table olives (Olea europaea) 0.54 486 
Kumquats (Fortunella species) 0.54 486 
Carambola (Averrhoa carambola) 0.27 243 
Persimmon (Sharon fruit) (Diospyros kaki) 0.54 486 
Jambolan (java plum) (Syzygium cumini) 0.54 486 
Kiwi (Actinidia deliciosa syn. A. chinensis) 0.54 486 
Lychee (Litchi) (Litchi chinensis) 0.48 432 
Passion fruit (Passiflora edulis) 0.54 486 
Prickly pear (cactus fruit) (Opuntia ficus-indica) 0.54 486 
Star apple (Chrysophyllum cainito) 0.54 486 
American persimmon (Virginia kaki) (Diospyros virginiana) 0.54 486 
Avocados (Persea americana) 0.54 486 
Bananas (Musa × paradisica) 0.73 657 
Mangoes (Mangifera indica) 0.48 432 
Papaya (Carica papaya) 0.6 540 
Pomegranate (Punica granatum) 0.54 486 
Cherimoya (Annona cherimola) 0.54 486 
Guava (Psidium guajava) 1.04 936 
Pineapples (Ananas comosus) 0.54 486 
Bread fruit (jackfruit) (Artocarpus altilis) 0.54 486 
Durian (Durio zibethinus) 0.54 486 
Soursop (guanabana) (Annona muricata) 0.54 486 
Anona (cherimoya) (Annona cherimola) 0.54 486 
Babaco (Carica pentagona Heilb., sin. Vasconcellea x  0.54 486 
Coco plum (Chrysobalanus icaco) 0.54 486 
Feijoa, Pineapple Guava (Feijoa sellowiana) 0.54 486 
Pawpaw (Asimina) 0.54 486 
Chayote (Sechium edule) 0.54 486 
Rambutan (Nephelium lappaceum)   0.54 486 
Carissa (Carissa sp.) 0.54 486 
Jujube (Ziziphus zizyphus) 0.54 486 
Longan fruit (Dimocarpus longan) 0.2 180 
Malabar plum (jambu) (Syzygium jambos) 0.54 486 
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IV.  Degradation of DKP from aspartame (from data reported in the technical section and 
from the MPLs/Use levels of aspartame as reported from table 6) 
Cat N°  Foods  restrictions/exception 
MPLs 
(mg/L 
or 
mg/kg) 
Used 
levels 
(mg/L or 
mg/kg) 
% 
DKP 
mg 
DKP 
from 
MPLs 
mg DKP 
from 
used 
levels 
1.4 
Flavoured fermented milk products 
including heat treated products 
only energy‐reduced products 
or with no added sugar  1000  1000  5  45  45 
3  Edible ices 
only energy‐reduced or with 
no added sugar  800  800  5  36  36 
4.2.2 
Fruit and vegetables in vinegar, oil, or 
brine  
only sweet‐sour preserves of 
fruit and vegetables  300  300  24  64  64 
4.2.3 
Canned or bottled fruit and 
vegetables 
only fruit energy‐reduced or 
with no added sugar  1000  1000  24  214  214 
4.2.4.1 
Fruit and vegetable preparations 
excluding compote 
only energy‐reduced  1000  1000  24  214  214 
4.2.5.1 
Extra jam and extra jelly as defined by 
Directive 2001/113/EEC 
only energy‐reduced jams 
jellies and marmalades  1000  1000  24  214  214 
4.2.5.2 
Jam, jellies and marmalades and 
sweetened chestnut puree as defined 
by Directive 2001/113/EEC 
only energy‐reduced jams, 
jellies and marmalades   1000  1000  24  214  214 
4.2.5.3 
Other similar fruit or vegetable 
spreads 
only dried‐fruit‐based 
sandwich spreads, energy‐
reduced or with no added 
sugar 
1000  1000  24  214  214 
5.1 
Cocoa and Chocolate products as 
covered by Directive 2000/36/EC 
only energy‐reduced or with 
no added sugars  2000  2000  10  178  178 
5.2 
Other confectionery including breath 
refreshening microsweets 
only cocoa or dried fruit 
based, energy reduced or with 
no added sugar 
2000 
1000 
10  178  89 
5.2 
Other confectionery including breath 
refreshening microsweets 
only cocoa, milk, dried fruit or 
fat based sandwich spreads, 
energy‐reduced or with no 
added sugar 
1000  10  89  89 
5.2 
Other confectionery including breath 
refreshening microsweets 
only starch based 
confectionary energy reduced 
or with no added sugar 
2000  10  178  89 
5.2 
Other confectionery including breath 
refreshening microsweets 
only confectionary with no 
added sugar  1000  10  89  89 
5.2 
Other confectionery including breath 
refreshening microsweets 
only breath‐freshening micro‐
sweets, with no added sugar  6000  10  535  89 
5.2 
Other confectionery including breath 
refreshening microsweets 
only strongly flavoured 
freshening throat pastilles 
with no added sugar 
2000  10  178  89 
5.3  Chewing gum 
only with added sugars or 
polyols, as flavour enhancer  2500  1450  0.1  2  1 
5.3  Chewing gum  only with no added sugar  5500  5420  0.1  5  5 
5.4 
Decorations, coatings and fillings, 
except fruit based fillings covered by 
category 4.2.4  
only starch based 
confcetionary energy reduced 
or with no added sugar 
2000  2000  10  178  178 
5.4 
Decorations, coatings and fillings, 
except fruit based fillings covered by 
category 4.2.4  
only confectionary with no 
added sugar  1000  1000  10  89  89 
5.4 
Decorations, coatings and fillings, 
except fruit based fillings covered by 
category 4.2.4  
only cocoa or dried fruit 
based, energy reduced or with 
no added sugar 
2000  2000  10  178  178 
5.4 
Decorations, coatings and fillings, 
except fruit based fillings covered by 
category 4.2.4  
only sauces  350  350  10  31  31 Opinion on the re-evaluation of aspartame (E951) as a food additive
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Cat N°  Foods  restrictions/exception 
MPLs 
(mg/L 
or 
mg/kg) 
Used 
levels 
(mg/L or 
mg/kg) 
% 
DKP 
mg 
DKP 
from 
MPLs 
mg DKP 
from 
used 
levels 
6.3  Breakfast cereals 
only breakfast cereals with a 
fibre content of more than 15 
%, and containing at least 20 % 
bran, energy reduced or with 
no added sugar 
1000  1000  0.2  2  2 
7.2  Fine bakery wares  only essoblaten ‐ wafer paper  1000  1000  0.2  2  2 
7.2  Fine bakery wares 
only fine bakery products for 
special nutritional uses  1700  1700  0.2  3  3 
9.2. 
Processed fish and fishery products 
including mollusks and crustaceans 
only sweet‐sour semi‐
preserves of fish and 
marinades of fish, crustaceans 
and molluscs 
300  300  5  13  13 
11.4.1  Table‐top Sweeteners in liquid form     QS  500000  24  106932  106932 
11.4.2  Table‐top Sweeteners in powder form     QS  500000  0.2  891  891 
11.4.3  Table‐top Sweeteners in tablets     QS  500000  0.2  891  891 
12.4  Mustard     350  350  24  75  75 
12.5  Soups and broths  only energy‐reduced soups  110  110  24  24  24 
12.6  Sauces     350  350  24  75  75 
12.7 
Salads and savoury based sandwich 
spreads 
only Feinkostsalat  350  350  24  75  75 
13.2 
Dietary foods for special medical 
purposes defined in Directive 
1999/21/EC (excluding products from 
food category 13.1.5) 
Products in this category can 
also use additives that are 
allowed in the corresponding 
food counterparts categories  
1000  1000  24  214  214 
13.3 
Dietary foods for weight control diets 
intended to replace total daily food 
intake or an individual meal (the 
whole or part of the total daily diet) 
   800  800  24  171  171 
14.1.3 
Fruit nectars as defined by Council 
Directive 2001/112/EC and vegetable 
nectars and similar products 
only energy‐reduced or with 
no added sugar  600  75  24  128  16 
14.1.4  Flavoured drinks 
only energy reduced or with 
no added sugar  600  600  24  128  128 
14.2.1  Beer and malt beverages 
only alcohol‐free beer or with 
an alcohol content not 
exceeding 1,2 % vol; ‘Bière de 
table/Tafelbier/Table beer’ 
(original wort content less 
than 6 %) except for 
‘Obergäriges Einfachbier'; 
Beers with a minimum acidity 
of 30 milli‐equivalents 
expressed as NaOH; Brown 
beers of the ‘oud bruin’ type 
600  600  0.7  4  4 
14.2.1  Beer and malt beverages  only energy‐reduced beer  25  25  0.7  0.2  0.2 
14.2.3  Cider and perry     600  600  0.7  4  4 
14.2.8 
Other alcholic drinks including 
mixtures of alcoholic drinks with non‐
alcoholic drinks and spirits with less 
than 15 % of alcohol 
   600  600  0.7  4  4 
15.1 
Potato‐, cereal‐, flour‐ or starch‐based 
snacks  
   500  500  24  107  107 
15.2  Processed nuts     500  500  24  107  107 
16 
Desserts excluding products covered 
in category 1, 3 and 4 
only energy‐reduced or with 
no added sugar  1000  1000  24  214  214 
17.1 
Food supplements supplied in a solid 
form including capsules and tablets 
and similar forms excluding chewable 
forms 
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Cat N°  Foods  restrictions/exception 
MPLs 
(mg/L 
or 
mg/kg) 
Used 
levels 
(mg/L or 
mg/kg) 
% 
DKP 
mg 
DKP 
from 
MPLs 
mg DKP 
from 
used 
levels 
17.2 
Food supplements supplied in a liquid 
form 
   600  24  128  480 
17.3 
Food supplements supplied in a 
syrup‐type or chewable form 
   5500  24  1176  480 
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Appendix C.   Summary of total estimated exposure to aspartame per age class and survey*: 
mean and high level (mg/kg bw/day) 
   MPLs   Use levels  
   Mean  High level  Mean  High level 
Toddlers 
Belgium (Regional_Flanders)  16.3     16.3    
Bulgaria (Nutrichild)  3.2  11.8  1.6  7.5 
Finland (DIPP)  6.3  21.2  6.3  21.2 
Germany (Donald 2006_2008)  4.3  13.2  4.3  13.2 
Italy (INRAN_SCAI_2005_06)  3.9     3.5    
The Netherlands (VCP_Kids)  14.2  36.9  14.1  36.0 
Spain (enKid)  8.3     8.3    
Children 
Belgium (Regional_Flanders)  11.4  27.1  11.4  27.1 
Bulgaria (Nutrichild)  2.9  9.3  1.8  6.3 
Czech Republic (SISP04)  5.2  12.1  5.2  12.1 
Denmark (Danish Dietary Survey)  3.7  8.7  3.7  8.7 
Finland (DIPP)  6.8  17.2  6.8  16.9 
Finland (STRIP)  5.3  11.7  5.2  11.7 
France (INCA 2)  6.5  15.9  6.4  15.3 
Germany (Donald 2006_2008)  6.4  14.9  6.3  14.2 
Greece (Regional_Crete)  2.7  8.0  2.7  8.0 
Italy (INRAN_SCAI_2005_06)  2.3  7.1  2.2  7.1 
Latvia (EFSA_TEST)  3.4  8.3  3.4  8.3 
The Netherlands (VCP_Kids)  12.8  32.9  12.6  32.4 
Spain (enKid)  6.0  17.3  6.0  17.3 
Spain (Nut_Ink05)  5.4  14.2  5.4  14.2 
Sweden (NFA)  7.0  16.0  6.9  16.0 
Adolescents 
Belgium (Diet_National_2004)  2.7  7.2  2.7  7.2 
Cyprus (Childhealth)  0.8  2.3  0.8  2.3 
Czech Republic (SISP04)  2.7  6.9  2.7  6.9 
Denmark (Danish Dietary Survey)  2.0  5.3  2.0  5.3 
France (INCA 2)  3.1  7.6  3.1  7.2 
Germany (National_Nutrition_Survey_II)  4.0  13.3  4.0  13.2 
Italy (INRAN_SCAI_2005_06)  1.1  4.1  1.1  4.1 
Latvia (EFSA_TEST)  2.1  5.6  2.1  5.6 
Spain (AESAN_FIAB)  1.2  3.1  1.2  3.1 
Spain (enKid)  2.4  6.3  2.4  6.3 
Spain (Nut_Ink05)  3.1  8.0  3.1  8.0 
Sweden (NFA)  3.5  9.5  3.5  9.5 
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   MPLs   Use levels  
   Mean  High level  Mean  High level 
Adults 
Belgium (Diet_National_2004)  3.8  14.0  3.8  14.0 
Czech Republic (SISP04)  1.1  3.4  1.1  3.4 
Denmark (Danish_Dietary_Survey)  1.1  3.3  1.1  3.2 
Finland (FINDIET_2007)  2.1  6.5  2.1  6.3 
France (INCA2)  3.4  8.9  3.4  8.9 
Germany (National_Nutrition_Survey_II)  4.6  17.3  4.6  17.1 
Hungary (National_Repr_Surv)  0.9  3.1  0.7  2.4 
Ireland (NSIFCS)  3.1  8.2  3.1  8.2 
Italy (INRAN_SCAI_2005_06)  0.9  3.1  0.9  3.1 
Latvia (EFSA_TEST)  1.2  3.2  1.2  3.2 
The Netherlands (DNFCS_2003)  8.6  27.5  8.5  27.5 
Spain (AESAN)  1.5  5.0  1.4  5.0 
Spain (AESAN_FIAB)  0.8  2.5  0.7  2.5 
Sweden (Riksmaten_1997_98)  2.3  5.9  1.6  4.1 
United Kingdom (NDNS)  4.3  20.6  4.2  20.0 
The elderly 
Belgium (Diet_National_2004)  4.4  23.5  4.4  23.5 
Denmark (Danish_Dietary_Survey)  0.8  2.6  0.8  2.6 
Finland (FINDIET_2007)  1.4  4.7  1.3  4.7 
France (INCA2)  2.8  11.3  2.8  11.3 
Germany (National_Nutrition_Survey_II)  4.1  18.7  4.1  18.7 
Hungary (National_Repr_Surv)  0.5  1.5  0.4  1.4 
Italy (INRAN_SCAI_2005_06)  0.8  2.7  0.8  2.7 
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Appendix D.   Summary of total estimated exposure to methanol from all sources per age class and survey*: mean and high level (mg/kg bw/day) 
  
from endogenous 
pathways (basal + pectine-
derived) 
from natural food 
occurence 
from food additive (using 
aspartame MPLs) 
Total exposure from all 
sources  
   Mean  High level  Mean  High level  Mean  High level  Mean  High level 
Toddlers 
Belgium (Regional_Flanders)  15.5     1.4     1.6     18.6    
Bulgaria (Nutrichild)  17.0  31.8  1.4  3.8  0.3  1.2  18.7  34.6 
Finland (DIPP)  18.0  33.1  0.2  0.9  0.6  2.1  18.9  35.1 
Germany (Donald 2006_2008)  14.7  29.1  0.5  1.9  0.4  1.3  15.6  29.9 
Italy (INRAN_SCAI_2005_06)  15.4     1.0     0.4     16.8    
The Netherlands (VCP_Kids)  13.4  24.2  0.6  2.6  1.4  3.7  15.5  26.3 
Spain (enKid)  13.7     0.2     0.8     14.7    
Children 
Belgium (Regional_Flanders)  13.5  24.4  1.1  3.1  1.1  2.7  15.8  28.1 
Bulgaria (Nutrichild)  16.0  29.0  1.4  3.3  0.3  0.9  17.6  31.8 
Czech Republic (SISP04)  13.1  23.2  0.3  0.9  0.5  1.2  13.9  24.5 
Denmark (Danish Dietary Survey)  13.1  24.6  0.6  1.4  0.4  0.9  14.0  25.7 
Finland (DIPP)  13.0  23.6  0.4  1.4  0.7  1.7  14.1  25.4 
Finland (STRIP)  9.4  16.7  0.4  1.1  0.5  1.2  10.4  18.1 
France (INCA 2)  11.2  20.1  0.6  1.5  0.6  1.6  12.4  21.8 
Germany (Donald 2006_2008)  11.5  21.1  0.5  1.8  0.6  1.5  12.7  22.8 
Greece (Regional_Crete)  9.8  18.0  0.8  2.1  0.3  0.8  10.8  19.6 
Italy (INRAN_SCAI_2005_06)  13.2  23.5  1.0  2.1  0.2  0.7  14.4  25.4 
Latvia (EFSA_TEST)  10.1  20.2  0.3  1.2  0.3  0.8  10.7  21.2 
The Netherlands (VCP_Kids)  11.4  21.1  0.6  2.1  1.3  3.3  13.2  23.5 
Spain (enKid)  11.5  24.1  0.3  1.1  0.6  1.7  12.5  25.5 
Spain (Nut_Ink05)  10.3  19.4  0.5  1.6  0.5  1.4  11.4  21.2 
Sweden (NFA)  11.0  20.3  0.3  1.1  0.7  1.6  12.1  21.9 
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   from endogenous 
pathways (basal + pectine)  from natural sources  from food additive (using 
aspartame MPLs) 
total exposure to all sources 
of methanol 
   Mean  High level  Mean  High level  Mean  High level  Mean  High level 
Adolescents 
Belgium (Diet_National_2004)  8.1  14.8  0.5  1.2  0.3  0.7  8.8  15.9 
Cyprus (Childhealth)  8.6  15.1  0.5  1.4  0.1  0.2  9.2  16.5 
Czech Republic (SISP04)  10.5  19.5  0.2  0.7  0.3  0.7  11.0  20.2 
Denmark (Danish Dietary Survey)  9.4  16.9  0.4  1.0  0.2  0.5  10.1  17.8 
France (INCA 2)  8.5  15.4  0.4  0.9  0.3  0.8  9.2  16.4 
Germany (National_Nutrition_Survey_II)  7.6  14.3  0.4  1.3  0.4  1.3  8.4  15.5 
Italy (INRAN_SCAI_2005_06)  10.1  17.5  0.6  1.3  0.1  0.4  10.8  18.8 
Latvia (EFSA_TEST)  8.8  17.3  0.3  0.8  0.2  0.6  9.3  18.1 
Spain (AESAN_FIAB)  9.1  15.6  0.3  0.8  0.1  0.3  9.5  16.4 
Spain (enKid)  9.1  16.1  0.2  0.7  0.2  0.6  9.5  17.2 
Spain (Nut_Ink05)  8.4  15.3  0.5  1.4  0.3  0.8  9.2  16.7 
Sweden (NFA)  8.4  15.1  0.2  0.6  0.3  1.0  8.9  15.8 
Adults 
Belgium (Diet_National_2004)  8.2  14.8  0.5  1.4  0.4  1.4  9.1  16.3 
Czech Republic (SISP04)  8.2  14.3  0.3  0.8  0.1  0.3  8.5  15.1 
Denmark (Danish_Dietary_Survey)  9.0  16.2  0.4  1.0  0.1  0.3  9.6  16.9 
Finland (FINDIET_2007)  8.5  15.4  0.6  1.6  0.2  0.7  9.3  16.8 
France (INCA2)  8.6  15.3  0.4  1.1  0.3  0.9  9.3  16.5 
Germany (National_Nutrition_Survey_II)  8.1  14.9  0.4  1.2  0.5  1.7  8.9  16.4 
Hungary (National_Repr_Surv)  9.1  15.8  0.3  0.8  0.1  0.3  9.5  16.3 
Ireland (NSIFCS)  9.6  16.7  0.3  0.9  0.3  0.8  10.2  17.9 
Italy (INRAN_SCAI_2005_06)  9.6  16.3  0.6  1.1  0.1  0.3  10.2  17.4 
Latvia (EFSA_TEST)  7.9  14.9  0.3  0.9  0.1  0.3  8.4  15.7 
The Netherlands (DNFCS_2003)  7.9  14.1  0.4  0.9  0.9  2.7  9.1  16.2 
Spain (AESAN)  9.1  16.6  0.4  1.2  0.1  0.5  9.7  17.9 
Spain (AESAN_FIAB)  9.7  16.9  0.6  1.3  0.1  0.3  10.3  18.2 
Sweden (Riksmaten_1997_98)  8.1  14.2  0.3  0.7  0.2  0.6  8.6  15.1 
United Kingdom (NDNS)  8.3  14.4  0.4  1.0  0.4  2.1  9.1  16.1 
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   from endogenous 
pathways (basal + pectine)  from natural sources  from food additive (using 
aspartame MPLs) 
total exposure to all sources 
of methanol 
   Mean  High level  Mean  High level  Mean  High level  Mean  High level 
The elderly 
Belgium (Diet_National_2004)  8.6  15.3  0.4  1.3  0.4  2.4  9.4  17.2 
Denmark (Danish_Dietary_Survey)  9.5  16.7  0.5  1.1  0.1  0.3  10.0  17.5 
Finland (FINDIET_2007)  8.5  15.0  0.4  1.4  0.1  0.5  9.0  16.5 
France (INCA2)  9.5  16.4  0.4  1.0  0.3  1.1  10.2  17.2 
Germany (National_Nutrition_Survey_II)  8.5  15.3  0.3  1.0  0.4  1.9  9.3  16.6 
Hungary (National_Repr_Surv)  9.3  15.3  0.2  0.6  0.0  0.2  9.5  15.8 
Italy (INRAN_SCAI_2005_06)  10.0  17.1  0.6  1.2  0.1  0.3  10.7  17.9 
* The different methodologies of European dietary surveys included in the EFSA Comprehensive Database are fully described in the Guidance on the use of the EFSA Comprehensive European  
  Food Consumption Database in Exposure Assessment (EFSA, 2011b). A summary is available p.11, Table 1 of the guidance. 
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Appendix E.   Summary of total estimated exposure to aspartic acid, phenylalanine and DKP 
(from the use of aspartame MPLs) per age class and survey*: mean and high level 
((mg/kg bw/day) 
   Aspartic acid  PHE  DKP 
   Mean  High level  Mean  High level  Mean  High level 
Toddlers 
Belgium (Regional_Flanders)  7.4     9.2     1.9    
Bulgaria  (Nutrichild)  1.5  5.3 1.8 6.6 0.5 2.0 
Finland  (DIPP)  2.8  9.6 3.5  11.9  0.5 1.5 
Germany (Donald 2006_2008)  2.0  5.9  2.4  7.4  0.4  1.2 
Italy (INRAN_SCAI_2005_06)  1.8     2.2     0.3    
The Netherlands (VCP_Kids)  6.4  16.7  8.0  20.7  1.5  4.1 
Spain (enKid)  3.7     4.6     0.7    
Children 
Belgium  (Regional_Flanders)  5.2  12.2 6.4 15.2 1.1  3.2 
Bulgaria  (Nutrichild)  1.3  4.2 1.6 5.2 0.4 1.7 
Czech  Republic  (SISP04)  2.3  5.5 2.9 6.8 0.4 1.1 
Denmark (Danish Dietary Survey)  1.7  3.9  2.1  4.9  0.4  1.0 
Finland  (DIPP)  3.1  7.8 3.8 9.7 0.7 1.6 
Finland  (STRIP)  2.4  5.3 3.0 6.6 0.7 1.6 
France (INCA 2)  2.9  7.2  3.6  8.9  1.0  2.7 
Germany (Donald 2006_2008)  2.9  6.7  3.6  8.4  0.6  1.9 
Greece  (Regional_Crete)  1.2  3.6 1.5 4.5 0.3 0.8 
Italy  (INRAN_SCAI_2005_06)  1.0  3.2 1.3 4.0 0.2 0.5 
Latvia  (EFSA_TEST)  1.5  3.8 1.9 4.7 0.5 1.6 
The Netherlands (VCP_Kids)  5.8  14.9  7.2  18.4  1.3  3.2 
Spain  (enKid)  2.7  7.8 3.4 9.7 0.5 1.6 
Spain  (Nut_Ink05)  2.4  6.4 3.0 8.0 0.6 1.6 
Sweden  (NFA)  3.1  7.3 3.9 9.0 0.7 1.5 
Adolescents 
Belgium  (Diet_National_2004)  2.7  7.2 2.7 7.2 0.4 1.2 
Cyprus  (Childhealth)  0.8  2.3 0.8 2.3 0.1 0.3 
Czech  Republic  (SISP04)  2.7  6.9 2.7 6.9 0.2 0.6 
Denmark (Danish Dietary Survey)  2.0  5.3  2.0  5.3  0.2  0.7 
France (INCA 2)  3.1  7.6  3.1  7.2  0.5  1.3 
Germany 
(National_Nutrition_Survey_II)  4.0  13.3 4.0 13.2 0.7  2.5 
Italy  (INRAN_SCAI_2005_06)  1.1  4.1 1.1 4.1 0.1 0.3 
Latvia  (EFSA_TEST)  2.1  5.6 2.1 5.6 0.3 0.9 
Spain  (AESAN_FIAB)  1.2  3.1 1.2 3.1 0.1 0.4 
Spain  (enKid)  2.4  6.3 2.4 6.3 0.2 0.6 
Spain  (Nut_Ink05)  3.1  8.0 3.1 8.0 0.5 1.5 
Sweden  (NFA)  3.5  9.5 3.5 9.5 0.3 0.9 
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   Aspartic acid  PHE  DKP 
   Mean  High level  Mean  High level  Mean  High level 
Adults 
Belgium  (Diet_National_2004)  3.8  14.0 3.8 14.0 0.7  2.8 
Czech  Republic  (SISP04)  1.1  3.4 1.1 3.4 0.1 0.3 
Denmark  (Danish_Dietary_Survey) 1.1  3.3 1.1 3.2 0.1 0.4 
Finland  (FINDIET_2007)  2.1  6.5 2.1 6.3 0.3 0.9 
France  (INCA2)  3.4  8.9 3.4 8.9 0.6 1.7 
Germany 
(National_Nutrition_Survey_II)  4.6  17.3 4.6 17.1 0.8  3.4 
Hungary  (National_Repr_Surv)  0.9  3.1 0.7 2.4 0.1 0.5 
Ireland  (NSIFCS)  3.1  8.2 3.1 8.2 0.5 1.1 
Italy  (INRAN_SCAI_2005_06)  0.9  3.1 0.9 3.1 0.1 0.3 
Latvia  (EFSA_TEST)  1.2  3.2 1.2 3.2 0.2 0.5 
The Netherlands (DNFCS_2003)  8.6  27.5  8.5  27.5  1.6  5.5 
Spain  (AESAN)  1.5  5.0 1.4 5.0 0.2 0.7 
Spain  (AESAN_FIAB)  0.8  2.5 0.7 2.5 0.1 0.3 
Sweden  (Riksmaten_1997_98)  2.3  5.9 1.6 4.1 0.4 1.0 
United Kingdom (NDNS)  4.3  20.6  4.2  20.0  0.8  4.1 
The elderly 
Belgium  (Diet_National_2004)  4.4  23.5 4.4 23.5 0.8  4.8 
Denmark  (Danish_Dietary_Survey) 0.8  2.6 0.8 2.6 0.1 0.2 
Finland  (FINDIET_2007)  1.4  4.7 1.3 4.7 0.2 0.8 
France  (INCA2)  2.8  11.3 2.8 11.3 0.5  2.0 
Germany 
(National_Nutrition_Survey_II)  4.1  18.7 4.1 18.7 0.8  3.8 
Hungary  (National_Repr_Surv)  0.5  1.5 0.4 1.4 0.1 0.2 
Italy  (INRAN_SCAI_2005_06)  0.8  2.7 0.8 2.7 0.1 0.3 
*  The different methodologies of European dietary surveys included in the EFSA Comprehensive Database are fully  
  described in the Guidance on the use of the EFSA Comprehensive European Food Consumption Database in Exposure  
  Assessment (EFSA, 2011b). A summary is available p.11, Table 1 of the guidance.  
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Appendix F.   Tables on acute toxicity studies on aspartame and DKP 
1.  Aspartame 
 Animals  Route  Dose  range  Reported Result  Comments and reference(s) 
Oral          
Rat  Male Sprague Dawley, Charles River 
(n=6/group) 
p.o. as 15-25 % 
suspension in 1 % 
Tween 80 
Up to 
5000 mg/kg 
No deaths within 7 
days at any dose 
Motor and behavioural activities 
unremarkable. Ref: E46, 1973 
Mouse  Male Sprague Dawley, Schmidt Ha/ICR  
(n=2 or 6/group) 
Rabbit  Male New Zealand White Luenberg 
(n=1 or 3/group) 
Intraperitoneal
/Intravenous         
Rat  Male Sprague Dawley, Charles River  
(n=6/group) 
i.p. in aqueous solution  Up to 
2033 mg/kg 
No deaths within 7 
days at any dose 
Motor and behavioural activities 
unremarkable. Ref: E46, 1973  Mouse  Male Sprague Dawley, Schmidt 11a/ICR  
(2 or 6/group) 
i.p. as 2 % aqueous 
suspension 
Up to 
1000 mg/kg 
Rat  
Male Charles River CD (n=6/group)  i.v. as 5 ml/kg bw of 
2 % aspartame in 0.9 % 
aqueous sodium 
chloride solution  
 100 mg 
No deaths up to 72 
hours post-injection  
Physical, opthalmoscopic, gross or 
microscopic parameters 
unremarkable. Phlebitis at site of 
implantation; kidney and 
endocardium  
inflammation. Ref: E84, 1974 
Dog 
Male Beagle (n=4/group)  i.v. as 5 ml injection of 
0.5 % aqueous sodium 
chloride solutions  
100 mg  No deaths up to 72 
hours post-injection  
Physical and biochemical 
parameters, ECC unremarkable. 
Ref: E85, 1974 
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2.  DKP 
 Strain  Route  Dose  range  Reported Result  Comments and reference(s) 
Oral          
Rat  Male Sprague Dawley, Charles River 
(n=6/group)  p.o. as 15-17.5 % 
suspension in 1 % 
Tween 80 (aqueous 2 % 
suspension for low 
doses) 
Up to 5000 
mg/kg 
No deaths within 7 
days at any dose 
Motor and behavioural activities 
unremarkable. Ref: E45, 1973 
Mouse  Male Sprague Dawley, Schmidt Ha/ICR 
(n=2 or 6/group) 
 
Rabbit  Male New Zealand White Luenberg 
(n=1 or 3/group) 
Intraperitoneal         
Rat  Male Sprague Dawley, Charles River 
(n=6/group) 
i.p. as 2% aqueous 
suspension 
Up to 1562 
mg/kg 
No deaths within 7 
days at any dose 
Motor and behavioural activities 
unremarkable. Ref: E45, 1973  
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Appendix G.   TABLES ON SHORT TERM AND SUBCHRONIC TOXICITY STUDIES ON ASPARTAME AND DKP 
1.  Aspartame 
Strain  Dose range   Duration  Reported Result  Comments and reference(s) 
Oral        
‘Young’ purebred beagles, 
7.2-13.2 kg (2M/2F per 
group) 
5/125 mg/kg bw/day 
via gelatine capsules 
8 weeks  100 % survival; variable 
pattern of body weight 
loss/maintenance/gain 
No consistent haematology, clinical chemistry or urinalysis 
findings; no consistent ocular findings; no gross pathology; no 
consistent effects on organ weights; no cytopathological 
changes. Refs: E21, 1969. 
Via diet        
Charles River CD rats, 7 wk 
old (5/sex per group) 
2000/4000/10 
000 mg/kg bw/day via 
diet; 
actual consumption 
within 10 % of planned 
4 weeks  100 % survival; no 
unequivocal effect on body 
weight or food consumption 
except decreased 
consumption in high dose 
females, wks 2-3. 
No adverse physical/behavioural changes; no treatment-related 
pathological changes except for clear, viscous fluid coating 
intestinal mucosa in treated rats. N.B. only examined 5 controls 
and all high dose animals; remaining animals were discarded. 
Refs: E3, 1972. 
Charles River CD rats, 
sexually mature (10/sex per 
group). Group allocation by 
stratified randomisation 
5/125 mg/kg bw/day 
via diet 
8 weeks  100 % survival; no 
unequivocal effect on body 
weight or food consumption 
At sacrifice, biochemistry and pathological examination was 
conducted on 5 animals from each dose and the control group. 
No signs of systemic toxicity or pharmacological effects. No 
treatment related changes in haematology or urinalysis; 
increased terminal blood sugar at 125 mg/kg bw/day but no 
other significant changes in clinical chemistry. Organ weights 
unaffected except for increased liver/body weight ratio in high 
dose males. No histopathological findings except bile duct 
hyperplasia/ pericholangitis in all groups. Refs: E20, 1969. 
Charles River CD rats, 
weanlings (5/sex per group) 
9:100 ratio in diet 
(aspartame) 
5:100 ratio in diet (Phe) 
9 weeks  Two deaths; one control 
male, one aspartame-treated 
male. Relative food 
consumption comparable 
between groups. No 
treatment-related effect on 
terminal body weight. 
No physical/behavioural abnormalities; no significant treatment 
related changes in haematology, clinical chemistry, urinalysis; 
no treatment-related changes in organ weight or pathological 
observations. Reduced body weight gain in treated groups, both 
compounds and both sexes; less marked in females than males. 
Refs: E4.   
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Ha/ICR mice, 8 wk old 
(5/sex per group) 
Planned: 2000, 4000, 
10 000 mg/kg bw/day 
via diet; 
Actual: 3000, 5000, 
13 000 mg/kg bw/day  
4 weeks  100 % survival; no 
unequivocal effect on body 
weight  
The actual intake of the test compound exceeded by 25-30 % in 
all dose groups, due to unforeseen increase in food 
consumption. No adverse physical/behavioural changes; no 
treatment-related pathological changes except for clear, viscous 
fluid coating intestinal mucosa in treated mice. N.B. only 
examined 5 controls and all high dose animals; remaining 
animals were discarded. Refs: E2, 1972.  
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2.  DKP 
Strain  Dose range  Duration  Reported Result  Comments  
Oral        
Charles River CD rats, 11 
wk old (10/sex per group) 
1000 mg/kg bw/day 
p.o. as 5 % aqueous 
suspension 
Daily for 
2 weeks 
100 % survival; no unequivocal 
effect on body weight 
No physical/behavioural changes; no treatment related changes 
in haematology, clinical chemistry, urinalysis; no treatment-
related pathological changes. Refs: E7, 1971. 
Ha/ICR mice, 4 wk old 
(10M per group) 
1000 mg/kg bw/day 
p.o. as 5 % aqueous 
suspension 
Daily for 
2 weeks 
100 % survival; no unequivocal 
effect on body weight 
No physical/behavioural changes; no treatment related changes 
in haematology, clinical chemistry, urinalysis; no treatment-
related pathological changes. Refs: E6, 1971. 
Via diet         
Charles River CD rats, 8 wk 
old (5/sex per group) 
1000/2000/4000/6000 mg/k
g bw/day via diet; 
actual consumption  
within 5 % of planned 
5 weeks  100 % survival; reduced body 
weight in high dose females due 
to reduced food consumption. 
No physical/behavioural changes; no dose-related changes in 
haematology, clinical chemistry, urinalysis; no dose-related 
changes in organ weight or treatment-related pathological 
changes. Evidence of colonic parasites, mild chronic bronchitis 
and mild chronic inflammation of liver and bile ducts. 
Refs: E8, 1972.  
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Appendix H.   TABLES ON GENOTOXICITY STUDIES ON ASPARTAME, METHANOL AND DKP
21 
1.  Aspartame genotoxicity studies in vitro 
Test system  Test Object  Doses  Reported Result  Comments and reference(s) 
Salmonella 
typhimurium 
Tester strains: 
TA1535,TA1537, 
TA1538, TA98, 
TA100 
Gene mutation  [μg/plate] 
10, 50, 100, 
500, 1000, 
5000 
 
Negative 
a)  Reported identity of test compound (SC-18862; Lot no.89300); non- 
GLP but well conducted and reported study; deviations from current 
OECD TG 471: Tester strains S. typhimurium TA102 or E. coli 
WP2uvrA bearing AT mutation were not used. 
Overall judgement: The methods implemented were thought to be 
sufficiently robust to support the results reported. Ref: E97, 1978 
Salmonella 
typhimurium  
Tester strains: 
TA1535, TA1537, 
TA1538, TA98, 
TA100 
Gene mutation  [μg/plate] 
10, 50, 100, 
500, 1000, 
5000 
 
 
Negative 
a)  Reported identity of test compound: SC-18862; Lot no.C-0096-
89300; 
Non-GLP but well conducted and reported study; Deviations from 
current OECDTG471: Tester strains (TA102 or WP2uvrA) bearing 
AT mutation were not used. 
Overall judgement: The methods implemented were thought to be 
sufficiently robust to support the results reported. Ref: E101 (1978) 
Salmonella 
typhimurium 
Tester strains: 
TA1535, TA1537, 
TA97, TA98, 
TA100 
Gene mutation  [μg/plate] 
100, 333, 
1000, 3333, 
10000 
 
Negative
 a) in TA1535, 
TA98, TA100  
Negative 
c) in TA1537; 
 Negative without S9 or 
with hamster liver S9 in 
TA97;  
TA97: small increases 
in mutant colonies with 
30 % rat liver S9 
GLP-study; Deviation from OECD 471: Tester strains S. 
typhimurium TA102 or E. coli WP2uvrA bearing AT mutation were 
not used; 
TA1337 was only assayed in the presence of S9 metabolism; 
Study authors judged small increase in mutant colonies with 30 % rat 
liver S9 as equivocal.  
Overall judgement: The methods implemented were thought to be 
sufficiently robust to support the results reported. Ref: NTP (2005) 
  
                                                      
21  Negative findings: the substance tested does not produce dose-related genotoxic effects in the test system compared to concurrent and/or historical controls. 
  Positive findings: the substance tested produces dose-related genotoxic effects in the test system compared to concurrent and/or historical controls. 
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Test system  Test Object  Doses  Reported Result  Comments and reference(s) 
Salmonella 
typhimurium 
Tester strains: 
TA98; TA100 
 
Gene mutation 
 
    [μg/plate] 
50, 100, 250, 
500, 1000, 
2000 
 
Negative 
a)  Major deviations from current OECD TG 471: Only two tester 
strains used; Highest dose-level employed was lower than 5 mg/mL; 
Second experiment performed was identical to the first one. 
Overall judgement: The methods implemented were thought not to 
be sufficiently robust to support the results reported. Ref: 
Rencuzogullari et al. (2004) 
 
Primary rat 
hepatocytes 
Unscheduled DNA 
Synthesis (UDS) 
5 and 10 mM  Negative  The study meets requirements of OECD TG 482 (1986). 
Overall judgement: The methods implemented were thought to be 
robust to support the results reported. Ref: Jeffrey and Williams 
(2000) 
Human lymphocyte  Chromosome 
aberrations (CA) 
0.5, 1.0 and 
2 mg/mLfor 
24 and 48 
hours 
performed 
only in the 
absence of S9 
metabolism 
Positive
 b)  Major deviations from current OECD TG 473, 479 and 487 for all 
studies conducted: Culture initiation and treatment schedule 
inappropriate; No treatment in the presence of S9 metabolism; No 
measurement of pH and osmolarity values. In addiction: For CA: 
Analyses of chromosomal aberrations performed mainly in M2 and 
M3 cells (Table 2); Method for scoring of aberrations do not refer to 
any published literature; CA do not exhibit a dose-response. For MN: 
Historical control range values not reported and used to accept 
validity of the study; MN formation concurrent with cytotoxicity 
(suggestive of indirect effects of aspartame); 
Overall judgement: The methods implemented were thought not to 
be sufficiently robust to support the results reported. Ref: 
Rencuzogullari et al. (2004) 
Sister chromatid 
exchanges (SCE) 
 Negative
 b) 
Micronuclei (MN)    Positive
 b) 
a)  With and without metabolic activation. 
b) Without  metabolic  activation. 
c)  With metabolic activation.   
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2.  Aspartame genotoxicity studies in vivo 
Test system  Test Object  Route  Doses  Reported 
Result 
Comments 
Rat 
Charles River 
CD strain 
15 males/group 
Dominant lethal 
assay 
Control 
(vehicle) and 
SC-18862: 
intragastric. 
Positive 
control 
(methyl 
methane 
sulphonate): 
i.p. 
0 (control), 
2000 mg/kg bw, 
two equally divided 
doses on single day 
(2 hour interval) 
Negative 
(paternal 
growth, 
maternal 
pregnancy rate, 
uterine and 
ovary 
examination 
data and 
incidence of 
fetal deaths) 
Reported identity of test compound: SC-18862, containing 0.2% 
DKP (SC-19192) 
No Guidelines available in 1973 (since 1984: OECD TG 478). 
Study protocol followed general recommendations 
Overall judgement: The methods implemented were thought to be 
sufficiently robust to support the results reported. Ref: E40 (1973)  
Rat 
Charles River 
CD strain 
15 males/group 
Dominant lethal 
assay 
Control 
(vehicle) and 
SC-18862: 
intragastric.Po
sitive control 
(methyl 
methane 
sulphonate): 
i.p. 
0 (control), 
2000 mg/kg bw, 
two equally divided 
doses on single day 
(2 hour interval) 
Negative 
(paternal 
growth, 
maternal 
pregnancy rate, 
uterine and 
ovary 
examination 
data and 
incidence of 
fetal deaths) 
Reported identity of test compound: SC-18862 containing 0.7% DKP 
(SC-19192); No Guidelines available in 1973 (since 1984: OECD 
TG 478). Study protocol followed general recommendations; 
Overall judgement: The methods implemented were thought to be 
sufficiently robust to support the results reported. Ref: E41 (1973) 
Rat 
Purina CD 
strain 
10 males /group 
Chromosome 
aberrations in 
bone-marrow 
erythrocytes 
Control 
(vehicle) and 
SC-18862: 
intragastric. 
Positive 
control 
(triethylene-
melamine): 
i.p. 
0 (control), 500, 
1000, 2000 and 
4000 mg/kg 
bw/day, given in 
three equally 
divided doses every 
three hours, for five 
consecutive days 
Negative  Reported identity of test compound: SC-18862, Lot#76040C, 
containing 0.7 % DKP; GLP: no statement, but well documented 
report; Deviations from current OECD TG 475: 50 spreads/rat 
instead of 100, but 10 instead of 5 rats.  
No mitotic index determination: ‘The mitotic index should be 
determined as a measure of cytotoxicity in at least 1000 cells per 
animal for all treated animals (including positive controls) and 
untreated negative control animals’. 
Overall judgement: The methods implemented were thought to be 
sufficiently robust to support the results reported. Ref: E43 (1972)  
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Test system  Test Object  Route  Doses  Reported 
Result 
Comments 
Rat 
Holtzman strain 
10 males/group 
Chromosome 
aberrationsin 
bone marrow 
erythrocytes and 
spermatogonial 
cells 
Oral 
(intragastric) 
0 (control), 400, 
800, 1200 and 
1600 mg/kg 
bw/day for five 
consecutive days 
1)Negative 
in bone marrow 
erythrocytes; 
2)Negative in 
spermatogonial 
cells 
Reported identity of test compound: SC-18862; Lot# A3427; Major 
deviations from current OECD TG 475: Sampling time selected 24 
hours + 5 hours; Colchicine (total 29 hours). It should have been 1.5 
cell cycle (12-18hours; The highest dose may also be defined as a 
dose that produces some indication of toxicity in the bone marrow 
(e.g. greater than 50 % reduction in mitotic index). In this study 
mitotic indices were not even scored; 50 metaphases per animal were 
scored. Dose-levels administered of test substance 0.4, 0.8, 1.2 and 
1.6 g/kg bw/day are different from those reported in the conclusion 
of report; The second positive control employed (cyclohexylamine) 
did not show positive results expected.  
Overall judgement: The methods implemented were thought not to 
be sufficiently robust to support the results reported. Ref: E12 (1970) 
Rat 
Purina CD 
strain 
10 males/group 
Host-mediated 
assay 
Control 
(vehicle) and 
SC-18862: 
oral. 
Positive 
control 
(dimethylnitro
samine): i.p. 
0 (control), 500, 
1000, 2000 and 
4000 mg/kg 
bw/day, given in 
three equally 
divided doses every 
three hours, for five 
consecutive days. 
Negative  Reported identity of test compound: SC-18862, Lot#76040C, 
containing 0.7 % DKP; No Guidelines available; Study protocol 
followed general recommendations. Single use of G-46 Salmonella 
typhimurium, tester strain strongly reduce the capability to identify 
different classes of genotoxins. 
Overall judgement: The methods implemented were thought to be 
sufficiently robust to support the results reported. Ref: E44 (1972) 
Mouse  
Sprague-
Dawley Ha/ICR 
Swiss strain 
10 males/group 
Host-mediated 
assay 
Oral 
(intragastric) 
0 (control), 1000, 
2000, 4000, 
8000 mg/kg 
bw/day three times 
daily at two hour 
intervals, for five 
consecutive days. 
Negative  Reported identity of test compound: SC.18862 Lot#76060R; No 
Guidelines available; Study protocol followed general 
recommendations; Single use of G-46 Salmonella typhimurium, 
tester strain strongly reduce the capability to identify different classes 
of genotoxins. 
Overall judgement: The methods implemented were thought to be 
sufficiently robust to support the results reported. Ref: E81 (1974)  
Mouse  
C57/black 
strain 
5 animals/group 
Chromosomal 
aberrations in 
bone marrow 
erythrocytes 
Oral  0 (control), 40 and 
400 mg/kg bw, 5 
days. 
Negative  Study is poorly reported. Concurrent positive control animal group to 
show whether the test system was functioning correctly was not 
included;  
Concurrent negative control group was included;   
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Test system  Test Object  Route  Doses  Reported 
Result 
Comments 
A minimum number of 100 metaphases per animal were scored; 
Dose-levels administered appear to be very low. Sampling of bone 
marrow cells 6 hours from last administration of test compound is 
not adequate for chromosomal aberration analysis.  
Overall judgement: The methods implemented were thought not to 
be sufficiently robust to support the results reported. Ref: Durnev et 
al. (1995) 
 
Mouse 
Swiss albino 
strain 
5 males/group 
Chromosome 
aberrations in 
bone marrow 
erythrocytes 
Oral 
(intragastric) 
ASP+Acesulfame 
K 
(3.5+1.5) mg/kg 
bw 
ASP+Acesulfame 
K 
(35+ 5) mg/kg bw 
ASP+Acesulfame 
K 
(350+15) mg/kg 
bw 
Negative  Study not relevant for evaluation of aspartame because aspartame 
was blended with acesulfame K. Ref: Mukhopadhyay et al. (2002) 
Rat 
Fisher 344/N 
strain 
5 males / group 
 
Micronuclei in 
bone marrow 
erythrocytes 
Oral 
(gavage) 
0 (control), 500, 
1000 or 
2000 mg/kg bw, 
3 times at 24 hour 
intervals. 
Negative  Lot 8415-14-02 RTI; Purity: > 98 %; GLP-study;  
Deviation from OECD TG 475: only male animals were used - 
Sampling time selected 24 h. It should have been 1.5 cell cycle (12-
18 hours). Cytotoxicity: %PCE not greatly altered but in slight 
decrease (60.8 to 39 %) in 1000 mg/kg group. 
Overall judgement: The methods implemented were thought to be 
sufficiently robust to support the results reported. Ref: NTP (2005).  
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Test system  Test Object  Route  Doses  Reported 
Result 
Comments 
Transgenic 
Mouse 
FVB/N-TgN (v-
Ha-ras)Led 
(Tg.AC) 
hemizygous 
15 males and  
15 
females/group 
Micronuclei in 
peripheral blood 
combined with 
carcinogenicity 
Oral 
(via diet) 
0, 3125, 6250, 
12500, 25 500, 
50 000 ppm for 9 
months 
Males: 490, 980, 
1960, 3960, 
7660 mg/kg bw 
Females: 550, 
1100, 2260, 4420, 
8180 mg/kg bw 
Negative  Lot 8415-14-02 RTI;Purity: > 98 %; GLP-study; 
Deviation from OECD 474 (use of transgenic animals covered by 
‘any appropriate species’): - study does not include positive control - 
Sampling time: authors refer to McGregor et al. (1990) but did not 
specify the actual time point. No evidence of carcinogenic activity in 
TgAc haplo insufficient male or female mice. 
Overall judgement: The methods implemented were thought to be 
sufficiently robust to support the results reported. Ref: NTP (2005). 
Transgenic 
Mouse 
B6.129-
Trp53
tm1Brd 
(N5) 
haploinsufficien
t  
15 males and 15 
females/group 
Micronuclei in 
peripheral blood 
combined with 
carcinogenicity 
Oral 
(via diet) 
0, 3125, 6250, 
12500, 25 500, 
50 000 ppm for 9 
months 
Males: 490, 970, 
1860, 3800, 
7280 mg/kg bw 
Females: 630, 
1210, 2490, 5020, 
9620 mg/kg bw 
 
3125 to 
25 500 mg/kg 
diet group: 
males and 
females 
negative 
50 000 mg/kg 
diet group: 
females judged 
to be positive 
based on a 
significantly 
increased 
frequency (x 
2.3) of 
micronucleated 
erythrocytes  
Lot 8415-14-02 RTI; Purity: > 98 %; GLP-study; 
Deviation from OECD 474 (use of transgenic animals covered by 
‘any appropriate species’): - study does not include positive control - 
Sampling time: authors refer to McGregor et al. (1990) but did not 
specify the actual time point. No evidence of carcinogenic activity in 
TgAc haploinsufficient male or female mice. 
Overall judgement: The methods implemented were thought to be 
sufficiently robust to support the results reported. Ref: NTP (2005) 
 
Transgenic 
Mouse 
Cdkn2a 
deficient 
Micronuclei 
in peripheral 
blood 
 
Oral 
(via diet) 
0, 3125, 6250, 
12500, 25500, 
50000 ppm for 9 
months. 
Negative 
 
Lot 8415-14-02 RTI; Purity: > 98 %; GLP-study; 
Deviation from OECD 474 (use of transgenic animals covered by 
‘any appropriate species’): study does not include positive control; 
sampling time: authors refer to McGregor et al. (1990) but did not 
specify the actual time point. No evidence of carcinogenic activity in  
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Test system  Test Object  Route  Doses  Reported 
Result 
Comments 
15 males and 15 
females/group 
 
  TgAc haploinsufficient male or female mice (no evidence: no 
chemical- related increases in malignant or benign neoplasms. 
Overall judgement: The methods implemented were thought to be 
sufficiently robust to support the results reported. Ref: NTP (2005) 
Mouse 
ddY strain 
4 males/group 
 
Comet assay in 
Stomach, colon, 
liver, kidney, 
bladder, lung, 
brain, bone 
marrow 
Oral 
(intragastric) 
2000 mg/kg bw  Negative in all 
organs assayed 
Deviations from minimum requirements: 1) Four animals used; 2) 
Only one dose-level employed (2000 mg/kg bw); 3) Two slides 
analysed (50 nuclei/slide); 4) Manual scoring: DNA migration was 
evaluated as the difference between length of the tail and diameter of 
the nucleus. 5) Isolated nuclei instead of whole cells were employed; 
6) Cell viability not reported; 7) the study does not include positive 
control. 
Overall judgement: The methods implemented were thought to be 
sufficiently robust to support the results reported. Ref: Sasaki et al. 
(2002) 
Mouse 
Swiss albino 
strain 
4 males/group 
 
Comet assay in 
bone marrow 
cells  
Oral 
(intragastric) 
0 (control), 7, 14, 
28 and 35 mg/kg 
bw 
Positive at 
higher dose-
level 
The study is generally poorly reported; Deviations from 
recommended protocol: 1) Insufficient number of cells scored (total 
of 50 cells/animal); 2) Historical control values not reported 
Overall judgement: The methods implemented were thought not to 
be sufficiently robust to support the results reported. Ref: 
Bandyopadhyay et al. (2008) 
Mouse 
Swiss albino 
strain 
(Number of 
animals not 
clearly 
reported) 
Micronuclei in 
bone-marrow 
erythrocytes 
Oral 
(intragastric) 
0 (control), 250, 
455, 500 and 
1000 mg/kg bw 
Positive  The study is generally poorly reported. Deviations from OECD TG 
474 guideline: 1) Number of animals employed is not reported; 2) 
The PCE/NCE ratio is described as ‘changed’ but no data are given 
3) No criteria for selection of higher dose-level. 4) no historical 
control data.  
Micronuclei in 
peripheral blood 
   Positive    
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Test system  Test Object  Route  Doses  Reported 
Result 
Comments 
  Chromosome 
aberrations in 
bone-marrow 
erythrocytes 
    Positive  Deviations from OECD TG 475: 1) Number of animals employed is 
not reported; 2) No mitotic indices scored; 3) Treatment with 
colcemid too short (1.5 hours instead of 3-5 hours); 4) Sampling 
times used (e.g. 24, 48 and 72 hous) not appropriate; 5) No criteria 
for selection of higher dose-level. 
Overall judgement: The methods implemented were thought not to 
be sufficiently robust to support the results reported. Ref: Kamath et 
al. (2010) 
Mouse 
Swiss albino 
strain 
(5 males/group) 
 
Chromosome 
aberrations in 
bone marrow 
erythrocytes 
Oral 
(intragastric)  
0 (control), 3.5, 35 
and 350 mg/kg bw 
Positive  Deviations from OECD TG 475 : 1) Insufficient number of cells 
scored; 2) Any supplementary information on cytotoxicity relevant 
for CA and SCE-analysis in the present experiment not given; 3) No 
positive control.:  
No Guidelines available. Number of cells scored (30 cells/animal for 
SCE ) insufficient for statistical analyss. 
Overall judgement: The methods implemented were thought not to 
be sufficiently robust to support the results reported. Ref. 
Alsuhaibani et al. (2010) 
SCE in bone-
marrow 
erythrocytes 
  
Negative 
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3.  Methanol genotoxicity studies in vitro 
Test system  Test Object  Doses Reported  Result  Comments 
Salmonella 
typhimurium 
Tester strains: 
TA1535, TA1537, 
TA1538, TA 98 
and TA100 
Gene mutation  No data. Various 
dilutions performed 
by geometric ratio 
starting from 
solubility or 
toxicity limit. 
Negative 
a)  Not assignable  
Survey of the capacity of 135 compounds incl. methanol. Concentration of 
test compound not given. Ref: DeFlora et al. (1984) 
E. coli  
Tester strains: 
WP2; WP2 (uvrA-, 
polA-); CM871 
uvrA-, recA-, lexA-
) 
DNA repair  No data. Various 
dilutions performed 
by geometric ratio 
starting from 
solubility or 
toxicity limit. 
a) Microtiter plate: 
negative
 a) 
b) 2-hour preincubation: 
without S9: negative; 
with S9: 1.5 to 2-fold 
increase: ‘weak positive’ 
c) spot-test: negative 
Not assignable 
Survey of the capacity of 135 compounds incl. methanol Concentration of 
test compound not given. Statement by MAK ( 1999): ‘As it was 
conceivable that the weak positive results obtained with methanol were 
caused by impurities, the authors classify methanol as an uncertain or 
questionable mutagen’ Ref: DeFlora et al. (1984) 
Neurospora 
Crassa 
 
Chromosome 
aberrations 
Not reported Negative  A study which included 57 compounds; No dose-levels for methanol 
reported; Test system not currently employed to detect aneugens. 
Overall judgement: The methods implemented were thought not to be 
sufficiently robust to support the results reported. Ref: Griffiths (1981) 
Salmonella 
typhimurium  
Tester strains: 
TA1535, TA1537, 
TA1538, TA98 
and TA100 
Gene mutation  No data  Negative 
(not described: with or 
without S9) 
Not assignable  
Not described: with or without S9as well as MeOH concentration. MeOH 
listed as one of 45 chemicals that gave negative results. No conclusion can 
be drawn from the publication. Ref: Simmon et al. (1977) 
Salmonella 
typhimurium 
Tester strains: 
TA1535, TA1537, 
TA1538, TA 98 
Gene mutation  5 doses up to 
3.6 mg/plate 
Negative
 a) Not  assignable 
Screening study on genotoxicity of 31 chemicals. Bacterial  
reverse mutation assay followed standard protocol of that time. No detailed 
results on methanol are reported. Deviations from current OECD Guideline 
471: - TA102, E. coli not included in the study - maximal concentration 
tested (3.6 mg/plate) lower than recommended - range, but not actual  
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Test system  Test Object  Doses Reported  Result  Comments 
and TA100 
 
concentration tested given. The study does not include positive control Ref: 
Gocke et al. (1981) 
Salmonella 
typhimurium 
Tester strains: 
TA1535, TA1537, 
TA1538, TA 98 
and TA100  
Gene mutation  2.5 mM/plate 
(733 µg/plate) 
Negative
 a)  DeFlora et al. (1981) cited from MAK-Liste - TA 102, E. coli not included. 
Ref: DeFlora et al. (1981) 
Salmonella 
typhimurium 
Tester strains: 
TA1535, TA1537, 
TA1538, TA 98 
and TA100 
Gene mutation  [µg/plate] 
5, 10, 50, 100, 500, 
1000, 5000 
Negative
 a)  Both in the absence and presence of rat liver S9 metabolism.  
Overall judgement: The methods implemented were thought to be 
sufficiently robust to support the results reported. Ref: Shimizu et al. (1985) 
E. coli  
Tester strain: 
WP2 uvrA 
Schizosaccharomy
ces pombe ade6-
60/rad10-198,h
- 
(P1 strain) 
Gene mutation  5 %  Negative 
a)   Non-GLP study; Material and methods described in sufficient details; use of 
mouse S10 metabolism; maximum concentration for mutagenicity test was 
based upon cytotoxicity at concentrations of 0.5, 2, 5 and 10 % (v/v); the 
study does not include positive control 
Overall judgement: The methods implemented were thought to be 
sufficiently robust to support the results reported. Ref: Abbondandolo et al. 
(1980) 
Aspergillus 
nidulans (diploid 
strain P1) 
Chromosome 
aberrations 
5.2, 5.6, 6, 7 % 
(v/v) 
Positive 
b) 
Cross over: negative 
b) 
Non-GLP study; Material and methods described in sufficient details; 
Exposure to test compound during early germination; No use of metabolic 
activation; Aneuploids (non-disjunctional diploids and haploids) at toxic 
concentration 5.6 and 6 % MeOH (survival: 19 and 10 %, respectively). 
Overall judgement: The methods implemented were thought to be 
sufficiently robust to support the results reported. Ref: Crebelli et al. (1989) 
Salmonella 
typhimurium  
Tester strains: 
TA1535, TA1537, 
Gene mutation 
(Pre-incubation) 
 
[µg/plate] 
10, 50, 100, 500, 
1000, 5000 
Negative 
a)  No GLP-statement; Deviation from OECD TG 471: - no historical control 
data  
Overall judgement: The methods implemented were thought to be 
sufficiently robust to support the results reported. Ref: NEDO (1987)  
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Test system  Test Object  Doses Reported  Result  Comments 
TA1538, TA 98 
and TA100 
E. coli  
Tester strain: 
WP2 uvrA 
Chinese Hamster 
lung fibroblasts 
(V79 cells) 
 
Gene mutation 
(azaguanine, 6-
thioguanine, 
ouabain) 
15.8, 31.7, 47.4, 
63.3 mg/mL 
exposure: 3 hours 
Negative
 a)  63.3 mg/mL inhibit cell colony formation by approximately 70 %; Mutant 
selection after 6 days;  
No GLP-statement; Deviation from OECD TG 476: - no historical data - 
concentration of methanol exceeded the maximum concentration 
recommended in in vitro studies (i.e. 5 mg/mL); 
Overall judgement: The methods implemented were thought not to be 
sufficiently robust to support the results reported. Ref: NEDO (1987) 
Chromosomal 
aberration 
7.1, 14.3, 
28.5 mg/mL for 2 
days 
Negative
 a)  28.5 mg/mL inhibit cell growth by approximately 50 %; Chromosome 
preparation at 6, 24, 48 hours after treatment; 200 cells/dose-level scored; 
No GLP-statement; Deviations from OECD TG 473: - treatment schedule 
and sampling times; - no cytotoxicity measured (mitotic index, cell counts 
or degree of confluence); - no historical data - concentration of methanol 
exceeded the maximum concentration recommended in in vitro studies (i.e. 
5 mg/mL); 
Overall judgement: The methods implemented were thought not to be 
sufficiently robust to support the results reported. Ref: NEDO (1987) 
Chinese Hamster 
lung fibroblasts 
(V79 cells) 
 
Sister 
chromatid 
exchanges 
(SCE) 
7.1, 14.3, 
28.5 mg/mL 
7.1, 14.3 mg/mL   
negative
 a) 
 28.5 mg/mL: 
without S9: positive 
with S9: negative 
Highest concentration (28.5 mg/mL) SCE-incidence of 9.41 ± 0.416 
significantly greater than controls 6.42 ± 0.227 [mean ± SE per 100 cells]); 
Sampling: 24-26 after treatment; 100 cells/dose level scored; No GLP-
statement; Deviation from OECD TG 479: - no duplicate cultures - no 
cytotoxicity measured (mitotic index, cell counts or degree of confluence) - 
concentration of methanol exceeded the maximum concentration 
recommended in in vitro studies (i.e. 5 mg/mL); 
Overall judgement: The methods implemented were thought not to be 
sufficiently robust to support the results reported. Ref: NEDO (1987)  
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Test system  Test Object  Doses Reported  Result  Comments 
E. coli (SA500)  Gene mutation 
(forward 
mutation) 
23-31 %  Negative  Study focussed on ethanol: Methanol was included for comparison. 
Methanol concentrations above 23 % were cytotoxic, reducing survival of 
the cells to less than 40 %. A 23 % methanol solution produced no 
mutagenic effects; cell survival was 53 %. However, assay performed with 
one E. coli strain E. coli (SA 500) as well as in the absence of metabolic 
activation system only. 
Overall judgement: The methods implemented were thought not to be 
sufficiently robust to support the results reported. Ref: Hayes et al. (1990)  
MCF-7 and HepG2 
cells 
 
Activation of 
the p53R2 gene 
Negative 
 
Assay based on chemical activation of the p53R2 gene as assessed by the 
incorporation of a p53R2-dependent luciferase reporter gene into human 
cells (MCF-7 and HepG2). The Panel considered this study ‘reliable’ but 
not suitable for the present evaluation, because P53R2 gene is activated by 
DNA damage induced by ionizing radiation, UV light, including adriamycin 
but not by general chemical mutagens.  
Overall judgement: The methods implemented were thought to be 
sufficiently robust to support the results reported. Ref: Ohno et al. (2005) 
Mouse lymphoma 
L5178Y(Tk+/Tk-) 
Gene mutation  5-50 µL/mL 
(approx. 3.95-
39.5 mg/mL) 
Negative 
b) 
Positive 
c) 
 
Significant increases in mutation frequency were observed at increased 
concentrations of S9. However, the lowest concentration tested (5 μL/mL) 
exceeded in terms of molarity (13.4 M) the maximum concentration 
recommended in OECD TG 476 (5 mg/mL, 5 μL/mL, or 0.01 M, whichever 
is the lowest). Therefore, indirect effects due to non-physiological culture 
conditions cannot be excluded. 
Overall judgement: The methods implemented were thought not to be 
sufficiently robust to support the results reported. Ref: McGregor et al. 
(1985, 1988) 
Saccharomyces 
cerevisiae 
(ATCC26422) 
Gene mutation  2-8 %  Negative 
b) 
 
Methanol (2-8 %) was assessed for induction of gene mutations in 
Saccharomyces cerevisiae ATCC26422 as a control culture within a study 
aimed at elucidating the effects of ethidium bromide. Methanol did not 
induce gene mutations, but was tested without metabolic activation system 
only. The Panel considered the study as ‘not reliable’ in view of assessing 
the genotoxic potential of methanol. 
Overall judgement: The methods implemented were thought not to be 
sufficiently robust to support the results reported. Ref: Hamada et al. (1988)  
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Test system  Test Object  Doses Reported  Result  Comments 
E. coli WP2 (λ) Prophage-
induction 
0.15, 0.31, 0.62, 
1.25, 2.5, 5 % 
Negative
 a)  Materials and methods described in sufficient details; In two independent 
experiments MeOH was tested up to toxic concentrations. 
Overall judgement: The methods implemented were thought to be 
sufficiently robust to support the results reported. Ref: De Marini et al. 
(1991) 
Chinese hamster 
(V79 cells) 
Sister 
chromatid 
exchanges 
(SCE) and 
micronuclei 
50 µL/mL  Negative  Treatment: single dose-level (50 µL/mL) which was 10 times greater than 
the maximum recommended dose-level to be used in in vitro studies (e.g. 
5 µL/mL) to keep culture physiological conditions; Assayed in the absence 
of S9 only; Treatment time: 48 hours, which was exceedingly long 
compared to 1.5-2 cell cycle length recommended by OECD TG 487. 
Overall judgement: The methods implemented were thought not to be 
sufficiently robust to support the results reported. Ref: Lasne et al. (1984) 
a)  With and without metabolic activation. 
b) Without  metabolic  activation. 
c)  With metabolic activation.  
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4.  Methanol genotoxicity studies in vivo 
Test system  Test Object  Route  Doses  Reported Result  Comments 
Mouse 
(Pregnant CD-1 
females) 
Micronuclei in 
peripheral 
blood 
reticulocytes  
Oral 
(intragastric) 
2500 mg/kg twice a 
day from GD 6 to GD 
10 
Negative both in blood 
of foetuses or mothers 
Only one dose-level assayed; Blood samples were collected 
eight days after last administration of compound but normal 
procedure indicate sampling not later than 72 hours; The 
frequency of MN in maternal and fetal reticulocytes was 
similar among the groups; the frequency of MN was not 
associated with either maternal or fetal hepatic folate 
concentrations. Furthermore, no significant difference in the 
frequency of MN in reticulocytes of foetuses that were 
affected by malformations compared to foetuses without 
malformations. The study does not include positive control. 
Overall judgement: The methods implemented were thought 
not to be sufficiently robust to support the results reported. 
Ref: Fu et al. (1996) 
Mouse 
ICR strain  
6 males/group 
Micronuclei in 
bone marrow 
erythrocytes 
Oral  1050, 2110, 4210, and 
8410 mg/kg bw, single 
dose 
Negative  GLP-study; Deviation from OECD TG 475: - only male 
animals were used - only one sampling time selected 
Overall judgement: The methods implemented were thought 
to be sufficiently robust to support the results reported. Ref: 
NEDO 1987 
Rats Hydroxymethyl 
DNA adducts 
Oral   500 mg/kg per day for 
5 days (stable isotope 
labelled methanol) 
Labelled DNA adducts 
lower than the number 
of endogenous 
hydroxymethyl DNA 
adducts in all tissues 
Concerns about the lower number of exogenous 
hydroxymethyl DNA adducts measured in the analysed 
tissues of rats following administration of [
13CD4]-methanol 
at 500 mg/kg bw for 5 days compared to the number of 
endogenous hydroxymethyl DNA adducts. The isotope effect 
factor employed was the mean of several widely varied 
published values. Furthermore, the measurements of N-
hydroxymethyl-dG and dA adducts was not direct but 
required an in vitro reduction process with NaCNBH3 to the 
corresponding N-methyl derivative. The measurements of 
endogenous N-hydroxymethyl-dA adducts in the untreated 
animal group and in methanol treated group at 500 mg/kg bw 
for 5 days were rather variable. The study does not include 
positive control  
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Test system  Test Object  Route  Doses  Reported Result  Comments 
Overall judgement: The methods implemented were thought 
not to be sufficiently robust to support the results reported. 
Ref: Lu et al., 2012 
Drosophila 
melanogaster 
wild type and 
Basc strains 
Sex-linked 
lethal 
mutations 
  1000 mM  Negative  Ref: Gocke et al. (1981) 
Mouse Chromosomal 
aberrations  
Oral  1000 mg/kg  Positive  Not assignable 
Increased the incidence of chromosomal aberrations 
(particularly aneuploidy and exchanges and the micronuclei 
of polychromatic erythrocytes). Results of the study were 
available as an abstract only. The study does not include 
positive control Ref: Pereira et al., 1982 
Mouse 
B6C3F1 strain 
15 males/group 
 Oral 
(gavage) 
  Increase in structural 
chromosome 
aberrations [exchanges 
(Robertsonian 
translocations) and 
aneuploidy; no breaks] 
Deviations from current OECD TG 475: - one dose only - one 
time point only - mitotic indices not determined. Significant 
increases in chromosome aberrations [exchanges 
(Robertsonian translocation), aneuploidy] in male B6C3F1 
were reported. However, concurrent vehicle control showed 
10 exchanges out 665 cells scored and chromatid and 
chromosome exchanges are not expected in healthy animals. 
Overall judgement: The methods implemented were thought 
not to be sufficiently robust to support the results reported. 
Ref: Ward et al. (1983) 
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5.  In vivo genotoxicity studies by other routes of exposure (inhalation and intraperitoneal administration) 
Test system  Test Object  Route  Doses  Reported Result  Comments 
Mouse  
C57black/6J 
10 males/group 
Micronuclei, SCE  Inhalation  0, 800, or 4000 ppm (0, 
1048, and 5242 mg/m
3) 
methanol, 6 hours/day, 
for 5 days 
Endpoints: 1. blood cells: 
micronuclei (MN) 2. 
excised lung cells: 
Chromatid Exchanges 
(SCEs), Sister 
chromosomal aberrations 
(CA) and micronuclei 
(MN), 3. excised testicular 
germ: synaptonemal 
damage. All endpoints 
studied gave negative 
results 
Inhalation route of administration not 
relevant for evaluation of aspartame. 
The study does not include positive 
control. However, the study may be 
used for weight-of-evidence approach. 
Overall judgement: The methods 
implemented were thought to be 
sufficiently robust to support the results 
reported. Ref: Campbell et al. (1991) 
Mouse 
male CD-1  
DNA damage 
(8-oxodG)  
Intraperitoneal 
1 x 2000 mg/kg bw  No increase of 8-oxodG at 
6 and 24 h in bone 
marrow, spleen lung, 
kidney of any species 
Limit dose of 2000 mg/kg bw MeOH 
based on guidelines established for the 
comet assay developed in accordance 
with the in vivo genetic toxicology 
guidelines of (OECD. Valid study but 
because of i.p. route of administration 
study considered not relevant for 
present evaluation of aspartame. 
However, the study may be used for 
weight-of-evidence approach. 
Overall judgement: The methods 
implemented were thought to be 
sufficiently robust to support the results 
reported. Ref: McCallum et al. (2011a; 
2011b)  
Mouse 
male CD-1 
Chronic 15 x 2000 mg/kg 
(one dose per day) 
Mouse 
male CD-1 mice 
OGG1 (-/-) 
1 x 2000 mg/kg bw 
Rabbit 
male New Zealand white 
(NZW)  
1 x 2000 mg/kg bw 
Monkey 
male(Macaca 
fascicularis) 
1 x 2000 mg/kg bw 
Mouse 
Swiss-Webster 
10 males/group 
Micronuclei  Intraperitoneal  300, 600, 1200 or 2500 
mg/kg b w on 4 
consecutive days 
Negative  Ref: US EPA 1991  
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Test system  Test Object  Route  Doses  Reported Result  Comments 
Mouse 
NMRI strain  
2 males and 2 
females/group 
Micronuclei in 
Bone-marrow 
erythrocytes 
Single 
intraperitoneal 
injection 
1920, 3200, 4480 mg/kg 
bw 
Negative  Overall judgement: The methods 
implemented were thought to be 
sufficiently robust to support the results 
reported. Ref: Gocke et al. (1981) 
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6.  DKP genotoxicity studies in vitro 
Test system  Test Object  Doses  Reported Result  Comments 
Salmonella 
typhimurium  
Tester strains: 
TA1535 TA1537 
TA1538, TA98 and 
TA100 
Gene mutation 
(plate incorporation) 
10 to 
5000 μg/plate 
Negative   Reported identity of test compound: SC19192; Lot# TJT-12-32; 
Deviations from current OECD Guideline: 1) Tester strains (TA102 or 
WP2uvrA) bearing AT mutation were not used; 2) Second experiment 
performed was identical to the first performed.  
Overall judgement: The methods implemented were thought to be 
sufficiently robust to support the results reported. Ref: E98 (1978) 
Salmonella 
typhimurium  
Tester strains: 
TA1535, TA1537, 
TA1538, TA98 and 
TA100 
Gene mutation 
(plate incorporation with 
and without metabolic 
activation) 
50 to 
10 000 µg/plate 
Negative   SC-19192, Lot TJT- 12-32. It meets requirements of previous version of 
OECD Guideline (OECD TG 471, adopted 26 may 1983); Deviations 
from current OECD TG 471: Tester strains S. typhimurium TA102 or E. 
coli WP2uvrA bearing AT mutation were not used; 
Second experiment performed was identical to the first performed. 
Overall judgement: The methods implemented were thought to be 
sufficiently robust to support the results reported. Ref: E106 (1978)  
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7.  DKP genotoxicity studies in vivo 
Test system  Test Object  Route  Doses  Reported 
Result 
Comments 
Rat 
10 males 
/group 
Chromosome 
aberrations in 
bone marrow 
erythrocytes 
Oral 
(intragastric) 
(10% 
suspension in 
tween-
80/water) 
0 (control), 250, 500, 
1000 and 2000 mg/kg 
bw/day for 5 
consecutive days, 
given in three equally 
divided daily doses 
Negative  Reported identity of test compound: SC-19192; Lot# 3R-A-7273; 
Deviations from current OECD TG 475: Sampling time selected 24 h; 
The highest dose may also be defined as a dose that produces some 
indication of toxicity in the bone marrow (e.g. greater than 50 % 
reduction in mitotic index). In this study mitotic indices were not even 
scored;50 metaphases per animal were scored; 
Overall judgement: The methods implemented were thought to be 
sufficiently robust to support the results reported. Ref: E30 (1972)  
Rat 
10 
males/group 
Host-
mediated 
assay 
Oral 
(intragastric) 
0 (control), 250, 500, 
1000, 2000 mg/kg 
bw/day, three equally 
divided doses for five 
consecutive days. 30 
minutes after the final 
dose, the animals 
were inoculated with 
Salmonella 
typhimurium, G-46, 
by intraperitoneal 
injection. Three hours 
later the bacteria were 
recovered and the 
peritoneal washing 
was evaluated for the 
presence of mutants. 
Negative  Reported identity of test compound: SC-19192; Lot# 3R-A-7273; No 
Guidelines available; Study protocol followed general 
recommendations; Single use of G-46 Salmonella typhimurium, tester 
strain strongly reduce the capability to identify different classes of 
genotoxins. 
Overall judgement: The methods implemented were thought to be 
sufficiently robust to support the results reported. Ref: E31 (1972)   
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Test system  Test Object  Route  Doses  Reported 
Result 
Comments 
Mouse 
 
Ha/ICR Swiss 
strain 
10 
males/group 
Host-
mediated 
assay 
Oral 0  (control),  1000, 
2000, 4000, 
8000 mg/kg bw/day, 
given in three equally 
divided doses at two 
hour intervals for five 
consecutive days 
low and mid dose: 
10 % DKP suspension 
(1 % aqueous Tween-
80) 
high and very high 
dose: 15 % DKP 
suspension (1 % 
aqueous Tween-80). 
Negative  Reported identity of test compound: SC-19192; Lot#6-R); 
Approximately 30 min. after the final dose, the animals were 
inoculated (i.p.) with Salmonella typhimurium ( G-46), 
intraperitoneally. Three hours later the bacteria were recovered and the 
peritoneal washing was evaluated for the presence of mutants. 
2000 mg/kg bw/day: 1 of 10 animals died (compound in lung). 
4000 mg/kg bw/day: 2 of 10 animals died: one animal with diarrhoea, 
dehydration, other animal blood clot (unknown cause). 8000 mg/kg 
bw/day: diarrhoea, dehydration, 70 % mortality. 1000 mg/kg bw/day: 
discrepancy between number of survivors given in tab. 1 (n=10) and 
results shown in tab. 2,3 (n=7). Furthermore, this group differed 
significant from controls (tab. 2,3). Both points are not addressed by 
the authors. 
Overall judgement: The methods implemented were thought not to be 
sufficiently robust to support the results reported. Ref: E82 (1974) 
Rat Dominant 
lethal assay 
Oral 
(intragastric) 
1000 mg/kg bw/day 
given in two equally 
divided doses on 
single day. 
Negative (paternal 
growth, maternal 
pregnancy rate, 
corpora lutea and 
implantation 
sites). 
Implantation sites 
were sub-
classified as: 1) 
Viable fetal 
swelling; 2) Early 
fetal deaths; 3) 
Late fetal deaths. 
Reported identity of test compound: SC-19192; Lot# A6906; No 
Guidelines available; Study protocol followed general 
recommendations; 
Overall judgement: The methods implemented were thought to be 
sufficiently robust to support the results reported. Ref: E42 (1973)   
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Appendix I.   TABLES ON REPRODUCTIVE AND DEVELOPMENTAL TOXICTY STUDIES ON ASPARTAME 
Species Endpoint  Doses  tested 
(mg/kg 
bw/day) 
Animals 
per group 
NOAEL 
(mg/kg 
bw/day) 
Observed adverse effects at 
higher dose(s) in pups 
Observed adverse 
effects in mothers 
(dose) 
Comments 
Mouse Embryotoxicity 
and 
teratogenicity 
(Segment 2) 
0, 1000 
(1400)
a), 2000 
(2700), 4000 
(5700) (diet) 
F:36,36,36,
36 
4000 N/A
b)  None  Pregnant animals: 27,25,27,21. 
Study E89, 1975 
Rat Embryotoxicity 
and 
teratogenicity 
(Segment 2) 
0, 2000 (2000), 
4000 (4100) 
(diet) 
F:30,30,30 4000 
(4100) 
N/A Decreased  feed 
consumption (high 
dose) 
Pregnant animals: 24,26,23. Study 
E5, 1970 
Rat Peri-  and 
postnatal 
development 
(Segment 3) 
0, 2000 (1800), 
4000 (3600) 
(diet) 
M/F:20,20,
20 
2000 
(1800) 
Transient effects on renal tubuli 
that were not observed in an 
extra group of pups examined 
at or shortly after weaning 
None  This study is a evaluation of F2A 
pups of study E11 on PP 5,15, 21. 
Study E9, 1972 
Rat   Reproductive 
performance 
and 
development 
(Segment 1) 
0, 2000 (2400), 
4000 (4900) 
(diet) 
F: 48,30,30 
M:14,14,14 
4000 
(4900) 
N/A  Mild but statistically 
significant decrease 
in bw during 
gestation but feed 
consumption 
unaffected (high 
dose) 
Exposure: M, 64 days PM
d; F: 14 
days PM, gestation, lactation; half F 
sacrificed GD 13, half allowed to 
litter. Study E10, 1972 
Rat Two-generation 
reproductive 
study 
0, 2000 (1800), 
4000 (3700) 
(diet) 
P1: 
F: 24,24,24 
M: 12,12,12 
P2:  
F: 19,20,20 
M: 10,10,10 
2000 
(1800) 
BW suppression and smaller 
size of pups at weaning 
(statistically significant) 
None Study  E11,  1971 
Rat Peri-  and 
postnatal 
development 
0, 2000 (2000), 
4000 (4000) 
(diet) 
F: 30,30,30  2000 
(2000) 
Number of viable pups per 
litter at birth and at weaning 
decreased (statistically 
Decreased bw at GD 
21 (low and high 
dose) and PP day 21 
GD 14- lactation d21. Study E39, 
1973  
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Species Endpoint  Doses  tested 
(mg/kg 
bw/day) 
Animals 
per group 
NOAEL 
(mg/kg 
bw/day) 
Observed adverse effects at 
higher dose(s) in pups 
Observed adverse 
effects in mothers 
(dose) 
Comments 
(Segment 3)  significant); no effect on bw.  (high dose) 
 
Rat Peri-  and 
postnatal 
development 
(Segment 3) 
0, 2000 (2500), 
4000 (4400) 
(diet) 
F:24,24,24 2000 
(2500) 
BW suppression of pups at 
birth (statistically significant) 
and weaning (not significant). 
Pup number increased but 
survival significantly 
decreased. Incomplete eyelid 
opening in 5/164 pups and lens 
opacity in 2/164 pups. 
Decreased bw during 
lactation 
GD 14- lactation d21. Study E47, 
1973 
Rat Peri-  and 
postnatal 
development 
(Segment 3) 
0, 2000 (1800), 
4000 (4000) 
(diet) 
F: 30,30,30  2000 
(1800) 
BW suppression of pups at 
birth (statistically significant) 
and weaning (not significant). 
Pup survival significantly 
decreased. Incomplete eyelid 
opening in 2/79 pups. 
Decreased feed intake 
at PP day 21 (high 
dose) and reduced bw 
at PP day 21 and 
during lactation (high 
dose). 
GD 14- lactation d21. Study E48, 
1973 
Rabbit Embryotoxicity 
and 
teratogenicity 
(Segment 2) 
0, 2000 (1880), 
4000 (1870) 
(diet) 
F: 16,16,16  2000 
(1880) 
Serious congenital anomalies in 
the ‘high’ dose group: Cleft 
palate, microstomia, open eyes, 
digital malformations; 
decreased fetal weight (by 
25 %). 
Severe depression 
(> 50 %) in feed 
consumption  
GD 6-19(morning); pregnant 
animals: P:14,16,16; aborted: 2,1,3. 
Study E54, 1974 
Rabbit Embryotoxicity 
and 
teratogenicity 
(Segment 2) 
0, 1000 (840), 
2000 (1450), 
4000 (1260) 
(diet) 
F: 14,14, 
14,14 
2000   N/A  Significant 
depression of feed 
consumption (35 %) 
in high dose. 
Abortions (17 %) in 
the high dose group. 
GD 6-19(morning); pregnant 
animal: 12,14,14,13 
Deaths: 0,1,1,0 
Abortions: 0,0,0,2 
Premature deliveries: 1,0,0,0. Study 
E53, 1973 
Due to insufficient amount of test 
compound not all animals were fed 
the correct diets.  
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Species Endpoint  Doses  tested 
(mg/kg 
bw/day) 
Animals 
per group 
NOAEL 
(mg/kg 
bw/day) 
Observed adverse effects at 
higher dose(s) in pups 
Observed adverse 
effects in mothers 
(dose) 
Comments 
Mid dose decreased number of 
fetuses 
Rabbit Embryotoxicity 
and 
teratogenicity 
(Segment 2) 
0, 2000 (670), 
3000 (1350), 
4000 (1160) 
(diet) 
F:15,15,15,
15 
4000 
(1160) 
N/A Feed  consumption 
decreased by up to 
29% in the high dose 
group.  
GD 6-19(morning); pregnant 
animals: 12,13,10, 12 
Deaths: 1,0,0,0,0 
Abortions: 2,2,1,0 
Premature deliveries: 1,1,0,0. Study 
E55, 1973 
Rabbit Embryotoxicity 
and 
teratogenicity 
(Segment 2) 
0, 1000 (1100), 
2000 (1900) 
(diet) 
F:30,30,30  2000  N/A  None  GD 6-19(morning); pregnant 
animals: 26,23,25 
Deaths: 0,1,3 
Abortions: 0,0,0 
Premature deliveries: 1,1,1 
Control group was pair-fed; High 
dose 3 fetuses of one litter open eye 
(considered by the authors as minor 
malformations). Study E62, 1973 
Rabbit Embryotoxicity 
and 
teratogenicity 
(Segment 2) 
0, 1400 (1380), 
2400 (2360) 
(diet) 
F: 26, 26, 
26 
2400 N/A
b)   Study  E63,  1973 
Rabbit Embryotoxicity 
and 
teratogenicity 
(Segment 2) 
0, 2000 
(intragastric) 
F:12,36 2000  N/A
c)  Study confounded by 
poor health and 
gastric intubation 
technique issues; high 
GD 6-18; pregnant animals: 5,11 
Deaths: 4,9 
Abortions: 1,2 
Feed consumption: control  
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Species Endpoint  Doses  tested 
(mg/kg 
bw/day) 
Animals 
per group 
NOAEL 
(mg/kg 
bw/day) 
Observed adverse effects at 
higher dose(s) in pups 
Observed adverse 
effects in mothers 
(dose) 
Comments 
maternal mortality; 
depression of feed 
consumption by 40% 
compensated by pair-
feeding of controls. 
21.2 g/kg; treated group 34.6 g/kg. 
Very low pregnancy rate. Authors 
mention infectious pulmonary 
disease and dosing errors. No 
malformations. Study E51, 1973 
Rabbit Embryotoxicity 
and 
teratogenicity 
(Segment 2) 
0, 2000 
(intragastric) 
F:24,72  2000  N/A  Study confounded by 
poor health and 
gastric intubation 
technique issues; 
pregnancy rate 
decreased in high 
dose group; 
depression of feed 
consumption by up to 
62% compensated by 
pair-feeding of 
controls. 
GD 6-18; NP animals: 3,25 
Deaths: 1(NP), 6 (P) + 6 (NP) 
Abortions: 3,0 
Controls had lower bw and fetal 
weight; increased no. of 
resorptions: 0.7 vs. 1.6 (not 
significant); historical control 0-1.1. 
Study E52, 1973 
 
Rabbit 
 
Embryotoxicity 
and 
teratogenicity 
(Segment 2) 
 
0, 750, 2000 
(intragastric) 
 
F: 32,37,95 
 
750 
 
Major malformations in 7 
fetuses of high dose group  
 
 
Study confounded by 
poor health and 
gastric intubation 
technique issues; 
pregnancy rate 
decreased in high 
dose group; 
depression of feed 
consumption by up to 
37% compensated by 
pair-feeding of 
controls. Increased 
no. of resorptions 0.9 
vs 0.5 in controls and 
decreased no. of live 
fetuses (high dose) 
 
GD 6-18; pregnant animals: 
27,25,61 
Deaths: 3,5,9 
Abortions: 3,0,0 
Premature deliveries:1,1,0 
Implantation scars at C-section: 
5,1,16. Study E79, 1974 
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Species Endpoint  Doses  tested 
(mg/kg 
bw/day) 
Animals 
per group 
NOAEL 
(mg/kg 
bw/day) 
Observed adverse effects at 
higher dose(s) in pups 
Observed adverse 
effects in mothers 
(dose) 
Comments 
 
Rabbit Embryotoxicity 
and 
teratogenicity 
(Segment 2) 
0, 500, 1000, 
2000 
(intragastric) 
F: 50,50,50 
(52),50 
1000  Decreased pup weight and 
skeletal abnormalities at the 
high dose only. 
A 67% decrease in 
feed intake and up to 
a 15% bw decrease 
(GD 22) at the high 
dose; high incidence 
of abortions in the 
high dose group that 
correlated with the 
severity in feed 
intake decrease in 
individual animals. 
GD 6-18; pregnant animals: 
42,46,48,37 
Deaths: 4,4,1,4. 
NP: 8,4,4,13 
Abortions: 0,2,0,24 
Premature deliveries: 3,0,1,0 
High number of abortions; 
Increased no. of resorptions (not 
significant). Study E90, 1975 
 
a)   In brackets, dose level consumed  
b)   N/A, Not applicable, (NOAEL was at the highest dose tested) 
c)   Study based on small number of animals. 
d)   Abbreviations: PM, pre-mating; F, female; M, male; GD, gestation day; G, gestation; L, lactation, P, pregnant; NP, non-pregnant  
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Appendix J.   Tables on human studies (unpublished and published) reporting phenylalanine and aspartate levels after aspartame dosing 
Subjects/Study  Doses   Duration  Plasma Phe  Plasma Aspartate   Comments 
HEALTHY          
 SINGLE  DOSE         
One 12 year-old healthy 
male and one 15-year old 
healthy female 
Loading dose of 
34 mg/kg bw 
aspartame; 2 
weeks later: 
equivalent 
amount of Phe 
(19 mg Phe/kg).  
  No significant differences reported.  NR  E66, 1973. Tolerance of loading 
doses of aspartame by normal 
adolescent. 
6 healthy males and 6 
healthy females /cross 
over 
 
Loading dose of 
34 mg/kg bw 
aspartame; 
equivalent 
amount of 
aspartate (13 
mg/kg).  
 
 
Increased from 5-6  μmol/dL 
(normal fasting level) to 
120 ± 30 μmol/L (after aspartame 
load), within normal postprandial 
range. Returned rapidly to normal.  
 
Unchanged (2-8 μmol/L). 
 
 
6 healthy lactating 
females/cross over 
 
Loading dose of 
50 mg/kg bw 
either aspartame 
or lactose. 
 
  Increased to peak value of 162 ± 49 
μmol/L (after aspartame load only), 
only slightly higher than those 
noted postprandially (120 ± 30 
μmol/L). 
 
Unchanged 
 
Small increases in breast milk 
aspartate and Phe to postprandial 
range. 
E93, 1977. Effect of aspartame 
loading upon plasma and 
erythrocyte free amino acid levels 
in normal adult subjects  
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Subjects/Study  Doses   Duration  Plasma Phe  Plasma Aspartate   Comments 
3 healthy males and three 
females/cross over 
 
Loading dose of 
100 mg/kg bw 
aspartame either 
dissolved in cold 
orange juice or as 
a slurry. 
 
  Increased levels to about 200-260 
μmol/L with aspartame in solution. 
Aspartame in a slurry: peak at 
about 510 μmol/L after 1 hour (2 
subjects), at over 300 umol/L after 
2 hours (2 other subjects), at about 
180 μmol/L after 3 hours (2 other 
subjects).  
 
Little/no effects with 
aspartame in solution. 
Increased with aspartame 
as a slurry in two out of 
the 6 subjects: peak of 36 
and 58 μmol/L; mean 
peak about 15 ± 18 
μmol/L (4 subjects no 
changes). 
 
 
 
3 healthy males and three 
females 
 
Loading dose of 
150 mg/kg bw 
aspartame  
 
  
Increased level, peak at about 351 
± 113 μmol/L  
 
 
Very small changes, peak 
at 10 ± 7 μmol/L  
 
 
3 healthy males and three 
females 
Loading dose of 
200 mg/kg bw 
aspartame  
  Increased level, peak at about 487 
± 15 μmol/L after about 2 hours 
 
Very small changes, peak 
at 7 ± 3.8 μmol/L at 90 
min 
 
3 healthy males and three 
females 
Loading dose of 
200 mg/kg bw 
aspartame  
  Increased level, peak at about 
487 ± 15 μmol/L after about 
2 hours 
Very small changes, peak 
at 7 ± 3.8 μmol/L at 90 
min 
 
3 healthy males and 3 
females/cross over 
High protein meal 
containing 
aspartame plus 
MSG at 34 mg/kg 
bw 
  Slightly increased, peak around 80-
90 μmol/dL after 3-4 hours (only 
slightly higher than those noted 
postprandially, 120 ± 30 μmol/L) 
Unchanged.  The addition of aspartame into 
the meal increased Phe content 
from 43 to 64 mg/kg. 
E95, 1977. Metabolic studies of 
aspartame and monosodium 
glutamate (MSG) ingested as a 
meal component.  
Opinion on the re-evaluation of aspartame (E951) as a food additive 
 
 
EFSA Journal 2013;11(12):3496  234 
Subjects/Study  Doses   Duration  Plasma Phe  Plasma Aspartate   Comments 
12 healthy infants (8-12 
months) 
Loading dose of 
34 mg/kg bw 
aspartame 
  Slightly increased, from 
63 ± 12 μmol/L (zero time) to 
97 ± 27 μmol/L after 0.5 hours. 
Unchanged or decreased 
from level observed at 
zero time (51 ± 33 
μmol/L), but higher 
compared to adults even at 
zero time (3 μmol/L).  
 
E107, 1977. Effect of aspartame 
loading upon plasma and 
erythrocyts, free amino acid 
levels and blood methanol levels 
in normal one-year old children. 
  Loading dose of 
50 mg/kg bw 
aspartame 
  Increased after aspartame 
ingestion, from 57 ± 5 μmol/L 
(zero time) to 116 ± 44 μmol/L 
after 1 hour.  
Unchanged from level 
observed at zero time 
(30.3 ± 15 μmol/L) but 
higher compared to adults 
even at zero time 
(4.2 ± 3.3 μmol/L).  
 
8 healthy infant s (8-12 
months) 
 
Loading dose of 
100 mg/kg bw 
aspartame 
  Increased after aspartame 
ingestion, from 48 ± 8 μmol/L 
(zero time) to 214 ± 56 μmol/L 
after 45 min. 
Unchanged from level 
observed at zero time 
(16.3 ± 7.4 μmol/L) but 
higher compared to adults 
even at zero time 
(1.6 ± 0.5 μmol/L) 
6 subjects sensitive to 
Chinese restaurant 
syndrome/cross over 
Loading dose of 
34 mg/kg bw 
aspartame and 
sucrose 
(1000 mg/kg bw) 
  Increased after aspartame loading 
from baseline (56.6 ± 8.2 μmol/L) 
to a peak of 130 ± 25 μmol/L after 
30 min. No significant changes 
after sucrose loading. 
No significant differences.  E110, 1979. Effect of aspartame 
loading in subjects who report 
symptoms of Chinese restaurant 
syndrome after glutamate 
ingestion. 
9 healthy subjects (6 
males and 3 females) 
Soup beverage 
meal without 
MSG or 
aspartame, with 
MSG (50 mg/kg 
bw) or with MSG 
(50 mg/kg bw) 
  Increased significantly after 
aspartame ingestion; mean peak 
level of 133 ± 50 μmol/L after 30 
min of ingestion of the meal, 
returning to baseline after 4 hours. 
Small but significant 
increases after aspartame 
ingestion; mean peak 
values of 49 ± 29 μmol/L 
at 30 min, which rapidly 
returned to baseline 150 
min after aspartame 
E111, 1979. Metabolic studies of 
aspartame and monosodium 
glutamate (MSG) when ingested 
together as part of a soup 
beverage meal.  
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Subjects/Study  Doses   Duration  Plasma Phe  Plasma Aspartate   Comments 
plus aspartame 
(34 mg/kg bw) 
ingestion. 
6 healthy subjects (3 
males and 3 females) 
Hamburger-milk 
shake alone or 
with MSG 
(150 mg/kg bw) 
or with MSG 
(150 mg/kg bw) 
plus aspartame 
(23 mg/kg bw)  
  Increased after aspartame ingestion 
compared to MSG alone; 
significant peak level of 
107 ± 23 μmol/L after 3 hours of 
ingestion of the meal. 
Small increases (not 
significant compared to 
MSG alone) after 
aspartame ingestion; peak 
values of 36 ± 19 μmol/L 
at 1 hour); 
32.5 ± 14 μmol/L after 1.5 
hour (p ≤ 0.05 compared 
to MSG alone). 
E112, 1979. Metabolic studies of 
aspartame and monosodium 
glutamate (MSG) ingested as 
components of a hamburger-milk 
shake meal system in normal 
adult subjects. 
6 healthy males  560 mg Phe in the 
form of 1000 mg 
aspartame or 
12 200 mg 
albumin or water 
  Increased from 488 ± 96 to 
75.8 ± 27.5 μmol/L at 0.25 hours 
after aspartame ingestion. AUC: 
40 % increased (not significantly) 
after aspartame ingestion: 
53 ± 26 μmol/L hr (aspartame); 
38 ± 15 μmol/L hr (albumine) 
Significantly increased at 
0.25 hours after aspartame 
ingestion. Peak at 6 
μmol/L. 
Ref: Moller, 1990 
8 healthy 
subjects/randomised 
cross-over 
500 mg 
aspartame alone 
or with 100 g of 
sucrose 
  Significantly increased after 
aspartame ingestion from 
62.1 ± 12.0 μmol/L (baseline) to 
75 ± 13.4 μmol/L (15 min after 
dosing). Not significantly increased 
from baseline (60.4 ± 11.3 μmol/L) 
after aspartame with sucrose. 
Not significantly changed.  Ref: Burns et al., 1991 
10 healthy 
subjects/randomised 
cross-over 
3000 mg 
aspartame in 
solution or in 
capsules 
 Significantly  increased: 
peak = 191 ± 65.4 μmol/L at 
35 ± 15 min, 
AUC = 15.340 ± 4.820 μmol/L/min 
(solution) vs 117 ± 39.5 μmol/L 
(capsules) at 123 ± 74 min, 
AUC = 8465 ± 3356 μmol/L/min. 
Significantly increased: 
peak = 26.2 ± 16.3 μmol/L 
at 30 ± 14 min (solution) 
vs. 10.4 ± 5 μmol/L 
(capsules) at 
106 ± 61.3 min. 
Ref: Stegink et al., 1987a  
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Subjects/Study  Doses   Duration  Plasma Phe  Plasma Aspartate   Comments 
12 healthy subjects  4 mg/kg bw 
aspartame 
  Not significantly increased. Not  significantly increased  Ref: Stegink et al., 1987b 
20 healthy 
subjects/randomised 
cross-over 
20 mg/kg 
aspartame 
(capsules or 
solution) 
 Significantly  increased: 
Cmax = 103.3 μmol/L at 
Tmax = 108.6 min (capsule) vs. 
Cmax 126.6 μmol/L at 
Tmax = 36.6 min (solution). AUCs 
not significally different. 
Not affected.  Ref: Burns et al., 1990 
Healthy subjects  Loading dose of 
34, 50, 100, 150, 
200 mg 
aspartame/kg bw 
  Significantly increased. Peak at 
110 ± 25 μmol/L, 
162 ± 49 μmol/L, 
203 ± 20.5 μmol/L, 
351 ± 113 μmol/L and 
487 ± 151 μmol/L after 30 min-2 
hours  
Not significant differences 
at 34, 50, 150, 200 mg/kg 
bw. Statistically 
significant increase with 
peak at 4.3 ± 2.3 μmol/L 
at 100 mg/kg bw (after 
0.5 hours aspartame 
ingestion). Increased but 
less than those observed 
post-prandially in infants 
or adults fed a protein 
containing meal.  
Ref: Stegink, 1984  
6 healthy subjects  184 mg 
aspartame (in a 
diet coke can), 
providing 104 mg 
Phe 
 Not  affected  over the 3-hours post 
ingestion period. 
  Ref: Mackey and Berlin, 1992 
6 healthy women/cross 
over  
Aspartame or 
lactose at 50 
mg/kg bw 
  Significantly increased: 4-fold over 
fasting values 45 min after 
aspartame loading. Returned to 
baseline in 4 hours. 
Not significant changes.  Ref: Stegink et al., 1979a. 
24 one-year old infants  34, 50 and 
100 mg/kg bw 
aspartame in a 
beverage 
  Significantly increased. Mean 
peak: 93 ± 14, 116 ± 44, 
223 ± 115 μmol/L at 34, 50, and 
100 mg/kg bw (similar to values 
Not significantly changed 
at 34 and 50 mg/kg bw. 
Significantly increased at 
100 mg/kg bw.  
Ref: Filer et al., 1983.  
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Subjects/Study  Doses   Duration  Plasma Phe  Plasma Aspartate   Comments 
observed in adults).  
  
REPEATED 
DOSES 
      
31 healthy man and 38 
women (21-45 years 
old)/double blind 
Placebo, 200 mg 
or 300 mg 
aspartame in 
capsule. Weekly 
dose escalation 
protocol: 0.6, 1.2, 
2.4, 4.5, 6.3, 8.1 g 
aspartame/day. 
Six weeks  No significant difference with 
placebo, fluctuations (mean below 
120 μmol/L). Peak = 120 μmol/L 
after 9 weeks. 
NR  E23, 1972. Short term tolerance 
of aspartame by normal adults. 
95 obese men and women 
(21-70 years old)/double 
blind 
Placebo, 200 mg 
or 300 mg 
aspartame in 
capsule. Weekly 
dose escalation 
protocol: 0.6, 1.2, 
2.4, 4.5, 6.3, 8.1 g 
aspartame/day. 
Six weeks  No significant difference with 
placebo, fluctuations (mean below 
120 μmol/L). Peak = 120 μmol/L 
after 3 weeks. 
NR  E24, 1972. Short term tolerance 
of aspartame by obese adults. 
Group 1: 18 males and 32 
females who participate 
in E23 study. Group 2: 12 
males and 5 females. 
1800 mg 
aspartame/day (2 
x 300 mg 
capsules, 3 x 
daily). 
27 weeks 
(group 1); 
21 weeks 
(group 2) 
No significant difference with 
placebo, fluctuations (mean below 
120 μmol/L). Peak = 110 μmol/L 
(male), 103 μmol/L (female), after 
1 week. 
NR  E60, 1973. Long term tolerance 
of aspartame by normal adults. 
62 males and 64 females. 
Group A: 2-3 year old. 
Group B: 4-6 year-old. 
Group C: 7-9 year-old. 
Group D: 10-12 year-old. 
Group E:13-20 year-
old/double blind 
Sucrose or 
aspartame: 
43.7 ± 1.66 (A) 
39.5 ± 0.99(B) 
58.1 ± 2.83(C)  
55 ± 3.57(D) 
42.9 ± 1.84 
13 weeks  No significant difference with 
sucrose, fluctuations. Peaks (asp): 
110 μmol/L 1 week after dosing 
(Group A, B), 114 μmol/L 1 week 
postdosing (Group C), 103 μmol/L 
3 weeks after dosing (Group D), 
96 μmol/L 1 week after dosing 
NR  E61, 1972. Long term tolerance 
of aspartame by normal children 
and adolescents.  
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Subjects/Study  Doses   Duration  Plasma Phe  Plasma Aspartate   Comments 
(E) mg 
aspartame/kg/day. 
(Group E). 
105 obese adults (21-70 
years old).  
Group 1: 69 subjects who 
participate in E24 study. 
Double blind. 
Group 2: 36 subjects. 
1800 mg 
aspartame/day (2 
x 300 mg 
capsules, 3 x 
daily). 
27 weeks 
(Group 1); 
21 weeks 
(Group 2) 
No significant difference with 
placebo, fluctuations (mean below 
120 μmol/L). Peak = 96 μmol/L 
after 8-11 weeks. 
NR  E64, 1972. Long term tolerance 
of aspartame by obese adults. 
52 men and women (21-
45 years old). Follow up 
of the E25 study. 
1800 mg 
aspartame/day (2 
x 300 mg 
capsules, 3 x 
daily). 
21 weeks   No significant difference with 
placebo, fluctuations (mean around 
120 μmol/L). Peak = 132 μmol/L 
after 1 week. The only significant 
difference between the treatment 
groups occurred in the Phe levels at 
week 16. 
NR  E67, 1973. Long term tolerance 
of aspartame by adults PKU 
heterozygotes. 
6 healthy adult 
subjects/cross over 
Test beverage 
alone or with 
aspartame 
(600 mg/hour or 
18 mg/kg bw) or 
DKP 
(150 mg/hour or 
4.5 mg/kg bw) 
8 
hours/Wash 
out of 1 
week 
between 
treatments 
Significantly increased after 
aspartame ingestion; mean plasma 
Cmax = 113 μmol/L (aspartame), 
58 μmol/L (placebo); 
Tmax = 5.83 hours (aspartame) and 
2.83 hours (placebo); Total AUC 
(0-9) = 788 μmol/L (aspartame), 
444 μmol/L (placebo). Plateau 
concentration after 5 servings. 
Small increased after DKP 
ingestion (not clinically significant 
changes). 
Slightly increased; Mean 
Cmax = 15 μmol/L 
(aspartame), 10.8 μmol/L 
(placebo). No significant 
difference for Tmax and 
AUC.  
UN05, 1987. Effect of repeated 
ingestion of beverage containing 
aspartame or DKP on amino acid 
and DPK concentrations in 
plasma and urine of normal 
healthy subjects. Stegink et al, 
1989. 
53 healthy adult subjects 
(23 males and 30 
females) for aspartame 
group; 
55 healthy subjects (28 
75 mg/kg/day 
(capsules of 
300 mg divided 
into 3 doses/day) 
24 weeks  No statistically significant 
differences.  
Mean: 49 ± 18 μmol/L after 
24 weeks (aspartame);  
Mean: 45 ± 6 μmol/L after 
No statistically significant 
changes. Mean: 
7.7 ± 5.1 μmol/L after 
24 weeks (aspartame); 
Mean: 7.1 ± 2 μmol/L 
UN 08, 1988. Safety of long term 
aspartame administration in 
normal subjects.  
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Subjects/Study  Doses   Duration  Plasma Phe  Plasma Aspartate   Comments 
males and 27 females) for 
placebo group/randomise 
double-blind, placebo-
controlled 
24 weeks (placebo). 
Cmax = 60 μmol/L, 
Tmax = 9.79 weeks (aspartame); 
Cmax = 54 μmol/L, 
Tmax = 8.22 weeks(placebo). 
after 24 weeks (placebo). 
Cmax = 11.1 μmol/L 
Tmax = 8.85 weeks 
(aspartame); 
Cmax = 10.1 μmol/L 
Tmax = 9.98 weeks 
(placebo)  
8 healthy adults (4 males 
and 4 
females)/randomised 
cross-over 
10 mg/aspartame 
bw/serving 
3 servings 
at 2 hours 
of interval 
(6 hours) 
Significantly increased: 16.4 to 
20.5 μmol/L above baseline value 
(51 ± 8.2 μmol/L) 30 to 45 minutes 
after each dose (within normal 
postprandial value at each time).  
Unaffected  Ref: Stegink et al., 1988 
6 healthy young adults (3 
males and 3 
females)/cross- over 
600 mg 
aspartame/serving 
8 servings 
at 1 hours 
of interval 
(8 hours) 
Significantly increased: 14.1 to 
23.5 μmol/L above baseline value, 
30 min after ingestion (within 
normal postprandial value at each 
time). Steady state after 4-5 
serving. 
Not significantly 
increased. 
Ref: Stegink et al., 1989 
PKU HETEROZYGOTE          
  SINGLE DOSE        
12 healthy subjects/4 
female PKU 
Heterozygotes 
Loading dose of 
34 mg/kg bw 
aspartame 
  Slightly increased from 110 to 
160 μmol/L after 1 hour but close 
than those noted postprandially 
(120 ± 30 μmol/L). 
Unchanged.  E93, 1977. Effect of aspartame 
loading upon plasma and 
erythrocyte free amino acid levels 
in normal adult subjects. 
4 healthy women (20-28 
years) and 4 PKU 
heterozygotes women.  
Loading dose of 
34 mg/kg bw 
aspartame 
 
  Remained within the normal range 
(60-182 μmol/L) in both healthy 
and PKU women. Peak at about 
140-150 μmol/L after 1 hour (PKU 
heterozygotes) and 50-120 μmol/L 
after 1 hour (normal subjects).  
NR  E108, 1978. Effect of aspartame 
in plasma and red cell amino 
acids of apparently healthy 
female adults and on presumed 
PKU heterozygotes. 
6 healthy men and  Loading dose of    Increased after aspartame ingestion  No significant changes in  E109, 1978. Effect of aspartame  
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Subjects/Study  Doses   Duration  Plasma Phe  Plasma Aspartate   Comments 
women and 5 PKU 
heterozygotes women.  
100 mg/kg bw 
aspartame 
in both normal and PKU subjects; 
mean maximum levels of 
200 ± 60 μmol/L after 30-90 min 
(normal subjects); ranging from 
355 ± 76 μmol/L at 30 min to 
417 ± 24 μmol/L at 90 min (in 
PKU subjects).  
both normal and PKU 
subjects. 
loading at 100 mg/kg bw upon 
plasma and erythrocyte levels of 
free amino acid in normal 
subjects and subjects presumed to 
be heterozygotes for PKU. 
8 healthy subjects and 6 
PKU 
heterozygotes/randomised 
cross-over 
10 mg/kg bw 
aspartame 
  Increased. Healthy subjects: from 
baseline of 51 ± 8.2 μmol/L to 
67 ± 7.5 μmol/L. PKU: from 
baseline of 90 ± 17.1 μmol/L to 
121 ± 20.8 μmol/L 
Not significantly 
increased. 
Ref: Stegink et al., 1987b 
12 healthy subjects (6 
men and 6 women) and 8 
PKU heterozygotes 
women 
Loading dose of 
34 mg 
aspartame/kg bw 
  Significantly increased. Peak at 
110 μmol/L after 1 hour (normal) 
and 160 μmol/L after 1 hour 
(PKU). 
Not affected.  Ref: Filer and Stegink 1989  
13 PKU heterozygotes (7 
women and 6 men) and 
13 healthy subjects (5 
women and 8 men) 
A meal providing 
303 μmol/kg Phe  
  Increased. Mean peak around 
100 ± 10 μmol/L after 3 hours 
(PKU); around 80 ± 10 μmol/L 
after 3 hours (control).  
NR  Ref: Curtius et al., 1994 
10 PKU heterozygotes (5 
women and 5 men) and 
10 healthy subjects (5 
women and 5 men) 
Same meal with 
addition of 
85 μmol/kg 
aspartame 
(providing 
75 μmol/kg Phe) 
  Increased. Mean plasma level: 
95 ± 7 μmol/L after 1 hour 
(control); 153 ± 21 μmol/L after 
3 hours (PKU heterozugous). Only 
slightly grater than the usual 
postprandial range for both controls 
and PKU heterozygotes.  
  
10 healthy subjects as 
control; subjects with 
classic PKU; subjects 
10 mg/kg bw 
aspartame 
 Significantly  increased  from 
44.5 ± 12.9 μmol/L (baseline) to 
58.0 ± 9.5 μmol/L (1 hour after 
NR  Ref: Caballero et al., 1986  
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Subjects/Study  Doses   Duration  Plasma Phe  Plasma Aspartate   Comments 
with atypical 
hyperphenylalaninemia; 
subjects PKU 
heterozygotes  
ingestion) in controls (+ 30 %); 
from 68.8 ± 13.8 μmol/L (baseline) 
to 82.3 ± 17.3 μmol/L (1 hour after 
ingestion) in PKU heterozygotes) 
(+ 20 %) 
6 PKU heterozygotes 
females and 12 healthy 
subjects (6 males and 6 
females) 
34 mg/kg 
aspartame in 
orange juice 
  Increased. Healthy subjects: from 
56.6 ± 12.1 μmol/L (baseline) to 
111 ± 25 μmol/L (within normal 
postprandial range); returned to 
baseline after 8 hours. PKU 
subjects: mean peak at 
160 ± 22.5 μmol/L (only slightly 
above postprandial values in 
human infant and adult). 
Not affected  Ref: Stegink et al., 1979b. 
REPEATED DOSES        
65 men and women PKU 
heterozygotes (21-45 
years old)/double blind 
Placebo, 200 mg 
or 300 mg 
aspartame in 
capsule. Weekly 
dose escalation 
protocol: 0.6, 1.2, 
2.4, 4.5, 6.3, 8.1 g 
aspartame/day; 
0.34, 0.67, 1.35, 
2.53, 3.54, 4.55 g 
Phe/day. 
6 weeks  No significant difference with 
placebo, fluctuations (mean below 
120 μmol/L). Peak = 168 μmol/L 
after 6 weeks. 
NR  E25, 1972. Short term tolerance 
of aspartame by adults PKU 
heterozygotes. 
6 heterozygotes PKU 
adult subjects/cross over 
Test beverage 
alone or with 
aspartame 
(600 mg/hour or 
18 mg/kg bw) or 
DKP 
(150 mg/hour or 
4.5 mg/kg bw) 
8 
hours/Wash 
out of 1 
week 
between 
treatments 
Significantly increased after 
aspartame ingestion; mean plasma 
Cmax = 167 μmol/L (aspartame), 
75.2 μmol/L(placebo); 
Tmax = 6.83 hours (aspartame) and 
3.08 hours (placebo); Total AUC 
(0-9) = 1162.6 μmol/L (aspartame), 
Unaffected  UN06, 1987. Effect of repeated 
ingestion of beverage containing 
aspartame or DKP on amino acid 
and DPK concentrations in 
subjects heterozygotes for PKU.  
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Subjects/Study  Doses   Duration  Plasma Phe  Plasma Aspartate   Comments 
599 μmol/L (placebo). Plateau 
concentration after 6 servings. 
Small increased after DKP 
ingestion (not clinically significant 
changes). 
6 adults PKU 
heterozygous/randomised 
cross-over 
600 mg 
aspartame/serving 
8 servings 
at 1 hours 
of interval 
(8 hours) 
Significantly increased from 23.5 
to 40.3 μmol/L above baseline 
30 min after ingestion. Steady state 
after 5 serving (slightly but 
significantly higher than usual 
postprandial values for 
heterozygotes PKU). 
Not affected  Ref: Stegink et al., 1990 
48 adults (21 men and 27 
women) PKU 
heterozygotes/ 
randomised, double blind, 
placebo-controlled, 
crossover 
Placebo or 15 or 
45 mg/kg day 
12 weeks  Significantly increased at 1 and 3 
hours following ingestion of 
45 mg/kg day aspartame. Placebo: 
90.4 ± 21.23 μmol/L (1 hour post 
dose) and 88.7 ± 22.36 μmol/L 
(3 hours post-dose). 45 mg/kg day 
group: 116.9 ± 29.48 μmol/L 
(1 hour post-dose) and 
112.5 ± 40.30 μmol/L (3 hours 
post-dose) 
NR  Ref: Trefz et al., 1993 
PKU HOMOZYGOTE          
  SINGLE DOSE        
2 14 year-old PKU 
homozygous boys: one on 
a liberalised Phe diet 
(70 mg/kg/day), the other 
on a restricted Phe diet 
(17 mg/kg/day). 
Loading dose of 
34 mg/kg bw 
aspartame; 
2 weeks later: 
equivalent 
amount of Phe 
(19 mg Phe/kg). 
Liberalised diet: 
  No significant differences reported.  NR  E26, 1972. Tolerance of loading 
doses of aspartame by PKU 
Homozygous children.  
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Subjects/Study  Doses   Duration  Plasma Phe  Plasma Aspartate   Comments 
total amount of 
3228 mg of Phe 
(dietary intake: 
2539 mg + Phe 
added from 
loading dose: 
689 mg); 
restricted diet: 
total amount of 
2037 mg of Phe 
(dietary intake: 
965 mg + Phe 
added from 
loading dose: 
1072). 
7 subjects homozygous 
for PKU and 7 healthy 
subjects 
200 mg 
aspartame in 
beverage with or 
without 
carbohydrate 
(CHO) 
  Not increased over baseline values 
(55 ± 8.5 μmol/L, healthy; 
1500 ± 230 μmol/L, PKU).  
NR  Ref: Wolf-Novak et al., 1990 
5 subjects homozygous 
for PKU  
184 mg 
aspartame (in a 
diet coke can), 
providing 104 mg 
Phe 
  Increased levels vary from 
15.6 μmol/L (above 
Baseline = 302 μmol/L) to 
106 μmol/L (above 
basline = 798 μmol/L) 
 
  Not considered clinically 
significant. Ref: Mackey and 
Berlin, 1992 
NR: not reported 
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Appendix K.   SAS internal report 
ESTABLISHING LOWER BOUND ASPARTAME DOSE TO REACH PHENYLALANINE 
PLASMA THRESHOLD LEVELS 
European Food Safety Authority
22 
European Food Safety Authority (EFSA), Parma, Italy 
EXECUTIVE SUMMARY 
Simulation models can combine several sources of variation that could arise due to diversity in the population, 
but also on the limited amount of information from which the summary measures are built. Summary data 
collected on Cmax phenylalanine plasma concentration for different studies on different doses were used to 
estimate the minimum (lower bound) dose of aspartame that is obtained for a particular phenylalanine plasma 
level threshold. The data contain arithmetic means and standard deviation of phenylalanine levels in plasma 
(μM), the number of individuals involved and the aspartame dose administered (mg/kg of body weight). The 
arithmetic measures were transformed to obtained geometric measures. In each simulation, individual 
phenylalanine levels in plasma for each dose were generated according to the number of individuals reported, 
geometric mean and the geometric standard deviations based on a lognormal distribution. For each simulated 
dataset a generalized additive model (Wood 2003, 2004, 2006a, 2006b and 2011), considering spline smoothing 
functions of aspartame doses, was used. The simulation model used allows studying the relationship between 
aspartame dose (mg/kg bw) and phenylalanine plasma level (μM) for healthy and heterozygote individuals. 
Flexible models were used to fit the simulated individual data based on geometric transformations of the 
summary measures drawn from lognormal distribution, the smoothed fitted model was evaluated in term of 
monotonicity and results shown that the model obtained was strictly increasing monotone, even when the model 
structure was left flexible, allowing for other type of relationship, but the data at hand proved to be 
monotonically increasing. The results obtained for the three different threshold used (240, 300 and 360 in μM) in 
normal individuals consistently produced aspartame dose lower bound that were above the ADI level (40 mg/kg 
of body weight) regardless of the confidence level (α) used. In the case in which the model was fitted for 
heterozygote individuals, thresholds of 300 or 360 μM shown consistent aspartame dose lower bounds above the 
ADI level when the level of confidence considered was 0.05, and only for the threshold of 360 when α  was 
equal to 0.01. If the threshold considered is 240 μM and α is 0.05, the aspartame dose lower bound could be 
below the ADI level (in about 18 % of the times), for the case in which the confidence level considered was 
0.01, then in 46.6 % of the simulations, the aspartame dose lower bound was below the ADI level for the 
phenylalanine threshold of 240 μM and 5.1 % for the phenylalanine threshold of 300 μM. It is important to 
highlight that for the heterozygote population, the results obtained should be interpreted with caution due to the 
limited number of doses found and the amount of individuals used to derive the summary data. 
 
KEY WORDS 
spline model, dose-response models 
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BACKGROUND 
The Commission has asked the European Food Safety Authority to re-evaluate the safety of food 
additives already permitted in the Union before 2009 and to issue scientific opinions on these 
additives, taking especially into account the priorities, procedures and deadlines that are enshrined in 
the Regulation (EU) No 257/2010 of 25 March 2010 setting up a programme for the re-evaluation of 
approved food additives in accordance with the Regulation (EC) No 1333/2008 of the European 
Parliament and of the Council on food additives. 
OBJECTIVES AND SCOPE OF THE REPORT 
The objective of this report is to: 
•  Establish lower bound doses of aspartame that give rise to different phenylalanine plasma 
level thresholds. 
•  Develop a simulation model that uses summary information regarding Cmax phenylalanine 
plasma level for certain aspartame bolus doses collected from different studies in humans that 
account for the variability in each dose groups and the limited number of individuals used to 
estimate the phenylalanine Cmax levels to obtain the lower bound aspartame dose for the pre-
specified thresholds. 
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1.  Introduction 
Simulation models are a powerful tool when dealing with summary data, it can combine several 
sources of variation that could arise from the outcome of interest in itself, due to diversity in the 
population under study, but also on the limited or scarce amount of information from which the 
summary measures are built. Moreover, when the purpose of the study is to establish the kind of 
relationship between outcomes and covariates of interest, these types of model also offer the 
advantage of generating (mimicking) the experimental conditions more than once, and thus accounting 
for possible variations that could occur if the experiment was conducted several times. Spline models 
(Wood 2003, 2004, 2006a, 2006b and 2011) is a non/semi-parametric flexible tool that could be used 
to establish the relationship between the outcome variable under consideration and the covariates that 
could potentially influence the outcome observed, offering the possibility to generate smoothing 
curves without having to specify any predefined mathematical expression. The SAS unit was asked to 
derive a simulation model that could be used to predict an estimated aspartame dose and confidence 
band through modelling the relationship between aspartame bolus doses and Cmax phenylalanine levels 
in plasma. For this purpose, simulation models in combination with spline modelling techniques were 
used. 
The objective of this report is to: 
•  Establish the lower bound doses for different phenylalanine plasma level thresholds  
•  Develop a simulation model that uses summary information regarding Cmax 
phenylalanine plasma level for certain aspartame bolus doses collected from different 
studies in humans that account for the variability in each dose groups and the limited 
number of individuals used to estimate the phenylalanine Cmax levels to estimate the 
lower bound aspartame dose for the pre-specified thresholds. 
 
2.  Methodology Proposed 
Summary data collected on Cmax phenylalanine plasma concentrations from different studies using 
different doses of aspartame were used to estimate the minimum (lower bound) dose of aspartame 
giving rise to a particular phenylalanine plasma level threshold concentration. The data contain 
arithmetic means (   ) and standard deviation (  ) of phenylalanine levels in plasma (  in μM), number 
of individuals involved ( ) and the aspartame dose administered (  in mg/kg of body weight). The 
data were taken from the following sources. 
Burns ST, Stargel, WW and Horwitz A, 1990. Bioavailability of phenylalanine and aspartate from 
aspartame (20 mg/kg) in capsules and solution. Metabolism, 39, 1200-1203. 
Stegink LD, Wolf-Novak LC, Filer LJ Jr, Bell EF, Ziegler EE, Krause WL and Brummel MC, 1987. 
Aspartame-sweetened beverage: effect on plasma amino acid concentrations in normal adults and 
adults heterozygous for phenylketonuria. The Journal of Nutrition, 117, 1989-1995. 
E93, 1977. Final Report On Effect Of Aspartame Loading Upon Plasma And Erythrocyte Free Amino 
Acid Levels In Normal Adult Subjects. Searle. 
E108, 1978. Effect of aspartame on plasma and red cell amino acids of apparently healthy female 
adults and on presumed phenylketonuric heterozygotes. Searle. 
E110, 1979. Effect of Aspartame Loading In Subjects Who Report Symptoms Of Chinese Restaurant 
Syndrome After Glutamate Ingestion. Searle. Opinion on the re-evaluation of aspartame (E951) as a food additive
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The arithmetic measures were transformed to obtain geometric measures (z   and S ), given that the 
plasma concentration of phenylalanine should follow a lognormal distribution (         ). The 
transformation was as follows: 
      
  
   
 
       
 
 
 
     
 1      
 
 
 
 
 
 
  
         1      
   
 
Simulation models (1000 simulations) were used in order to estimate the lower bound dose for three 
different phenylalanine plasma level thresholds (240, 300 and 360 μM) and two significance α levels 
(0.05 and 0.01). 
In each simulation, phenylalanine levels in plasma for each aspartame dose were generated according 
to the number of individuals reported, geometric mean (  ) and the geometric standard deviations (  ) 
based on a lognormal distribution with these parameters (   and   ). The number of samples drawn for 
each aspartame dose from the assumed lognormal distribution was equal to the number of individuals 
reported. Each simulated dataset containing aspartame dose and individual Cmax phenylalanine levels 
in plasma was fitted using a generalized additive model (Wood 2003, 2004, 2006a, 2006b and 2011), 
considering the smoothing functions to be spline functions of aspartame doses and the confidence 
band around the fitted model used to estimate the α-percentile lower bound for aspartame dose that 
can potentially give rise to the three different phenylalanine plasma level thresholds (240, 300 and 360 
μM). 
A generalized additive model (GAM, Hastie and Tibshirani, 1986, 1990) is a generalized linear model 
(GLM, McCullagh and Nelder, 1989) where the linear predictor is specified as a sum of smooth 
functions of some or all of the covariates collected. 
          ,         η      
                          … 
where    is the response variable;   ·   is a monotonic link function;   
  is the  th row of the strictly 
parametric part of the model (called design matrix) and    the parameter vector expressing the 
parametric association between the response and the covariate of interest, and the     ·  are the smooth 
functions of the covariates   .  In this report, for all models a thin plate regression spline was used. In 
order to avoid over fitting, the model parameters are estimated using a penalized maximum likelihood 
approach and smoothing parameters are chosen based on cross-validation method (Hastie and 
Tibshirani, 1986, 1990). Ample details on the method used to fit the model are presented in Wood 
(2004). 
The process was repeated 1000 times and the lower bound dose α-percentile (α  = 0.05 and α  = 0.01) 
for aspartame was retained to finally construct the distribution of lower bounds for each of the three 
different phenylalanine plasma level thresholds, which account for the uncertainty on the observed 
summary levels reported in terms of limited number of subjects for each of the aspartame dose groups. 
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Appendix L.   Assessment of both the validity and reliability of the long-term studies on 
aspartame and di-ketopiperazine based on the summaries of the UAREP reports. 
Only scientific issues have been considered in this examination of the UAREP reports (E102a, b, c). 
The Universities Associated for Research and Education in Pathology (UAREP) report consisted in an 
authentication review of selected materials submitted to the FDA relative to the application of Searle 
laboratories to market aspartame. It was issued on 18
th November 1978. 
From nearly 100 studies which Searle has presented to the FDA to market aspartame, 12 were selected 
by FDA and other parties for this review. They included: 
- five major studies of long term toxicity effects in the dogs, rats, and mice 
- two special neuropathology studies  
- the effects of aspartame in newborn rats  
- a two-generation reproduction toxicity study in the rat  
- a series of screening tests for endocrinological and physiological responses  
- a report covering a few inconsequential observations on pregnant monkeys  
- a major study of the effects of aspartame and its metabolites in embryogenesis and teratogenesis in 
rabbits.  
E-28, 106 week oral toxicity study in the dog. Forty Beagles (five/sex/treatment goup) were fed 
aspartame daily in different dosages. Seven haematology, ten clinical chemistry and eight urinalysis 
parameters were measured periodically throughout the experiment. An additional ten chemical 
constituents were determined at 78 and/or 106 weeks. All the dogs were killed at 106 weeks and 
complete necropsies and histopathologic examinations performed. 
E-33,34, E-70, E-75 and E-76 share the objective of testing the effects of aspartame in life time 
toxicity studies. E-33,34 involved 440 rats in five groups with the highest dosage being 8 g/kg 
bw/day), E-70 involved 280 rats in control and two treatment groups. E-75 and E-76 utilized each 360 
mice, E-75 evaluated again aspartame whereas E-76 provided 3 graded dosages of its conversion 
product, diketopiperazine. The duration of the four experiments ranged from 103 to 108 weeks. 
Validation of the histopathology diagnosis was carried out on 35 000 tissue sections from these 4 
experiments. As expected, some discrepancies did exist. More than 99 % of the slides were available 
for UAREP review.  
The discrepancies in diagnosis and the occasional missing slides had no predilection for any of the 
animal groups, or organ systems. UAREP’ pathologists concluded that: ‘certainly there was no 
evidence that either aspartame or DKP enhanced the production of tumours in these experiments’.  
E-86 Supplemental study of dog brains from a 106 week oral toxicity study (E-28) and E-87 
Supplemental study of rat brains from 2 tumorigenicity studies (E-33,34 and E-70). Because of the 
possibility that there might be an increased incidence of brain tumours in dogs in study E-28 and in 
rats in studies E-33,34 and E-70, additional sections of brain were cut from dogs (E-86) and rats (E-
86) and reviewed by Searle’s neuropathology consultant Dr J.R.M. Innes. A panel of neuropathology 
experts convened by UAREP: 
•  agreed completely with Dr Innes that there were no brain tumours in the dogs (E-86)  Opinion on the re-evaluation of aspartame (E951) as a food additive
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•  generally agreed well with Dr Innes (E-86) for the rat studies. The 20 brain tumours diagnosed 
showed no statistically significant increase in any group when the tumours for the two 
experiments were combined.  
E-9 Toxicological evaluation of aspartame in the neonatal rat. Groups of five male and five female 
newborn rats were sacrificed at 5, 15, and 21 days with analysis of five hematologic parameters and 
six chemical tests. The white blood cells counts were variable but statistically significantly depressed 
in the treatment groups. White blood counts were corrected for nucleated blood cells on the lab sheets 
but the uncorrected figures were used in the Entry report. This did not significantly affect the outcome 
of the statistical analysis. UAREP agreed with the EPL pathologic diagnostic of nuclear changes in 
renal tubular cells in the 15 and 21 day old rats, which apparently related to aspartame exposure.  
E-11 Two generation reproduction study in rats. This study was designed to characterize the effects of 
aspartame in the reproductive performance of the same strain of rats as used in other HLA-Searle 
experiments. UAREP agreed with the findings in E-11 report. Fewer discrepancies or problems were 
noted in this than in most of the other studies reviewed.  
E-19 Endocrine studies  
This report covers a battery of screening tests (7 hormone related tests and 6 physiologic responses 
tests) which were used by Searle for compound clinical testing. Some of these routine tests appeared 
to be carried out with less precision or documentation than some might desire. UAREP encountered 
some difficulty in reconstructing and interpreting the results of these routine tests.  
E-88 Experiments in mated and pregnant Rhesus monkeys. Searle informed that the E-88 report was 
based on fragmentary data developed independently of Searle and without Searle’s involvement in the 
design of the study. UAREP felt that this report was without design, inconsequential, and based on 
woefully inadequate and confusing data from an inadequate number of animals.  
E-90 An evaluation of the embryotoxic and teratogenic potential of aspartame in rabbits. These 
experiments involved 300 female rabbits and studied the effects of administering by gavage, 
aspartame and its metabolites, L-phenylalanine and L-aspartic acid, during fetal organogenesis in 
pregnant rabbits. The dosage level of administration was not equivalent to that recorded by the highest 
aspartame dose group. UAREP authenticated the findings in the skeletal system of the cleared whole 
fetuses. Seven of the 10 discrepancies that UAREP found were minor malformations occurring in 
fetuses which were previously reported by Searle to have other malformations. Although it was not 
possible to examine the body cross-sections because of their altered conditions, UAREP felt that its 
validation of the skeletal specimens was adequate indication of the accuracy and significance of Searle 
findings.  
Overall, UAREP has interpreted the results only to the experiments as designed, it has addressed itself 
to the question of whether the experiments were carried out according to protocol plans and the 
accuracy and reliability with which the experiments were performed and reported to the FDA. At 
times, UAREP has commented on the interpretation of the significance of the data. Attempt was made 
to quantitate not only the number but the magnitude and significance of discrepancies and problems 
noted.  
There were many instances in which the earliest recorded data were not available. UAREP failed to 
agree with Searle and Hazleton on less than 1  % of the computations and in most instances the 
differences were small in magnitude.  
For the histopathology slides, the full information on which the original pathologist based his 
diagnosis was still available. Autolysis of tissues was present in both the rat and mouse slides from 
HLA. UAREP pathologists did not feel that it was sufficiently severe to materially interfere with 
making diagnoses on all but a few slides.  Opinion on the re-evaluation of aspartame (E951) as a food additive
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Not only the agreement in diagnosis was generally good in the four larger studies but there was also 
good agreement in the smaller study in E-9.  
There was obviously considerable variation in the results within and between groups when measuring 
variability and statistical differences. Although a substantial number of minor and inconsequential 
discrepancies were noted in UAREP’s validation studies, there were few if any, discrepancies which 
would produce a change of greater than 5 % in the final numerical data being compared.  
The UAREP report finally stressed that the discrepancies it observed appeared randomly distributed 
between treated and control groups of animals.  
The Panel noted that UAREP and Bressler (1977) reported that in very many instances, the earliest 
original raw data were not available, some of the protocols appeared to be variable in time and fully 
documented only at termination of the study. They identified a lot of discrepancies and variability in 
the results of the studies under investigation. They underlined that:  
•  in all groups, many of the old animals were obviously in poor health and had tumours or 
advanced renal or liver diseases which, in the view of some of the UAREP investigators may 
have make it difficult to recognize a mild carcinogenic action of the study compound. In this 
connection limiting the experiment in time according to survival percentage was suggested 
•  the development of standard operating procedures along with the non intentional use of ill 
animals (in some studies, several animals in both control and treated groups received 
potassium penicillin G due to unidentified infection diseases outbreaks) and together with the 
availability of the data and transparency of the methodology are fundamental requirements for 
a study to be fully reliable. All of these requirements were unfortunately not usual practice 
when these studies have been carried out. 
The Panel noted that, both reports did not conclude that the studies were not useful but that they were 
rather in line with the current practice in the early ‘70s before the development of the standardised 
procedures and Good Laboratory Practice (GLP); therefore their results should be considered. In 
addition, UAREP did not find evidence that the studies investigated were deliberately treated to 
produce biased results.  
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GLOSSARY AND ABBREVIATIONS 
ADI  Acceptable Daily Intake  
ADME  absorption, distribution, metabolism and excretion  
AFC  Scientific Panel on Food Additives, Flavourings, Processing 
Aids and Materials in Contact with Food  
AFSSA  Agence française de sécurité sanitaire des aliments 
ANS  Scientific Panel on Food Additives and Nutrient Sources added 
to Food 
ANSES  Agence nationale de sécurité sanitaire de l’alimentation, de 
l’environnement et du travail 
bw body  weight 
β-aspartame (β-APM)  1-methyl N-L-β-aspartyl-3-phenyl-L-alaninate 
β-AP  β-aspartylphenylalanine  
CAS  Chemical Abstracts Service 
CE-C
4D  Capillary electrophoresis (CE) with capacitively coupled 
contactless conductivity detection (C4D)  
Cmax  Maximum Plasma Concentration 
COC  UK Committee on Carcinogenicity of Chemicals in Food, 
Consumer Products and the Environment 
DKP  5-benzyl-3,6-dioxo-2-piperazine acetic acid  
EFSA  European Food Safety Authority 
EC European  Commission 
EINECS  European Inventory of Existing Commercial chemical 
Substances 
ERF  European Ramazzini Foundation  
EU European  Union 
FSA  UK Food Standards Agency 
GD Gestational  Day 
GLP  Good Laboratory Practice 
GSH Glutathione   
HPLC  High-performance liquid chromatography  
ICGA International  Chewing  Gum  Association 
ISA  International Sweeteners’ Association  
JECFA  Joint FAO/WHO Expert Committee on Food Additives  
LD50  Lethal Dose, 50 % i.e. dose that causes death among 50 % of Opinion on the re-evaluation of aspartame (E951) as a food additive
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treated animals 
LNAA  large neutral amino acids 
LOAEL  Lowest Observed Adverse Effect Level 
MoA  Mode of Action 
MPL  Maximum Permitted Level 
NOAEC  No Observed Adverse Effect Concentration 
NOAEL  No Observed Adverse Effect Level 
OECD  Organisation for Economic Co-operation and Development 
PARNUTS  Food for Particular Nutritional Uses 
PKU Phenylketonuria   
QS  Quantum Satis  
RSDR  Relative standard deviation for reproducibility 
SCEs  Sister chromatid exchanges  
SCF  Scientific Committee on Food  
UK  COT  UK Committee on toxicity of chemicals in food, consumer 
products and the environment 
US EPA  US Environmental Protection Agency  
US FDA  US Food and Drug Administration 
WHO  World Health Organization 
 